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Abstract 
The contribution of over-the-counter (OTC) medicines sales data from 
pharmacies for public health (PH) has previously attracted interest in the UK. 
In this study, data for several OTC medicines were utilised to explore their 
contribution to (a) understand the impact of medicine reclassification or 
increased regulation on supply and (b) the surveillance of infectious diseases in 
the community in Wales. 
 
Following the reclassification of ophthalmic chloramphenicol (June 2005) an 
increase in primary care supply (OTC + prescription) of 54% (47,026 units) in 
eye drops and 29% (15,657 units) in eye ointment were observed (2004 to 
2010). Despite this increase the items of eye drops prescribed were similar 12 
months before and five years after the reclassification. The impact of 
regulatory changes concerning the non-prescription sale of opioid-containing 
analgesics was studied. In the 12 months following September 2009 legislative 
changes there was a significant fall in sales of codeine- and dihydrocodeine-
containing solid oral dosage forms (p<0.05). Similarly, following the pack size 
restriction of non-prescription pseudoephedrine and ephedrine products (April 
2008), significant (p<0.05) year-on-year reductions in the total weight of 
pseudoephedrine sold were observed. Sales of non-prescription ophthalmic 
chloramphenicol were monitored on a small area basis in two areas with known 
outbreaks of infective conjunctivitis. In both areas sales data did not 
demonstrate the required sensitivity. When monitoring seasonal influenza, 
significant positive correlations were observed between cough/cold/flu 
medicines sales and indicators of influenza activity in Wales. 
 
In alignment with the professional standards for PH practice for pharmacy 
produced by the Royal Pharmaceutical Society, the work undertaken 
demonstrated a number of potential uses of medicines sales data for PH. 
Routine data collection, particularly if captured at time/point of sale, would 
further enhance its usefulness in detecting and tracking PH incidents.  
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Chapter 1: 
 
General Introduction  
 2 
General Introduction 
 
1.1 Public health 
A more recent definition of public health was adapted from Donald Acheson’s 
early definition in the Acheson report (Acheson 1988) and it defines public 
health as: 
 
“The science and art of promoting and protecting health and wellbeing, 
preventing ill health and prolonging life through the organised effort and 
informed choices of society, organisation, public and private, communities and 
individuals.” (Wanless 2004) 
 
As with other recently cited definitions of public health (Armstrong 2007; 
Department of Health [DH] 2010; Faculty of Public Health 2010), the revised 
definition by Derek Wanless recognises that many factors contribute to the 
health and wellbeing of the population whether physically, psychologically, 
socially or environmentally. Furthermore, there is an emphasis on collaboration 
between, and input from, different government agencies, healthcare 
professionals and public health organisations. In the United Kingdom (UK), 
improving public health is an issue of significant importance and each country 
has committed to meet the various public health needs of its population 
through national public health strategies (DH 2010; Department of Health, 
Social Services and Public Safety 2010; NHS Scotland 2012; Welsh 
Government 2009a). 
 
The practice of public health can be broadly divided into three domains: health 
improvement, health protection and health services (Griffiths et al. 2005). The 
first domain, health improvement, includes key aspects that aim to reduce both 
inequalities in health and the wider social influences of health such as housing 
and employment. The second domain, health protection, includes prevention 
and control of infectious diseases, environmental hazards and emergency 
preparedness. The final domain, health services, emphasises on service 
delivery, promoting evidence-based public health practice and support 
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appropriate research, audit and evaluation of public health interventions. Other 
variations of the above model exist, such as a four-domain model that has been 
developed in England to create a new public health outcomes framework 
(Public Health England [PHE] 2013a). This new system encompasses 
additional health and well-being indicators that are used to support the 
development and practice of public health (PHE 2013a). 
 
In the UK, the National Health Service (NHS) supports many public health 
activities under each domain through its various health service contractors. By 
way of example, general medical practitioners (GPs) provide vaccine and 
immunisation services to NHS patients under the general medical services 
contract (DH 2013). Such would be considered an activity under the health 
protection domain. Similarly, community pharmacies contracted by the NHS to 
provide pharmaceutical services also engage in a variety of public health 
activities on a regular basis as per the contractual agreement (NHS Wales 
2006). 
 
1.2 Role of community pharmacy 
Community pharmacies in England and Wales deliver a variety of NHS funded 
services (NHS Wales 2006). The NHS services provided are divided into three 
categories, namely essential, advanced and enhanced services (NHS Business 
Services Authority and NHS Prescription Services 2012). As their name 
implies, essential services are services that must be provided by all pharmacy 
contractors as they are commissioned nationally, such as dispensing a NHS 
prescription and disposal of medicine waste. Advanced services are those that 
not compulsory but could be provided once the pharmacists and the pharmacy 
premises have met the required criteria. Lastly, enhanced services are services 
that are provided locally in agreement with the responsible NHS 
commissioning body based on the local health needs (NHS Wales 2009). In 
Wales, certain NHS services provided under the pharmacy contract are 
different to those provided in England as responsibility over the NHS in Wales 
was transferred to the devolved Welsh Government on 1 July 1999 (National 
Audit Office 2001). ‘Discharge Medicines Review’, as an example, is an 
advanced service provided by Welsh community pharmacy although a similar 
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provision in England (New Medicines Service) exists (Community Pharmacy 
Wales [CPW] 2011; Pharmaceutical Services Negotiating Committee [PSNC] 
2013). 
 
Under the specifications of essential services, a number of activities undertaken 
in community pharmacy are related to public health, namely disposal of 
unwanted medicines, promotion of healthy lifestyles, signposting patients to 
other NHS services and provision of support for self-care (CPW 2011). All of 
these provisions take advantage of the distribution of community pharmacies 
and make use of the medicine- and health-related knowledge that pharmacists 
and pharmacy staff possess. Of these four provisions, promotion of healthy 
lifestyles and support for self-care consist of many activities that are relevant to 
public health. The former ranges from providing opportunistic advice on 
healthy living and public health topics to participating in national or local 
public health campaigns. Support for self-care includes providing advice on 
self-management of minor and long-term conditions and recommending 
appropriate over-the-counter (OTC) medicines. These advice-giving and health 
supporting roles have long been fulfilled by community pharmacists, even 
before they were incorporated into the current pharmacy contract in 2005 
(Anderson 2007). 
 
Other public health roles of community pharmacy, many of which are enabled 
by locally agreed enhanced services arrangements, have been reported. 
Examples include provision of emergency hormone contraception (O’Brien 
2009), influenza vaccination (Warner et al. 2013), smoking cessation services 
(West et al. 2005), infection control and prevention (Watson et al. 2003), 
screening of cardiovascular and major diseases (Horgan et al. 2010; Ayorinde 
et al. 2013), and prevention and management of drug abuse, misuse and 
addiction (Britton and Scott 2006). Recently in Wales, vaccination for 
influenza was delivered for the first time by selected community pharmacies 
under the enhanced services arrangements (Public Health Wales [PHW] 2012). 
This gave community pharmacy the opportunity to contribute to public health 
protection by increasing the uptake of vaccination in high-risk patient groups. 
The extension of the public health role for community pharmacy in the 
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prevention of influenza had been welcomed by pharmacy organisations (Patel 
2012).  
 
The intention for community pharmacy to have a greater public health role has 
been presented in several government plans and policies for England, Scotland 
and Wales (DH 2005, 2010; Public Health Institute of Scotland 2003; Welsh 
Government 2009a). In accordance with the aims of these national strategies, a 
range of pharmacy-based health services, each tackling a unique public health 
issue, has been developed and promoted during the last decade (Agomo 2011; 
Anderson et al. 2008). However, one aspect of pharmacy practice that has 
considerable public health potential, but has not been fully exploited in the UK, 
is the knowledge and data community pharmacy businesses have on the sales 
of OTC medicines. These data have been suggested to hold potential value for 
pharmaceutical health surveillance, which could provide useful information on 
population health needs, disease pattern and inform health-related policy 
decisions (Jones 2009; Public Health Institute of Scotland 2003; Royal 
Pharmaceutical Society [RPS] 2013; Walker 2000). It is the public health 
potential of this data which is the subject of the current research.  
 
1.3 Reclassification of medicines 
In the UK, the Human Medicines Regulations (2012) classify human medicines 
into three legal categories, namely: Prescription-only medicines (POMs), 
Pharmacy (P) medicines and General Sales List (GSL) medicines. POMs can 
usually only be supplied direct to a patient in accordance with a valid 
prescription issued by a practitioner who possesses the authority to prescribe. 
An exemption to this requirement is in an emergency and under certain 
conditions where a pharmacist can make an emergency supply of a POM to a 
patient without first obtaining a prescription (RPS 2011a). Medicines that are 
considered reasonably safe to be used without any form of healthcare 
supervision are classified as GSL medicines and can be purchased from most 
retail outlets (Pitchford 2012). In contrast, P medicines can only be sold from a 
pharmacy under the supervision of a pharmacist (RPS 2011a). 
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The term OTC medicine refers to both P and GSL medicines, and they are also 
known as ‘non-prescription’ or ‘behind-the-counter’ medicines (RPS 2011a). 
The legal status of a human medicine is a part of the marketing authorisation 
that a product must receive before it can be sold in the UK. The Medicines and 
Healthcare products Regulatory Agency (MHRA) make licensing and 
classification decisions based on evidence of safety, quality and efficacy 
relating to a medicinal product (MHRA 2008a). The goal of conferring a legal 
status on a medicine is to govern the sale, supply and promotion of the product 
in a way that is proportionate to its safety, which, in turn, determines the ease 
of access by the general public. 
 
1.3.1 Reclassification 
According to European Union Directive on Medicinal Products for Human Use 
(2001/83/EC), a medicine shall be subject to prescription control if it meets the 
following criteria: 
 
 • dangerous when not used under medical supervision; or 
 • it is frequently and to a very wide extent used incorrectly, or 
 • further investigation of activity and/or side-effects is required; or 
 • are normally prescribed by a doctor to be administered parentally  
 
There is an underlying assumption that medicines that do not meet these 
criteria could be available without a prescription (MHRA 2012a). For a 
medicine that contains a new chemical entity it is normally first available as a 
POM. However, if accumulated experience over time provides sufficient 
evidence that use is safe without medical supervision, it may be possible to 
change (or switch) the medicine from POM to P status. Likewise, should it be 
further shown that professional advice, such as that provided by a pharmacist, 
is not required for the safe and effective use of the P medicine it may be 
granted GSL status. This process of altering the legal status of a medicine is 
known as reclassification (MHRA 2012a). 
 
The drivers behind the decision to reclassify a medicine from POM to P status 
are multifactorial. For patients, it has been suggested that OTC availability will 
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widen patient choice, increase their access to treatment, increase patient 
autonomy and create potential financial savings for those who are not exempt 
from NHS prescription charge (Blenkinsopp and Bradley 1996; Brass 2001; 
Brass et al. 2009; Cohen et al. 2005; MHRA 2012a; Prayle and Brazier 1998). 
For pharmacists, it enables them to offer a wider range of treatment to their 
patients (Bellingham 2002), become more involved in patients’ care and make 
better utilisation of pharmacists’ skills and knowledge (Brass et al. 2009). The 
government is also supportive of the reclassification policy in the hope that it 
will reduce its drug expenditure by shifting drug acquisition cost from the state 
to patients themselves (Blenkinsopp and Bradley 1996; Bond and Hannaford 
2003; Brass et al. 2009). Lastly, pharmaceutical companies are driven by their 
commercial interest to maximise profit and are actively seeking for 
opportunities to expand on the range of products that could be sold directly to 
consumers (Bond 2001; Blenkinsopp 2004). 
 
In the last ten years, there had been more than ten successful POM to P 
switches in the UK (Proprietary Association of Great Britain [PAGB] 2012). In 
supporting this trend, the UK pharmacy regulator, the General Pharmaceutical 
Council (GPhC), has also been considering making P medicines self-selectable 
on open display in pharmacies. The purposes of this proposed change were to 
further increase the accessibility and enhance patient selection of medicines 
without a prescription (GPhC 2012). 
 
Converse to the deregulation of a medicine, re-introduction of prescription 
requirement for an OTC product is also possible. This could be prompted by 
emergence of safety concerns which no longer justify a medicine’s OTC 
availability for self-medication (Figure 1.1). 
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Unfavourable risk-to-benefit ratio for OTC availability (reduce patient 
accessibility) 
 
 
 
 
Favourable risk-to-benefit ratio for OTC availability (increase patient 
accessibility) 
 
Figure 1.1 Relationship between risk-to-benefit ratio and over-the-counter (OTC) 
availability of a medicine (modified from Blenkinsopp and Bond 2005) 
 
 
Such reclassification could be related to the identification of previously 
unknown side effects, drug interactions or increased likelihood of misuse 
and/or abuse (Blenkinsopp and Bond 2005; Brass 2001). As an example, 
terfenadine was a non-prescription antihistamine available as a P medicine in 
the UK but was subsequently reclassified to POM status due to cardiac side 
effects (Wise 1997). Another strategy employed by medicine regulators to 
reduce the potential harm of an OTC medicine is by amending the licensing 
details of a medicine, through limiting the pack size, concentration and/or dose 
that a pharmacist can supply without a prescription (Blenkinsopp and Bond 
2005). This approach to restoring the balance between benefits and risks is 
exemplified with the reclassification of larger packs of paracetamol and aspirin 
in 1998 because of increase numbers of death caused by deliberate self-
poisoning (Committee on Safety of Medicines [CSM] 1997). At the time, non-
effervescent products containing paracetamol and salicylates that are of a pack 
size greater than 32 tablets/capsules were reclassified from P to POM status. 
The reduced non-prescription access to large packets of paracetamol had been 
suggested to have lowered the numbers of related deaths and thus protected the 
public’s health (Hawton et al. 2013). 
 
In the UK, a spontaneous adverse drug reaction (ADR) reporting system called 
the Yellow Card Scheme has been in operation for over 40 years to detect 
unknown side effects of medicines (MHRA 2013a). Initially the scheme was 
restricted to only receive reports from doctors but it has since been extended to 
GSL 
medicines 
P 
medicines 
POM 
medicines 
Reclassification 
 
Reclassification 
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all healthcare professionals as well as the general public. Currently, suspected 
ADRs associated with prescription and non-prescription medicines can both be 
reported via the Yellow Card Scheme. A notable example of the contribution 
of the scheme to OTC medicine safety was the identification of the possible 
link between aspirin and Reye’s Syndrome in children under 16 years (MHRA 
2013b). Whilst the Yellow Card Scheme has an important role in ensuring the 
safety of non-prescription medicines following their reclassification, the 
numbers of reports of ADRs associated with OTC medicines have been low 
(Avery et al. 2011) and could be due to under-reporting by healthcare 
professionals and consumers (Blenkinsopp and Bond 2005; Bond et al. 2003). 
 
1.3.2 Impact of reclassification of medicines 
The impact of medicine reclassification on patient and the wider healthcare 
environment is clearly of interest to medicine regulators who imposed the 
changes. As mentioned earlier, the increased access to medicines is linked to a 
number of potential safety risks to the public’s health (Blenkinsopp and Bond 
2005; Brass 2001). In circumstances where the reclassification decision was 
made to address a safety concern related to a medicine, evaluation of the 
impact of the reclassification policy is of even greater importance. There is a 
need of a way to assess whether a reclassification policy has indeed had an 
influence on patients’ access to medicines. How this access should be 
monitored is unclear but it has been suggested that sales volume can be used as 
a surrogate to estimate patients’ access (Brass 2001). The growing focus on the 
public health agenda for pharmacy has prompted calls for medicine sales data 
to be better gathered, utilised and shared (Armstrong 2007; Jones 2009; Walker 
2000). Nonetheless, there are few studies utilising medicines sales data to 
investigate the impact of medicines reclassification or regulatory changes 
related to a medicine. 
 
1.3.3 Review of relevant literature 
Using the multi-purpose (MP) search function (Ovid 2012), English language 
articles were identified in Medline and Embase database searches (via Ovid) 
between January 1996 and July 2013 using the following search terms ($ 
indicate truncation): 
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* over-the-counter or non-prescription or behind-the-counter or OTC 
    Total hits: 17,574 
 
* sale$ or wholesale$ or suppl$ or retail$ 
    Total hits: 553,683 
 
* restrict$ or policy or regulat$ or law or reclass$ or switch or deregulat$ 
    Total hits: 3,164,870 
 
Several search fields were searched by the MP search function, including: title, 
abstract, medical subject heading, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword and 
name of substance word. 
 
Boolean operator (‘and’) was used to combine the searches and produced 505 
matching articles. After screening the titles, abstracts and/or full texts, 10 
articles that utilised OTC medicine sales data to examine the impact of 
medicine reclassification policy or regulatory changes related to medicines are 
selected for review and are presented in Table 1.1. 
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Table 1.1 Studies utilising medicines sales data to examine the impact of medicine reclassification or regulatory changes related to medicines 
 
Source Study design Sample Country Medicine studied 
Outcome 
measure Outcome 
Wirtz et 
al. 2013 
4 years before and 
4 years after legal 
prohibition of 
non-prescription 
sale of antibiotics 
(interval depends 
on the country 
studied) 
National sample of 
between 46% to 86% of 
all private sector retail 
pharmacies in 
ambulatory care in the 
four Latin American 
countries 
Chile, 
Colombia, 
Venezuela, 
Mexico 
Penicillins, 
sulphonamides, 
trimethoprime, 
macrolides, 
quinolones, 
cephalosporins 
(1999 - 2006)  
Defined 
daily 
doses per 
1,000 
inhabitants 
per day 
(DID) 
Immediately after policy 
implementation, antibiotic 
consumptions reduced 
significantly in Chile (-5.56 
DID; p<0.05) and Colombia (-
1.0 DID; p=0.001). No 
significant change in DID was 
observed in both Venezuela and 
Mexico (p>0.05) 
       Deslandes 
et al. 2011 
2 years after 
reclassification to 
non-prescription 
availability 
National sample of 
community pharmacies 
(unspecified data 
coverage) in Wales, 
Scotland, Northern 
Ireland (NI) and two 
regions of England 
(North East and South 
Central Strategic Health 
Authority [SHA]) 
UK Azithromycin 
(2008) 
Unit pack 
sold per 
10,000 
population 
Between 2008 and 2010, a 
reduction in OTC sales was 
observed in all countries 
studied (packs per 10,000 
population). In Wales, from 
1.64 packs to 0.44, respectively. 
In Scotland, from 1.32 to 0.48 
packs. In NI, sales reduced 
from 0.35 to 0.16. In England, 
from 1.14 to 0.35 for North 
East SHA and from 1.14 to 0.35 
packs for South Central SHA 
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Table 1.1 (continued) Studies utilising medicines sales data to examine the impact of medicine reclassification or regulatory changes related to medicines 
 
Source Study design Sample Country Medicine studied 
Outcome 
measure Outcome 
Walker and 
Hinchliffe 
2010 
18 months 
before and 40 
months after 
reclassification 
to non-
prescription 
availability 
National sample 
of 89% and 87% 
of all community 
pharmacies in 
England and 
Wales, 
respectively 
UK Ophthalmic 
chloramphen-
icol (2005) 
Unit pack sold 
per 1,000 
population; 
number of 
dispensed 
prescription per 
1,000 population 
A marked increase in sales of OTC 
ophthalmic chloramphenicol was 
observed following the reclassification. 
Between 2007 and 2008, sales of eye 
drops were equivalent to 67% and 52% 
of their corresponding volume supplied 
on prescriptions in England and Wales, 
respectively. Year-on-year prescribing 
of ophthalmic chloramphenicol was 
unaffected in either country during the 
entire four years study period (p>0.05) 
       Dhippayom 
and Walker 
2006 
24 months 
before and 12 
months after 
reclassification 
to non-
prescription 
availability 
National sample 
of pharmacies 
(unspecified data 
coverage) in 
Wales 
UK Omeprazole 
(2004) 
Unit pack sold 
per 1,000 
population; 
number of 
dispensed 
prescription per 
1,000 population 
During the 12 months following the 
reclassification, a total of 5,758 packs 
of OTC omeprazole were sold across 
Wales. Over the same period, an 8.6% 
decline in sales of OTC histamine2 
(H2) antagonist was observed. The 
availability of OTC omeprazole had no 
impact (p>0.05) on the primary care 
prescribing of ulcer-healing drugs 
between 2002 and 2005 
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Table 1.1 (continued) Studies utilising medicines sales data to examine the impact of medicine reclassification or regulatory changes related to medicines 
 
Source Study design Sample Country Medicine studied Outcome measure  
Hawton et al. 
2004 
2 years before and 
4 years after 
implementation of 
legal restrictions 
on OTC pack 
sizes 
UK sample of 
pharmacies and 
general retail outlets 
(unspecified data 
coverage) 
UK Aspirin (1997) and 
paracetamol (1998) 
Mean pack size; number of unit pack 
sold; number of tablets sold; number of 
death by suicidal overdose; number of 
patients admitted to liver unit, listed for 
liver transplant and undergoing 
transplantation for paracetamol-related 
poisoning; number of non-fatal 
poisoning related to analgesics; number 
of tablets taken 
      Outcome 
 
In the one-year period after legislation was introduced, mean pack size for OTC paracetamol and aspirin containing products reduced from 
35 to 24 tablets per pack and from 65 to 25 tablets per pack, respectively. Cumulative total of non-prescription paracetamol tablets sold 
remained steady from 520 million in 1996/97 to 580 million in 2001/02. The 12-month total packs of aspirin sold OTC also remained 
steady from 11 million packs in 1996/97 to 12 million packs in 2001/02; the numbers of tablets sold have however halved. 
 
In the 12 months after the change in legislation, there was a 22% reduction in suicidal deaths from paracetamol and salicylates (p<0.001). 
Overall, liver unit admittance, liver transplants and actual transplantation from paracetamol-induced hepatotoxicity reduced by 
approximately 30% between 1998 and 2002 (all p<0.05). Non-fatal poisoning with paracetamol reduced by 15% in the first year following 
OTC pack size restriction (p<0.001). Mean numbers of tablet taken in paracetamol and salicylates overdose reduced up to 31% in the three 
years after the change in legislation (all p<0.05). 
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Table 1.1 (continued) Studies utilising medicines sales data to examine the impact of medicine reclassification or regulatory changes related to medicines 
 
Source Study design Sample Country Medicine studied 
Outcome 
measure Outcome 
Furler et 
al. 2002 
At least 2 years 
before and 1 
year after 
reclassification 
to non-
prescription 
availability 
(interval 
depends on the 
country studied) 
National 
sample of 97% 
of community 
pharmacies in 
Canada and 
unspecified 
data coverage 
in the US and 
the UK 
Canada, 
US, UK 
H2-receptor 
antagonist 
(1994 for 
UK, 1995 for 
US, 1996 for 
Canada) 
Per capita 
sales in US 
dollar; 
number of 
dispensed 
prescription 
per capita 
Non-prescription sales of H2-antagonist 
increased from 1994 to a peak of $2.05 per 
capita in 1996 in the US. A small increase in 
sales of H2-antagonist ($0.12) was observed 
in the UK in the 12 months after 
reclassification. Sales of H2-antagonist in 
Canada could not be determined. A decline 
in prescription supply of H2-antagonist was 
observed in the US only, from 0.14 in 1995 
to 0.12 prescription per capita in 1997 
       Sheen et 
al. 2002 
2 years after 
implementation 
of legal 
restrictions on 
OTC pack size 
National 
sample of 
pharmacies 
and general 
retail outlets 
with 97% data 
coverage 
UK Paracetamol 
(1998) 
Number of 
packs sold; 
weight of 
drug sold in 
grams 
The weight of paracetamol sold OTC fell by 
60% (242,597,912g/409,054,172g) during 
the two years after reclassification whilst the 
number of packs sold remained unchanged. 
These observations were accompanied by a 
73% (45,929,400g/26,453,320g) increase 
and a 76% reduction 
(510,17,070g/66,465,780g) in weight of 
ibuprofen and aspirin sold OTC over the 
same period, respectively 
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Table 1.1 (continued) Studies utilising medicines sales data to examine the impact of medicine reclassification or regulatory changes related to medicines 
 
Source Study design Sample Country Medicine studied Outcome measure 
Hawton et al. 
2001 
2 years before 
and 1 year after 
implementation 
of legal 
restrictions on 
OTC pack size  
National sample of 
pharmacies and 
general retail outlets 
with 97% data 
coverage 
UK Aspirin (1997) and 
paracetamol (1998) 
Mean pack size; number of packs sold; 
number of tablets sold; number of death 
from paracetamol or salicylate overdose; 
number of patients referred to liver units, 
listed for liver transplant and undergoing 
transplantation; number of overdoses 
and tablets taken; blood concentrations 
of the drugs; prothrombin time 
      Outcome 
 
Mean pack size reduced significantly for all paracetamol and aspirin related medicines 12 months after the legal changes (p=0.01). An 
increase in packs of paracetamol sold OTC was observed (p=0.003) but the total number of tablets sold remained unchanged (p>0.05). A 
significant reduction (p<0.05) in number of tablets sold for paracetamol compounds, salicylates and salicylate compounds was observed. 
In the 12 months after the change in legislation, number of deaths from paracetamol and salicylates poisoning fell by 21% (p=0.01) and 
48% (p=0.01), respectively. The rate of liver transplant decreased by 66% (p<0.0001). The number of non-fatal self-poisoning with 
paracetamol of any formulation decreased significantly by 11% (p<0.0001). The average number of tablets taken in paracetamol overdoses 
reduced by 7% (p=0.04). The mean blood concentrations of salicylates after overdose decreased (-17%), as did prothrombin time (-2%). 
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Table 1.1 (continued) Studies utilising medicines sales data to examine the impact of medicine reclassification or regulatory changes related to medicines 
 
Source Study design Sample Country 
Medicine 
studied 
Outcome 
measure Outcome 
Lundberg 
and 
Isacson 
1999 
1 year 
before and 6 
years after 
reclassificat
ion to non-
prescription 
availability 
Two 
community 
pharmacies in 
Tierp, 
Sweden 
Sweden Nasal drops 
and nasal 
sprays 
containing 
oxymetazoline 
or 
xylometazoline 
(1989) 
Number of 
packs sold and 
dispensed 
prescription per 
1,000 
inhabitants; 
physician visits 
for rhinitis; cost 
of physician 
visits for rhinitis 
From 1988 to 1995, OTC sales of nasal drops 
decreased from 208 to 30 packs per 1,000 
inhabitants, respectively. Sales of nasal spray 
increased from 152 to 669 packs per 1,000 
inhabitants, respectively. Supplies on prescription 
decreased from 143 packs in 1988 to 37 packs per 
1,000 inhabitants in 1992. Physician visit for 
rhinitis decreased from 10% in 1988 to 8% in 1994 
(p<0.05), which was equivalent a reduction of 
public expenditure from 2.1 to 1.6 million Swedish 
crowns 
       Carlsten 
et al. 1996 
2 years 
before to 4 
years after 
reclassifica-
tion to non-
prescription 
availability 
Estimated 
national sales 
of medicines 
to the general 
public 
(unspecified 
data 
coverage) 
Sweden 16 drugs* 
(1980 – 1992) 
Number of 
defined daily 
doses (DDD) for 
prescription 
sales and for 
OTC sales 
An increase in OTC sale was observed in the 2 
years post-reclassification for all medicines studied 
except for oxymetazoline and sodium 
cromoglycate. The increase in sales ranged between 
12% and 307%. There was a 26% reduction in 
prescription sales for 12 out 16 medicines studied 
compared to their corresponding volume sold 2 
years prior to reclassification 
*Oxymetazolin (1981), hydrocortisone (1983), clotrimazole (1983), econazole (1983), miconazole (1983), lignocaine (1987), ibuprofen (1988), oxymetazolin 
(1989), xylometazolin (1989), loperamide (1989), nicotine (1990), sodium fluoride (1991), oestriol (1991), hydrocortisone-miconazole (1992), loratadine 
(1992), sodium cromoglycate (1992) 
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Medicines sales data for different therapeutic classes of drugs were utilised to 
examine the impact of medicine reclassification and medicines regulations in 
different countries. Of the seven studies relevant to the UK, three investigated 
the legal restriction on the sales of OTC paracetamol and salicylates in 1998. 
The study by Sheen et al. (2002) assessed the impact of legislation on sales of 
medicines only. It was found that while mass of aspirin and paracetamol sold 
fell, that of ibuprofen has increased during the two years following pack size 
restriction. The authors suggested the increase use of ibuprofen posed an 
additional risk for gastrointestinal (GI) adverse events and this could burden 
the healthcare services. 
 
By contrast, the two studies conducted by Hawton et al. (2001, 2004) assessed 
the sales of medicines in conjunction with other data related to paracetamol, 
salicylate and ibuprofen poisoning. The additional information aided the 
interpretation of medicine sales statistics. The results revealed there was 
reduction in sales of some but not all of the OTC paracetamol and salicylate 
preparations. The results of the 2001 study indicated a decline in both 
paracetamol and salicylates sold OTC but the 2004 study indicated the sales of 
OTC paracetamol have reverted back to its pre-legislative change level. Thus 
there may be differences in the short-term and long-term impact of pack size 
restriction on sales of OTC medicines.  
 
The other four UK-related studies investigated the impact of switching a 
medicine from POM to P status. Two of the studies (Deslandes et al. 2011; 
Walker and Hinchliffe 2010) examined the reclassification of an antibiotic. 
Deslandes et al. (2011) found there was a low level of sales for oral 
azithromycin following its availability OTC but noted that sales data from one 
pharmacy multiple in all areas studied were missing. Similarly, sales figures 
for OTC ophthalmic chloramphenicol reported in a study by Walker and 
Hinchliffe (2010) was thought to be an underestimate of the actual supply 
picture due to missing sales data. However, unlike OTC azithromycin, a 
substantial increase in OTC supply of ophthalmic chloramphenicol was 
reported following its reclassification. 
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The impact of the reclassification of omeprazole on the prescribing and sale of 
ulcer healing drugs was examined in a study by Dhippayom and Walker 
(2006). Although it was shown the reclassification of omeprazole probably had 
an impact on OTC sales of H2 antagonist, sales of OTC omeprazole were only 
monitored for 12 months post-reclassification. This length of follow-up may 
not have been long enough for the full impact of reclassification to be observed 
and assessed. Furler et al. (2002) examined the impact of switching H2 
antagonist to non-prescription status in the US, UK and Canada. Although the 
study successfully demonstrated a variation in prescription and non-
prescription drug utilisation between the three countries, changes in sales were 
reported in US dollar spent per capita and such was difficult to be compared 
with findings of other studies. 
 
Lundberg et al. (1999) utilised the sales data for OTC nasal sprays and 
investigated the impact of their reclassification to non-prescription status on 
the prescribing of nasal decongestants and physician visits. Against the 
backdrop of reductions in prescribing and physician visit for rhinitis and 
sinusitis over the study period, increase in OTC sales of nasal sprays indicated 
an extended use of OTC medicines following reclassification. A large number 
of medicines reclassified in Sweden were studied by Carlsten et al. (1996). 
Overall there was an increase in OTC sales following medicine reclassification. 
However, the OTC medicines sales data utilised in this study were derived 
from hospital and prescription sales of medicines, of which the prescription 
sales were calculated based on an inconsistent sampling ratio of prescription 
data over the study period. As a result, the reported sales statistics for OTC 
medicines may have been unreliable. 
 
Wirtz et al. (2013) studied the impact of prohibiting OTC sales of antibiotics in 
four Latin American countries. Using medicine sales data, the study 
successfully quantified the sales of selected antibiotics and found the policy 
interventions had an impact on overall antibiotic consumption in some but not 
all of the countries studied. However, in countries where there had been a 
reduction in antibiotic use, it was not known whether this was due to a fall in 
antibiotics dispensed on legitimate prescriptions or due to a fall in those that 
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were illegally purchased OTC. The authors recommended complementing the 
analysis with a qualitative study of the policy interventions to better understand 
the potential causes of differential effects. 
 
1.3.3.1 Summary of relevant literature 
In summary, OTC medicines sales data have been utilised to examine the 
impact of POM to P reclassification. Of those that were relevant to the UK, 
only one study has collected data for more than three years and examined the 
long-term impact of POM to P switch of a reclassified medicine (Walker and 
Hinchliffe 2010). In the present study, the long-term impact of POM to P 
reclassification for ophthalmic chloramphenicol will be investigated. 
 
There were fewer studies that examined the effect of increased regulation on 
medicine utilisation. Of those that were reviewed, three out of four studies 
were related to the pack size restriction of non-prescription paracetamol and 
aspirin. Other therapeutic classes of OTC medicine that have recently 
undergone legal restriction changes in the UK have not been studied. This will 
be another focus of the current study which will investigate the impact of 
increased OTC medicine regulation on the OTC sales and prescribing of 
selected medicines. 
 
1.4 Disease surveillance 
There are a number of infectious diseases of interest to public health and which 
have the potential to be linked to the sale of OTC medicines. Some examples 
include: diarrhoea caused by norovirus and cryptosporidium (both linked to the 
sale of anti-diarrhoeal and rehydration products), headlice (linked to sales of 
insecticides), upper respiratory tract infections caused by influenza (linked to 
sales of cough and cold remedies) and infective conjunctivitis (linked to sales 
of ophthalmic anti-infectives). It has been suggested, therefore, monitoring the 
sales of these medicines may be of potential value to the surveillance of 
diseases and their outbreaks in the community (Health Protection Agency 
[HPA] 2010a). 
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On occasions community pharmacists may be the first healthcare professional 
to be aware of an emerging, local, public health issue. Their close contact with 
the local community and involvement in the sales of selected OTC medicines 
puts them in this unique position. They are, however, rarely in a position to 
capitalise on this because they may be unaware of what is happening in the 
surrounding areas and the public health implications of a shift in sales. It is by 
aggregating data from a number of pharmacies and working with a public 
health resource that the full public health implications may become apparent. 
 
The utilisations of medicines sales data for disease surveillance and outbreak 
detection have been advocated in the UK (Jones 2009; Public Health Institute 
of Scotland 2003; HPA 2010a; Walker 2000). However, the role of community 
pharmacy in this area of public health protection appears to be minimal in the 
UK (Agomo 2011). In the next section, the utilisation of medicines sales data 
in infectious disease surveillance and outbreak detection will be reviewed. 
 
1.4.1 Review of relevant literature 
English language articles were identified in Medline and Embase searches (via 
Ovid) between January 1996 and July 2013 using the following search terms ($ 
indicate truncation): 
 
* behind-the-counter or over-the-counter or OTC or non-prescription 
    Total hits: 17,574 
         
* infect$ or outbreak$ or pandemic$ or epidemic$ or disease$ or illness$ 
    Total hits: 6,834,717 
     
* biosurveillance or surveillance or monitor$ or detect$ or syndromic 
    Total hits: 3,055,984 
 
* sale$ or wholesale$ or suppl$ or retail$ 
    Total hits: 553,683 
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The search terms were searched in the following search fields: title, abstract, 
medical subject heading, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword and name of 
substance word. Boolean operator (‘and’) was used to combine the search 
results and revealed a total of 131 articles.  
 
After screening each article by title and/or abstract, 22 articles were identified 
as relevant to OTC medicines sales data and infectious disease or outbreak 
surveillance. The full texts of the 22 articles were examined to identify those 
with a similar study design and aim to the present study. 
 
Of the 22 articles identified, 6 articles focused on the description, design, 
implementation and experience of disease surveillance system that involved 
OTC medicines sales data. Another 6 articles were methodological papers that 
examined the statistical and analytical procedures relating to OTC medicines 
sales data and disease surveillance. The remaining 10 articles that utilised OTC 
medicines sales data for the monitoring of infectious diseases or detection of 
disease outbreaks in the community were included in the review (Table 1.2). 
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Table 1.2 Studies utilising medicines sales data to monitor or detect outbreaks of infectious diseases in the community 
 
Source Study duration Sample Setting 
Medicine 
monitored 
Comparison 
disease 
indicator 
Outcome 
Liu et al. 
2013 
13 months 
(July 2010-
2011) 
Retail outlets 
enlisted in the 
National Retail 
Data Monitor 
database cover 
33% of total 
OTC product 
sales 
nationwide 
Pittsburgh, 
US 
Anti-fever, 
cough and 
cold, chest 
rubs, 
electrolyte 
paediatric, 
throat 
lozenges 
Number of 
patients with 
influenza-like 
illness* (ILI) 
presenting at 
an urgent care 
centre 
Over the entire study period, cough and cold 
medicines (r2=0.39) and chest rubs (r2=0.37) 
sales were most strongly associated with ILI 
patient volume (all p<0.0001). Results from 
timer series modelling suggest changes in the 
sales of cough medicines preceded the changes 
in patient volume by two day during the flu 
season and showed the strongest positive 
correlation out of all of the medicines studied 
(cross-correlation=0.41, p<0.05) 
       Sočan et 
al. 2012 
3 years 
(December 
2006-2009) 
Medicines 
supplied by a 
pharmaceutical 
company 
(Gorenjske 
lekarne) to 13 
municipalities 
in northern 
Slovenia 
Slovenia Nasal 
decongestants, 
medicines for 
sore throat, 
antitussives, 
mucolytics 
Incident rate of 
ILI (clinical 
symptoms: 
malaise, 
headache, 
myalgia, sore 
throat, cough, 
shortness of 
breath) 
Curve for the sales of mycolytics and 
antitussive best matched with the curve of ILI 
incidents. Poisson regression model created 
based on i) total sales of all four medicines and 
ii) weighted combination of sore throat, nasal 
decongestants and mycolytics sales predicted 
the increase in ILI incident rate during the 12 
months testing period (week 49/2006-week 
39/2007) 
*Pharyngitis, upper respiratory infections, laryngitis; sinusitis, cough, viral syndrome, pneumonia, otitis media, conjunctivitis, bronchitis and flu as defined by 
ICD-9 disease code  
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Table 1.2 (continued) Studies utilising medicines sales data to monitor or detect outbreaks of infectious diseases in the community 
 
Source Study duration Sample Setting 
Medicine 
monitored 
Comparison disease 
indicator Outcome 
Kirian et 
al. 2010 
4 years 
(July 2003-
2007) 
Retail outlets 
enlisted in the 
NRDM 
database 
covering 47% 
of retail outlets 
during 2005-
2007 
San 
Francisco 
Bay area, 
US 
Diarrhoeal 
remedies 
(bismuth, 
attapulgite, 
subsalicylates
, loperamide) 
Number of 
gastrointestinal (GI) 
cases, number of 
diarrhoeal outbreaks 
(all-cause and 
Norovirus outbreak); 
number of outbreak-
related cases 
No significant correlation was found 
between non-prescription sale of the 
selected anti-diarrhoeal remedies and 
diarrhoeal cases (none exceeded 95% 
confidence interval), nor was the 
sales association with numbers of 
diarrhoeal-related outbreaks or 
number of outbreak-related cases per 
week (for both all-cause outbreaks 
and Norovirus cause outbreaks) 
       Edge et al. 
2006 
3 years 
(April 
2001-2004) 
19 pharmacies, 
representing 
53% of the 
provincial 
population and 
12% of all 
pharmacies in 
the study area 
Unknown 
province, 
Canada 
Antinauseant 
and 
antidiarrhoeal 
products 
Number of GI cases 
due to bacteria 
(Samonella, 
Campylobacter, E. 
Coli, Shigella, 
Yersinia), parasites 
(Cryptosporidium, 
Entamoeba, Giardia) 
and viruses 
(Norovirus, Rotavirus) 
Over the entire study period, the 
highest correlation was observed 
between sales of antinauseant and 
antidiarrhoeal and counts of 
Norovirus cases (r2=0.44) but sales 
data provided no earlier detection. 
Significant increases in the sales of 
medicines coincided with significant 
increase in cases of Norovirus 
infections in the winter of 2002/03 
and 2003/04 (all p<0.05) 
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Table 1.2 (continued) Studies utilising medicines sales data to monitor or detect outbreaks of infectious diseases in the community 
 
Source Study duration Sample Setting 
Medicine 
monitored 
Comparison disease 
indicator Outcome 
Das et 
al. 2005 
2 years and 
7 months 
(August 
2002-March 
2005) 
One large 
pharmacy 
chain 
(unspecified 
data 
coverage) 
New 
York 
City, 
US 
ILI medicines 
(products with 
text strings of 
‘flu’ or ‘tussin’ in 
product name); 
antidiarrhoeal 
medicines 
Ratio of 
fever/influenza-like 
syndrome to other 
syndrome visits to 
emergency 
department (ED); 
ratio of diarrhoea 
syndrome to other 
syndrome visits to 
ED  
Non-prescription sales of ILI medicines 
positively correlated with ED visits of 
fever/influenza-like syndrome (r2=0.60, 
p<0.001). During the 2003/04 influenza 
season, sales of ILI medicines exceeded 
above 95% confidence limit 2 to 3 weeks 
before the increase in ED fever/influenza 
like visits. A weaker positive correlation 
was observed between sales of 
antidiarrhoeal medicines and diarrhoeal 
related ED visits (r2=0.24, p<0.005) 
       Ohkusa 
et al. 
2005 
6 months 
(November 
2003-April 
2004) 
A 
nationwide 
sample of 
1,100 
pharmacies 
representing 
2% of all 
pharmacies 
in Japan 
Japan Common cold 
medicines 
(antipyretics, 
antitussives, 
expectorants, 
exogenous 
enzyme, 
bronchodilator, 
antihistamines, 
vitamins, herbal 
products)  
Number of influenza 
outpatients from 
national surveillance 
scheme; ILI cases 
from selected 
medical institutions; 
number of influenza 
diagnosis by a 
volunteer sample of 
paediatricians  
Pattern for the sale of OTC common cold 
medicines was dissimilar to that of 
influenza and ILI activity reported by all 
three surveillance systems between 
December and January. A sales peak was 
observed in early February and the onset 
preceded the peak ILI activity recorded by 
selected medical institutions by 1-2 weeks, 
and coincided peak ILI activity reported by 
the national surveillance scheme and 
volunteer sample of paediatricians 
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Table 1.2 (continued) Studies utilising medicines sales data to monitor or detect outbreaks of infectious diseases in the community 
 
Source Study duration Sample Setting 
Medicine 
monitored 
Comparison 
disease indicator Outcome 
Magruder 
et al. 2004 
1 years and 
5 months 
(September 
2001-
January 
2003) 
300 drug 
stores in the 
study areas 
(unspecified 
data 
coverage) 
Maryland, 
Washington 
DC, Virginia, 
US 
Influenza 
remedies 
Number of 
physician 
diagnosis of acute 
respiratory 
disease 
After correcting for annual cycle and day-
of-the-week effect associated with both 
medicine sales and physician diagnostic 
data, a positive correlation between OTC 
sales of influenza remedies and physician 
diagnoses of acute respiratory diseases was 
observed in all regions studied (r value 
ranged from 0.25 to 0.75). Changes in the 
sales of influenza remedies preceded 
changes in physician diagnoses in 2 out of 
6 regions studied (up to 3 days). No early 
detection or a delayed detection of acute 
respiratory disease was observed in 4 other 
study regions (up to 8 days)  
       Hogan et 
al. 2003 
4 years 
(1998-2001) 
Sample of 
pharmacies 
and general 
retail outlets 
with over 
90% market 
share 
Harrisburg, 
Indianapolis, 
Philadelphia, 
Pittsburgh, 
Salt Lake 
City and 
Scranton, US 
Electrolyte 
products 
Hospital 
discharge 
diagnosis of 
respiratory and 
diarrhoeal 
diseases* in 
children (<5 years 
old) 
A strong correlation between electrolyte 
sales and hospital diagnoses of respiratory 
and diarrhoeal disease (r=0.90, 95% CI, 
0.87-0.93) was observed for the 18 
outbreaks in the study period. On average, 
changes in the sales of medicine preceded 
changes in number of hospital diagnosis by 
1.7 to 2.5 weeks 
*Pneumonia, influenza, bronchiolitis caused by respiratory syncytial virus and other causes, rotavirus gastroenteritis, and all-cause paediatric gastroenteritis  
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Table 1.2 (continued) Studies utilising medicines sales data to monitor or detect outbreaks of infectious diseases in the community 
 
Source Study duration Sample Setting Medicine monitored 
Comparison disease 
indicator Outcomes 
Edge et al. 
2003 
4 months for 
Battfords 
outbreak 
(February-May 
2002); 24 months 
for Walkerton 
(January 1999-
Decemember 
2000) 
1 out of 3 
pharmacy in 
Battlefords; 1 
out of 6 
pharmacies in 
Walkterton 
Battlefords, 
Saskatchewa
n, Canada; 
Walkerton, 
Ontario, 
Canada 
Antinauseant 
and 
antidiarrhoeal 
products 
Number of acute 
gastrointestinal (GI)-
related visits to ED; 
Number of GI-
illness; Number of 
vomiting/diarrhoea 
visits to ED; number 
of outbreak-related 
cases 
Increase in OTC medicine sales 
coincided with a rise in ED 
visits and outbreak-related 
cases during both of the 
outbreaks. The quantity of 
selected OTC medicines sold 
exceeded above 3 standard 
deviations upper limit 13 days 
after onset of the diarrhoeal 
outbreak in Walkerton 
       
Goldenberg 
et al. 2002 
6 months (August 
1999-January 
2001) 
A major 
retailer chain 
(unspecified 
data 
coverage) 
Allegheny 
County, 
Pennsylvania, 
US 
Cough 
medicines 
Not applicable (the 
outbreak tested was 
simulated based on 
the mortality data of 
a historical anthrax 
outbreak which was 
used to estimate the 
change in OTC 
sales)  
Cough medicines sales data was 
unable to detect the anthrax 
outbreak within 3 days of onset 
but may be possible if more 
people were involved the 
outbreak. Sales data was also 
unable to detect onset of local 
influenza epidemic during the 
study period in Allegheny 
County 
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The majority of the studies reviewed were conducted in the US population and 
notably no study was conducted in the UK. Respiratory and GI-related 
infections have emerged as the two most extensively studied areas in terms of 
disease surveillance involving OTC medicines sales data. There were five 
papers on the monitoring of respiratory infections, four papers on GI-related 
infections and one paper on the detection of anthrax outbreak. 
 
1.4.1.1 Respiratory infections 
OTC medicines monitored in the studies reviewed were predominantly 
indicated for the symptoms of upper respiratory tract infections (URTI). A 
wide range of OTC products were implicated, including anti-fever, nasal 
decongestion, sore throat lozenges, cough medicines and chest rubs. In one 
particular study, sales data for herbal products, vitamins and enzyme 
supplements were also utilised (Ohkusa et al. 2005). Another study utilised the 
sales of OTC electrolyte products to monitor the combined incidence of 
respiratory as wells diarrhoeal diseases in children (Hogen et al. 2003). For 
some of the studies reviewed, the source and completeness of the medicines 
sales data in relation to the study population were not described (Das et al. 
2005; Magruder et al. 2004). 
 
Sales of OTC medicines were compared with a variety of reference data for 
which were used as indicators for disease or outbreak activity. For example, 
volumes of patient with influenza-like illness (ILI) presenting at secondary 
care (Liu et al. 2013) or emergency care services (Das et al. 2005) have been 
used. Magruder et al. (2004) utilised the number of physician diagnoses of 
acute respiratory diseases. Ohkusa et al. (2005) and Sočan et al. (2012) made 
use of numbers of influenza and ILI cases in the study population that were 
recorded by routine influenza surveillance schemes. 
 
The results from most of the studies suggest sales of common OTC cough, cold 
and flu medicines positively correlated with the indicators of ILI and influenza 
activity (Das et al. 2005; Liu et al. 2013; Magruder et al. 2004). This 
association potentially allows non-prescription medicines sales data to serve as 
an additional tool for respiratory disease surveillance. In one study, however, 
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sales data for medicines supplied both on prescriptions and sold OTC were 
aggregated to monitor ILI activity (Sočan et al. 2012). A time-dependent 
relationship between sales of medicines and ILI activity has been reported. 
This was found in a study by Liu et al. (2013) as the strength of the correlation 
between medicine sales and ILI activity varied with the time point of the flu 
season (pre-, during or post-flu season). Similarly, in another study, Ohkusa et 
al. (2005) observed a persistent mismatch between OTC sales of cold remedies 
and influenza activity as reported by three influenza surveillance systems 
during the early influenza season. The variation in association between sales of 
OTC medicine and disease indicators between the various studies may be 
attributed to the differences in OTC medicines monitored, disease indicators 
used, circumstance of the outbreak and/or the modelling methods used. 
 
Several studies also investigated the whether OTC medicines sales data were 
capable of providing an earlier warning for indicators of respiratory diseases. 
The results from the studies suggest there was a lack of consistency in the early 
detection capability of medicines sales data for ILI. For example, a study by 
Liu et al. (2013) found a change in the sales of cough and cold medicines 
preceded changes in ILI patient volume by 2 days during flu season but such 
was not observed in the post-flu season. Das et al. (2005) found increase in 
sales of selected cold medicines began 2-3 weeks earlier than fever/influenza-
like visits to emergency department but this was only observed for one out of 
the three winter seasons studied. In a study by Magruder et al. (2004), the early 
signal generated from the sales of influenza medicines for an increase in 
physician diagnosis of acute respiratory diseases was only demonstrated in one 
out of the six regions studied. The absence of a consistent pattern indicates the 
early detection value of OTC medicines sales data for ILI and/or influenza may 
not be universal. 
 
1.4.1.2 Gastrointestinal-related infections 
The monitoring of GI-related infectious diseases and detection of outbreaks 
have been studied using the sales data of a range of OTC anti-diarrhoeal, anti-
nauseant and electrolyte products. However, of the four studies reviewed (Edge 
2006, 2003; Hogan et al. 2003; Kirian et al. 2010) only the study by Kirian et 
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al. (2010) specified the products that constituted antidiarrhoeal remedies. 
Multiple disease indicators have been used, including numbers of hospital 
discharge diagnoses of respiratory and diarrhoea diseases (Hogan et al. 2003), 
volume of GI-related visits to emergency department (Edge et al. 2003) and 
GI-related disease case data obtained from public health departments (Edge et 
al. 2006; Kirian et al. 2010). Three of the studies utilised medicines sales data 
to detect the occurrence of known outbreaks (Edge et al. 2003; Hogan et al. 
2003; Kirian et al. 2010) and one study correlated sales with reportable GI-
related infections (Edge et al. 2006). 
 
The results from the studies reviewed indicated mixed results for the use of 
OTC medicine sales data in surveillance of GI-related diseases. A study by 
Hogan et al. (2003) found that the sales of OTC electrolyte products positively 
correlated with the number of hospital diagnoses of combined respiratory and 
diarrhoeal diseases in children. In the same study, sales of medicines indicated 
an early detection potential by preceding the disease signal generated by the 
hospital diagnoses by 1.7 to 2.5 weeks. However, the relationship between 
sales of electrolyte products and respiratory/diarrhoeal diseases in children was 
based on authors’ unpublished work. Whether this relationship would hold for 
other populations is not clear. 
 
In another study that involved two waterborne outbreaks (Edge et al. 2003), 
increases in sales of OTC anti-nauseant and anti-diarrhoeal products coincided 
with an increase in number of outbreak-related GI cases. For one outbreak the 
increase in sales exceeded the upper statistical threshold two weeks after the 
start of the outbreak. However, the relationship between medicine sales and the 
disease indicators (number of GI-related cases and ED visits) was only 
presented with descriptive figures and no statistical analysis was undertaken. 
 
The study by Kirian et al. (2010) did not find a significant correlation between 
sales of anti-diarrhoeal medicines and diarrhoea illness case counts, outbreak 
counts, or the number of outbreak-associated cases. In this study, the authors 
concluded the findings did not support the implementation of a GI outbreak 
surveillance system with the medicines sales data that were utilised. 
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Edge et al. (2006) investigated the relationship between sales of OTC anti-
diarrhoeal and anti-nauseant medicines and number of GI-related cases due to 
bacteria, parasites and viruses. It was found sales significantly and positively 
correlated with cases of Norovirus infections but not with either case of 
bacterial or parasitical infections. The finding suggests that medicine sales data 
may serve to be a supplemental tool for the virological surveillance of 
Noroviruses in the community. However, the relationship observed between 
sales of OTC anti-diarrhoeal and anti-nauseant medicines and Norovirus cases 
may be limited only to the population studied. 
 
Overall, there is conflicting evidence for and against the use of OTC medicines 
sales data in monitoring GI-related disease and/or outbreaks. Given each of the 
studies was unique, in terms of the disease indicators used, products monitored, 
outbreak setting and analytical method used, the generalizability of the findings 
of each of the studies were limited. 
 
1.4.1.3 Anthrax outbreak 
One early study investigated the potential of OTC cough medicines sales data 
in identifying a hypothetical anthrax outbreak (Goldenberg et al. 1999). The 
products monitored and the completeness of the medicines sales data were both 
undefined. Unlike the other studies mentioned previously, no comparison 
disease indicator data was used. Instead, changes in the sales of OTC cough 
medicines were statistically simulated based on data obtained from a previous 
anthrax outbreak, which occurred in an area different from where the cough 
medicines sales data was collected. The hypothetical nature of the study 
limited the generalizability of the results although it showed sales of OTC 
cough medicines may be sensitive to a large scale outbreak of anthrax. 
 
1.4.1.4 Summary of relevant literature 
In summary, the potential of medicines sales data for the surveillance of ILI 
and GI-related diseases has been demonstrated. However, many elements of 
the study design and the study settings varied from study to study. This 
reflected the difference in availability of surveillance information in different 
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countries and the pattern of medicines utilisation in different populations. 
These variabilities limited the generalizability of any findings. 
 
Two notable points were gathered from the studies reviewed. Firstly, no study 
has yet utilised medicines sales data to monitor the occurrence of eye 
infections in the community despite ophthalmic anti-infective preparations 
having been available OTC for many years. Secondly, the experience and use 
of OTC medicines sales data for the monitoring either GI-related or respiratory 
infections have not been reported for the UK population. These will form the 
basis of the present study which will focus on utilising OTC medicines sales 
data to identify outbreak of a common eye infection in the community and also 
for the surveillance of seasonal influenza in a UK population. 
 
1.5 Study aims 
The aims of the present study were to explore the application of OTC medicine 
sales data in (a) evaluating the impact of increased regulation and medicine 
reclassification on the volume of selected medicines prescribed in primary care 
and their sales OTC from community pharmacy, and (b) in the detection of 
infective conjunctivitis outbreaks and surveillance of seasonal influenza in 
Wales. 
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Impact of regulatory changes on supply of codeine and 
dihydrocodeine analgesics 
 
2.1 Introduction 
 
2.1.1 Analgesics containing codeine and dihydrocodeine 
Adult oral analgesics have the largest total market value of over-the-counter 
(OTC) medicines sold in the United Kingdom (UK) and is estimated to be 
worth over £370 million in 2009 (Proprietary Association of Great Britain 
[PAGB] 2011a). Studies have found they are the most commonly used OTC 
medicines among the UK population (Hanna and Hughes 2011; Porteous et al. 
2005; Urquhart et al. 2004) and many people keep home supplies of non-
prescription analgesics to self-manage pain (Wazaify et al. 2005). The high 
levels of non-prescription analgesic use reflect the findings that pain is one of 
the most common symptoms experienced in the UK adult population (McAteer 
et al. 2011). 
 
A wide range of non-prescription oral analgesics are available for OTC 
purchase in the UK and they can be sold either as General Sales List (GSL) 
medicines or Pharmacy (P) medicines. Analgesics sold as GSL medicines 
consist predominantly of three active ingredients, namely paracetamol, aspirin 
and ibuprofen. These GSL products are widely available from any retail outlets 
in small pack sizes typically less than 16 tablets per pack (Royal 
Pharmaceutical Society [RPS] 2011a). In contrast, oral analgesics that fall 
under the P medicine category are only obtainable from pharmacies. These 
products could contain the same active ingredient as analgesics in the GSL 
category but are available in larger pack sizes, or they could contain a drug that 
used to be a prescription-only medicine (POM) that was subsequently 
reclassified to a P medicine. Compound analgesics containing multiple active 
ingredients with a weak opioid are also classified as P medicines and are 
widely available from pharmacies. 
 
Codeine phosphate and dihydrocodeine (DHC) tartrate are both classified as 
weak opioids (World Heath Organization [WHO] 1996) and they can be found 
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in many OTC oral analgesics sold in the UK (Chemist and Druggist 2008). 
Whereas codeine can be found in a number of non-prescription medicines 
indicated for diarrhoea and coughs, the only indication of DHC is for pain 
(British National Formulary [BNF] 2013; Chemist and Druggist 2008). Under 
the Misuse of Drugs Act 1971, both codeine and DHC are classified as a class 
B controlled drug but they are permitted to be sold without a prescription in 
doses up to 25.6mg for codeine and 14.92mg for DHC (Medicines and 
Healthcare product Regulatory Agency [MHRA] 2009a). At the time of 
writing, OTC products containing codeine or DHC are only available as P 
medicines and not as GSL medicines. Therefore, although the term ‘OTC 
medicine’ has been used to refer to medicines under both the GSL and the P 
category (RPS 2011a); in the current study it is used to refer to the P medicine 
category which all non-prescription codeine and DHC containing preparations 
fall under. 
 
Codeine and DHC are commonly used as painkillers and their conversions to 
morphine and dihydromorphine in the liver are believed to be responsible for 
their analgesic effects in humans (Sweetman 2007). Codeine and DHC are both 
frequently prescribed on prescriptions in the UK (National Treatment Agency 
for Substance Misuse [NTA] 2011) and are either used alone or in conjunction 
with a non-opioid analgesic, such as paracetamol or ibuprofen (Knaggs and 
Hobbs 2012). According to the BNF (2013), codeine is indicated for mild to 
moderate pain taken orally at a dose of 30 to 60mg every 4 hours as required 
and DHC is indicated for moderate to severe pain taken orally at a dose of 
30mg every 4 to 6 hours when required. The WHO recommends codeine and 
DHC to be used in step two of the WHO analgesics ladder, which is the 
intermediate stage between a non-opioid analgesic, such as a non-steroidal 
anti-inflammatory drug (NSAID), and a strong opioid, such as morphine 
sulphate (WHO 1996). 
 
In the UK, codeine and DHC containing analgesics are not available for sale 
OTC as a single ingredient product. Instead, they are only sold in multi-
ingredient formulations combined with a non-opioid analgesic, namely 
paracetamol, ibuprofen or aspirin (Chemist and Druggist 2008). As of 2009, 
 35 
there were 42 non-prescription analgesics available OTC containing codeine 
and four products containing DHC (MHRA 2009a). Of the 42 codeine 
containing products, 36 were combined with paracetamol, two were combined 
with ibuprofen and four were combined with aspirin. The four DHC containing 
products were all combined with paracetamol (MHRA 2009a). Prior to a 
change in relevant legislations in 2009 (discussed in Section 2.1.3), these 
combined multi-ingredient painkillers had been marketed in the UK for a 
variety of mild to moderate pain, including headache, migraine, toothache, 
period pains and also for the relief of rheumatic pain, muscular aches and joint 
pains (Chemist and Druggist 2008). 
 
Compound oral analgesics sold OTC contain a lower amount of codeine and 
DHC compared to some of those available on a prescription. For example, a 
total quantity of 8mg to 12.8mg of codeine phosphate can be found per tablet 
in an OTC preparation, whereas between 8mg and 30mg can be found in a 
POM. The amount of DHC tartrate in an OTC preparation is usually 7.46mg 
per tablet, whereas in a POM between 10mg and 30mg can be found. Tablets 
containing even higher quantities of codeine or DHC up to 60mg as a single 
ingredient preparation can also be obtained on a prescription (BNF 2013). The 
efficacy of low dose codeine and DHC found in OTC products has been 
questioned in the past (Dickman 2008) and the BNF (2013) states that at these 
low doses (8mg codeine per compound tablet) they may not provide significant 
additional pain relief in comparison to using paracetamol or ibuprofen alone. A 
recent review of the literature also found there was little evidence to support 
the use of low dose compound analgesics containing opioids over non-opioid 
analgesics (Moore et al. 2010). 
 
Despite the low content of codeine and DHC found in OTC compound 
analgesics, the opioid component of these preparations are known to cause a 
number of side effects that are not normally associated with a non-opioid 
analgesic (BNF 2013). The side effects include nausea, vomiting, constipation 
and drowsiness. Furthermore, one particular concern associated with the use of 
OTC opioid analgesics is the risk of developing dependence after prolonged 
consumption (NTA 2011; Reed et al. 2011). In the next section, various aspects 
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relating to the inappropriate use of OTC analgesics containing codeine or DHC 
will be discussed. 
 
2.1.2 Misuse and abuse of Over-the-Counter medicines 
The term misuse and abuse are often used interchangeably in relation to a 
medicine but a clear distinction between them should be made. Misuse has 
been defined as “the use of drugs for medical purposes but in an incorrect 
manner” and abuse has been defined as “the use of drugs for non-medical 
purposes” (Hughes et al. 1999). The definition of misuse refers to scenarios 
such as a medicine not suited for long term use being taken for a extended 
period of time or outside the recommended dosage; such can apply to all 
medicinal products. Reasons cited for non-compliance of instruction for taking 
an OTC medicine include: attempt to enhance the medicinal effect 
(Blenkinsopp and Bond 2005), not read the package labels, medicine did not 
work within the expected period of time (Wazaify et al. 2005) and perceived 
fewer and less serious consequences associated with non-compliance for an 
OTC medicine (Bower et al. 2012). In contrast, the definition of abuse has 
been used to describe situations where a medicine is deliberately used outside 
its licensed indication to exploit the pharmacological effect of a drug, often for 
non-medical reasons. Certain OTC medicines have been found to be associated 
with a greater risk of abuse than others (Blenkinsopp and Bond 2005). 
 
In the UK, non-prescription medicines containing laxatives, sedative 
antihistamines, sympathomimetics and opioids are often implicated in 
problems associated with medicine misuse and/or abuse (Cooper 2011, 2013a, 
2013b). In particular, community pharmacists cited compound analgesics 
containing weak opioids to be the category of OTC medicines most commonly 
misused and/or abused by the general public (Hughes et al. 1999; MacFadyen 
et al. 2001; Matheson et al. 2002; Pates et al. 2002; Wazaify et al. 2006). 
Concerns regarding the misuse and/or abuse of OTC opioids have also been 
raised by the medical profession in the UK (Ford and Good 2007a, 2007b; 
Ferner and Beard 2008; Royal College of General Practitioners 2013). These 
concerns were prompted by adverse patient reports that involved chronic, 
excessive ingestion of non-opioid analgesics, often caused by ibuprofen taken 
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together at the same time in a compound analgesic containing codeine or DHC. 
Serious morbidities resulting from chronic overdose of these products, such as 
gastric ulcers and renal toxicity, have been documented in the medical 
literature (Dutch 2008; Frei et al. 2010; McDonough 2011; Medani et al. 2010; 
Ng et al. 2011; Robinson et al. 2010). In addition to the concerns raised by 
healthcare professionals, individual case reports of fatality and adverse patient 
outcomes due to inappropriate use of OTC compound analgesics containing 
opioids also appeared in the general media and attracted wide spread attention 
from the public (Anon. 2012a; Bunyan 2007; Martin 2007; Morton and 
Wighton 2009).  
 
A number of studies and government inquiries have been conducted in the UK 
to investigate the problem associated with the misuse and/or abuse of OTC 
medicines containing codeine and DHC. However, the prevalence of misuse 
and/or abuse of these preparations among the UK population remain unknown 
(All-Party Parliamentary Drug Misuse Group [APPDMG] 2009; Cooper 2011, 
2013a; MHRA 2006; NTA 2011). One estimated figure was provided by a UK-
based, online support group, Over-Count, which estimated 16,000 people were 
dependent on an OTC medicine (APPDMG 2009); a survey of the support 
group users revealed 95% of respondents reported having problems with OTC 
analgesics containing either codeine or DHC (Grieve 2009). 
 
An alternative data source that might indicate the scale of the problem is the 
substance misuse treatment data collected by drug treatment services. Such 
data indicate that in England there has been a year-on-year increase in the 
number of people seeking treatment for addiction to OTC opioids between 
2005 and 2010 (NTA 2011). The data for Wales over the same period also 
show there had been a steady number of treatment referrals each year (92 to 
135 referrals per year) for individuals suffering from addiction to weak opioids 
(Welsh Government, personal communication). 
 
Whilst these treatment data suggest a problem relating to misuse and/or abuse 
of OTC opioids potentially exists in the UK, affected individuals commented 
that these specialist treatment services are not suited to their needs and may be 
 38 
under utilised (Cooper 2011, 2013c). Consequently, such data may only 
provide a partial assessment of prevalence. Furthermore, the covert nature 
associated with OTC medicines misuse and/or abuse, the lack of patient 
support and clearly defined treatment pathway for those who are affected 
(APPDMG 2009; Cooper 2011; 2013b, 2013c; NTA 2011) further add to the 
difficulty in identifying and monitoring the scale of the problem. 
 
2.1.3 Sales of Over-The-Counter codeine and dihydrocodeine containing 
analgesics 
To address the concern relating to opioid containing analgesics and their risks 
of dependence, various legislative and non-legislative regulatory changes 
affecting the non-prescription availability of these products were introduced in 
the UK. 
 
The MHRA is the government agency responsible for regulating the 
effectiveness and safety of human medicines and medical devices in the UK. In 
2005, the MHRA considered the issues surrounding the non-prescription 
availability of codeine and DHC containing analgesics in light of reports of 
dependence through regular consumption (Anon. 2004; MHRA 2006). At the 
time, evidences obtained during the inquiry indicated there was a low rate of 
adverse events against a backdrop of large numbers of OTC sales (MHRA 
2006). Consequently, the inquiry concluded the problem associated with 
misuse and or/abuse of codeine and DHC containing analgesics was not 
extensive among the UK population and considered their continued availability 
to be appropriate. Nonetheless, several non-legislative changes regarding OTC 
sales of analgesics containing opioids were introduced in 2005 via a voluntary 
agreement between the MHRA and the medicine manufacturers (MHRA 
2005a, 2006): 
 
• Warnings about the risks of codeine and DHC addiction and medicine 
overuse headaches were to be added to the Summery of Product 
Characteristics (SPC) and Patient Information Leaflet (PIL) 
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• All codeine and DHC containing OTC products to be limited to a 
maximum pack size of 32 tablets by voluntary agreement with the 
manufacturers 
• Where large pack of these products is justifiable, such as for dispensing 
purposes, it is labelled and used for this purpose only 
• Sales promotion of these products to be handled with care and 
manufacturers should adopt a responsible approach to the sales of these 
products 
 
At the time of announcement of these measures, only large packs of analgesic 
containing codeine and paracetamol in the effervescent form (56, 60, 84, 90, 
100 tablets pack sizes) was affected by the pack size restriction. However, 
since there was no change in legislation these large packs continued to be 
available and were still being sold as a P medicine despite being labelled as for 
dispensing use only (MHRA 2009b). In addition to the aforementioned 
changes, the then professional regulator of pharmacists in the UK, the Royal 
Pharmaceutical Society of Great Britain (RPSGB), also published a 
professional guidance for pharmacists in supporting these measures. In this 
document it urged pharmacists that no more than one pack of opioid containing 
product, regardless of pack size, should be sold per transaction for non-
prescription use (RPSGB 2007). 
 
In early 2009, a report by the APPDMG (2009) was published following a two-
year inquiry into the problem relating to misuse and abuse of prescription and 
OTC medicines. In relation to OTC medicines, evidence and views submitted 
by individuals, professional groups and treatment services on the subject were 
examined as part of the inquiry. The report concluded that, among other 
recommendations, there was a need for a better awareness about the addiction 
potentials of codeine and DHC in OTC preparations. Furthermore, it was 
considered that a tougher restriction on pack size, promotion and stronger 
warning were warranted. As a consequence, mandatory measures via 
legislative changes were introduced in September 2009 and affected the sales 
of all non-prescription analgesics containing codeine and DHC (MHRA 
2009a). 
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These measures include: 
 
• Prominent labels displayed on the front of the pack stating codeine and 
DHC can cause addiction and these medicines are for three days use 
only  
• Prominent labels displayed on the back of the pack warning against use 
longer than three days that may cause medicine overuse headaches 
• Removal of indications relating to colds, influenza, cough, sore throats 
and reference to minor pain conditions from the SPC 
• Explicitly state in the PIL the indication, duration of treatment, risks of 
addiction and medicines overuse headaches related to these medicines 
• A dedicated section in the PIL to warn about the signs and symptoms of 
addiction and the need to seek medical intervention 
• All pack sizes greater than 32 tablets of codeine or DHC containing 
OTC medicines in solid dose form, including effervescent formulations, 
will no longer be available as P medicines but as POMs 
• The advertising and promotion code of practice for these products 
updated to reflect new indications and warnings against addiction and 
prolonged use 
 
At the time of announcement of these measures in September 2009, changes 
such as wording on the packaging and enclosed PIL could not be implemented 
immediately due to the time required to deplete the then available stock. 
However, measures such as restricting the sales of all codeine and DHC 
containing products to a maximum pack size of 32 tablets (including the 
effervescent formulations) were implemented immediately (Anon. 2009a). 
 
2.1.4 Recent findings 
The intentions behind the legislative changes implemented in 2009 were to (a) 
raise awareness about the misuse and abuse potentials of codeine and DHC 
containing products among the general public and healthcare professionals, and 
(b) reduce the likelihood of users inadvertently becoming addicted to these 
medicines by restricting their OTC pack size to prevent prolonged self-
medication. However, whether or not MHRA’s regulatory effort has had an 
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impact on the sale of OTC analgesics containing codeine or DHC was not 
known.  
 
In a recent study, experience reported by users who are dependent to OTC 
codeine and DHC containing products indicate obtaining supplies from 
community pharmacies have been unproblematic despite an increase in 
regulation (Cooper 2011). Strategies employed by individuals to prevent 
suspicion of misuse and/or abuse included making purchases from multiple 
pharmacies, rehearsing responses to questions asked by pharmacy staff or 
selectively visit pharmacies where they are less likely to be challenged (Cooper 
2011, 2013c). Consequently, the successfulness of 2005 and 2009 regulatory 
changes relating to OTC sales of codeine and DHC containing analgesics in 
preventing deliberate inappropriate use has been questioned (Cooper 2013b, 
2013c). 
 
Lastly, a number of unintended but possible outcomes of the regulatory 
changes on the sales of OTC codeine and DHC containing analgesics have not 
been explored. For instance, individuals could have simply shifted from buying 
large packs of these products to making more frequent purchases of smaller 
packs to compensate for the reduced number of tablets contained in a pack. 
Alternatively, individuals could have chosen or been referred by pharmacists to 
obtain supplies of opioid analgesics on a prescription instead. Whether or not 
any of these scenarios has been the case in Wales or in any other part of the 
UK is unclear and could mitigate the regulatory measures implemented by the 
MHRA. 
 
2.1.5 Aims 
The aim of the current study was to determine the impact of the voluntary 
(2005) and legislative (2009) regulatory changes on the OTC sales and 
prescribing of codeine and DHC containing analgesics in Wales. In addition, 
the present study also examined whether deprivation has any influence on the 
non-prescription sales of opioid containing analgesics.  
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2.2 Method 
 
2.2.1 Study design 
The study had an ecological design (Schoenbach and Rosamond 2000) and 
involved the retrospective analyses of primary care prescription data and 
pharmacy wholesale data for Wales between September 2004 and August 
2010. The deprivation data used for each of the 22 primary care organisations 
in Wales, known as Local Health Boards (LHBs), were derived from the Welsh 
Index of Multiple Deprivation (WIMD) 2008. There were two parts to the 
present study and they are briefly outlined below: 
 
2.1.1.1: The impact of voluntary and legislative regulatory changes 
The quantities of codeine and DHC containing analgesics sold OTC from 
community pharmacies and those dispensed on primary care prescriptions were 
determined. Any changes in the quantities supplied before and after the 
implementation of the regulatory changes were determined. 
 
2.1.1.2: Deprivation and Over-the-Counter sales of opioid analgesics 
The relationship between deprivation and sales of OTC codeine and DHC 
containing analgesics were examined. The deprivation levels for each of the 22 
LHBs in Wales were determined by calculating the percentages of Lower 
Layer Super Output Areas (LSOAs) that fell into the most deprived 20% 
quintile in Wales for the following deprivation domains: income, employment, 
health, education and overall deprivation (i.e. the WIMD). Quantities of 
codeine and DHC containing analgesics sold in the three most deprived were 
also compared with those sold in the three least deprived LHBs. In addition, 
the association between percentage of LSOAs that fell in the most deprived 
20% quintile and the mean quantity of codeine and DHC containing analgesics 
sold in the 22 LHBs were assessed using correlation. 
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2.2.2 Data 
 
2.2.2.1 Primary care prescription data  
Prescription data were extracted from CASPA.net (Comparative Analysis 
System for Prescribing Audit), a data store that permits NHS Wales primary 
care prescription data to be interrogated. The database, which was maintained 
by NHS Wales Informatics Service, contained prescribing data derived from all 
prescriptions issued by primary care prescribers and dispensed by NHS-
contracted community pharmacies, dispensing doctors and appliance 
contractors in Wales. 
 
Medicines in the prescription database were arranged following the same 
format as in the BNF under the corresponding chapter, section and subsection 
numbers (BNF 2013). The quantity of prescribed medicines could be extracted 
in a number of different output measures as the: number of items prescribed, 
quantities prescribed, average price per item prescribed or in defined daily 
doses. The prescription data could be extracted in either a quarterly or a 
monthly format. 
 
In the present study, the prescription data were extracted as the number of 
items prescribed and as the quantity of tablets or capsules (dosage unit) 
prescribed by general practitioners (GPs) for each of 22 LHBs in Wales. Data 
were extracted in a monthly format for a total of 72 months from September 
2004 to August 2010. 
 
2.2.2.2 Pharmacy wholesale data  
Under an agreement with IMS Health and the Welsh Government, pharmacy 
wholesale data were obtained from the Regional Sales Analysis (RSA) 
database using IMS Dataview; a computer software for analysing and 
extracting pharmaceutical sales data stored within the RSA database. 
 
The RSA database was a voluntary-based datastore and contained 
pharmaceutical sales data for medicines sold from medicine manufacturers, 
wholesalers and parallel importers to 614/708 (87%) NHS-contracted, 
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community pharmacies in Wales. The range of medicines in the RSA database 
for which data were made available to the Welsh Government by IMS Health 
was negotiated and agreed at the time of the data request, which had included 
both prescription-only and non-prescription medicines. As this process had 
taken place prior to the conception of the present study, it was not possible to 
access the complete set of medicines sales data that was held by IMS Health. 
 
The wholesale transactions between medicine suppliers and establishments 
such as drug stores, industrial medical centres, hospital and clinics, dispensing 
practices and prison and military facilities were not included in the RSA 
database utilised in the present study. Wholesale dealings between pharmacies 
and third party purchasers or inter-wholesale distributions were also excluded. 
In other words, the wholesale data used represented the quantity of medicines 
purchased by pharmacies for dispensing prescriptions as well as for the 
purpose of OTC sale to the general public at a later date. Herein, the pharmacy 
wholesale data as a surrogate for actual pharmacy-to-patient sales are referred 
to as pharmacy or OTC medicines sales data. 
 
The pharmacy sales data in the RSA database were available for extraction as 
the number of packs sold in a monthly format by Primary Care Organisation 
(PCO) geography. In Wales, there were 22 PCOs at the outset of the study, 
known as LHBs, but these had subsequently amalgamated in October 2009 to 
seven new LHBs as part of NHS Wales reorganisation (Welsh Government 
2009b, Appendix 1 and 2). These changes were reflected in the RSA database 
and the OTC sales figures after October 2009 were available in the seven new 
LHB format. Other additional information recorded in the RSA database 
included: details about the manufacturer, product name, product pack size, 
brand name and the active ingredient for a particular product. 
 
In the present study, pharmacy sales data extracted were the number of packs 
of selected codeine and DHC containing analgesics sold, each month, from 
September 2004 to August 2010 for each LHBs in Wales. Pack size 
information for each product was also extracted from the database to convert 
the quantity from number of packs sold into number of tablets or capsules sold. 
 45 
The inclusion and exclusion criteria for the selection of products are described 
in Section 2.2.3. 
 
2.2.2.3 Deprivation data  
At the time of the study, no official figure of deprivation was available for 
Wales at LHB level therefore they had to be derived before analysis on 
deprivation could be undertaken. This was achieved using the deprivation 
indexes published in WIMD 2008 (Welsh Government 2008), which were the 
official measures of deprivation for small areas in Wales. The WIMD 2008 
was made up of eight separate domains (or kinds) of deprivation. Each domain 
draws on a range of potential indicators specific to the type of deprivation in 
question to calculate a score (Appendix 3). Furthermore, each domain carried a 
different weighting which, in turn, determined its contribution to the overall 
deprivation index (i.e. WIMD). The eight domains of deprivation and their 
respective percent weighting towards the overall deprivation index are shown 
below: 
 
• Income (23.5) 
• Employment (23.5) 
• Education, skills and training (14) 
• Health (14) 
• Physical environment (10) 
• Access to service (5) 
• Housing (5) 
• Crime and fire (5) 
 
The indexes for overall deprivation and the four highest weighting component 
domains: income, employment, education (skills and training) and health were 
extracted from WIMD 2008 for each of the LSOA in Wales. LSOA is a 
geographical hierarchy developed by the Office for National Statistics as a 
standard way to divide up England and Wales. There were a total 1,896 LSOAs 
in Wales each having a minimum population of 1,000 and a mean population 
size close to 1,500 (Welsh Government 2011). A high deprivation score is 
associated with more deprivation and indicates there is a higher proportion of 
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deprived population living within an area than one with a lower score. Table 
2.1 shows the number LSOAs in each of the LHBs in Wales. 
 
Table 2.1 Number of Lower Layer Super Output Areas (LSOAs) in each Local Health 
Board (LHB) before and after NHS Wales reorganization 
 
Prior to October 
2009 After October 2009 LSOAs 
Bridgend 
Abertawe Bro 
Morgannwg University 
85 
NeathPort Talbot 91 
Swansea 147 
Blaenau Gwent 
Aneurin Bevan 
47 
Caerphilly 110 
Monmouthshire 58 
Newport 94 
Torfaen 60 
Anglesey 
Betsi Cadwaladr 
University 
44 
Conwy 71 
Denbighshire 58 
Flintshire 92 
Gwynedd 75 
Wrexham 85 
Cardiff Cardiff and Vale 
University 
203 
Vale of Glamorgan 78 
Merthyr Tydfil 
Cwm Taf 
36 
Rhondda Cynon & 
Taff 
152 
Carmarthenshire 
Hywel Dda 
112 
Ceredigion 47 
Pembrokeshire 71 
Powys Powys 80 
 
 
The level of deprivation for each LHB, in terms of the four selected 
deprivation domains (income, employment, education and health) and overall 
deprivation, was determined by calculating its percentage of LSOAs in the 
most deprived 20% quintile in Wales. LSOAs in the most deprived 20% 
quintile were areas with a deprivation score ranked between 1 and 380, with 
rank 1 being the area with the highest deprivation score thereby the most 
deprived. This method of aggregating LSOAs into larger geographical areas 
and estimation of deprivation follows the recommendation by the Office for 
National Statistics (Welsh Government 2011). Assignment of deprivation 
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scores and ranking of LSOAs were undertaken manually in Microsoft Excel 
spreadsheet.  
 
2.2.3 Medicines studied  
 
2.2.3.1 Prescription medicines 
Prescription medicines included in the analysis were single- and multi-
ingredient codeine and DHC containing analgesics identified in the CASPA.net 
prescription database, which corresponded to codeine or DHC containing 
products listed in the BNF (2013) section 4.7.1 (Non-opioid analgesics), 4.7.2 
(Opioid analgesics) and 4.7.4 (Anti-migraine drugs). The reason for including 
section 4.7.1 (non-opioid analgesics) was that preparations such as co-codamol 
(codeine phosphate and paracetamol) or co-dydramol (DHC and paracetamol) 
were classified in the BNF as ‘non-opioids’ although they all contained an 
opioid component in addition to paracetamol. 
 
Preparations studied were those in solid oral dosage forms, namely tablet, 
capsule or soluble (effervescent) preparations. Other oral or non-oral dosage 
forms such as liquids, pastilles or suppositories, were excluded from the study. 
Products in the prescription database that had neither a non-proprietary title or 
a British Approved Name, such as paracetamol 500mg, buclizine 
hydrochloride 6.25mg and codeine phosphate 8mg tablets (Migraleve Pink), 
were manually identified in the database using Martindale: The Complete 
Drug Reference (Sweetman 2007). The identified products were subsequently 
included in the study if they had met the inclusion criteria. Both proprietary 
and non-proprietary preparations were included in the prescription analysis, 
including any OTC packs that were prescribed on a prescription. A list of all 
codeine and DHC containing analgesics extracted from the NHS prescription 
database is shown below in Appendix 4 and Appendix 5, respectively. 
 
2.2.3.2 Over-the-Counter medicines  
Codeine or DHC containing analgesics available for extraction in the RSA 
database were identified using the ‘Oral analgesics’ chapter of Chemist and 
Druggist: Guide to OTC Medicines and Diagnostics (September 2008 issue). 
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Preparations included in the analysis were proprietary, adult preparations in 
tablet, capsule or soluble (effervescent) oral dosage forms. 
 
After the initial selection, a manual search of the RSA database was undertaken 
to identify any other eligible products in the database that were not identified 
by the aforementioned reference book (September 2008 issue). Manually 
identified products were included if they had contained either codeine or DHC 
as the active ingredient and were indicated for pain. The details about a 
preparation were verified using the PILs found on the Electronic Medicine 
Compendium website (Datapharm 2013). Non-proprietary products listed in 
the RSA database that could either be sold OTC or prescribed on a 
prescription, such as 32 tablets pack of co-codamol 8mg/500mg, were 
excluded from the OTC sales analysis (explanation see Section 2.4.2.3). A full 
list of codeine and DHC containing analgesics extracted from the RSA 
database is shown below in Appendix 6 and Appendix 7, respectively.  
 
2.2.4: Data processing and organisation  
The data utilised in the present study were obtained from multiple sources and 
it was necessary for them to be processed and organised into suitable formats 
before statistical tests could be carried out. 
 
Prescription data and pharmacy sales data were transferred from their 
respective databases into Microsoft Excel spreadsheet as described in 
Appendix 8 and Appendix 9, respectively. The total quantities of codeine and 
DHC containing analgesics supplied on prescription and that sold OTC for 
Wales were calculated in Microsoft Excel spreadsheet by combining the 
supplies in the 22 LHBs. The totals were subsequently rearranged into five 12-
month blocks (September to August) to allow comparisons of supplies between 
the different 12-month periods. 
 
The deprivation data were obtained already in Microsoft Excel spreadsheet and 
the percentages of LSOAs in the most deprived 20% quintile of Wales for each 
of the 22 LHBs were calculated in Microsoft Excel. 
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All processed and reorganised data were manually screened for errors before 
transferring to statistic software for analysis (PASW v18). 
 
2.2.5 Data Analysis 
 
2.2.5.1 Impact of the legislative changes  
The total quantities of codeine and DHC containing analgesics supplied on 
prescription and those sold OTC for Wales were reported for each 12-month 
period together with the corresponding median and interquartile range (IQR) 
for the component months. The quantities supplied were compared between 
two consecutive 12-month periods using Wilcoxon’s signed-rank test. Separate 
comparisons were conducted for OTC and prescription supplies of codeine and 
DHC containing analgesics by formulation (soluble and non-soluble) and by 
output measure of the quantity (number of items/packs supplied and number of 
tablets/capsules supplied). 
 
2.2.5.2 Deprivation and sales of codeine and dihydrocodeine analgesics 
The total of OTC codeine and DHC containing analgesics sold in number of 
tablets or capsules in each 12-month period were calculated for each of the 22 
LHBs in Wales. The 12-month total sales for each LHB were standardised by 
10,000 population using mid-2008 population estimates (Appendix 1). 
 
The standardised, 12-month sales in the three most deprived LHBs were 
compared with those in the three least deprived LHBs in Wales using 
Wilcoxon’s Signed Rank Test in terms of the four selected components of 
deprivation (income, employment, education and health) and overall 
deprivation. 
 
To explore the association between deprivation and sales of analgesics 
containing codeine and DHC, the mean of the standardised 12-month sales was 
calculated for each LHB. Spearman’s rank correlation was used to calculate the 
correlation coefficient (r) between the percentages of LSOAs in the 20% most 
deprived quintile and their corresponding mean of the standardised 12-month 
sales of codeine or DHC containing analgesics for the 22 LHBs in Wales. 
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A p-value < 0.05 was considered to be statistically significant. All statistical 
analyses were performed using PASW version 18 (PASW Inc., Chicago, IL, 
USA). 
 
2.3 Results 
 
2.3.1 Over-the-Counter supply 
Figure 2.1 shows the total quantities and their respective percentages of 
selected codeine or DHC containing analgesics sold OTC in Wales from 
September 2004 to August 2010. Codeine containing products accounted for 
93% of the total sales over the study period (94,523,146/101,652,158 tablets or 
capsules). Sales of DHC containing products were predominantly made up by 
sales of non-soluble products, which sold significantly more than the soluble 
equivalent in the 12 months to August 2010 (98% more, p=0.002). 
 
 
Figure 2.1 Cumulative over-the-counter sales of selected codeine and 
dihydrocodeine (DHC) containing analgesics in Wales from September 2004 to August 
2010, expressed as the number of tablets/capsules sold and their respective 
percentage 
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2.3.1.1 Soluble codeine 
The year-on-year totals of codeine containing analgesics sold OTC from 
community pharmacies in Wales are shown in Figure 2.2 and Table 2.2. Over 
the six-year study period, the sales of soluble codeine containing products in 
number of packs sold have remained steady whilst the number of tablets sold 
declined by 25% (2,272,120/9,185,640). The largest reductions in tablet sold 
was observed in 2006/07 and 2007/08, which saw 16% (1,546,008/9,496,356) 
and 10% (816,456/7,950,348) reductions, respectively, compared to the 
previous years. Wilcoxon’s signed rank test revealed there was no significant 
differences (p>0.05) for the number of packs sold between any two 
consecutive 12-month periods. However, quantities of tablets sold in 2006/07 
were significantly less than those sold in 2005/06 (p=0.003).  
 
 
 
 
Figure 2.2 Total quantities of selected codeine containing analgesics sold over-the-
counter in Wales each year (September to August) 
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Table 2.2 Total 12-monthly sales of over-the-counter soluble codeine containing 
analgesics in Wales, together with their respective median and interquartile range 
(IQR) for the component month. Sales in each 12-month period (September to 
August) were compared with the previous 12 months. A p-value < 0.05 is indicated in 
bold 
  Total Median IQR p-value 
Packs 
2004/05 217 967 17 844 3 746  
2005/06 220 601 18 828 2 834 0.388 
2006/07 247 552 20 310 6 672 0.099 
2007/08 243 527 19 940 6 100 0.638 
2008/09 247 434 20 737 3 880 0.695 
2009/10 236 341 19 325 4 926 0.308 
Tablets 
2004/05 9 185 640 74 8170 173 037  
2005/06 9 496 356 80 4312 142 350 0.308 
2006/07 7 950 348 69 0898 213 687 0.003 
2007/08 7 133 892 58 4792 183 696 0.136 
2008/09 7 295 008 61 3584 119 488 0.530 
2009/10 6 913 520 56 9040 155 144 0.239 
 
 
2.3.1.2 Non-soluble codeine 
Over the six-year study period, OTC sales of non-soluble codeine containing 
analgesics, expressed as the number of packs sold, demonstrated a similar trend 
pattern to the sales of the same products expressed as the number of 
tablet/capsules sold (Figure 2.2). Both of the measures saw a significant 
increase in sales (packs, tablets/capsules) compared to the previous 12 months 
for 2005/06 (p=0.012, p=0.005); followed by significant reductions in 2008/09 
(p=0.002, p=0.002) and 2009/10 (p=0.002, p=0.002). A significant increase in 
the number of tablets/capsules sold was observed in 2006/07 (p=0.015) but 
there was no significant change in the number of packs sold. In 2007/08, a 
significant reduction in number of packs sold was observed (p=0.006) but not 
in the number of tablets/capsules sold (Table 2.3). 
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Table 2.3 Total 12-monthly sales of over-the-counter non-soluble codeine 
containing analgesics in Wales, together with their respective median and 
interquartile range (IQR) for the component month. Sales in each 12-month period 
(September to August) were compared with the previous 12 months. A p-value < 
0.05 is indicated in bold 
 
  Total Median IQR p-value 
Packs 
2004/05 391 799 32 658 3 596  
2005/06 418 431 35 108 1 408 0.012 
2006/07 421 157 35 544 4 051 0.814 
2007/08 368 234 29 568 5 659 0.006 
2008/09 274 962 22 518 4 756 0.002 
2009/10 227 011 18 502 3 522 0.002 
Tablets /  
Capsules 
2004/05 8 122 822 68 1645 70 115  
2005/06 8 740 072 73 2139 34 777 0.005 
2006/07 9 281 248 78 0027 86 646 0.015 
2007/08 8 511 244 68 4635 143 199 0.071 
2008/09 6 442 784 53 4517 94 325 0.002 
2009/10 5 450 212 45 1686 73 606 0.002 
 
 
2.3.1.3 Soluble dihydrocodeine 
The year-on-year totals of soluble DHC containing analgesics, expressed as the 
number of packs and tablets sold, are shown in Figure 2.3. Sales in number of 
packs of soluble DHC sold declined steadily, year-on-year, from 2004/05 
(5,787 packs) to 2009/10 (1,566 packs) and significant reductions were 
observed in 2007/08 (p=0.013) and 2009/10 (p=0.008). The equivalent number 
of tablets sold followed the same declining trend year-on-year and significant 
reductions were also observed in 2007/08 (p=0.002) and 2009/10 (p=0.008) 
(Table 2.4). 
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Figure 2.3 Total quantities of selected dihydrocodeine containing analgesics sold 
over-the-counter in Wales each year (September to August) 
 
Table 2.4 Total 12-monthly sales of over-the-counter soluble dihydrocodeine 
containing analgesics in Wales, together with their respective median and 
interquartile range (IQR) for the component month. Sales in each 12-month period 
(September to August) were compared with the previous 12 months. A p-value < 
0.05 is indicated in bold 
 
  Total Median IQR p-value 
Packs 
2004/05 5 787 22 495  
2005/06 3 195 262 86 0.583 
2006/07 3 486 276 174 0.638 
2007/08 2 449 212 62 0.013 
2008/09 2 874 218 74 0.205 
2009/10 1 566 154 191 0.008 
Tablets 
2004/05 96 048 6 894 31 575  
2005/06 59 532 4 932 1 185 0.345 
2006/07 69 432 6 804 2 619 0.239 
2007/08 29 388 2 550 942 0.002 
2008/09 34 488 2 616 330 0.209 
2009/10 18 792 1 848 1 617 0.008 
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2.3.1.4 Non-soluble dihydrocodeine 
Quantities of non-soluble DHC containing products demonstrated a year-on-
year increase in sales (packs, tablets/capsules) from 2004/05 (34767, 850276) 
and reached a plateau in 2007/08 (49706, 1293340). Thereafter the sales 
declined year-on-year up to 2009/10 (Figure 2.3). Sales in number of packs and 
tablet/capsules both followed the same trend pattern and a significant increase 
in sales for both measures was observed in 2005/06 (both p=0.002), followed 
by significant reductions in 2008/09 (p=0.034, 0.002, respectively) and 
2009/10 (p=0.028, 0.003, respectively) compared to their respective previous 
12 months (Table 2.5). 
 
Table 2.5 Total 12-monthly sales of over-the-counter non-soluble dihydrocodeine 
containing analgesics in Wales, together with their respective median and 
interquartile range (IQR) for the component month. Sales in each 12-month period 
(September to August) were compared with the previous 12 months. A p-value < 
0.05 is indicated in bold 
 
  Total Median IQR p-value 
Packs 
2004/05 34 767 2 969 554  
2005/06 47 512 4 032 696 0.002 
2006/07 49 090 4 078 316 0.347 
2007/08 49 706 4 117 674 0.874 
2008/09 46 557 3 875 478 0.034 
2009/10 39 130 3 218 335 0.002 
Tablets /  
Capsules 
2004/05 850 276 73 028 13 748  
2005/06 1 176 740 102 308 16 769 0.002 
2006/07 1 252 620 103 366 9 702 0.136 
2007/08 1 293 340 106 480 14 679 0.433 
2008/09 1 218 012 102 614 13 718 0.028 
2009/10 1 030 344 84 636 9 944 0.003 
 
 
2.3.2 Prescription supply 
The total quantities and their respective percentages of codeine or DHC 
containing analgesics supplied on primary care prescriptions in Wales between 
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September 2004 and August 2010 are shown in Figure 2.4. Non-soluble 
codeine containing preparations accounted for 68% of the total supplies on 
prescriptions (832,322,057/1,224,665,236 tablets or capsules), followed by 
non-soluble DHC containing preparations at 25% (307,700,571/1,224,665,236 
tablets or capsules), soluble codeine at 7% (84,630,826/1,224,665,236 tablets) 
and DHC products at 0% (11,782/1,224,665,236 tablets). 
 
In the final 12 months for which data were available (September 2009 to 
August 2010), the number of tablets/capsules sold for both non-soluble codeine 
and non-soluble DHC were significantly greater than their soluble equivalent 
(93% and 99% greater, both p=0.002). 
 
 
 
Figure 2.4 Cumulative total quantities of codeine and dihydrocodeine (DHC) 
containing analgesics supplied on primary care prescriptions in Wales expressed as 
the number of tablets/capsules sold (September 2004 to August 2010)  
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2.3.2.1 Soluble codeine 
The year-on-year totals for codeine containing analgesics supplied on primary 
care prescription in Wales from 2004/05 to 2009/10 are shown Figure 2.5. 
There was a year-on-year reduction in both the number of items and 
tablets/capsules prescribed for soluble preparations from 2004/05 to 2009/10, 
all of which were statistically significant compared to the previous 12 months 
(all p< 0.05, Table 2.6). Overall, soluble preparations saw the number of items 
prescribed reduced by 34% (55,513/161,943) and the number of tablets 
prescribed reduced by 30% (5,089,412/16,894,235) over the six-year study 
period. 
 
 
 
Figure 2.5 Total quantities of codeine containing analgesics supplied on primary 
care prescription in Wales each year (September to August) 
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Table 2.6 Twelve-monthly totals of soluble codeine containing preparations 
supplied on primary care prescriptions in Wales, together with their respective 
median and interquartile range (IQR) for the component month. Supplies in in each 
12-month period (September to August) were compared with the previous 12 
months. A p-value < 0.05 is indicated in bold 
 
  Total Median IQR p-value 
Items 
2004/05 161 943 13 529 536  
2005/06 151 396 12 561 1 427 0.002 
2006/07 137 508 11 580 639 0.002 
2007/08 122 342 10 173 805 0.002 
2008/09 111 179 9 245 674 0.002 
2009/10 106 430 8 908 669 0.006 
Tablets 
2004/05 16 892 435 1 414 590 60 826  
2005/06 15 931 444 1 315 365 153 098 0.002 
2006/07 14 670 289 1 240 388 62 243 0.002 
2007/08 13 211 488 1 104 682 77 153 0.002 
2008/09 12 122 147 1 007 269 73 571 0.002 
2009/10 11 803 023 988 941 68 364 0.041 
 
 
2.3.2.2 Non-soluble codeine 
There was a steady increase in the quantities of non-soluble codeine containing 
analgesics supplied on primary care prescriptions in Wales (Figure 2.5). 
Number of items increased year-on-year from 1,134,309 items in 2004/05 to 
1,649,438 items in 2009/10, equivalent to a 45% (515,129/1,134,309) increase 
in overall supply over the six-year study period. Similarly, the number of 
tablets/capsules supplied increased constantly from 107,878,825 in 2004/05 to 
161,481,832 tablets/capsules in 2009/10, equivalent to a 50% 
(53,603,007/161,481,832) overall increase. Both measures of quantity 
demonstrated a significant increase in prescription supply every year compared 
to their previous 12-month period (all p<0.05; Table 2.7).  
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Table 2.7 Twelve-monthly totals of non-soluble codeine containing preparations 
supplied on primary care prescriptions in Wales, together with their respective 
median and interquartile range (IQR) for the component month. Supplies in in each 
12-month period (September to August) were compared with the previous 12 
months. A p-value < 0.05 is indicated in bold 
 
  Total Median IQR p-value 
Items 
2004/05 1 134 309 95 470 13 723  
2005/06 1 287 632 106 902 9 111 0.002 
2006/07 1 522 058 116 843 8 615 0.002 
2007/08 1 515 222 126 104 7 315 0.003 
2008/09 1 598 259 133 807 10 150 0.006 
2009/10 1 649 438 138 180 10 133 0.012 
Tablets / 
 Capsules 
2004/05 107 878 825 9 099 895 1 378 566  
2005/06 124 358 015 10 327 359 966 596 0.002 
2006/07 136 427 288 11 326 584 789 268 0.002 
2007/08 146 822 763 12 236 095 669 321 0.003 
2008/09 155 353 334 12 985 601 912 110 0.004 
2009/10 161 481 832 13 518 967 1 019 613 0.004 
 
 
2.3.2.3 Soluble dihydrocodeine 
Quantities of soluble and non-soluble DHC containing analgesics supplied on 
primary care prescription are shown in Figure 2.6. During the 2004/05 period, 
there was no soluble DHC containing analgesics prescribed on NHS 
prescriptions in Wales. Thereafter, quantities supplied on prescription between 
2004 and 2010 remained low with the most prescribed in 2008/09 at a total 38 
items and 3,742 tablets, respectively. The supplies on prescription during the 
2008/09 period were significant greater than the 2007/08 period (p=0.013, 
0.008, respectively, Table 2.8). 
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Figure 2.6 Total quantities of dihydrocodeine containing analgesics supplied on 
primary care prescription in Wales, between September and August, each year 
 
 
Table 2.8 Twelve-monthly totals of soluble dihydrocodeine containing preparations 
supplied on primary care prescriptions in Wales, together with their respective 
median and interquartile range (IQR) for the component month. Supplies in in each 
12-month period (September to August) were compared with the previous 12 
months. A p-value < 0.05 is indicated in bold 
 
  Total Median IQR p-value 
Packs 
2004/05 0 - - - 
2005/06 25 1 3 - 
2006/07 28 2 3 0.653 
2007/08 22 2 3 0.503 
2008/09 38 3 2 0.013 
2009/10 28 2 1 0.159 
Tablets 
2004/05 0 - - - 
2005/06 1 624 80 258 - 
2006/07 1 460 116 138 0.937 
2007/08 1 884 179 115 0.433 
2008/09 3 742 310 112 0.008 
2009/10 3 072 262 145 0.103 
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2.3.2.4 Non-soluble dihydrocodeine 
The total items of non-soluble DHC containing analgesics supplied on 
prescription saw a modest increase from 576,652 items in 2004/05 to 586,407 
items in 2005/06. Thereafter, items supplied declined year-on-year from 
572,161 items in 2006/07 to 504,499 in 2009/10. The prescribing of the same 
preparations expressed in number of tablets/capsules supplied followed a 
similar trend with a slight increase from 2004/05 (52,180,390 tablets or 
capsules) to 2005/06 (54,010,992 tablets or capsules); followed by a steady 
year-on-year decline up to 2009/10 (Figure 2.6). A significant reduction in both 
number of items and tablets/capsules supplied was observed in 2008/09 (both 
p=0.034) and 2009/10 (p=0.003 and 0.002, respectively) compared to the 
previous 12-month (Table 2.9).  
 
Table 2.9 Twelve-monthly totals of non-soluble dihydrocodeine containing 
preparations supplied on primary care prescriptions in Wales, together with their 
respective median and interquartile range (IQR) for the component month. Supplies 
in in each 12-month period (September to August) were compared with the previous 
12 months. A p-value < 0.05 is indicated in bold 
 
  Total Median IQR p-value 
Items 
2004/05 576 652 48 468 5 049 - 
2005/06 586 407 49 651 3 808 0.239 
2006/07 572 161 48 018 1 062 0.050 
2007/08 553 045 45 979 3 215 0.060 
2008/09 530 426 44 619 6 311 0.034 
2009/10 504 499 42 170 3 593 0.003 
Tablets /  
Capsules 
2004/05 52 180 390 4 402 178 495 517  
2005/06 54 010 992 4 583 491 323 670 0.071 
2006/07 53 175 410 4 459 792 73 396 0.158 
2007/08 51 497 446 4 300 577 299 669 0.060 
2008/09 49 518 062 4 158 384 328 752 0.034 
2009/10 47 318 271 3 958 551 335 884 0.002 
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2.3.3 Deprivation 
Each of 1,896 LSOAs in Wales were ranked from 1, most deprived, to rank 
1,896, least deprived based on their corresponding deprivation score for the 
selected deprivation components. After assigning all 1,896 LSOAs to their 
respective LHB, those LSOAs that fell in the most deprived 20% quintile in 
Wales (rank 1 to 380) were identified. Deprivation was presented as 
percentages of LSOA in the most deprived 20% quintile in Wales for each of 
the 22 LHBs and are shown in Table 2.10. 
 
Overall, the median percentages (IQRs) of LSOAs in the most deprived 20% 
quintile for Wales with respect to income, employment, education and health 
deprivation were 17 (17), 15 (26), 18 (21) and 14 (19), respectively. Merthyr 
Tydfil, Blaenau Gwent and Rhondda Cynnon & Taff were the three most 
deprived LHBs in term of employment, education, health and overall 
deprivation, whereas Merthyr Tydfil, Blaenau Gwent and Neath Port Talbot 
were the three most deprived LHBs for income deprivation. The three least 
deprived LHBs in Wales for education, health, income and overall deprivation 
were Ceredigion, Monmouthshire and Powys. Gwynedd, Monmouthshire and 
Powys were the three least deprived LHBs for employment deprivation. 
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Table 2.10 Percentages (n) of Lower Layer Super Output Areas (LSOAs) in 20% most 
deprived quintile in Wales for each 22 Local Health Boards (LHBs) based on the 
Welsh Index of Multiple Deprivation 2008 
 
LHB Income Employ- ment Education Health 
Overall 
Index 
Anglesey (44) 11 (5) 9 (4) 16  (7) 11 (5) 11 (5) 
Blaenau Gwent 
(47) 
**34 (16) **53 (25) *43 (20) 
**47 
(22) 
**43 (20) 
Bridgend (85) 20 (17) 33 (28) 22 (19) 32 (27) 25 (21) 
Caerphilly (110) 25 (27) 34 (37) 31 (34) 31 (34) 26 (29) 
Cardiff (203) 30 (61) 19 (39) 30 (60) 27 (54) 27 (54) 
Carmarthenshire 
(112) 11 (12) 17 (19) 10 (11) 13 (14) 13 (15) 
Ceredigion (47) †4 (2) 4 (2) †0 (0) †0 (0) †2 (1) 
Conwy (71) 17 (12) 10 (7) 10 (7) 10 (7) 13 (9) 
Denbighshire 
(58) 17 (10) 17 (10) 16 (9) 16 (9) 16 (9) 
Flintshire (92) 12 (11) 5 (5) 17 (16) 13 (12) 11 (10) 
Gwynedd (75) 7 (5) ††3 (2) 4 (3) 7 (5) 5 (4) 
Merthyr Tydfil 
(36) 
*36 (13) *56 (20) **39 (14) *58 (21) *50 (18) 
Monmouthshire 
(58) 
††5 (3) †0 (0) ††3 (2) †0 (0) †2 (1) 
NeathPort Talbot 
(91) 
***32 (29) 40 (36) 19 (17) 29 (26) 31 (28) 
Newport (94) 29 (27) 20 (19) 27 (25) 22 (21) 29 (27) 
Pembrokeshire 
(71) 10 (7) 7 (5) 8 (6) 8 (6) 7 (5) 
Powys (80) ††5 (4) ††3 (2) †††4 (3) ††4 (3) ††4 (3) 
Rhondda Cynon 
& Taff (152) 28 (43) 
***45 (69) ***34 (51) 
***36 
(55) 
***36 (55) 
Swansea (147) 28 (41) 19 (28) 24 (35) 21 (31) 24 (36) 
Torfaen (60) 23 (14) 15 (9) 30 (18) 10 (6) 18 (1) 
Vale of 
Glamorgan (78) 13 (10) 10 (8) 6 (5) 9 (7) 9 (7) 
Wrexham (85) 13 (11) 7 (6) 21 (18) 18 (15) 14 (12) 
*Most, **Second-most,  ***Third-most deprived 
†Least, ††Second-least,  †††Third-least deprived 
 
 
Wilcoxon’s signed rank test revealed the sales of OTC non-soluble codeine in 
the three most deprived LHBs were significantly greater than those in three 
least deprived LHBs in Wales with respect to employment (p=0.001), 
education (p=0.043), health (p=0.043) and overall deprivation (p=0.043) but 
was not observed for income deprivation (p>0.05). No other significant 
difference between the three most and least deprived LHBs was observed for 
the sales of any other formulations of codeine or DHC containing analgesics 
(all p>0.05, Table 2.11). 
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Table 2.11 Mean 12-monthly sales of non-soluble codeine in the three most and 
three least deprived Local Health Boards (LHBs) in Wales (median [interquartile 
range]) per 10,000 population between September 2004 and August 2010 in number 
of tablets/capsules sold. Wilcoxon’s sign rank test was used compare the sales and a 
p-values less than 0.05 is considered statistically significant 
 
 Three most deprived LHBs 
Three least 
deprived LHBs 
p-
value 
Employment 30,489 (11,582) 28,041 (16,425) 0.001 
Education 30,489 (11,582) 29,675 (25,481) 0.043 
Health 30,489 (11,582) 29,675 (25,481) 0.043 
Overall 
deprivation 30,489 (11,582) 29,675 (25,481) 0. 043 
 
 
Spearman’s rank correlation revealed no significant relationship between the 
sales of codeine or DHC containing analgesics and percentages of LSOAs in 
the most deprived 20% quintile in Wales for the four selected deprivation 
components and overall deprivation (all p>0.05). The mean 12-monthly sales 
of codeine and DHC analgesics in number of tablets/capsules sold are 
presented in Table 2.12. 
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Table 2.12 Mean 12-monthly sales of over-the-counter codeine and dihydrocodeine containing analgesics (number of tablets or capsules sold per 10,000 
population) in each Local Health Board (LHB) in Wales between September 2004 and August 2010. The three highest quantities of sales by formulation are 
boxed and indicated in bold 
 
 
 
LHB 
 Codeine  Dihydrocodeine  Codeine + Dihydrocodeine    
 Soluble Non-Soluble All  Soluble Non-Soluble All  Soluble Non-Soluble All 
Anglesey  8 531 18 181 26 712  347 2 083 2 430  8 878 20 264 29 142 
Blaenau Gwent  131 623 29 485 161 108  324 3 670 3 995  131 947 33 155 165 103 
Bridgend  18 300 28 793 47 093  92 4 346 4 438  18 392 33 139 51 531 
Caerphilly  88 443 36 864 125 307  325 6 037 6 362  88 768 42 901 131 669 
Cardiff  20 415 28 210 48 625  159 3 246 3 405  20 574 31 457 52 031 
Carmarthenshire  26 740 30 593 57 333  118 3 903 4 020  26 858 34 496 61 354 
Ceredigion  45 628 38 617 84 245  485 4 433 4 918  46 113 43 050 89 163 
Conwy  20 659 33 662 54 322  286 3 967 4 254  20 945 37 630 58 575 
Denbighshire  10 768 19 661 30 429  399 3 027 3 426  11 167 22 688 33 856 
Flintshire  9 096 19 134 28 230  348 3 300 3 649  9 445 22 434 31 879 
Gwynedd  17 555 27 856 45 411  413 4 682 5 095  17 968 32 538 50 506 
Merthyr Tydfil  19 180 46 173 65 353  132 6 151 6 283  19 311 52 324 71 636 
Monmouthshire  66 557 36 290 102 847  249 6 594 6 843  66 807 42 883 10 9690 
NeathPort Talbot  20 808 24 468 45 276  285 3 383 3 668  21 093 27 851 48 944 
Newport  32 346 19 213 51 559  234 2 538 2 771  32 580 21 751 54 331 
Pembrokeshire  14 813 20 506 35 319  304 3 712 4 017  15 118 24 218 39 336 
Powys  12 219 14 611 26 830  139 2 103 2 242  12 358 16 714 29 072 
Rhondda Cynon Taff  16 907 30 855 47 763  114 4 073 4 187  17 022 34 928 51 950 
Swansea  14 114 31 791 45 905  224 5 716 5 940  14 338 37 508 51 845 
Torfaen  39 176 26 120 65 296  272 3 389 3 661  39 448 29 509 68 957 
Vale of Glamorgan  20 931 27 318 48 248  51 1 962 2 013  20 982 29 280 50 262 
Wrexham  14 403 28 993 43 397  397 3 015 3 412  14 800 32 008 46 808 
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2.4 Discussion 
 
2.4.1 Main findings 
A number of regulatory measures concerning the sale and supply of OTC 
analgesics containing codeine and DHC were implemented in the UK between 
2004 and 2010. Overall, the results indicate that there was a reduction in both 
the numbers of packs and tablets/capsules sold in Wales primarily due to a fall 
in sales of codeine-based products. The study observed changes in sales which 
may be explained by the various policies introduced and events occurred 
during the six-year study period. 
 
Firstly, a significant fall in soluble codeine containing analgesics in number of 
tablets/capsules sold was observed 12 months after the voluntary restriction on 
pack size was introduced. However, the equivalent number of packs sold 
remained unaffected. These observations suggest whilst OTC soluble codeine 
containing analgesics continued to be sold at a frequency similar to that seen 
prior to the voluntary agreement, the overall quantities sold have actually 
reduced. This was not an unexpected outcome for the 2005 voluntary 
agreement given large packs of soluble codeine containing analgesics were no 
longer recommended for sale OTC despite they were still classed as a P 
medicine.  
 
Secondly, the OTC sales for non-soluble codeine and DHC containing 
analgesics started to decline during the months leading up the legislative 
changes in 2009. Whilst the exact reasons for this could not be determined, the 
timing of the reductions coincided with several notable events and publications 
that were concerned with the misuse and/or abuse of OTC medicines. This 
included the launch of a high profile inquiry by the APPDMG (2009) into the 
addiction of OTC medicines and the publication of a professional guidance by 
the RPSGB (2007) advising pharmacists to limit the sales of opioid containing 
analgesics. Moreover, numerous articles on the subject matter also appeared in 
professional journals (Anon. 2007a; Colquhoun 2008; Dickman 2008; Dunkley 
2007; Ford and Good 2007a, 2007b) and were reported in the general media 
(Bunyan 2007; Martin 2007; Morton and Wighton 2009). These may possibly 
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have increased the awareness and vigilance among pharmacy staff regarding 
the inappropriate use of non-prescription codeine and DHC analgesics; and 
contributed to diminishing sales even before legal measures were introduced. 
 
Lastly, in the final 12 months of the study, during which large pack sizes of 
opioid containing analgesics were reclassified from P to POM status, a 
significant reduction in sales of non-soluble codeine containing analgesics was 
observed for the first time. This suggests the legislative measures introduced in 
2009 were probably effective at reducing the OTC sales of these products 
whereas the 2005 voluntary measures appeared to have had little or no 
influence on OTC sales. 
 
Over the six-year study period, the study did not find an increase in the number 
of packs sold OTC for either soluble or non-soluble codeine and DHC 
containing analgesics. This suggests that the practice of making more frequent 
purchases of these products to compensate for the reduced pack size was not 
wide spread among the pharmacy users in Wales. Concerns as to individuals 
switching from purchasing OTC opioid analgesics to obtaining them on a 
doctor’s prescription were also unfounded.  
 
For the OTC products monitored, there was no relationship between the 
deprivation and sales of OTC analgesics that contained codeine or DHC. This 
finding does not support the link between increase use of OTC medicines and 
socioeconomical deprivation and is in agreement with findings reported by 
other UK based studies (Bradley 1998; Boardman et al. 2005; Porteous et al. 
2005; Urquhart et al. 2004). However, the sales of non-soluble codeine 
containing analgesics in the three most deprived LHBs, in terms of 
employment, education, health and overall deprivation, were significantly 
greater than those sold in the three least deprived LHBs in Wales. The reason 
for this could not be identified in the present study and will require further 
investigation.  
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2.4.2 Study limitations 
 
2.4.2.1: Ecological study 
The current study utilised retrospective data on a population level and, 
therefore, was unable to identify the factors that might have influenced 
patients’ decisions to obtain or pharmacists’ decisions to supply an OTC 
medicine. Similarly, it was not possible to identify the factors that were 
responsible for the high level of non-prescription sales in the three most 
deprived LHBs in Wales. A better understanding of the characteristics of those 
who purchased the medicines, such as demographics, socioeconomical 
background, health status and prescription exemption status, would be useful. 
 
Examination of OTC medicines sales data was useful for explaining some of 
the changes observed in OTC sales. For example, the data demonstrated a 
restriction on maximum pack size resulted in a fall in the number of 
tablets/capsules of soluble codeine analgesics sold but had no impact on the 
number of packs sold. On the other hand, however, sales data were less useful 
for assessing the impact of other regulatory efforts, such as the impact of 
additional information in PIL or warning labels on the product packaging. 
Consequently, which of the regulatory changes, and to what extent, were 
responsible for the reduction in OTC sales of the products monitored could not 
be determined. It was likely that the impact on OTC sales of codeine and DHC 
containing products had been the combined effect of all of the regulatory 
measures that were implemented. 
 
2.4.2.2: Pharmacy wholesale data 
Pharmacy wholesale sales data were obtained from IMS Health and 
represented non-prescription sales of opioid analgesics from a range of 
pharmaceutical suppliers to community pharmacies in Wales. The coverage of 
the medicines wholesale data was good and included 87% (614/708) of all 
NHS-contracted community pharmacies in Wales. The remaining pharmacies 
for which data were not available belonged to a large pharmacy chain that did 
not contribute data to the RSA database. The pharmacy sales data obtained for 
this pharmacy chain as part of another study (Chapter 4) indicate its non-
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prescription sale of a different OTC preparation (ophthalmic chloramphenicol) 
represented approximately 31% of the all non-prescription sales in Wales. 
Whether or not a similar proportion of opioid containing analgesics had been 
sold by the same company over the current study period was unknown. It is 
probable that the sales figures reported in the present study were an 
underestimate of the actual supply. 
 
Pharmacy sales data collected by IMS Health have been utilised by a number 
of published studies (Cohen et al. 2010; Davis et al. 2009; Dhippayom and 
Walker 2006; Sheen et al. 2002) and government reports (Walker 2006) to 
estimate consumptions of OTC medicines in the primary care. These sales data 
represent stock bought by community pharmacies from their suppliers rather 
than actual sales to customers. Despite the difference they are considered to be 
a good proxy for actual sales. One reason for this is because most community 
pharmacy, where possible, tries to sell most if not all of its stock to generate 
cash flow for future stock purchases. However, one potential weakness about 
using pharmacy wholesale data to estimate supply is that they may be sensitive 
to factors unrelated to customer demand. For example, bulk order discounts or 
advance purchases in anticipation of peak period of sales and/or medicine 
shortages may skew the sales picture. However, the available sales data suggest 
these had not been the case for the products monitored over the study period. 
 
In the UK and Australia, studies have reported that internet pharmacy is 
becoming increasingly used by as an alternative route for procuring OTC 
analgesics containing codeine and DHC (APPDMG 2009; Cooper 2011; 
Grieve 2009; NTA 2011; Nielsen et al. 2010). Although it has been speculated 
that the scale of internet-supplied codeine and DHC containing analgesics is 
probably low, how much additional consumption of these medicines were 
facilitated by internet pharmacies is difficult to quantify (Cooper 2011, Grieve 
2009). Since the pharmacy sales data obtained from IMS Health did not 
include medicines that were sold by online pharmacies, whether or not there 
was a reduction in non-prescription supply in these settings was unknown. 
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2.4.2.3: Medicines studied 
The current study examined the non-prescription sales of opioid containing 
analgesics and prescription supplies of the same class of drugs in Wales. The 
available data suggest there was no evidence of a switch from individuals 
purchasing these preparations OTC to obtaining them from their GPs on a 
prescription. However, since the supply for other class of OTC or prescription-
only analgesics were not investigated, it remains unclear whether the demands 
for opioid containing analgesics were reduced or have been met by the use of 
another agent OTC or on prescription. One example of such would be when the 
maximum pack size of OTC paracetamol tablets was reduced that the non-
prescription sales of ibuprofen tablets increased (Sheen et al. 2002). The 
reclassification of several other analgesics from POM to P status during the 
study, such as sumatriptan for the acute relief of migraine (2005), naproxen for 
period pain (2008) and diclofenac for headache and muscular pain (2008), 
could have confounded the sales picture of OTC opioid containing analgesics 
(Grieve 2009, PAGB 2011a). 
 
During the six-year study period, Paramol was the only proprietary brand of 
non-prescription DHC containing analgesic sold in the UK and its sales data 
were complete in the RSA database. In contrast, sales data for codeine 
containing analgesics achieved a less than complete coverage of all products 
available OTC. One notable omission from the sales data was own-brand 
preparations sold by large pharmacy multiples (e.g. Boots brand co-codamol 
8/500mg tablets). As these own-brand preparations are often retailed at a lower 
price compared to their proprietary equivalent, the potential cost savings may 
have incentivised some individuals to purchase the former over the latter. Sales 
statistics from market research company suggest 31% of the non-prescription 
adult oral analgesics market are dominated by own-brands (Chemist and 
Druggist 2012). Whether or not the impact of regulatory changes observed in 
the current study had been the same for the own-branded codeine and DHC 
containing analgesics was unknown and will require additional sales data to 
explore this further.  
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OTC sales data for seven proprietary brands of codeine containing analgesics 
(Codis 500, Nucare, Olbas, Solpadeine, Solpadeine Migraine, Uniflu, Vantage) 
were unavailable to the study. These seven brands have, between them, 
marketed 16 codeine containing preparations out of a total of 76 that were 
available between 2004 and 2010 (Chemist and Druggist January 2004, 
November 2008, August 2010 issue). Although the quantities sold for these 16 
preparations could not be determined, two of the preparations (Nucare, Uniflu) 
came off market during early period of the study (late 2005/early 2006) while 
another eight products (Solpadeine) were rebranded into Solpadeine Plus for 
which data were available in the RSA database. Therefore, it is anticipated that 
the current study captured the majority of non-prescription sales and reflected 
the overall market trend for proprietary preparations.  
 
Pharmacy sales data for both generic and proprietary preparations were 
available for study in the RSA database but only the latter were included in the 
analysis. The reason for adopting this method was to avoid over-estimating 
OTC supply, which could arise if a generic product, such as co-codamol x 32 
tablets (8mg codeine phosphate and paracetamol 500mg), was treated as sold 
OTC when it was in fact used to dispense a prescription. Differentiating the 
outcome of a generic product as to whether it was sold OTC or used to 
dispense a prescription was not possible because such information was not 
recorded in the RSA database. The obvious disadvantage about this cautious 
approach was that some of the generic products with a P medicine licence were 
likely to have been sold OTC. As a result, the sales figures reported in the 
present study are likely to be underestimates of the actual supply in Wales. 
 
2.4.2.4: Deprivation 
The WIMD was designed specifically to measure deprivation at a small area 
level, namely LSOAs (Welsh Government 2011). However, pharmacy sales 
and primary care prescription data were both only available in LHB geography. 
Although calculating the percentages of LSOA in the most deprived 20% 
provided a way to estimate deprivation at LHB level, these were only estimates 
and showed how concentrated deprivation was over a large geographical area. 
Cautions must therefore be exercised when interpreting the findings from the 
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correlation analysis, as not all deprived people live in areas of high deprivation 
nor are they all likely to purchase analgesics containing opioids. Other 
limitations related specifically to the WIMD have been published elsewhere 
(Welsh Government 2011). The current study could be improved by analysing 
OTC sales and deprivation data at LSOAs level, but this was not achievable as 
both prescription and OTC sales data were only available in LHB format.  
 
2.4.2.5 Trainings and sales protocols 
In community pharmacies in the UK, Medicine Counter Assistants (MCAs) are 
often involved in the sales and supply of OTC medicines (Banks et al. 2007; 
Ward et al. 1998). In order to ensure MCAs can safely and effectively assist 
with the sales of non-prescription medicines it is a requirement that all MCAs 
have undergone, or be undertaking an accredited training programme before 
commencing their role (General Pharmaceutical Council [GPhC] 2011). In 
addition to the minimum training requirements, extra in-house materials may 
be provided in some pharmacies to engage their staff in further learning and/or 
promote company-specific policies. For example, pharmacy staff may be 
encouraged to recommend own-brand medicine over a proprietary equivalent 
to drive profit or the patient referral criteria/protocol for a condition may be 
different from one company to another. It was possible that these variations in 
pharmacy training and sales protocol for MCAs may have confounded the sales 
picture, particularly as not all codeine and DHC containing analgesics or 
generic products were included in the study. The exact impacts of these 
variations on OTC sales could not be determined and should be investigated 
further. 
 
2.4.3 Comparison with existing literature 
 
2.4.3.1 Impact of voluntary and legislative changes 
Restriction of medicine pack size as a strategy to reduce the misuse and abuse 
potential of OTC medicines have previously been implemented in the UK. One 
notable example was the pack size reduction of paracetamol containing 
products in 1998 (Committee on Safety of Medicines [CSM] 1997) following 
an increase in number of deaths and reports of deliberate self-harm by 
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paracetamol poisoning (Bray 1993; Hawton et al. 1997). Several studies 
investigated the impact of the new legislation and found that limiting OTC 
pack size of paracetamol also reduced the quantity of non-prescription 
tablets/capsules sold (Hawton et al. 2001, 2004, 2013). A more recent example 
would be the pack size restriction of OTC pseudoephedrine and ephedrine 
containing products in April 2008 and it too demonstrated a reduction in OTC 
sales 12 months after the pack size restriction (MHRA 2009c). The outcomes 
of these prior regulatory efforts are in line with those observed in the current 
study and indicate pack size restriction was at least one of the reasons for the 
decline in OTC sales of opioid containing analgesics. 
 
The sales data for Wales suggest the 2005 voluntary agreement affected the 
sales of soluble but not non-soluble codeine containing analgesics. This was 
unsurprising because the only opioid containing analgesics that had a pack size 
greater than 32 tablets were soluble preparations. Non-soluble codeine 
containing analgesics appeared to be unaffected probably because they were 
already limited to a maximum pack size of 32 tablets due to a legal restriction 
on the quantity of paracetamol that could be sold OTC (RPS 2011a). Other 
compound analgesics, such as those containing ibuprofen or aspirin combined 
with codeine, were not confined to a maximum pack size of 32 tablets but no 
large packs of these products were available in the UK (Anon. 2002). A similar 
observation of a reduction in large (60 tablets packs) but not small pack sizes 
(32 tablets packs) of codeine containing analgesics have also been reported by 
others following the 2005 voluntary agreement (Reed et al. 2011). 
 
The beginning of a year-on-year decline in the sales of non-soluble codeine 
and DHC containing analgesics occurred in 2007. This coincided with the 
publication of a professional document by the RPSGB (2007), which 
recommended OTC sales of opioid containing analgesics were to be limit to 
one pack, of any pack size, per purchase. Furthermore, the updated guidance 
also stated soluble co-codamol that contained 100 tablets per pack should be 
reserved for dispensing use only. These recommendations were reported to be 
viewed authoritatively by medicine counter assistants who are often involved 
in the sales of non-prescription analgesics (Cooper 2011, 2013b). As such, 
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sales that could have otherwise involved multiple or large packs of these 
products might have therefore been prevented. The simultaneous reductions in 
both number of packs and tablets/capsules sold which began in 2007 indicate 
there was a direct relationship between the two variables. This possibly reflects 
the impact of the ‘one pack per purchase’ policy on the sales of codeine and 
DHC containing analgesics. 
 
As mentioned earlier, multiple factors could have contributed to the reduction 
of codeine and DHC containing analgesics sold. Besides an increased 
awareness about the misuse and/or abuse potentials of these medicines among 
pharmacy (Anon 2007a, 2007b; Colquhoun 2008; Dickman 2008; Dunkley 
2007) and medical professionals (Ford and Good 2007a, 2007b; Hanoch 2007; 
Matheson 2007), pharmacy counter assistants also reported to have received 
additional training on the subject matter (Cooper 2011, 2013b). Furthermore, 
community pharmacies adopted strategies to prevent inappropriate sales, such 
as monitor the frequencies of purchase, use technology to notify sales that 
involve multiple packs, make records of OTC transactions and inform nearby 
pharmacies of suspicious requests (Cooper 2011, 2013b). A national awareness 
campaign on the appropriate use of OTC analgesics was also launched and 
warned of the dangers of addiction to OTC analgesics (British Pain Society 
2010). Lastly, the introduction of legislative changes in 2009 was accompanied 
by wide spread communications within the pharmacy profession aimed to raise 
awareness of the legislative changes (Anon. 2009a, 2009b, 2009c; Maguire 
2010; RPSGB 2009). Whilst the impact of these measures have not been fully 
evaluated, it was likely that at least some of these activities have deterred 
customers from purchasing and/or altered pharmacy staff behaviour when 
faced with requests for OTC codeine or DHC containing analgesics. 
 
2.4.3.2 Influence of deprivation 
Research examining the association between socioeconomical deprivation and 
use of OTC medicines have utilised various measures of deprivation or 
consumption of OTC medicine and thus direct comparison between the studies 
is difficult (Boardman et al. 2005; Poretous et al. 2005). In addition, a patient’s 
perception of his or her needs for an OTC medicine may be different 
 75 
depending on the ailment or medicine in question and could influence the 
decision whether to self-medicate or obtain a prescription from their GP. The 
link between deprivation and use of different types OTC medicines must 
therefore be assessed with care. 
 
Of the data that are published, Boardman et al. (2005) and Poretous et al. 
(2005) reported that a poorer self-reported health status was linked to an 
increase in OTC medicine use. However, no significant correlation was 
observed between health deprivation and use of non-prescription opioid 
analgesics in the current study. Increased use of OTC medicines was found to 
be associated with affluence in English (Boardman et al. 2005) and Scottish 
(Porteous et al. 2005) populations as well as in GP attendees (Bradley 1998; 
Urquhart et al. 2004). A need to pay for prescription levy, as an indicator for 
affluence, was also found to be significantly associated with increased OTC 
medicine use (Urquhart et al. 2004; Wazaify et al. 2005). McIntyre et al. 
(2003) reported that parents or carers of young children living in more affluent 
areas were more likely to purchase OTC medicines for future needs. Increased 
education has been associated with increased OTC medicine use (Porteous et 
al. 2005). 
 
Most notably, many of the studies mentioned above reported a positive 
correlation between affluence and use of OTC medicines. However, their 
results should be compared cautiously with those of the current study not only 
because none of them investigated the use non-prescription opioid analgesics, 
but also a low deprivation index does not mean a population is necessarily 
more affluent. The fact that there appears to be no association between 
deprivation and OTC supply of opioid analgesics only serve to suggest 
increased socioeconomical deprivation was probably not a major contributing 
factor to non-prescription opioid analgesic use in the Welsh population. 
 
The reason as to why there had been a larger quantity of opioid containing 
analgesics sold OTC in the more deprived compared with the less deprived 
LHBs is uncertain. However, socioeconomical deprivation has been shown to 
be associated with higher prevalence of pain (Aggarwal et al. 2003; Brekke et 
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al. 2002; Blyth et al. 2001) and may be a possible explanation for what had 
been observed. Had there been a higher prevalence of pain among the more 
deprived population this could also explain the unintended finding that, in a 
separate analysis involving the same prescription and deprivation data, a 
significant positive correlation (p<0.001) was observed between opioid 
analgesics supplied on prescription and all of the four deprivation components 
and overall deprivation (results not shown). 
 
Given the emerging misuse and abuse potential associated with OTC 
analgesics containing opioids, one might be tempted to attribute their high 
consumptions in these more deprived areas to inappropriate use drawing on the 
known link between social deprivation and illicit drug use (Galea et al. 2004; 
Lloyd 1998). Such speculation, however, is unfounded as user demographic 
can differ from one substance to another and few OTC codeine dependent 
users actually reported concurrent illicit drug use (Cooper 2011; Grieve 2009; 
Nielsen et al. 2010, 2012). Investigations into the demographic features of 
codeine dependent users in Australia revealed codeine dependent users are 
more likely to have lower education, less likely to be in full-time employment 
and more likely to report fair to poor health than non-dependent codeine users 
(Nielsen 2010). Whether the same features could be extrapolated for the UK 
population is unknown and will require further investigation. 
 
A number of studies outside of the UK reported a link between use of OTC 
codeine analgesics and a range of mental health problems and it has been 
suggested practicing self-medication enable individuals to cope with mental 
health symptoms (McAvoy et al. 2011; Nielsen et al. 2010). These findings 
were in agreement with those of a survey study conducted in the UK, which 
found 54% of codeine dependent participants reported as suffering from 
coexisting problems such as anxiety, panic attacks, depression, alcoholism or 
addiction to other drugs/medicines (Grieve 2009). This apparent link between 
mental illness and use of OTC opioid containing analgesics potentially 
explains the absence of an association between health deprivation and OTC 
sales reported in the current study, as none of the indicators considered by 
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WIMD to calculate the health deprivation scores were related to mental health 
problems (Welsh Government 2011). 
 
2.4.3.3 Abolition of NHS prescription charge 
Significant changes in healthcare policy have taken place in Wales during the 
six-year study period and one of the developments was the abolition of NHS 
prescription co-payment levy in April 2007 (Cohen et al. 2010). Studies have 
found that for some patients the prescription levy can act as a significant 
barrier to the use of prescribed medicines (Schafheutle et al. 2002, 2004; The 
Prescription Charges Coalition 2014). Whilst it was possible that this may have 
had an influence on the quantity of medicines prescribed, a study has found 
that there had only been a modest change in the overall dispensing rate 12 
months post-abolition (Cohen et al. 2010). The present study supports this 
finding as codeine and DHC containing analgesics have demonstrated a similar 
prescribing trend in Wales before and after the policy change. As such, the 
likelihood that individuals have shifted from purchasing OTC opioid 
containing analgesics to obtaining them on prescription because of free 
prescriptions was probably small. Furthermore, OTC-to-prescription switching 
would not explain why there had been a reduction in quantities of soluble 
codeine containing sold in tablets but not in the number of packs sold. 
 
2.4.4 Implication of findings 
In light of the emerging issues of misuse and abuse of OTC analgesics 
containing opioids, regulatory measures introduced in 2005 (voluntary 
agreement) and 2009 (legislative changes) justified their continued non-
prescription availability in the UK. Perhaps from a regulatory prospective, a 
reduction in their OTC sale indicated the policy interventions have been 
successful in reducing the likelihood of harm caused by these medicines. 
However, many important aspects related to the inappropriate use and/or OTC 
sale of these products remain to be addressed (Cooper 2013b, 2013c, 
Mackridge et al. 2013, Burton 2012). 
 
One aspect that has been repeatedly mentioned is the absence of reliable data 
on what scale addiction to OTC analgesics really is among the UK population 
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(APPDMG 2009; Cooper 2011; 2013a; NTA 2011). This information on 
prevalence would allow changes in trends to be monitored, effectiveness of 
interventions to be evaluated and, ultimately, inform regulatory decisions as to 
whether analgesics containing an opioid should continue to be available 
without a prescription. While pharmacy sales data provided useful insights into 
the supply of OTC codeine and DHC containing analgesics in the primary care 
and the impact of relevant policy changes, their contribution to understanding 
the scale of the addiction problem is limited. The hidden nature of addiction to 
OTC medicine presents many challenges for researchers and policy makers 
(APPDMG 2009), and identifying a way to accurately quantify prevalence of 
users having problems with OTC analgesics should be a priority. In England, 
the commissioning guidance on the treatment of OTC and prescription 
medicine dependence (Public Health England [PHE] 2013b) urged local 
authorities to work with primary care service providers to monitor prescribing 
and purchasing pattern of opioid containing drugs. The utilisation of OTC 
medicines sales data is likely to play a vital role in fulfilling these goals. 
 
The introduction of smaller pack sizes of OTC opioid containing analgesics 
meant the relative costs of these products have increased. This could be viewed 
favourably as it might have a deterrent effect upon individuals who misuse 
and/or abuse OTC codeine and DHC analgesics (Cooper 2011). However, it 
was also possible that the increased costs have deterred legitimate requests and 
limited people’s ability and/or desire to practise self-medication. This 
illustrates a potential problem for the current pack size restriction policy and 
how it could exacerbate health inequalities. Furthermore, it highlights 
pharmacy sales data’s inability to identify how much of a reduction in sales 
had impacted on inappropriate as oppose to appropriate self-medication. 
 
As noted by Bond and Hannaford (2003) and Walker (2000), a weakness 
associated with the current regulation of OTC medicine is the lack of 
comprehensive post-market surveillance data. Given the increased regulations 
and heightened vigilance that have made opioid analgesics more difficult to 
obtain in high street pharmacy settings (Cooper 2013b), it was unsurprising 
that some dependent users reported to have turned to alternative sources of 
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supply, such as from internet pharmacies (Cooper 2011; Grieve 2009; Nielsen 
et al. 2010; APPDMG 2009). The anonymous and borderless nature of the 
internet makes the detection and monitoring of inappropriate use of opioid 
containing analgesics even more difficult, and reports of unchallenged sales 
involving multiple packets and repeated requests are concerning (APPDMG 
2009; Cooper 2011; Nielsen et al. 2010). The missing sales information from 
internet pharmacies could have a consequential impact on the evaluation of the 
regulatory measures. Furthermore, the increase in OTC sales of generic and 
own-brand of opioid analgesics (IRI UK 2009), for which data were 
unavailable to public health organisations, represents another unknown source 
of non-prescription supply and should be included in future studies. 
 
Pharmacy sales data revealed significantly greater quantities of OTC opioid 
containing analgesics have been sold in the three most rather than the three 
least socioeconomically deprived LHBs in Wales. More research is needed to 
understand exactly why this was the case. Interestingly, the present study 
unintentionally found that one of the most deprived LHBs, Blaenau Gwent, 
was also obtaining the highest quantities of opioid analgesics on primary care 
prescriptions in Wales. Recent evidence suggest many codeine or DHC 
dependent users have initially been prescribed with opioid-based painkillers for 
genuine medical reasons but these were subsequently replaced by taking an 
OTC analgesic after prescription treatment had ended (APPDMG 2009; 
Cooper 2011; Nielsen et al. 2010). Whether or not this was taking place in 
Blaenau Gwent was unknown but the possible link between the high level of 
prescribing and OTC use of opioids should be investigated. This demonstrates 
the strength of dual monitoring of both OTC sales and prescribing data to 
identify usage pattern that might not have otherwise been picked up by 
examining either dataset alone. 
 
Drug misuse referral data for Wales indicate the number of treatment referrals 
for cases involving ‘Other Opiates’, such OTC preparations containing codeine 
and DHC, remained unchanged from 114 referrals in 2005 to 116 referrals in 
2011 (Welsh Government, personal communication). In England, the number 
of people presented at drug treatment services with problems specifically 
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related to OTC opioid have, on the other hand, increased year on year over the 
same period (NTA 2011). These observations suggest despite an increase in 
regulation of the non-prescription sales of these products from pharmacies 
problems relating to their use continued to affect some individuals. Whether or 
not, over time, the increased regulation concerning the non-prescription supply 
of OTC opioid containing analgesics would translate to a fall in the number of 
people addicted to OTC analgesics remains a question to be answered and long 
term monitoring will be needed.  
 
2.5 Summary 
In the 12 months following the 2005 voluntary agreement, OTC sales of 
soluble codeine containing analgesics in number of tablets/capsules sold have 
significantly reduced but the number of corresponding packs sold remained 
unaffected. Sales of non-soluble codeine and DHC containing preparations 
were both unaffected by the 2005 voluntary agreement but year-on-year 
reductions in sales were observed between 2007 and 2010. In the 12 months 
following the legislative changes in 2009, a significant reduction in quantities 
sold for all formulations of codeine or DHC containing analgesics compared to 
the previous 12-month period was observed except for soluble codeine 
preparations.  
 
Analysis of employment, education, income, health, and overall deprivation 
against sales of OTC opioid containing analgesics at LHB level indicate there 
was no association between increased socioeconomical deprivation and non-
prescription analgesic use. However, it was found the sales of OTC opioid 
containing analgesics were significantly greater in the three most deprived than 
the three least deprived LHBs in Wales. Further research is needed to 
investigate whether the reductions in OTC sales have actually translated into a 
fall in number of people dependent to OTC opioid containing analgesics. 
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Impact of regulatory changes on supply of 
pseudoephedrine, ephedrine and phenylephrine 
 
3.1 Introduction 
Minor ailments have been defined as conditions that are self-limiting and/or 
conditions that can be diagnosed easily by patients themselves (Proprietary 
Association of Great Britain [PAGB] 2010). Coughs, constipation and colds 
are some conditions defined as 'minor' in the published literature (Banks 2010; 
Pillay et al. 2010). When it comes to minor ailments, many people use no 
medication, for example, because they are often not considered serious or 
perceived to require no treatment (PAGB 2005a). However, up to 41% of 
people claim to self-medicate with non-prescription medicines prior to seeking 
advice from healthcare professionals (Banks 2010; Porteous 2006) and do so 
most often by making purchases from community pharmacy (PAGB 2005a). 
 
The main reasons for self-medicating with an OTC medicine include patient 
autonomy, convenience and potential financial-savings for the users (Banks 
2005, Brass 2001; Ryan and Yule 1990) especially for individuals who have to 
pay for NHS prescriptions (Schafheutle et al. 1996, 2002, 2004). Self-
medication is also promoted by other interested parties, including the 
government who have a desire to reduce NHS drug spending (Aronson 2004; 
PAGB 2011a, 2011b), need to reduce the burden on the NHS by making better 
use of pharmacists' and doctor’s skills (Bellingham 2002; Royal 
Pharmaceutical Society of Great Britain [RPSGB] 2003) and the goal of 
pharmaceutical companies’ to increase sales of their products and thereby 
increase profit (Blenkinsopp 2004). 
 
Nasal congestion symptoms are commonly encountered in the primary care 
with 15% of adults and children in the United Kingdom (UK) (Banks 2010). 
Whilst it is usually considered to be a self-limiting condition that can be treated 
safely with over-the-counter (OTC) medicines (PAGB 2010), many patients 
choose to consult their general practitioner (GP), costing the National Health 
Service (NHS) up to £17.4 million in prescribing costs every year (Pillay et al. 
2010). The onset of nasal congestion could be due to a number of causes, such 
 83 
as a common cold (Blenkinsopp et al. 2009; National Institute for Health and 
Care Excellence [NICE] 2011), influenza infection (Eccles 2005) or hay fever 
(NICE 2012a), all of which are health conditions frequently experienced in 
primary care (PAGB 2005a). Nasal congestion can also be associated with 
nasal allergies other than hay fever (Blenkinsopp et al. 2009), nasal polyps, 
sinusitis (NICE 2009a) or changes in atmospheric humidity (British National 
Formulary [BNF] 2013). Studies have found over 50% of sufferers who 
reported nasal congestion have self-medicated with OTC medicines (PAGB 
2005a). 
 
3.1.1 Nasal decongestants 
There is a wide range of pharmacological treatments for nasal congestion 
available OTC. Common active ingredients and the background to their use are 
discussed below. 
 
3.1.1.1 Ephedrine 
Ephedrine is a sympathomimetic that possesses both alpha- and beta-
adrenergic activity (Sweetman 2007) and is indicated for the reversal of 
hypotension and nasal congestion (BNF 2013). Its usefulness is due to its 
stimulation of the central nervous system which increases cardiac output and 
induces peripheral vasoconstriction (Sweetman 2007). Other uses of ephedrine 
such as a bronchodilator or for the treatment of diabetic neurophatic oedema 
are becoming obsolete due to the availability of other, more effective 
treatments (BNF 2013). 
 
When ephedrine is used as a nasal decongestant, it can be given orally or 
applied topically and is suitable for individuals over six years of age. The BNF 
(2013) only acknowledges the use of ephedrine as a nasal decongestant via the 
topical route due to its unwanted systemic effect on the cardiovascular system 
if given orally (Blenkinsopp et al. 2009). Furthermore, the BNF (2013) 
recommends the use of ephedrine containing nasal drops be limited to short-
term use for no longer than seven days as they can give rise to rebound 
congestion (rhinitis medicamentosa) on termination of treatment. The oral 
forms of ephedrine can be found in multi-constituent products, in combination 
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with other active ingredients such as chlorphenamine, paracetamol or 
diphenhydramine, for the purpose of treating coexisting symptoms such as 
headaches or excessive nasal secretions that are frequently associated with a 
cold or a flu (Sweetman 2007). As of April 2010, there were seven proprietary 
brands of ephedrine containing preparations available in the UK. All except 
one (CAM Mixture) were multi-ingredient products (Chemist and Druggist: 
Monthly Pricelist April 2010). Their OTC indications included treatment for 
cold or flu symptoms, wheezing and bronchitis (Chemist and Druggist: Guide 
to OTC Medicines + Diagnostics, September 2008). 
 
3.1.1.2 Pseudoephedrine 
Pseudoephedrine (PSE) is a stereoisomer of ephedrine with notably fewer 
central nervous system effects and therefore its use may be preferable in many 
patients (Sweetman 2007; Blenkinsopp et al. 2009). PSE is only available 
orally in the UK and, therefore, unlike topical ephedrine it does not cause 
rebound congestion after prolonged use (BNF 2013). According to the BNF 
(2013) the only licensed indication for PSE is the symptomatic relief of nasal 
congestion and its use in children under six years old is not recommended 
(NICE 2011). In the UK, PSE can be found in single ingredient as well as 
multi-ingredient preparations (Sweetman 2007). The latter are often combined 
with ingredients such as paracetamol or ibuprofen for treating concurrent 
symptoms associated with a cold, flu or allergy (Chemist and Druggist: Guide 
to OTC Medicines + Diagnostics, September 2008). 
 
3.1.1.3 Phenylephrine 
Phenylephrine (PE) is a sympathomimetic that possesses predominantly alpha-
adrenergic activity (Sweetman 2007). Its usefulness as a nasal decongestant is 
not formally acknowledged in the BNF (2013) due to its unproven efficacy 
(Eccles 2007; Hatton et al. 2007; Horak et al. 2009; Kollar et al. 2007). Despite 
the lack of evidence, PE-based products have long been available OTC because 
they were licensed many years ago at a time when robust evidence for efficacy 
was not required (Eccles 2007). As a nasal decongestant, PE may be given 
orally or applied topically in the form of nasal drops; the former route is not 
associated with rebound congestion after prolonged use but can give rise to 
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unwanted cardiovascular side effects, such as hypertension (Sweetman 2007). 
Similar to ephedrine and PSE containing products, PE is frequently found in 
preparations with other active ingredients intended to treat a range of common 
cold and flu symptoms (e.g. Beechams All-In-One), but is also available as a 
single-ingredient product (e.g. Sudafed Non-Drowsy Congestion Relief). The 
use of PE use in children under six years old is not recommended due to the 
unfavourable balance of benefits and risks (NICE 2011). 
 
3.1.1.4 Other nasal decongestants 
Oxymetazolin (OXY) and xylometazolin (XLY) are sympathomimetics with 
marked alpha-adrenergic activity but, unlike ephedrine, PSE and PE, they are 
used only topically as nasal sprays or nasal drops (Sweetman 2007). OXY and 
XLY are considered to be more potent topically than ephedrine-based products 
and are active over a longer relief period with the effect lasting between 5 and 
10 hours. However, in practice, they are unsuitable for long-term use (no 
longer than seven days) due to the likelihood of rebound congestion 
(Blenkinsopp et al. 2009). In the UK, OXY and XYL are classified as General 
Sales List (GSL) medicines therefore availability and sales are not restricted to 
pharmacy settings and may be purchased from any retail outlet (RPS 2011a). 
OTC products containing either of these two ingredients are marketed in the 
UK for nasal congestion due to allergic rhinitis, sinusitis or the common cold. 
As with other sympathomimetic drugs, they are not recommended for children 
under six years of age (NICE 2011). 
 
Another popular OTC treatment for nasal congestion is steam inhalation using 
volatile substances, such as eucalyptus oil, peppermint oil and menthol. These 
substances are used by dissolving them in warm water and inhaling the moist 
air. Alternatively, they may be applied to clothing or handkerchiefs and inhaled 
when required (Blenkinsopp et al. 2009; NICE 2011). Lozenges or pastilles 
containing peppermint oil and related cooling compounds have also been 
formulated and they induce the decongestant effect through menthol vapours 
reaching the nasal cavity via the nasopharynx during swallowing (Eccles 
1994). Aromatic decongestants may not be suitable for infants and the BNF 
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(2013) advise saline nasal drops (sodium chloride 0.9%) be used instead (NICE 
2011). 
 
The use of topical saline preparations as an adjunct therapy has been found to 
be beneficial for nasal congestion symptoms and is well-tolerated (Harvey et 
al. 2009). Its mechanism of action is unknown but is thought to involve 
cleansing of the nasal passage, removal of inflammatory mediators and the 
promotion of ciliary beat frequency (Rabago and Zgierska 2009). In the UK, 
topical saline preparations are available in a wide range of formulations such as 
sprays, pumps, nebulisers or solutions. Both saline and inhalation based 
products are readily available for purchase OTC as GSL medicines and are 
indicated for nasals congestion due to a cold, influenza, hay fever or catarrh 
(Chemist and Druggist: Guide to OTC Medicines + Diagnostics, September 
2008).  
 
3.1.2 Changes to Over-the-Counter sale and supply 
In March 2007, the Medicines and Healthcare products Regulatory Agency 
(MHRA), the government agency responsible for regulating the safety and 
effective use of human medicines and healthcare devices in the UK, launched a 
public consultation and collated views on changing the legal status of OTC 
products containing PSE and ephedrine from P to POM (MHRA 2007a). The 
consultation was triggered by two events that took place at around the same 
time; first of which was the reclassification of methylamphetamine to a class A 
controlled drug (Anon. 2006) and the second was the discovery of illicit 
manufacturing of methylamphetamine using OTC medicines containing PSE 
and ephedrine (Hampshire Constabulary 2007; Association of Chief Police 
Officers [ACPO] 2007). 
 
Methylamphetamine, commonly known as methamphetamine, crystal meth or 
ice, is a highly addictive central nervous system stimulant that can cause long-
term physical and psychological damage to the user (Darke et al. 2008). The 
manufacture of methylamphetamine was a serious issue for the MHRA to 
consider not only because OTC products containing ephedrine and PSE had 
been used as precursors in the illicit manufacture, but the process was 
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relatively straight forward and could be undertaken by anyone with low a level 
of skill and in a domestic environment (Commission on Human Medicines 
[CHM] 2007; ACPO 2007). There was also an anecdotal report of test 
purchases of large quantity of oral nasal decongestants from pharmacies that 
went unchallenged and this also raised some concerns (Anon. 2007c).  
 
The MHRA undertook a public consultation on the reclassification of PSE and 
ephedrine containing products (MHRA 2007a). The consultation attracted a 
response from a range of interested parties, including law enforcement 
agencies, patient and substance misuse organisations, the medical profession, 
the pharmacy profession and the industry. Among those who supported a 
change of legal status from P to POM were those who agreed that the 
continued availability of OTC ephedrine and PSE posed a significant risk that 
could increase the use of methylamphetamine. Others objected to the proposal 
on the basis that the move could negatively impact on GP workload (Walker 
2007), reduce patient choice (Angwin 2007) and showed a perceived lack of 
trust in the pharmacy profession (Styles 2007). 
 
Having taken into account the scale of the problem and the potential for harm 
from methylamphetamine in the UK, the CHM concluded that the legal status 
of medicinal products containing PSE and ephedrine should remain as a P 
medicine providing the risk of misuse in the illicit manufacture of 
methylamphetamine was contained. To support the decision, a voluntary pack 
size restriction on PSE and ephedrine containing products was agreed between 
the product manufacturers and the MHRA in August 2007, which saw 
maximum quantity of PSE and ephedrine limited to 720mg and 180mg per 
pack, respectively. Furthermore, purchases of these products were restricted to 
one pack per transaction (Anon. 2007d). These changes generated a 
considerable amount of attention within the pharmacy profession and were 
accompanied by plans to increase awareness of misuse and promote 
widespread training of pharmacy staff (Anon. 2007e, 2007f, 2007g, 2007h). 
 
Following the voluntary agreement to restrict the pack size of PSE and 
ephedrine containing products, a further public consultation in October 2007 
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considered specific proposals to make the sale and supply of these products 
subject to prescription control (MHRA 2007b). The intention was to ensure the 
limit on pack size was implemented by all manufacturers. At the time, 
respondents to the consultation were generally supportive of the proposal albeit 
some concerns over the date of implementation and restriction to one pack per 
sale (MHRA 2008b). Subsequently, legislation was enacted on 1 April 2008 
(MHRA 2008c) and it became unlawful to sell or supply: 
 
• any preparation containing more than 720mg or 180mg of PSE or 
ephedrine, respectively, without a prescription, 
• a combination of products that between them add up to more than 
720mg of PSE or 180mg of ephedrine without a prescription in one 
transaction, and 
• any PSE-containing products together with an ephedrine product 
without a prescription  
 
3.1.3 Concerns 
In the four years up to 2011, following the introduction of OTC sales 
restrictions on PSE and ephedrine containing products, the various measures 
implemented to help to minimise the risk of their misuse have been reported to 
be successful and no trigger has yet prompted a further review of their 
availability OTC by the MHRA (MHRA 2012b). For example, UK-wide sales 
figures of PSE containing products have indicated a year-on-year decline from 
2008 up to 2011 (MHRA 2009c, 2010, 2011a, 2012b). However, whether the 
sales of these products in Wales followed the same UK-wide trend is unknown 
and would be of interest to study. In addition, concerns raised at the time of the 
consultation regarding increased GP workload and prescribing costs as a result 
of stricter control of OTC nasal decongestants (Royal College of Physicians 
2007; Royal College of General Practitioners 2007) have not been examined. 
The impact of increased regulation of OTC nasal decongestants on other 
primary healthcare services, such GPs, would be of interest to government, 
medicine regulators and healthcare professionals.  
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3.1.4 Aims 
The aims of this study were to determine the impact of pack size restriction on 
(a) OTC sales of PSE, ephedrine and PE containing preparations; and (b) 
quantify the prescribing of nasal decongestants on primary care prescriptions in 
Wales. 
 
3.2 Method 
 
3.2.1 Study design  
This ecological study involved the retrospective analysis of pharmacy 
wholesale data and primary care prescription data for Wales. Changes in 
quantities sold for selected, OTC PSE, ephedrine and PE containing 
preparations, before and after the imposition of legal restrictions on sale of PSE 
and ephedrine OTC, were determined. In addition, any changes in the quantity 
of nasal decongestants supplied on primary care prescriptions in Wales were 
also determined. 
 
3.2.2 Data 
 
3.2.2.1 Primary care prescription data  
Prescription data for Wales were extracted from the NHS Wales prescription 
database using CASPA.net (Comparative Analysis System for Prescribing 
Audit) and was the same data source as described in Chapter 2 (Section 
2.2.2.1). The data were obtained for the period between April 2004 and March 
2011 (84 months) on a monthly basis and represented prescribing by GPs. In 
the current study, the quantity supplied on prescription was presented as the 
number of prescription items. 
 
3.2.2.2 Pharmacy wholesale data  
Pharmacy wholesale data were extracted using the IMS Health Dataview 
application from the Regional Sales Analysis (RSA) database. This was the 
same database as described in Chapter 2 (Section 2.2.2.2) and the purchase of 
medicines by pharmacies from wholesalers was utilised as a surrogate for 
pharmacy-to-patient sales (herein referred to as the pharmacy sales data). In the 
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present study, pharmacy wholesale data for Wales were extracted as the 
monthly number of packs sold for the selected OTC preparation between April 
2004 and March 2011 (84 months). The quantities supplied in packs were also 
converted into the weight of active ingredient sold based on the pack size 
information that were also available in the RSA database. Chemist and 
Druggist: Monthly Pricelist April 2010 was used as a reference source to 
determine the amount of PSE, ephedrine or PE contained in a particular 
product. Calculations of the weight of the active ingredient were undertaken in 
Microsoft Excel spreadsheet. 
 
3.2.3 Medicines studied  
 
3.2.3.1 Medicines supplied on NHS prescription  
Prescription medicines studied included all preparations listed under the 
following chapters of BNF 65 (2013) and indicated for the symptomatic relief 
of nasal congestion: 
 
• Aromatic inhalations (3.8) 
• Systemic nasal decongestants (3.10) 
• Topical nasal decongestants (12.2.2) 
 
In addition, a manual search of the prescription database was undertaken by the 
researcher to identify any nasal decongestants not listed under the relevant 
BNF chapters. As an example, PE capsules were not listed in BNF 65 chapter 
3.10 but were available in the Wales prescription database for extraction. The 
active ingredient contained in manually identified preparations and their 
corresponding clinical indications were confirmed using Martindale: The 
Complete Drug Reference (Sweetman 2007) and Chemist and Druggist: 
Monthly Pricelist (April 2010 issue). Both proprietary and non-proprietary 
preparations were included in the study and they are shown in Appendix 10 
and Appendix 11. 
 
3.2.3.2 Over-the-Counter medicines  
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All proprietary PSE, ephedrine or PE containing products that were sold OTC 
during the period of the study in the UK were identified using May 2004, April 
2006, April 2008 and April 2010 issues of Chemist and Druggist: Monthly 
Pricelist. Next, the main active ingredient responsible for producing the nasal 
decongestant effect was identified on individual product basis and preparations 
for which sales data was available in the RSA database were extracted for OTC 
sales analysis. The preparations included both P and GSL products in oral 
dosage forms (tablets, capsules, effervescent powders or liquids). Furthermore, 
a manual search of the RSA database was undertaken by the researcher after 
the initial selection to identify if there were other preparations that could be 
purchased without a prescription and none were identified. Lists of all OTC 
PSE and PE containing products included in the pharmacy sales data analysis 
are shown in Appendix 12 and Appendix 13, respectively. Data for none of the 
OTC ephedrine containing products sold in the UK were available in the RSA 
database and thus were not included in the current study. 
 
3.2.4 Data processing and organisation  
Prescription and pharmacy wholesale data for Wales were transferred from 
their respective database into Microsoft Excel spreadsheet as described in 
Appendix 8 and Appendix 9. The quantities supplied OTC and prescribed on 
prescription were arranged into 12-month blocks, from April to March for each 
year, to allow the comparison between the periods before and after 
implementation of the legal policy. There were four 12-month blocks prior to 
the legal restriction on OTC pack size (April 2004 to March 2008) and three 
12-month blocks after (April 2008 to March 2011). All processed or 
reorganised data were manually screened for error before transferring to 
statistic software for analysis. 
 
3.2.5 Analysis 
 
3.2.5.1 Descriptive analysis  
The supply of OTC PSE and PE in Wales was presented as 12-monthly totals 
from April 2004 to March 2011 in i) number of packs and ii) weight of the 
active ingredient supplied in grams. Prescription supplies of nasal 
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decongestants were presented only as the number of items supplied. The 
median and the interquartile range (IQR) for the component month for each of 
the 12-month periods were also determined. 
 
3.2.5.2 Impact of regulatory changes on Over-the-Counter sales  
Changes in the supply of PSE, PE and other nasal decongestants, on 
prescription and OTC from pharmacies, were determined between two 
consecutive 12-month periods and any difference was explored using 
Wilcoxon’s signed-rank test. A p-value < 0.05 was considered to be 
statistically significant. Statistical analyses were performed using PASW 
version 18 (PASW Inc., Chicago, IL, USA). 
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3.3 Results 
 
3.3.1 Over-the-Counter supply 
The number of packs and weight of active ingredient supplied each for PSE 
and PE containing products are shown in Figure 3.1. Overall, OTC supply of 
PSE containing products declined in Wales between 2004 and 2011. This 
corresponded to a 48% (49,543/103,173) reduction in number of packs sold 
and a 53% (32,699/61,323) reduction in weight of PSE sold. Over the same 
period, PE containing products demonstrated a 40% (81,024/204,015) 
reduction in the number of packs sold but the cumulative weight reduced only 
by 6% (772/12,953). 
 
 
 
Figure 3.1 Twelve-monthly sales of over-the-counter pseudoephedrine (PSE) and 
phenylephrine (PE) containing preparations in Wales 
 
 
3.3.1.1 Pseudoephedrine 
OTC supplies of PSE containing products and their respective median and IQR 
for each 12-month period are shown in Table 3.1. 
  
 94 
Table 3.1 Total supplies (median, interquartile range) of over-the-counter 
pseudoephedrine containing products in Wales for each 12-month period (April to 
March) between 2004 and 2011. Quantities supplied were compared between two 
consecutive periods and an asterisk (*) marks any significant difference (p<0.05) 
 
 Packs p-value  Weight (grams) p-value 
2004/05 103 173 (8 733, 4 171)   
61 323 
(5 069, 1 713)  
2005/06 95 465 (7 900, 2 516) 0.239  
58 313 
(4 825, 1 143) 0.388 
2006/07 90 015 (7 409, 4 222) 0.182  
55 432 
(4 956, 2 071) 0.209 
2007/08 88 354 (5 667, 4 635) 0.875  
53 428 
(3 985, 2 541) 0.875 
2008/09 86 185 (5 618, 4 133) 0.388  
46 629 
(3 106, 2 152) 0.023* 
2009/10 67 684 (4 185, 3 084) 0.023*  
36 608 
(2 233, 1 629) 0.028* 
2010/11 53 630 (3 641, 1 773) 0.006*  
28 624 
(1 977, 908) 0.006* 
 
 
Year-on-year there were reductions in number of packs sold, from 2005/06 to 
2010/11 of 7% (7 708/103 173), 6% (5 450/95 465), 2% (1 661/90 015), 2% (2 
169/88 354), 21% (18 501/86 185) and 21% (14 054/67 684), respectively. 
Year-on-year percent reductions in the weight of PSE sold, from 2005/06 to 
2010/11, were 5% (3 010/57 313), 5% (2 881/55 432), 4% (2 004/55 432), 
13% (6 799/46 629), 21% (10 021/36 608) and 22% (14 904/28 642), 
respectively. A marked decline in supply was noted from 2008 (Figure 3.1), 
which coincided with the implementation of legal restrictions on the sale of 
OTC PSE and ephedrine containing products. 
No significant difference in the number of packs nor weight of PSE supplied 
was found compared to the previous 12 months for 2005/06, 2006/07 and 
2007/08 (all p> 0.05). In 2008/09, the weight of PSE supplied was significantly 
less than in 2007/08 (p=0.023) although there was no reduction in the number 
of packs supplied (p=0.388). This coincided with the first 12-month period 
after the legal policy was introduced. Thereafter, in the last two years of the 
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study (2009/10 and 2010/11), the supply of PSE in terms of both the number of 
packs and weight were both significantly less than the previous 12-month 
period (Table 3.1). 
 
3.3.1.2 Phenylephedrine 
Sales of PE containing products and their respective median and IQR for each 
12-month period are shown in Table 3.2. 
 
 
Table 3.2 Total supplies (median, interquartile range) of over-the-counter 
phenylephrine containing products in Wales for each 12-month period (April to 
March) between 2004 and 2011. Quantities supplied were compared between two 
consecutive periods and an asterisk (*) marks any significant difference (p<0.05) 
 
 Packs p-value  Weight (grams) p-value 
2004/05 204 015 (18 230, 15 275)   
12 953 
(1 121, 1 009)  
2005/06 194 625 (14 805, 15 176) 0.480  
13 416 
(1 161, 1 305) 0.530 
2006/07 158 315 (12 934, 12 004) 0.023*  
15 367 
(1 229, 1 146) 0.530 
2007/08 162 296 (10 607, 15 170) 0.875  
15 859 
(1 001, 1 535) 0.937 
2008/09 172 310 (7 841, 16 037) 0.388  
17 040 
(764, 1 563) 0.388 
2009/10 137 895 (8 117, 13 112) 0.182  
13 712 
(814, 1 344) 0.272 
2010/11 122 991 (5 619, 10 671) 0.182  
12 181 
(572, 1 061) 0.182 
 
 
Wilcoxon’s signed rank test indicated no significant difference (p> 0.05) 
between any two consecutive 12-month periods from 2004/05 to 20010/11 for 
the supply of PE containing products. The only exception was in 2006/07 when 
there was a significant reduction in number of packs sold in comparison to 
2005/06 (p=0.023). 
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3.3.2 Prescription supply 
The supply of non-systemic nasal decongestants (aromatic inhalation [BNF 
section 3.8] + topical nasal preparations [BNF section 12.2.2]) and PSE 
containing nasal decongestants on primary care prescriptions are shown in 
Figure 3.2. 
 
 
 
 
Figure 3.2 Total 12-monthly items of non-systemic nasal decongestants (aromatic 
inhalation [BNF section 3.8] + topical nasal preparations [BNF section 12.2.2]) and 
pseudoephedrine (PSE) containing products supplied on primary care prescriptions in 
Wales 
 
 
Overall, the numbers of items of non-systemic nasal decongestants supplied on 
prescription between 2004 and 2011 remained steady. The volume supplied in 
each 12-month period fluctuated between 30,000 and 35,000 items. In contrast, 
PSE containing decongestants reduced by 38% (10,412/27,354) from 27,354 
items to 16,942 items over the same period. 
 
In comparison to non-systemic and PSE containing nasal decongestants, 
supplies of ephedrine and PE containing products on prescription were low. 
For example, in the final 12 months of the study up to March 2011, there were 
less than 1% of PSE and non-systemic decongestants supplied on prescription. 
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Throughout the entire study period, the highest total quantity of ephedrine 
containing products prescribed and supplied in any 12-month period was 225 
items in 2004/05 and 105 items in 2010/11 for PE containing products. 
 
Table 3.3 shows the total supply, median and IQR for non-systemic and PSE-
containing decongestants supplied on prescription for each of the 12-month 
periods between 2004 and 2011. 
 
Table 3.3 Total items (median, interquartile range) of non-systemic (aromatic 
inhalation [BNF section 3.8] + topical nasal preparations [BNF section 12.2.2]) and 
pseudoephedrine (PSE) containing nasal decongestants dispensed in Wales for each 
year (April to March). Supplies were compared to with the previous 12-month period 
and any significant difference (p<0.05) is marked by an asterisk (*) 
 
 Non-systemic decongestants p-value  PSE p-value 
2004/05 32 311 (2 409, 913)   
27 354 
(2 221, 685)  
2005/06 32 721 (2 720, 462) 0.875  
29 850 
(2 293, 1 155) 0.019* 
2006/07 30 801 (2 535, 546) 0.060  
27 165 
(2 302, 483) 0.023* 
2007/08 33 909 (2 781, 478) 0.010*  
28 177 
(2 313, 646) 0.347 
2008/09 34 478 (2 846, 360) 0.530  
26 453 
(2 161, 425) 0.136 
2009/10 34 020 (2 781, 414) 0.182  
22 467 
(1 892, 509) 0.002* 
2010/11 33 495 (2 740, 258) 0.347  
20 825 
(1 672, 424) 0.023* 
 
 
Year-on-year analysis of non-systemic nasal decongestants indicated there was 
generally no significant difference (p>0.05) in the number of items prescribed 
between any two 12-month periods except in 2007/08 there was a significant 
increase (p=0.010). For PSE containing decongestants, there was a significant 
increase in numbers of items supplied compared to the previous year in 
 98 
2005/06 (p=0.019) whilst there were significant reductions in 2006/07 
(p=0.023), 2009/10 (p=0.002) and 2010/11 (p=0.023). 
 
3.4 Discussion 
The results from the present study indicate that the total weight of PSE 
supplied OTC fell significantly in the first 12 months following the 
introduction of policy restrictions but the overall numbers of packs sold were 
unaffected. This was not an unexpected outcome as pharmacy retailers and 
product manufactures were likely to have stopped large pack sizes during that 
period. Upon closer inspection of the current pharmacy sales data, it was noted 
products that contained greater than 720mg of PSE were discontinued after 
April 2008. This suggests the legal restrictions on PSE and ephedrine 
containing products had an immediate impact on the OTC market. 
 
In contrast, during 2009/10 and 2010/11, the total weight as well as the number 
of packs of PSE containing products sold, simultaneously declined compared 
to the previous 12 months. This suggests there was an overall reduction in the 
number of packs sold from pharmacies. This could have been the result of both 
legal and non-legal measures that were being promoted at the time. For 
example, sales of a PSE and ephedrine containing products in the same 
transaction were no longer permitted without a prescription. Multiple pack 
purchases were also unlikely as the total quantity of PSE or ephedrine would 
have exceeded the legal limit. Non-legal measures, including the increased 
awareness and training among pharmacy staff about the misuse potential of 
PSE and ephedrine containing products and sales alerts, may have contributed 
to an increase in the number of refused sales (Anon. 2007i, 2008a; 
LearnSomething 2007). Furthermore, educational material on how to identify 
unusual product requests were developed (RPSGB 2008). The increase in staff 
vigilance may have also prevented inappropriate sales of PSE and ephedrine 
containing products but could also have deterred legitimate requests. 
 
A decline in the sales of PSE containing products have been reported across the 
UK following the sales restriction policy. The reported reductions varied from 
7% to 26%, year-on-year, between 2009 and 2012 (MHRA 2009c, 2010, 
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2011a, 2012b). The findings from the current study suggest that OTC sales in 
Wales followed the same trend and the levels of reduction were comparable to 
that seen across the UK as whole. A recent report suggested that the UK-wide 
decline in the sales of PSE containing products reached a plateau in 2012 
(MHRA 2012b). Whether or not this has also occurred in Wales is unclear and 
will require further monitoring. 
 
Attempts to explain the reduction in sales of PSE containing product on the 
basis that there was a shift to consumers using PE based products appeared not 
to be the case. The absence of a shift could have been due to the unproven 
efficacy of PE in relieving nasal congestion symptoms (Horak et al. 2009) or 
consumers being simply unwilling to use a different preparation to the one they 
were used to. However, it was possible that sales of other OTC nasal 
decongestants which were not included in the current study, such as topical 
preparations, increased and warrants further investigation. The introduction of 
free prescriptions in Wales in 2007 (Cohen et al. 2010) probably contributed 
little or no impact on the reduction of PSE sold OTC as items of nasal 
decongestants supplied on prescription have remained steady throughout the 
study. 
 
The decline in sales of PSE containing products was not accompanied by an 
increase in primary care prescribing of nasal decongestants over the same time 
period. As a consequence, there is no evidence to substantiate the concerns that 
individuals would seek to obtain a prescription for PSE or ephedrine containing 
nasal decongestants from their GPs. Consequently, the restrictions to reduce 
access to PSE and ephedrine containing products OTC in 2008 did not result in 
additional drug costs to the NHS as some initially suggested (Anon. 2007j, 
Berg 2007). The present study has shed little light as to what caused the decline 
in the prescribing of PSE containing nasal decongestants during the study 
period. It is possible this was due to a general increase in awareness among GP 
prescribers regarding illicit manufacturing of methylemphetamine from PSE or 
ephedrine containing products (Anon. 2007k). 
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There were two other changes to the sales of OTC products containing nasal 
decongestants during the study which could also have influenced the results. 
The first change was in March 2008 when the MHRA announced OTC cough 
and cold preparations containing PSE or PE should no longer be used in 
children younger than two years old (Anon. 2008b; MHRA 2008d). The 
second was in February 2009 when the MHRA extended this recommendation 
to include children under six years of age, and advised the use of PSE and 
ephedrine decongestants to be reserved as second-line treatment for children 
aged between six and twelve years (Anon. 2009d; MHRA 2009d). On 
reviewing the products included in the current study, several of them would 
have been affected by these announcements, including Benylin 4 Flu tablet and 
liquid, Day Nurse capsule and liquid, Lemsip Sinus capsule and Sudafed Non-
Drowsy tablet. The current study was, however, unable to identify what 
proportion of the OTC sales were related to paediatric use and therefore the 
influence of this updated practice guidance on sales is unknown. 
 
3.4.1 Study Limitations 
 
3.4.1.1 Ecological study 
The pharmacy sales data used in the current study were useful for quantifying 
the supply trends but were unable to provide an explanation for the changes 
observed. A qualitative study exploring the views of consumers’ and the 
pharmacy staffs’ may have helped to identify the factors responsible for the 
changes and would aid future regulatory decisions. 
 
The appropriateness of OTC sales and prescription supplies of the nasal 
decongestants under study could not be determined from the work undertaken. 
In order to investigate whether pharmacists and their staff were making legal 
and clinically appropriate supplies of nasal decongestants OTC would require 
an observational study with a pre-determined assessment criteria for the OTC 
sales of nasal decongestants. 
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3.4.1.2 Prescription data 
The prescription data obtained from the NHS prescription database were 
comprehensive and are routinely used to study patterns of prescribed medicines 
in primary care. However, the current study only included prescriptions that are 
written by GPs and excluded those written by non-medical prescribers, such as 
independent nurse or pharmacist prescribers (discussed in detail in Section 
4.4.2.2). As a result, the prescription figures reported in the present study were 
probably underestimates of the actual prescribing figure. 
 
Unlike the OTC sales data, which were presented as the total number of packs 
and weight of active ingredients sold, the unit of measure used for the 
prescription data was the number of prescription items supplied. Given that GP 
prescribers could have requested more than one pack of nasal decongestants to 
be supplied to a patient per item, a direct comparison between quantities of 
medicine sold OTC and those supplied on prescription in those units of 
measure could have been problematic. However, this was not considered a 
major issue for the current study because the purpose of the prescription data 
was to detect a shift in the use of nasal decongestants following introduction of 
the legal policy rather than for it to be directly compared with OTC supply. 
 
3.4.1.2 Pharmacy wholesale data 
Pharmacy wholesale data were obtained from the RSA database and 
represented the sales of medicines from pharmaceutical wholesalers to 87% 
(614/708) of all NHS-contracted community pharmacies in Wales. As a result 
of the missing data for the remaining 13% of community pharmacies, 
wholesale figures reported in the current study are probably underestimates of 
the actual supply picture. Details relating to the coverage and accuracy of the 
RSA dataset are discussed in Sections 2.4.2.2 and 4.4.2.4, respectively. 
 
One important assumption about using pharmacy sell-in data as a proxy for 
actual pharmacy-to-patient sales was that a pharmacy would have sold most, if 
not all, of the stock it had purchased within a four-week period. The approach 
of using pharmacy sell-in data as a marker of sales has been adopted by other 
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studies in the UK investigating medicine utilisation in the primary care setting 
(Cohen et al. 2010; Davis et al. 2009; Dhippayom and Walker 2006). 
 
In contrast to pharmacy-to-patient sales data, one notable confounder for sell-in 
data is its vulnerability to factors unrelated to actual customer demand. For 
example, the timing of stock purchase could have been skewed by promotional 
activities by the manufactures or bulk-buying discount offered at a particular 
time of the year. Advance purchase in anticipation of demand, particularly for 
seasonal items such as to cold and flu products, was also possible. While these 
scenarios might have been the case for the products monitored in the present 
study, the sales figures were quantified in a 12-monthly format and therefore 
any seasonal variations would have been accounted for in the analysis. 
 
There has been one report of the illegal production of methylamphetamine in 
the UK using PSE containing nasal decongestants bought over the internet 
(MHRA 2011a). The supplies of these products obtained via the online route 
were raised as a concern at the time of reclassification in 2007 (Anon. 2007l). 
Pharmacy wholesales data utilised in the current study only included data for 
pharmacies located in Wales. Therefore, it is possible that supplies for products 
monitored in the current study could also have been obtained from online 
pharmacies located elsewhere in the UK or overseas. Given the recognised 
potential of growth and the indication that pharmacy users are increasingly 
turning to internet pharmacies to purchase medicines (Bloodworth 2012), the 
online retail sector could account for a significant proportion of OTC sales in 
the future and this needs to be investigated further. 
 
3.4.1.3 Medicines studied 
During the six-year study period wholesale data for 25 and 66 proprietary OTC 
products containing PSE and PE, respectively, were obtained. Whilst this data 
had included many leading brands of OTC nasal decongestants sold in the UK, 
not all of the products on the market were included in the study. 
 
An analysis of proprietary PSE and PE containing products available OTC in 
the UK between 2004 and 2010 showed product coverage in the current study 
 103 
was 40% (25/65) for PSE and 84% (66/79) for PE containing products 
(Chemist and Druggist: Monthly Pricelist May 2004, April 2006, April 2008, 
April 2010 issue). As a result, the sales figures reported are likely to be 
underestimates of the actual supply in Wales. 
 
Another notable omission for the current study was that sales data for 
ephedrine containing products were not available in the RSA database. 
Consequently, these preparations were not investigated. Other nasal 
decongestants that could have been bought OTC, such as topical 
sympathomimetics, inhalation-based products or own-brand (generic) products, 
were also not monitored in the present study. These sales data potentially hold 
explanations for the decline in the sales of PSE containing decongestants. 
Future studies should utilise data with a more comprehensive coverage of 
products to ensure a full overview of the OTC market is possible. Other 
potential confounding issues related to Medicine Counter Assistant (MCA) 
training and sales protocol have been discussed in Section 2.4.2.5. 
 
3.5 Summary 
In the three-year period following the introduction of legal restrictions on the 
sales of PSE and ephedrine containing products in the UK, the supply of OTC 
PSE based products in Wales have significantly reduced. The magnitude of the 
reductions were consistent with those observed for the UK as a whole, 
providing reassurance that the legal measures introduced in 2008 have had the 
desired impact in Wales. Furthermore, the reduction in OTC sales of PSE 
containing products was not accompanied by an increase in GP prescribing of 
nasal decongestants on primary care prescriptions. This suggests that concerns 
related to the increase in GP workload and primary care prescribing that would 
adversely impact the NHS drugs bills have not materialised. 
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Reclassification of ophthalmic chloramphenicol 
 
4.1 Introduction 
 
4.1.1 Reclassification of medicines 
The practice of self-medication using over-the-counter (OTC) medicines is an 
important element of self-care and is often the starting point for individuals to 
maintain and/or improve their health status (Yiangou 2011). In order for 
patients to undertake appropriate self-medication, medicines need to be 
accessible without the need of a prescription. Whilst the policy regarding 
availability of OTC medicines varies from country to country (Blenkinsopp 
and Bond 2005), in the United Kingdom (UK), medicines which are classified 
as Pharmacy (P) medicines are available for sale from pharmacies only and 
those classified as General Sales List (GSL) medicines can be purchased from 
general retail outlets by self-selection (Human Medicines Regulations 2012). 
Medicines under both the P and GSL categories are free from prescription 
control, whereas Prescription-Only Medicines (POM) can only be obtained on 
a prescription.  
 
As mentioned in Chapter 1 (Section 1.3), the range of medicines available 
OTC could be expanded through medicine reclassification (MHRA 2012a). 
This involves a medicine being ‘switched’ from POM to P status or from P to 
GSL status. Among the drivers for a wider range of OTC medicines are 
patients’ desire for greater autonomy and choices of medicines (Brass et al. 
2009; Hanna and Hughes 2011), pharmacists’ wish to extend their clinical role 
in the care of their patients (Bellingham 2002; Tasker et al. 2008; Weidmann et 
al. 2011), desire for greater profits by the pharmaceutical industry 
(Blenkinsopp 2004; Bond 2001) and government’s need to reduce drug 
spending by the National Health Service (NHS) (Blenkinsopp and Bradley 
1996; Bond and Hannaford 2003; Brass et al. 2009). The decision to reclassify 
a medicine and making it more widely available depends on the balance of 
risks and benefits associated with the increased access of the drug in question 
(Table 4.1). This assessment of risks versus benefits is undertaken by the 
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Medicines and Healthcare Products Regulatory Agency (MHRA), which is the 
medicine regulator in the UK (MHRA 2012a). 
 
Table 4.1 Considerations of risks and benefits associated with making a medicine 
available without a prescription (Source: Brass et al. 2009) 
 
Risk considerations Benefit considerations 
Unintended misuse Improved access to effective drugs 
Intentional misuse with 
therapeutic intent Improved clinical outcomes 
Accidental ingestion Improved public health 
Intentional overdose Enhanced involvement by consumers in their health care 
Worsened outcomes due to 
self-management 
Economical benefits of non-
prescription availability 
 
 
There have been many successful POM to P switches in the last decade 
(Proprietary Association of Great Britain [PAGB] 2011a). These 
reclassification initiatives were supported by the publication of several health 
strategies by the Department of Health (DH), which pledged to improve 
public’s access to non-prescription medicines by increasing the range of 
treatment available from pharmacies and the number of reclassified medicines 
each year (DH 2000, 2003a, 2003b, 2005, 2008). This commitment by the UK 
government was recently reiterated in a plan to reduce the processing time of 
reclassification applications in order to maintain a steady stream of newly 
reclassified medicines (Anon. 2012b, 2012c). 
 
By making more medicines available OTC, the government hope it would 
allow individuals to engage better in practicing self-care, make better 
utilisation of pharmacists’ clinical skills, knowledge and resources, and reduce 
the number of minor ailments seen by doctors in order to free up their time for 
patients with more serious health problems (Blenkinsopp and Bond 2005). 
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However, it should noted that these potential benefits associated with medicine 
reclassification are not routinely evaluated. As a consequence, whether or not 
many of the reclassified medicines in the UK have had the desired, positive 
impact on patients’ health and the wider healthcare system are not always 
clear. 
 
In 2002, Royal Pharmaceutical Society of Great Britain (RPSGB), the then 
professional body and regulator of pharmacists in the UK, published a long list 
of potential candidates for POM to P switches to support government’s 
reclassification policy (RPSGB 2002). The therapeutic class of medicines 
proposed for reclassification was wide ranging, covering both minor ailments 
such as dyspepsia and chronic conditions such as hypertension. Over the years, 
many of the medicines suggested for deregulation at the time have since 
became available OTC in the UK (PAGB 2011a). 
 
Whilst the reclassification effort has traditionally focused on medicines used in 
minor and self-limiting conditions, medicines for long-term use, such as 
simvastatin for the primary prevention of cardiovascular event (RPSGB 2004), 
and diseases normally managed by general practitioners (GPs), such as 
tamsulosin for the symptom of benign prostatic hyperplasia, have also been 
reclassified (PAGB 2012). This emerging trend of reclassification for 
medicines used in chronic diseases is in line with the strategic intent of the UK 
government, which was to enable patients to practice self-medication for even 
long-term conditions (DH 2008). 
 
The present study examined one particular medicine that was the first of its 
therapeutic class to become reclassified from POM to P status in the UK and it 
is discussed in the next section. 
 
4.1.2 Ophthalmic chloramphenicol and reclassification 
Chloramphenicol is a broad-spectrum antibiotic that is effective against a large 
number of gram-positive and gram-negative bacteria (Sweetman 2007). Use of 
chloramphenicol via the systemic route is limited due to the potential of a rare 
but serious side effect relating to bone marrow toxicity (Dameshek 1952; 
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Sweetman 2007). Consequently, indiscriminate use of chloramphenicol in 
minor infections is discouraged (Havener 1994). Nonetheless, chloramphenicol 
remains to be a potential treatment for life threatening infections such as 
typhoid fever or bacterial meningitis (British National Formulary [BNF] 2013; 
Sweetman 2007). 
 
As a topical preparation, ophthalmic chloramphenicol are widely used because 
of their broad antibacterial action against common ocular pathogens (Chalita et 
al. 2004). In comparison to other topical antibacterials, chloramphenicol 
possesses the highest overall efficacy among ciprofloxacin, ofloxacin, 
norfloxacin, bacitracin, tetracycline, neomycin, erythromycin, tobramycin and 
gentamicin against ocular bacteria obtained from clinically symptomatic eyes 
(Egger et al. 2001). Due to their superior bactericidal activity, the BNF has 
been and continues to recommend ophthalmic chloramphenicol as the 
antibiotic of choice for superficial eye infections, such as bacterial 
conjunctivitis (BNF 2013). In England, prescription statistic indicates that two-
thirds of all prescriptions for ocular antibiotics were for ophthalmic 
chloramphenicol (Sheikh and Hurwitz 2001).  
 
In the UK, ophthalmic chloramphenicol in an eye drops formulation was first 
reclassified from POM to P status in June 2005. Optrex Infected Eyes® was 
the first proprietary product to be sold on the OTC market. The ointment 
formulation was subsequently reclassified in July 2007 and was available 
under a number of different brands (Brochlor®, Galpharm Vision® and Optrex 
Infected Eyes®). The licensed indication of OTC ophthalmic chloramphenicol 
was for the treatment of acute bacterial conjunctivitis in adults and children 
over two years of age. It was the first antibiotic to receive non-prescription 
status in the UK albeit for ophthalmic use only (Adcock 2005). 
 
Infective conjunctivitis is the most common eye infection encountered in 
primary care in the UK accounting for up to 40% of all eye related GP 
consultations (McDonnell 1988; Sheldrick et al. 1993). Before ophthalmic 
chloramphenicol was available OTC, pharmacists had few non-prescription 
medicines available to them to manage patients with minor eye infections 
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(Hardy et al. 1993a). At the time, preparations containing propamidine 
(Brolene® eye drops) or dibrompropamidine (Golden Eye® ointment) were 
the only topical antibacterials that could be sold without a prescription. 
Although these products have frequently been used in managing patients with 
non-urgent ocular infections in a pharmacy setting (Hardy et al. 1993a; Seston 
et al. 2001), the lack of evidence for their effectiveness (BNF 2013) was a 
concern for many pharmacists (Hardy et al. 1993a). As a consequence, the 
majority of patients with infective conjunctivitis were referred to their GPs 
instead (Seston et al. 2001). It was found that most of these primary care cases 
of suspected infective conjunctivitis were managed by a prescription for 
ophthalmic chloramphenicol (Sheldrick et al. 1993). The inability to counter-
prescribe ophthalmic chloramphenicol was a major frustration for many 
pharmacists and, unsurprisingly, it was one of the most frequently suggested 
candidates for medicine reclassification (Bond et al. 1993). 
 
Following a wide spread public consultation in 2004 (MHRA 2004), the 
proposal to make ophthalmic chloramphenicol available OTC as P medicine 
was welcomed by various representatives of healthcare professionals, including 
nurses, GPs and ophthalmologists (MHRA 2005b). At the time, it was thought 
the benefit of timely access to effective treatment outweighed the risks 
associated with wider availability, such as antibiotic resistance (Brennan 2005), 
potential of misdiagnosis (Rumney 2005) and unnecessary medicalisation of 
what is, in most patients, a self-limiting condition (Tuft 2005). The theoretical 
risk of bone marrow toxicity associated with the use of topical 
chloramphenicol was also considered during the consultation process (MHRA 
2004). However, evidence from large national and international case-controlled 
studies suggested the risk were extremely low (Lancaster et al. 1998; Laporte 
et al. 1998; Wiholm et al. 1998). 
 
4.1.3 Recent findings 
Since the launch of OTC ophthalmic chloramphenicol two important issues 
have emerged. First, there is an increasing body of evidence that suggests 
topical antibiotics are of limited benefit in patients with acute infective 
conjunctivitis (Everett et al. 2006; Jefferies et al. 2011; Rose et al. 2005; Rose 
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2007). As a result of these findings, the latest recommended strategy for 
managing infective conjunctivitis has changed from empirical prescribing to 
advise patients to practice simple self-care measures, such as hand washing, 
regular cleansing and lubrication of the eyes (National Institute for Health and 
Care Excellence [NICE] 2012b). An alternative approach involving ‘no or 
delayed antibiotic’ has also been suggested (Drugs and Therapeutics Bulletin 
[DTB] 2011). Adopting these management strategies is associated with the 
added benefit of minimising the risks of promoting bacterial resistance and 
reducing unnecessary medicalisation of patients (Everett et al. 2006). Findings 
from a recent study suggest these two updated advice for the management of 
infective conjunctivitis may have reduced the prescribing of ophthalmic 
chloramphenicol by GPs in England (Davis et al. 2009). However, whether or 
not these evidences had the same impact on the sales and supply of OTC 
ophthalmic chloramphenicol from pharmacies is unclear. 
 
Secondly, a substantial increase in primary care supply of ophthalmic 
chloramphenicol three years after the reclassification has been observed in 
Wales (Walker and Hinchliffe 2009, 2010). In England, pharmacy sales data 
for ophthalmic chloramphenicol also demonstrated a marked increase in OTC 
supply during the first two years following reclassification (Davis et al. 2009). 
This increase in total overall use could not be explained by a shift in sale to 
another OTC product or by a change in how antibiotics were prescribed by GPs 
(Walker and Hinchliffe 2009). As a result, concerns have been raised regarding 
pharmacists over supplying OTC ophthalmic chloramphenicol (Behjat-Amery 
2012) and whether or not they were aware of the latest practice 
recommendations (Davies et al. 2009). It may be argued that the increased 
sales of OTC ophthalmic chloramphenicol during the early years after 
reclassification was due to the launch a new product and is a reflection of 
normal market growth. However, whether or not the increasing sales trend has 
continued five years after its OTC availability is not known.  
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4.1.4 Aims 
The aim of the current study was to (a) determine the quantity of ophthalmic 
chloramphenicol supplied OTC from community pharmacies in Wales and (b) 
examine the impact of OTC availability on primary care prescriptions five 
years after reclassification. The temporal relationship between ophthalmic 
chloramphenicol supplied OTC and on primary care prescriptions was also 
examined to explore whether their supplies occurred at the same time. 
 
4.2 Method 
 
4.2.1 Study design  
The study had an ecological design (Schoenbach and Rosamond 2000) and 
involved a retrospective analysis of pharmacy wholesale data, retail data from 
a multiple chain pharmacy and primary care prescription data for ophthalmic 
chloramphenicol preparations in Wales. 
 
4.2.2 Data 
The data utilised in the present study were obtained from three different 
sources as outlined below: 
 
4.2.2.1 Primary care prescription data 
Prescribing data for Wales was obtained from the NHS Wales prescription 
database and was the same prescription data as utilised in the Chapter 2 
(Section 2.2.2.1). In the present study, data were extracted as the number of 
items prescribed in a monthly format for each of the 22 Local Health Boards 
(LHBs) in Wales for the period between June 2004 and December 2010 (79 
months). 
 
4.2.2.2 Pharmacy wholesale data 
Pharmacy wholesale (or buy-in) data were extracted from the Regional Sales 
Analysis (RSA) database and this was the same pharmacy sales database as 
utilised in Chapter 2 (Section 2.2.2.2). The RSA database contained sales 
information of medicines from wholesalers to pharmacies rather than actual 
point of sales data. In the present study, the pharmacy wholesale data were 
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extracted in a monthly format for the period June 2005 to December 2010 (66 
months) for each of the 22 LHBs in Wales. The amalgamation of the 22 to 
seven new LHBs in Wales in October 2009 has been described elsewhere in 
this thesis (Section 2.2.2.2). 
 
4.2.2.3 Pharmacy retail data 
Company A was a national, multiple-chain pharmacy in the UK which did not 
contribute data to the RSA database. Under an arrangement with Public Health 
Wales (PHW) and the Welsh Government, pharmacy retail data for the 94 
community pharmacies owned by Company A in Wales were obtained for the 
period between January 2008 and December 2010. This dataset represented 
actual pharmacy-to-patient sales data and complemented the missing portion of 
the pharmacy wholesale data in the RSA database. Sales figures for 
chloramphenicol eye drops, between June 2005 and December 2007, and eye 
ointment, between July and December 2007, were not available. Sales during 
these periods were estimated using linear regression as described in Section 
4.2.4. 
 
The data obtained from Company A included the weekly number of items sold 
from each of their pharmacies together with postcode information. Each of 
Company A’s pharmacies was allocated to their corresponding LHBs using a 
list of pharmacy contractor’s in Wales provided by PHW (personal 
communication). The weekly retail figures were aggregated into their 
corresponding month to conform to the format of pharmacy wholesale data 
which was available on a monthly basis. 
 
4.2.3 Medicines studied  
 
4.2.3.1 Prescription medicines 
All ophthalmic chloramphenicol preparations listed under section 11.3.1 (Anti-
bacterial eye preparations) of the BNF 65 (2013) were included in the present 
study. A manual search of the NHS prescription database was also undertaken 
by the researcher to identify any other ophthalmic preparations that contained 
 113 
chloramphenicol. A list of product included in the analysis is shown in 
Appendix 14. 
 
4.2.3.2 Over-the-Counter medicines 
Chemist and Druggist: Monthly Pricelist (June 2011 issue) was used to 
identify all available proprietary ophthalmic chloramphenicol preparations sold 
OTC in the UK. A list of all available OTC products can be found in Appendix 
15. At the time of the study, OTC ophthalmic chloramphenicol was only 
available as a P and not as a GSL medicine. 
 
After the identification of all available products in the UK a manual search of 
the RSA database was undertaken and matching preparations found in the RSA 
database were included in the present analysis. Preparations listed in the RSA 
database by their generic name, such as chloramphenicol 0.5% eye drops, were 
excluded from the analysis. This was due to the uncertainty as to whether such 
product was sold OTC or used to dispense a prescription. A list of the 
ophthalmic chloramphenicol preparations extracted from the RSA database is 
shown in Appendix 16. 
 
Pharmacy retail data supplied by Company A included every brand (including 
own-brand) of ophthalmic chloramphenicol preparations sold from its 
pharmacies and were included in the analysis. A list of all preparations sold 
from Company A’s pharmacy is shown in Appendix 17. 
 
4.2.4 Estimation of Over-the-Counter supply 
The sales of ophthalmic chloramphenicol from Company A, between June 
2005 and December 2007 for eye drops (30 months) and July and December 
2007 for eye ointment (6 months), were estimated using linear regression. The 
line of best fit generated from the linear regression model was extrapolated 
backwards based on cumulative sales between January 2008 and December 
2010 from Company A. The availability of data for the eye drops and the eye 
ointment are illustrated in Table 4.2 and Table 4.3, respectively. 
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Table 4.2 Availability of prescription, pharmacy wholesale and Company A retail 
data for over-the-counter chloramphenicol eye drops. Sales from Company A’s 
pharmacy between June 2005 and December 2007 were estimates (shaded grey) 
calculated from the available data between January 2008 and December 2010. 
Check mark (✓) indicates a complete set of data for the corresponding period. 
Asterisk (*) marks the first 12-month period post-reclassification of the eye drops 
formulation 
 
 Prescription  Pharmacy wholesale 
Company A 
retail 
2004/05 ✓    
2005/06* ✓  ✓ 
Estimates 2006/07 ✓  ✓ 
2007/08 ✓  ✓ 
2008/09 ✓  ✓ ✓ 
2009/10 ✓  ✓ ✓ 
 
 
 
Table 4.3 Availability of prescription, pharmacy wholesale and Company A retail 
data for over-the-counter chloramphenicol eye ointment. Sales from Company A’s 
pharmacy between July and December 2007 were estimates (shaded grey) 
calculated from the available data between January 2008 and December 2010. 
Check mark (✓) indicates a complete set of data for the corresponding period. 
Asterisk (*) marks the first 12-month period post-reclassification of the ointment 
formulation 
 
 Prescription  Pharmacy wholesale 
Company A 
retail 
2004/05 ✓    
2005/06 ✓    
2006/07 ✓    
2007/08* ✓  ✓ Estimates 
2008/09 ✓  ✓ ✓ 
2009/10 ✓  ✓ ✓ 
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The linear regression model was defined by the equation: 
 
Yi = b0 + b1Xi 
 
where Yi was the estimated cumulative sales each month; Xi was the number 
of months after reclassification of eye drops or ointment (June 2005 and July 
2007 are denoted as month 1, respectively) and b1 and b0 represented the 
gradient and y-axis intercept for the line of best fit, respectively. The 
coefficient of determination (R2) was reported to indicate the goodness of fit 
for the model together with the corresponding p-value. The linear relationship 
between cumulative sales of OTC ophthalmic chloramphenicol from Company 
A and number of months after reclassification was verified using the available 
pharmacy wholesale data. This involved estimating the cumulative wholesale 
figures for the eye drops, between June 2005 and December 2007, and the eye 
ointment, between July and December 2010, based on available wholesale data 
between January 2008 and December 2010, and comparing the estimated to the 
actual observed cumulative sales. 
 
To calculate the total quantity of OTC ophthalmic chloramphenicol sold in 
Wales, the estimated sales during the data-missing period and actual sales from 
Company A were combined with the pharmacy wholesale figures.  
 
4.2.5 Data processing and organisation  
The data utilised in the present study were obtained from multiple sources and 
it was necessary for them to be processed and organised into a suitable format 
before statistical analysis could be undertaken. These processes are described 
below. 
 
Prescription and pharmacy wholesale data were manually transferred from 
their respective database into Microsoft Excel spreadsheet as illustrated in 
Appendix 8 and Appendix 9, respectively. Retail data for Company A were 
supplied already in a Microsoft Excel spreadsheet. Once all the data were in 
Microsoft Excel spreadsheet they were organised into a number of 12-month 
blocks to allow comparison before and after the reclassification. The 12-month 
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period for the supply of eye drops were defined as between June and May and 
the ointment between July and June. 
 
There were six 12-month blocks for both eye drops and ointment supplied on 
prescription (2004/05 to 2009/10); five 12-month blocks for eye drops sold 
OTC (2005/06 to 2009/10) and three 12-month blocks for ointment sold OTC 
(2007/08 to 2009/10). All processed and reorganised data were manually 
screened for errors before transferring to the statistical software for analysis 
(PASW v18). 
 
4.2.6 Analysis  
 
4.2.6.1 Descriptive analysis  
The supplies of OTC and prescription ophthalmic chloramphenicol were 
expressed as the total number of packs sold and total number of items 
dispensed, respectively. For each of the 12-month periods, the total supply was 
reported together with the median and the interquartile range (IQR) for the 
component month. Box-plots were used to visualise the distribution of the data 
and an example is shown in Figure 4.1. 
 
 
 
Figure 4.1 An example demonstrating the components of a boxplot  
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The line across the inside of the box indicated the median value of the data. 
Upper and bottom edge of the box indicated the 75th and 25th percentile of the 
data and the range between the two edges represented the IQR. The ends of the 
vertical lines (whiskers) extended to 1.5 times the height of the box or, if no 
value was within that range, to the minimum and maximum values of the data. 
Values that were beyond the upper and lower quartile by one and a half IQRs 
were classified as outliers, indicated by circles. And if values were more than 
three IQRs away, they were classified as extreme outliers, indicated by 
asterisks. 
 
4.2.6.2 Impact of reclassification  
The impact of reclassification of ophthalmic chloramphenicol on GP 
prescribing was explored using Wilcoxon’s sign rank test by comparing the 
quantities supplied on prescription during the 12-month period before 
reclassification with those after the reclassification. For the eye drops, 
quantities supplied in 2004/05 were compared to those in 2005/06, 2006/07, 
2007/08, 2008/09 and 2009/10. For the eye ointment, quantities supplied in 
each of the three 12-month periods before reclassification (2004/05, 2005/06, 
2006/07) was compared to those supplied in the 12-month periods after 
(2007/08, 2008/09, 2009/10). 
 
4.2.6.3 Association between Over-the-Counter and prescription supply  
Correlation between quantity supplied on prescription and sold OTC for 
ophthalmic chloramphenicol was examined using Pearson's product-moment 
correlation. Calculations were based on actual prescribing and pharmacy sales 
data for ophthalmic chloramphenicol between January 2008 and December 
2010 (36 months). 
 
All data analysis and statistics were performed using PASW version 18 
(PASW Inc., Chicago, IL, USA). A p-value < 0.05 was considered to be 
statistically significant.  
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4.3 Results 
 
4.3.1 Estimation of Over-the-Counter sales from Company A 
The linear regression model generated cumulative sales equations for the eye 
drops (R2 = 0.998, P < 0.0001) and the eye ointment (R2 = 0.995, P < 0.0001) 
sold by Company A and estimated the cumulative sales for the respective 
periods when no retail data was available. The linear equation used to model 
the cumulative sales of the eye drops was: 
 
 Yi = −34526 + 1135 (month[s] after reclassification of the eye drops) 
 
And the linear equation used to model the cumulative sales of the eye ointment 
was: 
 
 Yi = −3731 + 482 (month[s] after reclassification of the eye ointment) 
 
Based on the linear equations, the estimated total sale for the eye drops from 
Company A was 35,185 packs between June 2005 and December 2007. The 
estimated total sale for the eye ointments was 2,892 packs between July and 
December 2007. The total cumulative sales of ophthalmic chloramphenicol 
OTC in Wales (pharmacy wholesale + Company A [actual and estimated OTC 
sales]) are shown in Figure 4.2. 
 
Validation of the linear regression model using the pharmacy wholesale data 
indicated that the estimated cumulative sale for the eye drops (R2 = 0.998, p < 
0.0001) between June 2004 and December 2007 was 102,694 packs. This 
equates to a 4% (4,184/102,694 packs) overestimation of the actual cumulative 
sales during the corresponding period. Estimated cumulative sale for the eye 
ointment (R2 = 0.995, p < 0.0001) between July and December 2007 was 
12,312 packs and was 13% (1,441/10,871) more than the actual cumulative 
wholesale supply during the corresponding period.   
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Figure 4.2 Cumulative sales of over-the-counter chloramphenicol eye drops and eye 
ointment in Wales between June 2005 and December 2010. Data including estimated 
sales from Company A are indicated by (△) for the eye drops and (○) for the eye 
ointment. Solid-filled symbols (▲) and (●) represent actual sales data 
 
 
4.3.2 Over-the-Counter ophthalmic chloramphenicol  
Over the six-year study period, sales of OTC chloramphenicol eye drops 
demonstrated a marked seasonal variation with the highest number of packs 
sold (median, IQR) in March (5291, 1258) and the lowest in October (3303, 
119). In contrast, sales of the ointment formulation between 2007/08 and 
2009/10 revealed no discernible trend (Figure 4.3)   
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a) 
 
b) 
 
 
Figure 4.3 Boxplot showing the median and the interquartile range (IQR) for each of 
the month for ophthalmic chloramphenicol (a) eye drops and (b) eye ointment sold 
in Wales between June 2005 to May 2010 and July 2007 to June 2010, respectively. 
Circles (○) and asterisks () indicate outliers and extreme outliers, respectively 
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Quantities of OTC ophthalmic chloramphenicol sold each month, their 
cumulative total for each 12-month period together with the median and IQR 
for the component month are shown in Table 4.4 and Table 4.5. 
 
Table 4.4 Sales of over-the-counter chloramphenicol eye drops in number of packs 
sold for Wales (IQR = interquartile range) 
 
 2005/06 2006/07 2007/08 2008/09 2009/10 Median (IQR) 
June 1 597 5 413 5 103 4 457 3 854 4 457 (1249) 
July 4 991 4 700 4 869 4 472 3 793 4 700 (397) 
August 5 909 3 716 4 617 3 608 3 529 3 716 (1009) 
September 3 777 3 383 3 539 4 264 3 571 3 571 (238) 
October 3 262 3 188 3 908 3 381 3 303 3 303 (119) 
November 3 015 3 613 4 156 3 633 3 875 3 633 (262) 
December 3 412 5 464 5 504 5 271 4 026 5 271 (1438) 
January 3 232 4 867 5 489 4 201 3 700 4 201 (1 167) 
February 3 712 4 871 4 734 4 447 4 192 4 447 (542) 
March 3 871 5 291 5 886 4 272 5 530 5 291 (1 258) 
April 3 923 5 317 5 170 4 256 5 218 5 170 (962) 
May 4 995 6 480 4 733 3 652 4 763 4 763 (262) 
Total 45 696 56 303 57 708 49 914 49 354  
Median 3 745 4 869 4 802 4 260 3 865  
IQR 936 1651 748 802 667  
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Table 4.5 Sales of over-the-counter chloramphenicol eye ointment in number of 
packs sold for Wales (IQR = interquartile range) 
 
 2007/08 2008/09 2009/10 Median (IQR) 
July 2 272 1 419 1 346 1 419 (463) 
August 4 445 1 357 1 326 1 357 (1 560) 
September 2 355 1 732 1 367 1 732 (494) 
October 1 963 1 565 1 229 1 565 (367) 
November 1 217 1 084 1 462 1 217 (189) 
December 1 511 1 406 1 180 1 406 (166) 
January 1 502 1 674 1 589 1 589 (86) 
February 1 127 1 360 1 144 1 144 (117) 
March 1 424 1 116 1 798 1 424 (341) 
April 1 418 1 200 1 411 1 411 (109) 
May 2 073 1 229 1 237 1 237 (422) 
June 1 568 1 170 1 891 1 568 (361) 
Total 22 875 16 312 16 980  
Median 1 540 1 359 1 357  
IQR 700.3 263 258.8  
 
 
The sales of chloramphenicol eye drops demonstrated a 21% (12,012/57,708) 
increase from 45,696 packs in 2005/06 to a peak of 57,708 packs in 2007/08. 
This was followed by a statistically significant reduction to 49,914 packs in 
2008/09 (p=0.012) and a further reduction to 49,315 packs in 2009/10 
(p>0.05). The sales of the ointment were highest in 2007/08, which coincided 
with the 12-month period immediately after becoming available OTC, at a total 
of 22,875 packs. During the second 12-month period post-reclassification, 
sales declined significantly by 29% (6,563/22,875) to 16,312 packs in 2008/09 
(p=0.015) and thereafter remained steady in 2009/10.  
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4.3.3 Prescription ophthalmic chloramphenicol  
Similar to preparations sold OTC, a marked seasonal pattern was also observed 
for chloramphenicol eye drops supplied on prescriptions during the study. The 
month of highest supply (medians, IQR) was March (8,470, 861) and lowest 
was August (5,637, 353). The supply of ointment on prescription demonstrated 
no discernible seasonal pattern over the study period (Figure 4.4). 
 
The monthly items of chloramphenicol eye drops and ointment supplied on 
prescription in Wales, their 12-monthly totals, median and IQR for the 
component month are shown in Table 4.6 and Table 4.7, respectively. 
 
The quantity of chloramphenicol eye drops supplied on prescription was the 
highest in 2004/05 (86,916 items), the 12-month period immediately before the 
reclassification of ophthalmic chloramphenicol eye drops. In the 12 months 
immediately after (2005/06), a significant reduction (p=0.015) in items 
prescribed was observed compared to the previous year (80,844 items) and 
further reduced (p>0.05) in 2006/07 (78,308 items). This declining trend 
reversed in 2007/08 with a significant increase in items prescribed (p=0.010) 
compared to the previous 12 months; back to the level comparable to that seen 
prior to reclassification (84,305 items). Thereafter, the year-on-year supply on 
prescription remained steady for 2008/09 (p=0.638) and 2009/10 (p=0.530). 
 
For the eye ointment, the quantities prescribed followed a decreasing trend 
from 2004/05 (57,516 items) to 2007/08 (47,192 items). Reductions were 
statistically significant in 2005/06 (p=0.023) and 2007/08 (p=0.002) compared 
to the previous 12 months. A significant increase in ointment prescribed was 
observed in 2008/09 (p=0.028).  
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a) 
 
b) 
 
 
Figure 4.4 Boxplot showing the median and the interquartile range (IQR) for each of 
the month for ophthalmic chloramphenicol (a) eye drops and (b) eye ointment 
prescribed in Wales between 2004 and 2010, respectively. Circles (○) and asterisks 
() indicate outliers and extreme outliers, respectively 
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Table 4.6 Number of items of chloramphenicol eye drops supplied on primary care prescriptions in Wales and their respective 12-monthly totals together 
with median and interquartile range (IQR) for the component month 
 
 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 Median (IQR) 
June 7 180 7 958 7 029 7 126 7 157 7 574 7 169 (342) 
July 6 480 6 338 6 369 6 986 6 553 7 131 6 517 (481) 
August 5 696 5 697 5 577 6 145 5 416 5 470 5 637 (200) 
September 5 763 5 685 5 214 5 344 6 135 5 731 5 708 (326) 
October 5 727 5 568 5 586 6 500 6 473 6 148 5 938 (771) 
November 6 395 6 161 5 721 6 442 6 320 6 835 6 358 (230) 
December 7 272 6 429 6 085 7 018 8 494 7 637 7 145 (970) 
January 8 380 6 977 6 975 8 390 8 139 6 565 7 558 (1344) 
February 9 309 7 835 7 188 8 096 7 464 7 639 7 737 (523) 
March 9 096 8 521 8 364 7 938 8 418 9 187 8 470 (575) 
April 7 913 6 793 7 208 7 373 7 114 7 493 7 291 (326) 
May 7 705 6 882 6 992 6 947 6 623 7 178 6 970 (233) 
Total 86 916 80 844 78 308 84 305 84 306 84 588  
Median 7 226 6 611 6 672 7 002 6 869 7 155  
IQR 2 342 1 808 1 529 1 340 1 612 1 369  
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Table 4.7 Number of items of chloramphenicol eye ointment supplied on primary care prescriptions in Wales and their respective 12-monthly totals 
together with median and interquartile range (IQR) for the component month 
 
 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 Median (IQR) 
July 4 763 4 497 4 390 2 957 4 605 4 599 4 548 (187) 
August 4 494 4 340 4 378 2 877 3 976 3 905 4 158 (446) 
September 4 537 4 446 4 282 3 371 4 328 4 355 4 342 (130) 
October 4 495 4 293 4 486 3 970 4 553 4 357 4 422 (184) 
November 4 635 4 622 4 506 3 955 4 085 4 365 4 436 (438) 
December 5 004 4 391 4 162 3 889 4 490 4 318 4 355 (264) 
January 5 523 4 631 4 775 4 461 4 403 3 780 4 546 (322) 
February 5 007 4 625 4 421 4 334 4 287 4 101 4 378 (275) 
March 4 862 5 305 5 014 4 235 4 938 4 788 4 900 (189) 
April 4 488 4 371 4 641 4 504 4 264 4 366 4 429 (133) 
May 4 644 4 594 4 856 4 217 4 107 4 082 4 406 (467) 
June 5 064 4 666 4 499 4 422 4 775 4 394 4 583 (307) 
Total 57 516 54 781 54 410 47 192 52 811 51 410  
Median 4 704 4 546 4 493 4 094 4 366 4 356  
IQR 501 254 361 900 446 300  
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4.3.4 Overall supply trend in primary care 
The combined prescription and OTC supply of chloramphenicol eye drops, 
each year, from 2004/05 to 2009/10 is shown in Figure 4.5 (part a). Overall, 
there was an increase in use of the eye drops, prescribed and sold, from 86,916 
units in 2004/05 to a peak of 142,013 units in 2007/08. Thereafter, supplies 
plateaued in 2008/09 (134,220 units) and 2009/10 (133,942 units). The highest 
proportion of eye drops supplied OTC occurred in 2006/07, which saw an 
equivalent of 71% (56,303/78,308) of the respective number of items supplied 
on prescription. The supply of chloramphenicol eye drops in primary care by 
the end of the study period was 54% higher (47,026 units/86,916 units) than it 
was at the beginning of the study (2004/05). 
 
Chloramphenicol eye ointment became available OTC in July 2007 and their 
total quantity supplied on prescription and sold OTC for each 12-month period 
are shown in Figure 4.5 (part b). The highest proportion of ointment sold OTC 
compared to items supplied on prescription occurred in 2007/08, where the 
sales represented 48% (22,875/47,192) of the respective prescription volume. 
Sales in 2008/09 and 2009/10 fell to 31% (16,312/52,811) and 33% 
(17,061/51,410) of their respective prescription volumes. The overall impact of 
the OTC availability of chloramphenicol ointment in 2007 was to increase its 
primary care supply in Wales by 29% (15,657/54,410) compared to the 
previous year. Thereafter, the overall, combined supply each year remained 
consistently higher than in any 12-month period prior to 2007 when the 
ointment was only available on prescription.  
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a) 
 
b) 
 
 
Figure 4.5 Number of items or packs of chloramphenicol (a) eye drops (June to May) 
and (b) eye ointment (July to June) supplied on prescription or sold over-the-
counter for each 12-month period in Wales, respectively. The combined total supply 
each year is indicated on each column head in bold. The asterisk (*) and double-
asterisk (**) mark the period when the eye drops and eye ointment became available 
OTC, respectively 
 
 
The combined quantities of eye drops and ointment supplied OTC and on 
prescription for each 12-month period is shown in Figure 4.6. The peak supply 
of all ophthalmic chloramphenicol was observed in 2007/08.  
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Figure 4.6 Supply of ophthalmic chloramphenicol (eye drops + ointment) on 
prescription and that sold over-the-counter (OTC) in Wales. The combined total 
supply each year (June to May) is indicated on each column head in bold. The 
asterisk (*) and double-asterisk (**) mark the period when chloramphenicol eye 
drops and ointment became available OTC, respectively 
 
 
4.3.5 Impact of reclassification 
The results from Wilcoxon’s sign rank test are summarised in Table 4.8. The 
largest year-on-year reduction in the supply of prescription eye drops occurred 
in 2005/06 when the equivalent OTC pack became available from pharmacies. 
This represented a significant reduction (p=0.015) of 7% (6,072/86,912) 
decline in the number of items prescribed compare to the previous year. In the 
following 12-month period (2006/07) there was a further 3% (2,536/80,844) 
reduction in the quantities prescribed compared to the previous 12-month 
period. Quantity prescribed during the 2006/07 period was also significantly 
less (p=0.003) than that supplied prior to reclassification. No other significant 
difference in the number of prescribed items was observed between 2004/05 
and any other 12-month periods (p>0.05). 
 
The largest year-on-year decrease in the ointment formulation supplied on 
prescription occurred in 2007/08 when equivalent OTC pack became available 
from pharmacies. During 2007/08, there was a 13% (7,218/54,410) reduction 
in number of items prescribed and was significantly less than any other periods 
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prior to the reclassification of the ointment (2004/05, p=0.003; 2005/06, 
p=0.003; 2006/07, p=0.002). The quantity prescribed in 2009/10 was also 
significantly less than any other periods prior to reclassification (2004/05, 
p=0.002; 2005/06, p=0.012; 2006/07, p=0.034). Quantity of ointment 
prescribed in 2008/09 were significantly less (p=0.005) than that in the 
2004/05 period only. 
 
 
Table 4.8 Total numbers of items of chloramphenicol eye drops and ointment 
supplied on primary care prescriptions in Wales and their respective median and 
interquartile range (IQR) for the component month 
 
 Eye Drops (June - May) 
 Total Median (IQR) p-value* 
2004/05 86 916 7 226 (2 342)  
2005/06 80 844 6 611 (1 808) 0.015 
2006/07 78 308 6 672 (1 529) 0.003 
2007/08 84 305 7 002 (1 340) 0.308 
2008/09 84 306 6 869 (1 612) 0.347 
2009/10 84 588 7 155 (1 369) 0.814 
 Ointment (July – June) 
 Total Median (IQR) p-value* 
2004/05 57 516 4 704 (501)  
2005/06 54 781 4 546 (254)  
2006/07 54 410 4 493 (361)  
2007/08 47 192 4 094 (900) 0.003, 0.003, 0.002 
2008/09 52 811 4 366 (446) 0.005, 0.060, 0.158 
2009/10 51 410 4 356 (300) 0.002, 0.012, 0.034 
* P-values reported for the eye drops were comparison with the 2004/05 period; 
ointment were compared with the 2004/05, 2005/06 and 2006/07 periods, respectively. 
A p-value < 0.05 is indicated in bold. 
 
 
4.3.6 Association between Over-the-Counter and prescription supply  
The number of items of combined chloramphenicol eye drops and ointment 
dispensed on prescription and sold OTC each month, between January 2008 
and December 2010, are shown in Figure 4.7. Pearson’s product moment 
correlation coefficient (r) revealed a significant and positive correlation (r=0.7, 
p<0.001) between the supplies of ophthalmic chloramphenicol (eye drops and 
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ointment combined) on prescription and that sold OTC from community 
pharmacies in Wales. 
 
 
 
 
Figure 4.7 Number of items and packs of ophthalmic chloramphenicol supplied on 
prescription and sold over-the-counter (OTC), respectively, between January 2008 
to December 2010 
 
 
4.4 Discussion 
 
4.4.1 Main findings 
The pharmacy sales data presented in this study are the most comprehensive 
dataset studied to date for chloramphenicol products and include data from all 
NHS-contracted community pharmacies in Wales. The study successfully 
quantified the supply of OTC ophthalmic chloramphenicol following 
reclassification and investigated the impact on primary care prescription over a 
five-year period. The results demonstrated the OTC availability of ophthalmic 
chloramphenicol contributed to an increase in supply in primary care that is 
greater than previously reported (Walker and Hinchliffe 2010). In addition, the 
year-on-year growth in the sales of OTC eye drops plateaued in 2008 and no 
further growth was observed. In contrast, the sales of non-prescription 
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chloramphenicol ointment declined year-on-year since becoming available 
OTC. 
 
It would appear that despite relatively large numbers of packs of both 
chloramphenicol eye drops and ointment sold OTC, this had no impact on the 
items dispensed on prescription for ophthalmic chloramphenicol over the five-
year period studied. As a consequence there has been no cost saving on drug 
expenditure for the NHS in Wales as was anticipated with the increased 
availability of a medicine (Bond and Hannaford 2003; Blenkinsopp and 
Bradley 1996). When the temporal relationship between OTC sales of 
ophthalmic chloramphenicol and items dispensed on prescription was explored, 
a positive relationship was identified. This may, in part, suggest community 
pharmacists and GP prescribers were responding to similar presenting 
symptoms although whether or not prescribing and/or OTC sales were 
appropriate is unclear. 
 
4.4.2 Study limitations  
 
4.4.2.1 Ecological study  
The present study was limited by its ecological nature, and consequently it was 
not possible to identify the factors that contributed to the increased supply of 
OTC ophthalmic chloramphenicol. This could be explored by a cross-sectional 
survey study to examine influence of various factors, such as demographic 
features of the individuals who bought ophthalmic chloramphenicol, their 
ocular history and presenting symptoms, the expertise and characteristics of the 
pharmacist or pharmacy staff consulted. 
 
4.4.2.2 Prescription data  
Primary care prescribing data were extracted from an established and routinely 
used database which included details of NHS prescriptions dispensed by every 
community pharmacy in Wales. Whilst this source of data was comprehensive 
in capturing prescriptions issued by GPs, the study did not include 
prescriptions issued by non-medical prescribers, such as nurse or pharmacist 
prescribers (National Prescribing Centre 2012). Given the omission of 
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prescriptions issues by non-medical prescribers, it is likely that the prescribing 
of ophthalmic chloramphenicol reported in the current study was an 
underestimate of the actual figure. Whilst data obtained from NHS Wales 
Informatics Service indicate NHS prescriptions written by non-medical 
prescribers in Wales only account for 1% of all primary care prescriptions 
dispensed (personal communication), whether or not this was the case for 
ophthalmic chloramphenicol is unclear and will require further investigation. 
 
4.4.2.3 Estimation for Over-the-Counter supply  
Pharmacy sales data in the RSA database represented the sales of selected 
medicines from wholesalers to community pharmacies. Although the RSA 
database offered a good coverage and captured data from 87% of all 
community pharmacies in Wales, sales data from one major pharmacy chain 
(Company A) was not included. The missing data were obtained direct from 
the pharmacy chain concerned and complemented the wholesale data obtained 
from IMS Health. 
 
Unlike the pharmacy wholesale data, which were available for the entire post-
reclassification period (2005 to 2010), sales data from Company A were only 
available for a three year period from 2008 to 2010. Consequently, the quantity 
of ophthalmic chloramphenicol sold from Company A for both the eye drops 
and ointment following reclassification and up to 2008 had to be estimated. It 
was possible that the sales pattern during the early years of a new product 
could have been different to that seen during the period when Company A sales 
data were available. This potential confounder was explored and tested using 
the available pharmacy wholesale data. 
 
The results based on the available pharmacy wholesale data revealed the linear 
regression model overestimated the cumulative sales of the eye drops by 4% 
(1,407 packs) and the ointment by 13% (376 packs). As a result, the predicted 
sales figures for OTC ophthalmic chloramphenicol sold from Company A 
during the data missing period could have also been overestimated. However, 
the number of packs of ophthalmic chloramphenicol overestimated by the 
linear regression model were relatively small compared to the overall volume 
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of sale during the entire study period and therefore the impact on the results 
was probably minimal. 
 
4.4.2.4 Pharmacy wholesale data  
The data from IMS Health have been widely used by the pharmaceutical 
industry to map market trends. The majority of the data (97%) is extracted 
from invoices with a small percentage of data (3%) derived from a sample of 
approximately 300 independent retailers. Each geographical area is consisted 
of a different amount of projected information but in most cases the difference 
is estimated to be small. IMS Health have declared data may be on some 
occasions edited to compensate for grey market trading. For example, edits are 
made when very large volume of a product are purchased by one pharmacy 
address for onward supply to other pharmacies within the same company. 
Editing sales data in this scenario avoids distorting the local sales picture. 
Similarly, when a larger independent pharmacy chain buys for a purchasing 
group, sales are also reallocated across the businesses in the purchasing group. 
IMS Health claims these procedures ensure wholesale data are geographically 
accurate. 
 
One important difference to note between the pharmacy data utilised in the 
present study is that data from Company A represented transactions between 
the pharmacy and customers, whereas data from IMS Health represented 
supplies from wholesalers to pharmacies. As with previous studies that 
employed IMS Health data (Walker and Hinchliffe 2010; Davis et al. 2009; 
Deslandes et al. 2011), the latter is thought to be a good proxy for pharmacy-
to-customer sales for a number of reasons. Firstly, community pharmacies rely 
on a regular turn-over of stock to facilitate cash flow which generates revenue 
for future purchase of stock. Therefore, it is imperative that pharmacy 
businesses avoid accumulation of unsold stock and minimise stock wastage 
where possible. Secondly, the limited amount of space for on-site storage 
means a large quantity of backup stock is unlikely to be kept in a pharmacy. 
This may be particularly the case for chloramphenicol eye drops as they are 
required to be stored in a fridge where space is usually at a premium. Therefore 
advance purchase for on-site storage is unlikely. Finally, promotions offered by 
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wholesalers to pharmacies, such as bulk-purchase discounts at a particular time 
of the year, could potentially distorted sales. However, there was no evidence 
of this taking place from the available pharmacy wholesale data. 
 
4.4.2.5 Range of Over-the-Counter products  
As of January 2011, there were seven proprietary brands of chloramphenicol 
eye drops and five proprietary brands of eye ointment available OTC in the UK 
(Chemists and Druggists, January 2011 Issue). Of these the pharmacy 
wholesale data have captured the sales of five brands of the eye drops and four 
brands of the eye ointment. The two brands of chloramphenicol eye drops that 
were not included in the present study (Numark 0.5% Antibiotic Eye Drops® 
and I-Care Antibiotic Eye Drops®) were less widely known, one of which was 
sold only by selected independent pharmacies and the other was not sold by 
any Boots or Company A pharmacies in Wales. Whilst the market share for 
these two brands appears to be low, their contributions to the supply of 
ophthalmic chloramphenicol in Wales are not known. 
 
4.4.2.7 Proprietary and non-proprietary ophthalmic chloramphenicol  
In the RSA database wholesale data for both proprietary and non-proprietary 
(generic) ophthalmic chloramphenicol preparations were available. The 
proprietary products were identifiable by brand/product name and therefore 
whether they were sold OTC could be determined. On the other hand, generic 
ophthalmic chloramphenicol preparations were listed in the RSA database by 
drug name only (i.e. chloramphenicol eye drops 0.5%). Consequently, it was 
not possible to ascertain whether such products were sold OTC or used to 
dispense a prescription. For this reason, only OTC proprietary preparations 
were included in the current study. Whilst it was possible that even an OTC 
pack could have been used to dispense a prescription for ophthalmic 
chloramphenicol, this occurrence was considered to be rare due to the higher 
cost normally associated with a branded product than a generic equivalent. The 
possibility remains that sometimes a large chain multiple pharmacy may use its 
own-brand ophthalmic chloramphenicol preparations to dispense a 
prescription. However this was not an issue for the sales data provided by 
Company A as the data represented actual pharmacy-to-patient sales.  
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The prescribing of a proprietary ophthalmic chloramphenicol preparation on 
NHS prescriptions was another concern for the present study and this was 
explored by analysing NHS prescription data for Wales. The results suggest 
between 2005 and 2010, the mean number of items of proprietary 
chloramphenicol eye drops and eye ointment dispensed on NHS prescriptions 
were 31 and 34 items per year, respectively. These numbers were small 
compared to the 83,613 items of eye drops and 51,062 items of ointment 
dispensed per year over the same period (results not shown). These findings 
provided some reassurance that only very few packs of OTC proprietary 
ophthalmic chloramphenicol have been used to dispense a prescription and the 
majority were sold for non-prescription use. 
 
4.4.2.8 Unit of measure  
The unit of measure used for the prescription data was the number of 
prescription items dispensed. In contrast, pharmacy sales data was reported in 
number of product packs sold. Theoretically, more than one pack of 
chloramphenicol eye drops or eye ointment could be supplied against one 
prescription item if the total quantity requested by the prescriber required 
multiple packs to fill. However, as a single pack of the eye drops and the eye 
ointment is the usual quantity of ophthalmic chloramphenicol supplied per item 
on prescriptions (Walker and Hinchliffe 2010), the impact of the difference in 
units of measure was probably small on the results. 
 
4.4.2.9 Temporal correlation 
Although a positive relationship was observed between OTC sales and items 
supplied on prescription, this needs to be interpreted with caution as it only 
serves to demonstrate an association between the two variables but provides no 
explanation for the observation. Whether or not community pharmacists and 
other GP prescribers are capable of making clinically appropriate supplies of 
ophthalmic chloramphenicol remains to be studied. To date, there has been no 
published study evaluating the appropriateness OTC sales of ophthalmic 
chloramphenicol by pharmacists from community pharmacies.  
 
4.4.2.10 Licensed indication 
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The licensed indication of OTC ophthalmic chloramphenicol was limited to the 
treatment of acute infective conjunctivitis in adults and children over two years 
of age, whereas that obtained on a prescription was not subject to the same 
restrictions (BNF 2013). Therefore, it was probable that the prescribing data 
had included supplies of ophthalmic chloramphenicol that are otherwise 
contraindicated in an OTC sales context. What proportion of the prescribed 
ophthalmic chloramphenicol in primary care in Wales was due to this could not 
be determined as data on prescribing by age group was not available. 
 
4.4.2.11 Training and sales protocol 
The potential issues relating to Medicine Counter Assistant (MCA) training 
and sales protocol have been discussed in Section 2.4.2.5. 
 
4.4.3 Comparison with existing literature 
The high levels of OTC sales for ophthalmic chloramphenicol reported in the 
current study is somewhat different to that seen with other reclassified 
medicines in the UK. For example, in March 2004, omeprazole was 
reclassified from POM to P status indicated for the relief of heart-burn 
symptoms associated with acid-reflux (Royal Pharmaceutical Society [RPS] 
2011b). In the first 12-month after the reclassification, the total quantity of 
omeprazole supplied OTC was reported to be equivalent to 1% of the number 
of items dispensed on primary care prescriptions in Wales (Dhippayom and 
Walker 2006). In another study, Deslandes et al. (2011) investigated the sales 
of OTC azithromycin following its reclassification from POM to P status in 
2008. It was reported that its supply OTC declined during the two years 
following reclassification and in 2010 the quantities sold across the UK were 
less than one pack per 10,000 population. Lastly, simvastatin, a lipid-lowering 
agent, was reclassified from POM to P status in the UK for the primary 
prevention of cardiovascular events in 2004 (DTB 2005). However, five years 
after becoming available OTC the medicine manufacture decided to 
discontinue the OTC product because of poor sales (Anon. 2010a). 
 
Patients’ perception and understanding about infective conjunctivitis could 
have played a role in driving the non-prescription sales. In a qualitative study 
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conducted by Everitt et al. (2003), it was found the majority of study 
participants were confident in making a diagnosis of infective conjunctivitis. 
The infection was considered to be relatively minor but perceived there was a 
need for treatment in order to clear the infection. Whilst the present study was 
unable to identify the exact reasons behind the increased sales of OTC 
ophthalmic chloramphenicol, it was likely the improved access to treatment 
presented the opportunity for the self-management of infective conjunctivitis 
compared to when it was only available on  a prescription. The apparent high 
volume of non-prescription sale reflected the finding that many individuals 
prefer to self-manage a minor condition rather than consult a GP (Porteous et 
al. 2006). Furthermore, the removal of patient barriers such as the need to 
make a GP appointment (Seston et al. 2001), convenience (Schafheutle et al. 
1996) and reduced cost of travelling to and from doctor’s surgery (Ryan and 
Yule 1990) may have provided further incentives for people to practice self-
medication, even if they had to purchase the treatment themselves in a country 
with no co-payment prescription levy. 
 
A number of factors have been identified that could influence pharmacists’ 
adoption of a newly reclassified medicine (Kennedy and Moody 2000; Paudyal 
et al. 2012a). In particular, the evidence of safety and efficacy of a product was 
one of the aspects considered by pharmacists when making OTC 
recommendations. In this regard, pharmacists’ familiarity with ophthalmic 
chloramphenicol through dispensing prescriptions might have served as 
positive evidence for these desired properties and thereby promoted sales 
through better adoption. Sometimes a newly reclassified medicine is granted 
OTC availability at a lower dose and/or strength compared to same drug 
available on a prescription (Blenkinsopp and Bond 2005). The lack of evidence 
of efficacy for a new dose/strength has been found to deter some pharmacists 
from recommending such product (Paudyal et al. 2012b). This was not an issue 
for ophthalmic chloramphenicol as preparations available OTC and those on 
prescription were of identical dose and strength.  
 
Prior to the availability of OTC ophthalmic chloramphenicol, patients 
presented at a community pharmacy with a suspected eye infection were often 
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treated with topical preparations containing propamadine or 
dibromopropamidine (Hardy et al. 1993a; Seston et al. 2001). However, many 
pharmacists were concerned with these preparations’ limited benefit in 
bacterial infections (Hardy et al. 1993a) and expressed the desire to be able to 
counter prescribe ophthalmic chloramphenicol (Bond et al. 1993). It was 
therefore unsurprising to find pharmacists highly value the addition of OTC 
ophthalmic chloramphenicol to their armamentarium (Colquhoun et al. 2009). 
The perceived opportunity by pharmacists to extend beyond their traditional 
dispensing role to better care for their patients may have encouraged non-
prescription sales. 
 
Contrary to the reduction of ophthalmic chloramphenicol dispensed on primary 
care prescriptions in England (Davis et al. 2009), items dispensed in Wales 
remained steady throughout the five-year study period. One possible 
explanation for the difference in prescribing trend between the two countries 
was the abolition of the NHS prescription charge in Wales in April 2007. The 
removal of the prescription levy may have encouraged patients in Wales to 
obtain a free prescription of ophthalmic chloramphenicol from their doctors. 
This was illustrated in the present study by the observation of a small but 
distinguishable increase in eye drops dispensed on prescription 12 months after 
the prescription charge was abolished (June 2007 to May 2008). This 
phenomena is consistent with the observations made by others of a modest 
increase in prescription items following the abolition of prescription co-
payment charges in Wales (Dhippayom and Walker 2008; Groves et al. 2010).  
 
In comparison to England, it was cheaper for non-exempt patients to purchase 
OTC ophthalmic chloramphenicol (average price of eye drops and ointment 
were £4.72 and £5.24 respectively) than paying for the NHS prescription levy 
(£6.50/item in 2005 and £7.40/item in 2011). Consequently, this may have 
contributed to the reduction of primary care prescribing of ophthalmic 
chloramphenicol in England. The practice of self-medication using OTC 
medicines is known to be a common cost-reduction strategy adopted by 
patients (Schafheutle et al. 1996, 2002, 2004). Besides patients’ own effort in 
trying to contain the cost of medicines, GPs may also recommend the purchase 
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of OTC medicines as a way to help to patients to overcome the prescription 
cost barrier (Wazaify et al. 2005; Weiss et al. 2001). This encouragement is, in 
part, driven by GPs’ own agenda in trying to lessen their prescribing budgets 
by transferring the cost of medicines onto the patients (Schafheutle et al. 2004). 
It was possible that both patients and primary care prescribers in England had a 
financial inclination to promote the use of OTC ophthalmic chloramphenicol 
compared to GPs in Wales. The impact of the abolition of NHS prescription 
charge in Wales on the prescribing of ophthalmic chloramphenicol will need to 
be examined further. 
 
It has been suggested that decrease in the prescribing of ophthalmic 
chloramphenicol in England was due to a change in the management strategy 
of infective conjunctivitis from empirical prescribing to no or delayed 
prescribing of antibiotics (Davis et al. 2009). Whether or not primary care 
prescribers in Wales were aware of these changes are unknown. Other reasons, 
such as a change in prescriber preference from prescribing one topical 
antibiotic to ophthalmic chloramphenicol, may have confounded the supply 
picture. This was investigated in a separate analysis where the prescribing of 
all other ophthalmic anti-bacterials listed in BNF section 11.3.1, from June 
2004 to May 2010, was quantified for Wales. However, the results 
demonstrated that there was no marked change in the prescribing of other 
ophthalmic antibacterials (results not presented) and thus failed to explain the 
sustained high level of prescribing for ophthalmic chloramphenicol.  
 
Walker and Hinchliffe (2009) reported a year-on-year increase in OTC sales of 
ophthalmic chloramphenicol eye drops in Wales during the three-year period 
post-reclassification. Likewise, Davis et al. (2009) reported a similar increase 
in England two year after reclassification. The present study demonstrated the 
sales of OTC chloramphenicol eye drops eventually stabilised four years post-
reclassification. This length of time taken for OTC ophthalmic 
chloramphenicol to reach stability was longer than that seen with other 
reclassified medicines (Carlsten et al. 1996; Temin 1983). This demonstrates 
the need to monitor the sales of a reclassified medicine long-term in order to 
study the full impact of medicines reclassification on the OTC market. 
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4.4.4 Implications of findings 
During the five-year period after the reclassification of ophthalmic 
chloramphenicol, their overall supply in primary care increased substantially 
before appearing to stabilise. The improved access to treatment for acute 
bacterial conjunctivitis appeared to have benefited new users who would not 
have otherwise consulted a GP about the condition. Despite the relatively large 
volume of ophthalmic chloramphenicol supplied OTC, there has been no 
impact on the supply of the same drug on primary care prescriptions in Wales 
even after five years. Consequently, the reclassification of ophthalmic 
chloramphenicol did not translate into any cost savings for the NHS drug 
budget or has reduced the workload of GPs in managing patients with infective 
conjunctivitis in Wales. 
 
The latest evidence from published studies suggest a ‘no or delayed antibiotic’ 
approach to the management of acute infective conjunctivitis is likely to be 
appropriate for the majority of presentations in the primary care (DTB 2011; 
Everitt et al. 2006; Jefferis et al. 2011; Rose et al. 2005). In view of the latest 
advice, the updated practice guidance published by the RPS on the sale of OTC 
ophthalmic chloramphenicol was imperative (RPS 2011c). In the updated 
guidance for pharmacists, previously underemphasised information, such as the 
need to discuss with patients about the self-limiting nature of acute infective 
conjunctivitis and use non-medicinal measures to manage symptoms, were 
included. Whether or not these new recommendations will impact on 
pharmacists’ counter-prescribing behaviour could be evaluated by further 
monitoring of the OTC sales of ophthalmic chloramphenicol. 
 
The inappropriate supply of non-prescription ophthalmic chloramphenicol 
from pharmacies continues to cause concern among healthcare professionals 
(Behjat-Amery 2012; Davis et al. 2009; Price 2013). Whether or not 
community pharmacists possess the required clinical and communication skills 
to identify and appropriately manage cases of infective conjunctivitis remains 
unknown. In addition, it was not known from the sales data to what extent 
MCAs were involved in the sales of OTC ophthalmic chloramphenicol. Further 
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research on this matter would be helpful as MCAs have for many years been 
delegated with the task to conduct sales of OTC medicines and it has been 
shown they do not always comply with sales protocol (Watson et al. 2008). 
Other primary care prescribers, such as GPs, have been found to misdiagnose 
and mismanage a range of ocular conditions, including infective conjunctivitis 
(Buckley 1990; Harrison et al. 1988; Statham et al. 2008). While most 
unwarranted use of ophthalmic chloramphenicol pose little or no serious health 
risk to patients, it may however delay the diagnosis of an underlying disease 
and/or the timely commencement of proper treatment. The risk associated with 
the use of OTC medicine resulting in a delay in patients receiving appropriate 
treatment was illustrated in a study Hardy et al. (1993b), which found self-
medication among hospital attendees for ocular conditions were considered to 
be ineffective or detrimental to their condition in 96% of the cases. 
 
Given the conventional signs and symptoms relied upon by pharmacists and 
MCAs are diagnostically non-informative in distinguishing bacterial from viral 
form of infective conjunctivitis (Rietveld et al. 2004), it is not improbable that 
some of the increase in OTC sales have arisen because of misdiagnosis and 
therefore represent inappropriate use. This may not only have lead to the 
ineffective relief of symptoms in individuals but more importantly it may pose 
as a potential threat to the wider public health if antibacterial resistance 
develops (Price 2013). Therefore, the appropriateness for the supply of OTC 
ophthalmic chloramphenicol from pharmacies may need to be re-evaluated by 
the UK medicine regulator. 
 
4.5 Summary 
Following the reclassification of ophthalmic chloramphenicol in the UK in 
2005, overall primary care supply of ophthalmic chloramphenicol in Wales 
increased, year-on-year, for three years before stabilising in 2008. Thereafter, 
the supply remained steady and showed no signs of decline until the end of the 
study period in 2010. Despite the high volume of ophthalmic chloramphenicol 
sold OTC it had no impact on prescription items over the entire study period. 
Whilst a temporal relationship was observed between OTC and prescription 
supplies of ophthalmic chloramphenicol, the appropriateness of supplies from 
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pharmacies remains unknown. The benefits and risks of having ophthalmic 
chloramphenicol available OTC and the impact of updated practice guidance 
on OTC sales need to be studied further to better understand its current, high 
level of use. 
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Detection of infective conjunctivitis outbreak 
 
5.1 Introduction 
Public health surveillance has been defined by the Word Health Organization 
(WHO) as the: 
 
“continuous, systematic collection, analysis and interpretation of health-
related data needed for the planning, implementation, and evaluation of public 
health practice” (WHO 2013). 
 
Compared to epidemiological research where the emphasis is usually on 
providing a snapshot of the health status of the population without a pre-
determined set of actions or response, public health surveillance is 
characterised by its on-going nature, regular output and dissemination of 
health-related data in a timely basis. In addition, the outputs from these 
surveillance systems are usually actively monitored and interpreted against 
historical data or thresholds of health, and are directly linked to actions in order 
to respond to a public health threat (Department of Health [DH] Public Health 
England Transition Team 2012). The key objective of public health 
surveillance is to provide essential factual information that is required by 
public health agencies or decision makers to guide interventions, make policy 
decisions and evaluate public health services (Nsubuga et al. 2006). 
 
The utility of public health surveillance data are wide-ranging and, depending 
on the actions that can be taken, they can be viewed as immediate, periodical 
or archival (Table 5.1). Each public health objective and the actions needed to 
make a successful intervention may require a different kind of surveillance 
information and system design. For example, the detection of acute infectious 
disease outbreaks or environmental hazards will require the active surveillance 
of related disease indicators to provide rapid information collection, transfer 
and analyses. This would allow identification of the problem and deployment 
of containment measures. In contrast, surveillance for chronic diseases or 
evaluation of the impact of policy change on health requires the gathering of 
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data over a long period of time since the associated changes occur more 
gradually, and may not require the same data collection mechanism as the 
detection of an immediate threat. 
 
 
Table 5.1 Utility of public health surveillance data (Source: adapted from Thacker 
et al. 1998) 
 
Immediate detection of 
Epidemics 
Newly emerging health problems 
Changes in health practices 
Changes in antibiotic resistance 
Changes in distribution at risk for disease 
Periodic dissemination 
for 
Estimating magnitude of a health problem 
Assessing control activities 
Setting research priorities 
Determining risk factors for disease 
Facilitating planning 
Monitoring risk factors 
Monitoring changes in health practices 
Documenting distribution and spread of disease 
and injury 
Store information for 
Describing natural history of diseases 
Facilitating epidemiological and laboratory 
research 
Validating use of preliminary data 
Setting research priorities 
Documenting distribution and spread of disease 
and injury 
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The importance of public health surveillance to public health practice has been 
acknowledged by various strategic documents published in England and Wales 
(DH 2010; Welsh Government 2009a). Specifically, it was highlighted that the 
gathering of information and intelligence for health-related data from a range 
of systems was crucial to the success of health protection operations, such as 
emergency preparedness and development of evidence-based public health 
policies (DH Public Health England Transition Team 2012). A wide range of 
health-related data have been utilised for public health surveillance, which 
includes both data primarily intended for surveillance purposes as well as data 
that do not have surveillance as the main goal (Table 5.2 and Table 5.3). This 
chapter focuses on the role of public health surveillance specifically in the area 
of disease monitoring and outbreak detection. 
 
 
Table 5.2 Sources of health-related data intended for surveillance purposes (Source: 
Department of Health Public Health England Transition Team 2012) 
 
Data and systems primarily for surveillance 
purposes 
 
Mortality data  
Infectious disease reporting and analysis  
Accidents and poisonings reporting and analysis  
Environmental hazards reporting and analysis  
Acute and chronic disease registers  
Congenital anomaly registers  
Behavioural monitoring and analysis  
Monitoring systems for other determinants e.g. 
obesity, poor housing 
 
Meteorological data analysis for health  
Health-care seeking behaviour monitoring e.g. 
general practice attendance, telephone calls 
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Table 5.3 Sources of information and intelligence unintended for surveillance 
purposes but for service planning, management and evaluation purposes (Source: 
Department of Health Public Health England Transition Team 2012) 
 
Public health information and intelligence for 
service planning, management and evaluation 
 
Screening programme data  
Drug misuse and treatment data  
Immunization programme data  
Hospital episodes statistics  
General practice episode statistics  
Termination of pregnancy statistics  
 
 
5.1.1 Syndromic surveillance 
In the United Kingdom (UK), a number of data sources are routinely used to 
monitor prevalence and incidence of infectious diseases in primary care. This 
includes reports of clinical diagnosis, microbiological results from patient 
samples, mortality and morbidity statistics (Health Protection Agency [HPA] 
2010b). The surveillance systems that facilitate the collection of these data are 
well established and are now useful for monitoring long-term disease trends 
(Fleming 1999, Public Health Wales [PHW] 2011a). One common element 
with these surveillance datasets is that they all rely on individuals accessing a 
healthcare service, where his or her symptoms are assessed by a healthcare 
professional, before a diagnosis is recorded or passed on for laboratory 
investigation. This implies that (a) the presence of a disease can only be 
detected if and when an individual begins to access healthcare service where 
these data are collected and, (b) these traditional surveillance methods may not 
be able to detect the early stages of a disease outbreak when symptoms are less 
severe. More notably, a number of other factors could contribute to the time 
delay between the first onset of symptoms and reports of disease to public 
health agencies. For example, difficulty in accessing healthcare service, time 
required to conduct clinical assessment, unwillingness to seek medical 
attention at the first instance of experiencing symptoms (Banks 2010) and time 
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needed for transporting patient samples, can all affect the timeliness of 
detection by a surveillance system that relies on healthcare service based data. 
This potential time delay could negate public health planning efforts and hold 
back time critical countermeasures from being deployed that minimise the 
spread of a communicable disease outbreak. 
 
Syndromic surveillance, also referred to as real-time surveillance (Harder et al. 
2011), or electronic surveillance (Lombardo et al. 2003), is an investigational 
approach to outbreak detection that makes use of non-traditional health data 
based on generic symptoms or proxy measures that constitute a provisional, but 
not confirmed, diagnosis of a disease (Buehler et al. 2004). For example, data 
derived from clinical indicators such as emergency hospital patient admission 
record (Wagner et al. 2004) or physician consultation rate (Harcourt et al. 
2011) are among some that have been used as inputs in syndromic surveillance 
programmes (Table 5.4). Other systems have utilised data derived from non-
clinical sources, such as the sales of over-the-counter (OTC) medicines (Edge 
et al. 2006), number of telephone health help line calls (Cooper et al. 2007) or 
school absenteeism (Kara et al. 2011), as potential correlates for certain disease 
activities in the population (Table 5.4). 
 
The key rationale behind these new approaches to disease surveillance is that 
such health indicators, although not based on confirmed aetiology, have been 
found to correlate with the levels of some common infections in the population 
(van den Wijngaard et al. 2011). Another reason why these datasets are 
considered to be beneficial is that that they may provide an earlier warning for 
emerging diseases than traditional surveillance systems (Dailey et al. 2007; 
Mandl et al. 2004). This is because the data input used by syndromic 
surveillance systems are often measures of events that might precede a clinical 
diagnosis, such as changes in health-seeking behaviour or the actions of a 
person suffering early disease onset (e.g. purchase non-prescription 
medications or miss school), thereby providing the first sign of an emerging 
disease outbreak (Henning 2004).  
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Table 5.4 Sources of health-related data used for syndromic surveillance 
 
Sources of data for syndromic surveillance  
Telephone health helpline (Cooper et al. 2007)   
Emergency hospital attendance (Elliot et al. 2012)  
Over-the-counter medicine sales (Edge et al. 2006)  
School absence (Kara et al. 2011)  
Employee absence (van den Wijngaard et al. 2011)  
Prescription medication dispense (Chen et al. 2005)  
Internet search and weblog (Johnson et al. 2004)  
Hospital chief complaint (Wagner et al. 2003)  
GP clinical diagnosis (Fleming and Elliot 2008)  
 
 
The HPA collects a range of data from multiple sources for a variety of 
communicable diseases as part of its routine syndromic surveillance operation 
for England and Wales (HPA 2013a). This involves mainly data on general 
practitioner (GP) consultations (Fleming and Elliot 2008), telephone health 
help line calls (Cooper and Chinemana 2004), emergency department (Elliot et 
al. 2012) and out-of-hours GP service attendance (HPA 2013b). These 
syndromic surveillance systems have demonstrated their usefulness for the 
detection of gastrointestinal (GI) related (Cooper et al. 2006; Cooper et al. 
2008; Smith et al. 2010) and seasonal influenza outbreaks (Cooper et al. 2007; 
Smith et al. 2006) in the UK population. More recently, these systems have 
been successfully used in 2009 to track the activity of large scale, unexpected 
outbreaks of pandemic influenza (Harcourt et al. 2011; Smith et al. 2011, HPA 
2013c), monitor the impact of potential environmental hazards on public health 
(Elliot et al. 2010) and support public health protection during periods of 
heightened surveillance, such as for the London 2012 Olympic and Paralympic 
Games (Harcourt et al. 2012).  
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5.1.2 Pharmaceutical sales data 
Outside of the UK, pharmaceutical sales data for OTC (or non-prescription) 
medicines has been utilised by syndromic surveillance systems for the 
detection of a range of disease outbreaks (Andersson et al. 2013; Buehler et al. 
2008). For instance, in New York City, sales of anti-diarrhoeal medications 
and medications for influenza-like-illnesses (ILI) from pharmacies have been 
used as part of the routine surveillance program for seasonal influenza 
monitoring (Das et al. 2005). Another larger syndromic surveillance system, 
National Retail Data Monitor, has been collecting real-time sales of several 
thousand OTC health care products from 18,000 pharmacies across the United 
States for routine surveillance of respiratory-related outbreaks (Wagner et al. 
2003). In 2009, during the H1N1 influenza pandemic, a national influenza 
surveillance program was established in Canada using the sales of respiratory-
related OTC medicines collected from over 1,800 retail pharmacies. The 
system successfully tracked the activity of the pandemic and complemented 
other surveillance systems that operated at the time (Anon. 2009e). While 
national surveillance schemes such as those mentioned above have yet to be 
implemented and integrated into public health practice in most other countries, 
findings from many studies provided support for its contribution to healthcare 
(Andersson et al. 2013; Edge et al. 2006; Liu et al. 2013; Magruder et al. 2004; 
Ohkusa et al. 2005; Pelat et al. 2010; Vaergu et al. 2006). To date, successes in 
using OTC medicine sales data as a data input have been reported for the 
detection of GI-related outbreaks (Andersson et al. 2013; Das et al. 2005; Edge 
et al. 2006; Hogan et al. 2003; Pelat 2010), respiratory diseases (Magruder 
2003; Magruder et al. 2004) and seasonal and non-seasonal outbreaks of 
influenza (Liu et al. 2013; Ohkusa et al. 2005; Sočan et al. 2012; Vaergu et al. 
2006; Welliver et al. 1979). 
 
A combination of factors makes OTC medicines sales data a potential 
attractive option for syndromic surveillance. First, it has been shown OTC 
medicines are commonly used for treating minor ailments (McIntyre et al. 
2003; Vingilis et al. 1999), and many people self-medicate prior to seeking a 
consultation with a healthcare professional (Banks 2010; Urquhart et al. 2004). 
As a consequence, for some people the purchase of an OTC medicine may be 
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the first and only point of contact with healthcare services. This potentially 
provides an opportunity for early increase in disease cases to be identified 
before they are reported to other primary care or secondary care services. 
 
Secondly, a wide range of medicines are available OTC and already a number 
of them have the potential to be linked to diseases that are of interest to public 
health. Examples include rehydration salts or anti-diarrhoeal products for 
cryptosporidium outbreaks; cough, cold and flu remedies for ILI or influenza 
outbreaks and ophthalmic chloramphenicol for infective conjunctivitis. 
 
Thirdly, many large retail pharmacy businesses, through automatic and 
electronic systems, already collect, utilise and maintain OTC medicine sales 
data on a routine basis. Making use of these existing systems, infrastructures 
and equipment is more cost efficient than developing a system primarily 
intended for surveillance. 
 
Fourthly, as medicine sales data is already routinely gathered the data 
collection process does not add any additional burden on the data providers, 
and the availability of historical data means baseline level of sales can be 
determined at the early stage of surveillance.  
 
Finally, with the aid of computer technology, an electronic record is made 
instantly available at the time of each sale, including the type of product sold 
and the location of each sale. These records can be easily transmitted to 
facilitate real-time or near real-time monitoring which is difficult to achieve 
with surveillance data that are based on a confirmed clinical diagnosis. 
 
The usefulness of OTC medicine sales data for early disease detection or the 
determination of an outbreak has not yet been established in the UK. Outside 
the UK, however, studies have been published and shed light on answers to 
some important questions about the application of such data in public health 
surveillance. For example, which products correlate with what type of disease 
(Li et al. 2005; Magruder 2003); how to identify meaningful categories of 
products for monitoring (Pelat et al. 2010; Wallstrom and Hogan 2007); how to 
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identify an unusual change in sales that correspond to a disease outbreak 
(Dailey et al. 2007); how to adjust for potential confounders that affect sales 
(Magruder 2004) and what criteria should be used to evaluate system 
performance (Buehler et al. 2004). One major barrier to using medicines sales 
data for diseases surveillance is the practical difficulties in obtaining the data. 
Pharmacy businesses also have concerns over security and the commercial 
sensitivities around supplying the data. In addition, there is currently little 
incentive for commercial companies to exploit medicine sales data for their 
public health potential. 
 
5.1.3 Description of conjunctivitis outbreaks 
The results from Chapter 4 indicate that sales of OTC ophthalmic 
chloramphenicol from community pharmacy were synchronised with the 
prescribing of the same drug by GPs in Wales. This was not unexpected given 
the majority of ophthalmic chloramphenicol supplied was likely to have been 
for the same indication in both settings i.e. the treatment for infective 
conjunctivitis. The possibility that sales of OTC ophthalmic chloramphenicol 
from community pharmacy may be an indicator of an outbreak of infective 
conjunctivitis in the community motivated the current study. 
 
The Health Protection Team (HPT) is part of the Health Protection Division of 
PHW and is responsible for providing advice and support on community 
disease control issues as well as communicable disease management in Wales. 
One of its core functions is to investigate outbreaks of disease in healthcare 
premises or clusters of disease of unknown origin (PHW 2010a). Through a 
unique collaboration with PHW, the present study investigated whether the 
sales data for OTC ophthalmic chloramphenicol from community pharmacy 
was capable of detecting two known conjunctivitis outbreaks in Wales. Each of 
the outbreaks is described in more detail below. 
 
5.1.3.1 Pontypool Outbreak (February 2010) 
The first outbreak was reported to the HPT on 12th February 2010 (week 7, 
2010) by the on duty nurse who was working at a GP practice located in 
Pontypool, Torfaen, Wales. At the time, it was reported that 13 children 
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(between the age of three and four years old as well as teenagers) with 
symptoms of acute infective conjunctivitis had been seen at the practice. The 
practice was advised by the HPT to be vigilant of any new cases of infective 
conjunctivitis and was reminded to disseminate infection prevention and 
control measures to those who might be affected. None of the 13 cases returned 
to the practice for further consultation. Following the initial report of the 
outbreak, a further eight new cases presented at the practice three days later on 
15th February 2010. Individuals affected were children of 14 years of age all of 
whom attended a local school in Trevethin. After 15th February 2010 no new 
reports of infective conjunctivitis were notified to HPT. It was not known if 
any of the affected individuals had been supplied with a prescription for topical 
antibiotics. Laboratory results obtained from three of the affected children 
revealed the infections were of a bacterial origin. 
 
5.1.3.2 Aberdare Outbreak (November 2010) 
The second outbreak (Aberdare) was recorded by the HPT week commencing 
15th November 2010 (week 46, 2010). The incident was reported by a school 
nurse who was working at a secondary school located in Aberdare, Rhondda 
Cynon Taf, Wales. The suspected outbreak involved five female students 
between the age of 13 and 15 years old who showed signs of acute infective 
conjunctivitis as identified by the school nurse. The five affected students were 
excluded from school and were advised to seek medical attention from their 
GPs but it was not known if a prescription for topical antibiotics had been 
supplied. In addition, the school and the carers or families of the five students 
were provided with advice on infection control and prevention measures, such 
as hand-washing and avoidance of sharing personal items. Since this initial 
incident, no other new cases was identified at the school nor was the HPT 
aware of any other outbreak in the nearby vicinity. No other action thereafter 
was taken by the HPT. It was suspected the infections were of bacterial origin 
due to sharing of eye make up between the students although no eye swab was 
taken. 
 
5.1.4 Aims 
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By utilising pharmacy retail data obtained from Company A (Section 4.2.2.3), 
the aim of the present study was to determine whether pharmacy sales data for 
ophthalmic chloramphenicol were sensitive to and could detect the occurrence 
of two known conjunctivitis outbreaks in the local community. The specific 
objectives were: 
 
(a) quantify the sales and prescribing of ophthalmic chloramphenicol from 
Company A pharmacy and by local GPs, respectively, in each of the areas 
where the outbreak had been reported and, 
 
(b) determine if there was a statistically significant difference in the quantity of 
ophthalmic chloramphenicol supplied during the period of the outbreak and 
that during a non-outbreak period in previous years. 
 
5.2 Method 
 
5.2.1 Study design 
The study had an ecological design (Schoenbach and Rosamond 2000) and 
involved the retrospective analysis of pharmacy retail data and primary care 
prescription data for ophthalmic chloramphenicol preparations supplied in 
Pontypool and Aberdare, Wales, during the period January 2008 to December 
2010. 
 
5.2.2 Data 
Primary care prescription data for ophthalmic chloramphenicol were obtained 
from CASPA.net, a data store that contained NHS Wales primary care 
prescribing data. This was the same prescription data source as utilised through 
out the work presented in this thesis. Pharmacy retail sales data (herein refer to 
as pharmacy sales data) for OTC ophthalmic chloramphenicol were obtained 
from Company A, which was a national, multiple-chain pharmacy in the UK. 
This source of data was identical to that utilised in Chapter 4 (Section 4.2.2.3) 
and represented actual sales of ophthalmic chloramphenicol from pharmacy to 
patients. The data extraction processes for each of the areas studied is 
described separately below: 
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5.2.2.1 Pontypool 
All GP practices located in the Pontypool area were identified using the NHS 
Wales Service Directory available online on NHS Wales website (NHS Wales 
2011). This revealed a total of nine GP practices situated in the area at the time 
of the study (Figure 5.1). Forty-three GP prescribers were based at these nine 
surgeries during the study period and identified using the CASPA.net 
prescription database. Monthly prescribing data for each of the GP prescribers 
during the period from January 2008 to December 2010 were extracted. 
 
Pharmacy sales data obtained from Company A were available from January 
2008 to December 2010. Data supplied included the weekly number of packs 
of product sold for each Company A’s 94 pharmacies across Wales together 
with postcode information. The location for each Company A pharmacy was 
cross-referenced to the Welsh Pharmacy Contractors List supplied by PHW. 
Any Company A pharmacy located in the Pontypool area was identified. This 
revealed one Company A pharmacy was in the area in question. Weekly sales 
figures for this pharmacy were extracted and aggregated into their 
corresponding month accordingly. The location of the pharmacy in relation to 
the nine GP practices in Pontypool is shown in Figure 5.1.  
 
5.2.2.2 Aberdare 
Using the same method as described above, a total of six primary care GP 
practices were identified in the Aberdare area at the time of the study (Figure 
5.2). The CASPA.net prescription database indicated a total of 17 GP 
prescribers who based in the six GP practices. Monthly prescribing data for 
each of the GP prescribers were extracted for the period from January 2008 to 
December 2010. Similarly, a Company A pharmacy was located in the 
Aberdare area and its weekly sales figures were extracted and aggregated into 
their corresponding month accordingly. The location of the pharmacy in 
relation to the nine GP practices in Aberdare is shown in Figure 5.2.  
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Figure 5.1 Locations of general practices ( ) in Pontypool, Torfaen, Wales, for 
which prescribing data were extracted from the NHS Wales prescription database. 
The solid-filled marker ( ) indicates the practice that identified and reported the 
outbreak. Star () marks the location of Company A pharmacy. Major towns and 
villages are indicated by a cross 
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Figure 5.2 Locations of general practices ( ) in Aberdare, Rhondda Cynon Taf, 
Wales, for which prescribing data were extracted from the NHS Wales prescription 
database. The solid-filled marker ( ) indicates location of the school that was 
involved in the outbreak. Star () marks the location of Company A pharmacy. 
Major towns and villages are indicated by a cross  
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5.2.3 Medicines studied 
 
5.2.3.1 Prescription medicines 
Chloramphenicol containing preparations listed under section 11.3.1 (Anti-
bacterial eye preparations) of the British National Formulary (BNF) 65 (BNF 
2013) were included in the study. In addition, a manual search of the 
prescription database was conducted to identify any other ophthalmic 
preparations that also contained chloramphenicol to be subsequently included 
in the analysis. A list of prescribed products included in the current study can 
be found in Appendix 14. 
 
5.2.3.2 Over-the-Counter medicines 
Pharmacy retail data included all proprietary and Company A’s own-brand of 
ophthalmic chloramphenicol preparations (eye drops and eye ointment) sold. A 
list of all ophthalmic chloramphenicol products sold from company A and 
included in the present study can be found in Appendix 17. 
 
5.2.4 Data processing and organisation 
Data utilised in the current study were obtained from different sources and had 
to be processed and organised into a suitable format before statistical analysis. 
Primary care prescription data were extracted from the NHS Wales 
prescription database and transferred to a Microsoft Excel spreadsheet 
(Appendix 8). Pharmacy retail data from Company A were supplied in a 
Microsoft Excel spreadsheet. All processed and reorganised data were 
manually screened for errors before transferring to the statistical software for 
analysis. 
 
5.2.5 Analysis 
The supply of ophthalmic chloramphenicol on prescription and the number of 
pack sold OTC in Pontypool and Aberdare were quantified for the period from 
January 2008 to December 2010. The year-on-year changes in the quantities 
supplied were visualised using box plots as described in Chapter 4 (Section 
4.2.6.1). 
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Over the three-year study period, the numbers of items prescribed each month 
were presented on an unadjusted time series chart. Weekly sales of OTC 
ophthalmic chloramphenicol from Company A were presented on an 
unadjusted time series chart as well as on a four-week moving average chart. 
The purpose of presenting the weekly sales data in four-week moving averages 
was to aid the identification of sales trends. 
 
The moving averages are the unweighted means of a constant number of past 
observations that are calculated based on values from the beginning to more 
recent observations of a time series. The number of observations used for 
computing the mean is called the order of the series. Since the order of the time 
series was an even number, the centred moving average method was used to 
determine the data points for the four-week moving average time series (Yaffee 
and McGee 1999). 
 
5.2.5.1 Determine changes in prescription supply 
To investigate the potential impact of the reported outbreaks on the prescribing 
of ophthalmic chloramphenicol, the total number of items supplied during the 
month of the outbreak in 2010, together with total quantities supplied in the 
corresponding month in 2008 and 2009, were determined for each of the 
respective areas. The median and interquartile range (IQR) for the number of 
ophthalmic chloramphenicol items prescribed per GP prescriber were also 
calculated for the month of the outbreak in 2010 and for the corresponding 
months of 2008 and 2009. Wilcoxon’s signed rank test was used to identify 
any statistically significant difference between the quantities supplies per GP 
prescriber during the month of outbreak in 2010 and the corresponding month 
of 2008 and 2009. 
 
5.2.5.2 Determine the changes in Over-the-Counter sales 
Total packs of OTC ophthalmic chloramphenicol sold from Company A’s 
pharmacy, during the period one week before to one week after the reported 
outbreak, were determined for each of the respective areas studied. For the 
Pontypool outbreak, the three-week period corresponded to week six, seven 
and eight of 2010. For the Aberdare outbreak the three-week period 
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corresponded to week 45, 46 and 47 of 2010. The median and IQR were also 
calculated for ophthalmic chloramphenicol sold per brand for the three-week 
period of 2008, 2009 and 2010 for each of the respective areas. Wilcoxon’s 
signed rank test was used to identify any statistically significant difference 
between sales of ophthalmic chloramphenicol of two different three-week 
periods.  
 
All data analysis and statistics were performed using PASW version 18 
(PASW Inc., Chicago, IL, USA). A p-value < 0.05 was considered to be 
statistically significant. 
 
5.3 Results 
 
5.3.1 Pontypool 
 
5.3.1.1 Over-the-Counter ophthalmic chloramphenicol 
Weekly sales of ophthalmic chloramphenicol preparations from Company A 
pharmacy in Pontypool are shown in Figure 5.3. The number of packs sold 
varied from week to week and no seasonal or periodic trend was discernible. 
Transformation of weekly sales of ophthalmic chloramphenicol into four-week 
moving average also revealed no consistent pattern of sale between the 
different years (Figure 5.4).  
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Figure 5.3 Weekly sales of over-the-counter ophthalmic chloramphenicol 
preparations (eye drops and ointment) from one Company A pharmacy located in 
Pontypool, Wales. The arrow marks the week (week number) of the reported 
conjunctivitis outbreak (2010) 
 
 
 
 
Figure 5.4 Four-week moving average chart for the sales of over-the-counter 
ophthalmic chloramphenicol preparations (eye drops and ointment) from one 
Company A pharmacy located in Pontypool, Wales. The arrow marks the week (week 
number) of the reported conjunctivitis outbreak (2010) 
 
 
A sharp increase in the sales of OTC ophthalmic chloramphenicol was 
observed in week 7 of 2010. This rise in sales coincided with the report of 
conjunctivitis outbreak to PHW on the same week (Figure 5.3). A similar 
increase was not observed during the corresponding week in the previous 
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years. However, it was noted that although there was no change in sales in 
week 7 of either 2008 or 2009, a small increase in sales had occurred two 
weeks after in week 9 of 2008 and 2009. Overall, the sales of combined OTC 
ophthalmic chloramphenicol preparations increased, year-on-year, from 87 
packs in 2008 to 197 packs in 2010. Significantly more packs (p-value, 
median, IQR) were sold in 2009 (0.011, 8, 3.75) and 2010 (0.002, 16.5, 6.75) 
compared to 2008 (Figure 5.5). 
 
 
 
 
Figure 5.5 Boxplot showing the median and interquartile range for the number of 
packs of over-the-counter ophthalmic chloramphenicol (eye drops and ointment) 
sold from one Company A pharmacy located in Pontypool, Wales for the component 
month each year (January to December) 
 
 
The total sales, median and IQR for OTC ophthalmic chloramphenicol sold 
OTC between week six and week eight of 2008, 2009 and 2010 in Pontypool 
are shown in Table 5.5. Sales of OTC ophthalmic chloramphenicol during the 
three week period that corresponded to the Pontypool outbreak in 2010 were 
significantly greater than those sold during the corresponding period in 2008 
(p=0.042) when no conjunctivitis outbreak was known to have occurred. No 
significant difference was observed between the sales of ophthalmic 
chloramphenicol in 2010 and those sold during the corresponding period in 
2009 (p>0.05).  
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Table 5.5 Total ophthalmic chloramphenicol (eye drops and ointment) supplied in 
Pontypool and Aberdare during respective periods of the reported conjunctivitis 
outbreaks, together with median (and interquartile range [IQR]) for the number of 
OTC packs sold per brand and items prescribed per GP prescriber for each of the 
areas. The quantity of ophthalmic chloramphenicol sold OTC or supplies on 
prescription in 2010 were compared to their corresponding quantity in 2008 or 2009 
using Wilcoxon’s sign rank test. A p-value < 0.05 is indicated in bold 
 
  Total OTC packs† (Median, IQR); p-value  
Total prescribed items‡ 
(Median, IQR); p-value 
Po
nt
yp
oo
l 2008 4 (0, 0.75); p = 0.042  185 (3, 7); p = 0.467 
2009 7 (0, 1); p = 0.107  132 (2, 5); p = 0.003 
2010 19 (0.5, 1.75)  200 (3, 6)  
A
be
rd
ar
e 2008 9 (0.5, 1.75); p = 0.803  92 (4, 8.5); p = 0.553 
2009 8 (0, 1.5); p = 1.00  113 (5, 11.5); p = 0.528 
2010 8 (0.5, 1)  110 (5, 9) 
† Period reported for Pontypool (week 6 to 8); Aberdare (week 45 to 47) 
‡ Period reported for Pontypool (February); Aberdare (November) 
 
 
5.3.1.2 Prescribed ophthalmic chloramphenicol 
The numbers of items of ophthalmic chloramphenicol supplied on GP 
prescription in Pontypool are shown in Figure 5.6. During the three-year study 
period the items prescribed each year followed a similar pattern to one another 
with more items prescribed in January to March and less items prescribed in 
September to November. A peak in the prescribing of ophthalmic 
chloramphenicol was observed in February 2010. This coincided with the 
month in which the infective conjunctivitis outbreak in Pontypool was reported 
to PHW (week 7, 2010). The overall trend of ophthalmic chloramphenicol 
supplied on prescription in Pontypool remained steady, year-on-year, with 
1,680 items in 2008, 1,614 items in 2009 and 1,656 items in 2010. No 
significant differences (p>0.05) were observed between any two 12-month 
periods (Figure 5.7).  
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Figure 5.6 Monthly numbers of items of ophthalmic chloramphenicol preparation 
(eye drops and ointment) supplied on primary care prescriptions in Pontypool, Wales 
for each year. Asterisk (✻) marks the month when the infective conjunctivitis 
outbreak was reported to Public Health Wales (2010) 
 
 
 
 
Figure 5.7 Boxplot showing the items of ophthalmic chloramphenicol preparations 
(eye drops and ointment) prescribed on primary care prescriptions in Pontypool, 
Wales for the component months each year (January to December) 
 
 
The total items, median and IQR for ophthalmic chloramphenicol supplied on 
prescriptions during the month of the Pontypool outbreak are shown in Table 
 166 
5.5. The number of items prescribed per GP prescriber in February 2010 was 
significantly higher (p=0.003) than the number of items supplied in the 
corresponding month of 2009 when no outbreak was known to have occurred. 
No significant differences in number of items prescribed were observed 
between February 2010 and February 2008 (p>0.05). 
 
5.3.2 Aberdare 
 
5.3.2.1 Over-the-Counter ophthalmic chloramphenicol 
Weekly sales of OTC ophthalmic chloramphenicol from Company A pharmacy 
between January 2008 and December 2010 in Aberdare are shown in Figure 
5.8. Both time-series charts (Figure 5.8 and 5.9) demonstrated no discernible 
seasonal pattern during the period studied. During the week of the reported 
outbreak in 2010 (week 46), there was no marked change in sales of OTC 
ophthalmic chloramphenicol. However, A noticeable increase in sales that was 
not present during week 12 of 2008 and 2009 was observed in 2010 (Figure 
5.8). 
 
 
 
Figure 5.8 Weekly sales of over-the-counter ophthalmic chloramphenicol 
preparations (eye drops and ointment) from one Company A pharmacy in Aberdare, 
Wales. The arrow marks the week and week number when the suspected 
conjunctivitis outbreak was reported to Public Health Wales (2010) 
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Figure 5.9 Four-week moving average chart showing the sales of over-the-counter 
ophthalmic chloramphenicol (eye drops and ointment) from one Company A 
pharmacy in Aberdare, Wales. The arrow marks the week when the suspected 
conjunctivitis outbreak was reported to Public Health Wales (2010) 
 
 
Overall, the sales of ophthalmic chloramphenicol preparations increased, year-
on-year, from 78 packs in 2008 to 120 packs in 2010. No significant difference 
(p>0.05) in the sales of OTC ophthalmic chloramphenicol was detected 
between any two 12-month periods. An outlying data point indicated higher 
than normal volumes of OTC ophthalmic chloramphenicol had been sold from 
Company A pharmacy during the month of March 2010 (Figure 5.10). This 
was confirmed by Wilcoxon’s signed rank test, which showed the volume sold 
during March 2010 was significantly higher than that sold in the corresponding 
month in 2008 and 2009 (p=0.019 and 0.024, respectively). However, no 
conjunctivitis outbreak was known to PHW for the Pontypool area in March 
2010. 
 
The total sales, median and IQR for ophthalmic chloramphenicol sold OTC in 
Aberdare during the three-week period of 45, 46 and 47, each year from 2008 
to 2010, are shown in Table 5.5. The numbers of packs sold during the three-
week period were similar between each year and Wilcoxon’s sign rank test 
indicated there was no significant difference (p>0.05) in quantities sold 
between the outbreak and non-outbreak periods. 
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Figure 5.10 Boxplot showing the median and interquartile range (IQR) for the 
number of packs of over-the-counter (OTC) ophthalmic chloramphenicol (eye drops 
and ointment) sold from one Company A pharmacy located in Aberdare, Wales for 
the component months each year (January to December). Circles (○) indicate values 
that are beyond the upper and lower quartile by one and a half IQRs and are 
classified as outliers 
 
 
5.3.2.2 Prescription ophthalmic chloramphenicol 
The numbers of items of ophthalmic chloramphenicol supplied on primary care 
prescription in Aberdare are shown in Figure 5.11. During the three-year study 
period, prescribing of ophthalmic chloramphenicol showed a similar pattern in 
2008 and 2010 with more items prescribed in December to February and fewer 
in August to November.  
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Figure 5.11 Monthly numbers of items of ophthalmic chloramphenicol preparation 
(eye drops and ointment) supplied on primary care prescriptions in Aberdare, Wales 
for each year. Asterisk (✻) marks the month when the infective conjunctivitis 
outbreak was reported to Public Health Wales (2010) 
 
 
Overall, the total quantity of ophthalmic chloramphenicol prescribed each year 
remained steady from 2008 to 2010 with a total of 1,228 items, 1,224 items and 
1,212 items supplied, respectively. No significant differences (p>0.05) in 
quantity prescribed were observed between any two 12-month periods. 
However, an outlying data point indicated that a higher than normal volume of 
prescribing occurred during the month of February 2010 (Figure 5.12). The 
volume of prescribing during this month was significantly higher than that 
during the corresponding month in 2009 (p=0.028) but indifferent to 2008 
(p>0.05). To the knowledge of PHW, no known conjunctivitis outbreak was 
reported for the area surrounding Aberdare in February 2010. 
 
Results from Wilcoxon’s signed rank test indicated no significant differences 
(p>0.05) in number of items prescribed were observed between November 
2010 and other November months in any other years (Table 5.5). This indicates 
there was no difference in volume of ophthalmic chloramphenicol prescribed 
between the months of a known and no known conjunctivitis outbreak.  
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Figure 5.12 Boxplot showing the items of ophthalmic chloramphenicol preparations 
(eye drops and ointment) prescribed on primary care prescriptions in Aberdare, 
Wales for the component months each year (January to December) 
 
 
5.4 Discussion 
 
5.4.1 Main findings 
This was the first study in Wales that explored the potential of OTC medicine 
sales data from community pharmacy for the detection of a small outbreak of 
conjunctivitis. The results showed that during the period of the outbreak in 
Pontypool, sales of OTC ophthalmic chloramphenicol were significantly higher 
than those sold in the corresponding period in one (2008) of the two non-
outbreak years. Similarly, numbers of items for ophthalmic chloramphenicol 
prescribed by local GPs in the month of the outbreak were also found to be 
significantly higher than those prescribed in the corresponding month in one 
(2009) of the two non-outbreak years. In contrast, ophthalmic chloramphenicol 
supplied on prescription and sold OTC during the Aberdare outbreak 
demonstrated no significant difference to the quantity supplied during their 
corresponding period in the non-outbreak years. 
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Despite the positive findings with the Pontypool outbreak, the results need to 
be interpreted with caution for two reasons. First, the quantities of ophthalmic 
chloramphenicol supplied OTC and on prescription during the outbreak period 
were not consistently higher than that supplied during their corresponding non-
outbreak periods. This reduces the confidence for medicine sales to detect the 
occurrence of conjunctivitis outbreaks in the community. Second, due to the 
low volume of ophthalmic chloramphenicol sold from Company A pharmacy 
in study area, the changes in sale was small and could have been caused by 
factors unrelated to the outbreak. As a result of these confounding issues, the 
current study was unable to determine conclusively if medicine sales data was 
capable of detecting local outbreaks of infective conjunctivitis. 
 
In addition to the above, the current study illustrated there was no change in 
both the sale or prescribing of ophthalmic chloramphenicol during the outbreak 
in Aberdare. This suggests small outbreaks may be particularly difficult to 
identify using medicine sales data. Nonetheless, this exploratory study had a 
number of weaknesses in terms of study design and data collection which 
could inform future work. These will be discussed in the following section. 
 
5.4.2 Study limitations 
 
5.4.2.1: Prescription data 
The prescription data used in the present study were obtained from the NHS 
Wales prescription database, which was a robust and routinely used data source 
for analysing primary care prescriptions dispensed by NHS-contracted 
community pharmacies in Wales. All ophthalmic chloramphenicol preparations 
that were prescribable on NHS prescriptions in primary care were included in 
the study.  
 
The prescription data were derived from prescriptions written by all GPs whose 
practices were located in the immediate vicinity of the reported outbreaks. It 
was possible an individual who lived outside Pontypool or Aberdare visited the 
areas and obtained a prescription for ophthalmic chloramphenicol from a local 
GP for causes unrelated to the two outbreaks studied. How much of an impact 
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this confounder had on the prescribing figures is unknown for either of the 
areas studied. 
 
Another potential confounder about the prescription data was that patients 
could have consulted a non-medical prescriber, such as an independent nurse 
or pharmacist prescriber, about their eye conditions. If this was the case, any 
prescription issued as a result would have not been included in the study and 
the quantities reported could be an underestimation of the real supply picture. 
The impact of the missing data on overall prescribing is likely to be small as 
information received from NHS Wales Information Services indicate items of 
ophthalmic chloramphenicol prescribed by non-medical prescribers only 
accounted for 1% of all primary care prescriptions in Wales (personal 
communication). However, despite the low levels of non-medical prescribing 
for ophthalmic chloramphenicol overall, it was unclear to what extent this was 
taking place during the two conjunctivitis outbreaks studied.  
 
The prescription data obtained for the current study were aggregated figures for 
all ophthalmic chloramphenicol prescribed and differentiation between adult 
and paediatric prescribing was not possible. In both outbreaks the individuals 
reported to have been affected were mainly children between the age of ten and 
fifteen years old (personal communication), it was possible that the levels of 
prescribing for ophthalmic chloramphenicol in certain age groups had 
increased but not in others or, alternatively, had been masked by background 
levels of prescribing in others age groups. It may be worthwhile in future 
studies capturing age-specific data to avoid such problem. 
 
Finally, the data available in the NHS Wales prescription database were only 
available as a total figure compiled on a quarterly or monthly basis, therefore 
separating the prescribing of ophthalmic chloramphenicol into shorter and 
more frequent time intervals was not possible. If weekly prescribing data had 
been available, it could have allowed short-lived changes in prescribing pattern 
to be identified as a signal of interest may be less likely to become diluted over 
time or masked by unrelated background supplies. Furthermore, weekly 
prescribing data would have been more comparable to pharmacy sales data as 
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this was also available on a weekly basis. These potential weaknesses had been 
identified before the study was undertaken but it was thought the number of 
individuals seeking treatment as part of an outbreak would be greater. 
 
5.4.2.2: Pharmacy retail data 
Company A pharmacy was a large, national chain pharmacy in the UK with a 
total of 94 community pharmacies across Wales. Despite their extensive 
network nationally, sales data obtained from Company A represented 11% 
(1/9) and 20% (1/5) of all the community pharmacy located in the Pontypool 
and Aberdare areas, respectively (NHS Wales 2011). This small number of 
pharmacy clearly would have reduced the sensitivity of the medicines sales 
data to detect any changes in OTC ophthalmic chloramphenicol sold in the 
local area. The possibility that individuals could have visited another pharmacy 
in or outside of either of the outbreak areas could have further contributed to 
the low number of sales observed in the present study. 
 
Whilst a minimum recommended coverage of pharmacy or medicine market 
share required for a successful syndromic surveillance system based on 
pharmacy sales data has yet to be established, the pharmacies utilised in this 
study were probably inadequate to undertake any appropriate syndromic 
surveillance, particular when a coverage greater than that of the current study 
has been reported by others (Hogan et al. 2003; Kirian et al. 2010; Magruder 
2004; Pelat et al. 2010; Wagner et al. 2003). 
 
Although the incomplete capture of data could have limited the sensitivity and 
accuracy of the study in detecting small outbreaks of conjunctivitis (Wagner et 
al. 2003), it is worth noting that the study had intended to utilise pharmacy 
sales data available at the time. Whilst it appears relatively straightforward to 
recruit more pharmacies to capture the data, barriers such as the lack of an 
appropriate IT infrastructure and the confidentiality of the data precluded this. 
Furthermore, the additional time and resources required to obtain and analyse 
pharmacy sales data from all community pharmacies in areas studied were not 
permissible within the constraints of the current study.  
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5.2.4.3: Medicines studied 
At the time of the study, the licensed indication of OTC ophthalmic 
chloramphenicol was for the treatment of acute infective conjunctivitis in 
adults and children over two years of age. The same medicine, however, when 
supplied on a prescription could be used in any age for a range of eye 
infections (BNF 2013). It was possible that during the period of the study 
ophthalmic chloramphenicol might have been prescribed to patients for other 
eye-related infections or for whom the OTC version was not suitable. 
 
However, despite the differences in their licensed indications, the impact of 
this on the study findings was probably small as infective conjunctivitis has 
been found to be the commonest eye-related diagnosis made by GPs in primary 
care, and ophthalmic chloramphenicol has been identified as the largest 
contributor to prescriptions issued as a result of these consultations (Sheldrick 
et al. 1993). Moreover, the BNF (2013) has been and continues to recommend 
ophthalmic chloramphenicol as the first-line choice of treatment for 
uncomplicated cases of infective conjunctivitis by in the UK, which makes 
them the likely drug of choice for infective conjunctivitis encountered in the 
primary care.  
 
Besides ophthalmic chloramphenicol, other anti-infective ophthalmic 
preparations that could have been purchased without a prescription, such as 
propamidine or dibrompropamidine containing products, were also available at 
the time of the study. While the sales of these anti-infectives might have been a 
more sensitive marker for incidences of infective conjunctivitis in the 
population, their use in infective conjunctivitis was not recommended (BNF 
2013) and there were no published data at the time that suggested they would 
be effective. 
 
The selection of ophthalmic chloramphenicol as the first candidate to be 
monitored for detecting outbreaks of infective conjunctivitis was a logical first 
step given its licensed indication for OTC use was exclusively for the treatment 
of acute infective conjunctivitis. Nonetheless, future studies may need to 
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collate sales data of other ophthalmic preparations that could be used to treat 
eye conditions easily confused with the symptoms of infective conjunctivitis. 
 
5.4.2.4: Severity and prevalence of the outbreaks 
The numbers of individuals reported to have been involved in both outbreaks 
were small. Information obtained from the public health nurses who responded 
to the two outbreaks at the time indicated the number of known affected 
individuals was 21 in Pontypool and 5 in Aberdare (personal communication). 
As a consequence, it was possible that there had not been enough additional 
supplies of ophthalmic chloramphenicol to cause an abrupt change in OTC sale 
or prescribing above their baseline level. Although it was possible that the 
actual number of people affected by the outbreak was greater than the official 
number of reported cases, to what extent under-reporting was occurring was 
also unknown and could not be estimated. 
 
In addition to the low numbers of people affected, the nurse noted that the 
Pontypool outbreak may have been contained by itself as affected children who 
studied at the local school entered spring holiday period just as when the 
outbreak had begun. This was thought to be one of the reasons why the 
outbreak was not as widespread as it could have been. For the outbreak that 
took place in Aberdare, the public health nurse commented that, at the time, the 
school had been given advice to send any symptomatic children to their GPs, 
and infection control and prevention measures were promptly issued. These 
public health interventions were likely to have limited the numbers of those 
who would otherwise have been affected and minimised the spread of the 
outbreak. 
 
Lastly, the symptoms of acute conjunctivitis experienced by those who were 
affected needed to be severe enough in order to prompt health-seeking 
behaviours, such as the purchase of OTC treatment from a pharmacy or obtain 
a prescription from a doctor. Given the symptoms normally associated with 
acute infective conjunctivitis are mild (Everitt et al. 2006; Rose et al. 2005), it 
was probable that some individuals, even though exhibiting the symptoms of 
infective conjunctivitis, had not sought any treatment and thus were not 
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captured by either the OTC sales data or the prescription data in either of the 
areas. Alternatively, they could have managed their symptoms using non-
medicinal, conservative measures for infective conjunctivitis (National 
Institute for Health and Care Excellence [NICE] 2012b). 
 
5.4.3 Comparison with existing literature 
Acute infective conjunctivitis is the most common eye-related problem seen in 
the primary care responsible for up to 41% of all eye-related consultations in 
the general practice. Elderly patients and children are known to be most 
susceptible to the infection (Scott and Dhillon 1998). This epidemiological 
feature was possibly reflected by the fact that both of the outbreaks studied 
involved school age children. One of the reasons that infections among these 
two groups are more common is that person-to-person contact is high and hand 
hygiene often poor thereby facilitating person-to-person transfer. Both of the 
outbreaks took place in the early spring and winter months, thereby confining 
individuals to stay indoor and increasing the likelihood of transmission. 
 
For both outbreaks, the size, severity and overall impact on public health were 
minimal and therefore the social and economical cost to the local community 
was low. This was not unexpected given most primary care cases of acute 
infective conjunctivitis in children are mild and resolve within several days 
even without treatment (Rose et al. 2005). However, infection control measures 
and preventative advice disseminated at the time probably also played a role in 
containing the size and the spread of the outbreak, such as excluding the 
children from school, practice of good hand hygiene and prescribing of 
ophthalmic antibiotics by clinicians. 
 
The current study monitored the sales of OTC ophthalmic chloramphenicol to 
indicate the presence of a conjunctivitis outbreak in small areas. This was the 
first study in the UK that has utilised pharmacy sales data for ophthalmic 
chloramphenicol for such purpose. Consequently, comparison of the current 
findings with other UK studies has not been possible. Outside the UK, 
experience in using medicines sales data to identify outbreaks of other 
infectious diseases exist (Edge et al. 2006; Hogan et al. 2003; Magruder 2003; 
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Vaergu et al. 2006) but none has investigated infective conjunctivitis or any 
other ocular infection.  
 
Although infective conjunctivitis has not been studied previously as part of a 
syndromic surveillance programme, comparison with more successful 
programmes identified a number of notable differences. These differences 
might serve as an indication as to why the present study was unsuccessful in 
identifying the two small conjunctivitis outbreaks. 
 
Firstly, disease outbreaks that have been successfully identified through the 
sale of non-prescription medicines usually involve a substantially greater 
number of affected individual than that in the current study (Andersson et al. 
2013; Edge et al. 2006; Hogan et al. 2003; Magruder 2003; Vaergu et al. 
2006). Secondly, medicine sales data utilised in these investigations were all 
available on a more frequent basis, such as weekly if not daily. Thirdly, sales 
data were often obtained from a more extensive coverage of pharmacies or 
retail outlets in the area of the outbreak than that in the current study. It has 
been suggested that in order to detect a local outbreak, a near complete 
coverage of data would be required for a syndromic surveillance system to 
achieve a successful detection (van den Wijngaard et al. 2011). Perhaps it is 
because of these more stringent requirements for robust, high quality data and 
an outbreak of a substantial size, syndromic surveillance systems have been 
reported to be less useful for small outbreak detection (Buehler et al. 2008). 
 
It has been suggested that one of the advantages of using medicines sales data 
for disease surveillance is its ability to provide an earlier warning about an 
outbreak than is possible with a traditional surveillance system (Dailey et al. 
2007). This suggestion was based on the knowledge that some people, instead 
of seeking medical attention in the first instance of experiencing disease 
symptoms, would attempt to manage their illnesses first using non-prescription 
medicines (Proprietary Association of Great Britain [PAGB] 2005a, 2009). 
Whilst this is clearly a possible scenario for OTC ophthalmic chloramphenicol 
in the treatment of acute infective conjunctivitis, no data has been published to 
demonstrate this is the case. The present study was unable to investigate 
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whether an earlier warning for a conjunctivitis outbreak was possible with sales 
data of ophthalmic chloramphenicol because the data obtained was unable to 
identify the outbreak in both of the areas studied. 
 
5.4.4 Implications of findings 
The potential value of pharmaceutical sales data for public health has been 
recognised as part of ‘Our Healthy Future’, the public health strategic 
framework for Wales (Jones 2009; Welsh Government 2009a). In particular, 
medicine sales data has a role in realising the goal to improve health 
information and intelligence to help local authorities focus on the health and 
wellbeing challenge of local populations and communities. In the present 
study, an infective conjunctivitis outbreak served as an example of an acute 
public health problem occurring in the community that could be identified 
using medicine sales data from pharmacies. Over time, as more medicines, 
covering a wider range of therapeutic areas, become reclassified from POM to 
P and from P to GSL status, medicine sales data as a tool to identify health 
needs may extend beyond acute illnesses to include chronic conditions. 
 
The literature on surveillance and outbreak detection of infective conjunctivitis 
using medicine sales data is very limited in the UK. Recently published studies 
on the subject of infective conjunctivitis have mainly focused on developing 
effective diagnostic tools (Jefferis et al. 2011), understanding changes in the 
level of ophthalmic chloramphenicol prescribing (Davis et al. 2009) and 
devising the best management strategy for the illness in the primary care 
(Everitt et al. 2006; Rose et al. 2005; Rietveld et al. 2005). In part, the lack of 
attention in the area of surveillance is probably because occurrences of major 
outbreaks of infective conjunctivitis are few and far between in the UK, thus 
providing little initiative for research. However, despite most cases of acute 
infective conjunctivitis are not life-threatening and would not cause any 
permanent damage to individual health, the impact of a large scale outbreak on 
any local health care services could be substantial because of the combined 
number of people that could be affected. Early warnings about the presence of 
a local outbreak would be particularly beneficial for vulnerable groups in 
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settings such as hospitals, care homes or schools to allow for extra vigilance 
and preventative actions in these facilities. 
 
Currently in Wales the detection of a conjunctivitis outbreak relies on passive 
reporting of unusual events by individual healthcare professionals or people 
who work with vulnerable groups, such as school teachers or nurses working in 
care homes. This means the occurrence of a potential local outbreak may not 
always be apparent because of a lack of awareness of what is happening in the 
surrounding area. Furthermore, notification of an outbreak to public health 
agencies could be delayed by the time needed for a person to contact or access 
the healthcare system. The current method of surveillance is also unable to 
capture individuals who have not accessed local healthcare services, therefore 
the spread and impact of an outbreak could be underestimated. The use of 
pharmacy sales data for ophthalmic chloramphenicol could potentially address 
these surveillance gaps and serve to be a useful tool for public health agencies 
in responding to conjunctivitis outbreaks. However, experience from the 
present study suggests for this to be feasible, a good coverage of pharmacy sale 
data would be needed and such data is currently unavailable to public health 
agencies in Wales. 
 
To further explore the potential of pharmacy sales data for the detection of 
conjunctivitis outbreak, sales data should be obtained from rest of the 
community pharmacies that were located in the outbreak area. If possible, sales 
for other ocular anti-infectives beside ophthalmic chloramphenicol should also 
be obtained and examined to see if there was a change in their sale that could 
signal the outbreak. Period of study could be extended to allow additional 
comparison of sales between outbreak and non-outbreak periods. 
 
5.5 Summary 
During the period of a conjunctivitis outbreak in Pontypool, Wales, OTC sales 
and primary care prescription of ophthalmic chloramphenicol were both 
significantly greater than the quantities supplied in the corresponding non-
outbreak periods of previous years. In contrast, no significant change in the 
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supply of OTC and prescribed ophthalmic chloramphenicol was observed 
during a conjunctivitis outbreak that took place in Aberdare. 
 
Whilst the findings from one of the outbreaks suggest the sales of OTC 
ophthalmic chloramphenicol may be a sensitive indicator for the presence of a 
conjunctivitis outbreak in the community, the increase in sales observed was 
small due to the low numbers of data-providing pharmacy in the study area. 
Furthermore, the quantity of ophthalmic chloramphenicol prescribed or sold 
was not consistently higher than that supplied during their corresponding non-
outbreak periods in previous years. Consequently, the current study was unable 
to determine whether pharmacy sales data for ophthalmic chloramphenicol was 
sufficiently sensitive to detect outbreaks of local conjunctivitis. 
 
Future work needs to ensure a better coverage of pharmacy sales data is 
obtained in the outbreak area and will require greater collaboration between 
PHW and the local community pharmacy businesses. 
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Chapter 6: 
 
Monitoring of seasonal influenza and related 
symptoms in the community 
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Monitoring of seasonal Influenza and related symptoms in 
the community 
 
6.1 Introduction 
 
6.1.1 Influenza 
Influenza, also known as the 'flu', is a common, usually self-limiting, acute 
infection that primarily affects the upper respiratory tract (Wilks et al. 2003). It 
can also lead to illnesses that are more serious such as secondary bacterial 
pneumonia in vulnerable patients, including elderly and people who are 
immunocompromised (Torok et al. 2009). Of the three distinct types of viruses 
that cause influenza; type A, B and C, the first two are responsible for most 
clinical presentations and are capable of causing wide spread infection in 
humans (Wilks et al. 2003). The term ‘epidemic’ has been defined as “the 
occurrence in community or region of cases of an illnesses in excess of normal 
expectancy” (Porta 2008). Both the type A and the type B viruses are known to 
cause influenza epidemics. The term ‘pandemic’ has been defined as “an 
epidemic occurring worldwide, or over a very wide area, crossing 
international boundaries, usually affecting a large number of people” (Porta 
2008). To date, all pandemics have so far been caused by the type A virus 
(Torok et al. 2009). The type C virus is the least common of the three and does 
not cause epidemics or pandemic (Torok et al. 2009). 
 
In England and Wales, data derived from incidences of influenza-like illnesses 
(ILIs), a term used to describe a group of clinically diagnosed symptoms that 
indicates influenza infection, revealed influenza epidemic occurs almost every 
year (Fleming and Elliot 2008). In the United Kingdom (UK) and other 
countries in Northern Hemisphere, a higher number of incidents related to 
influenza is observed in the winter months, typically between November and 
April. For countries in the Southern Hemisphere, the peak incidence usually 
occurs between May and September (Treanor 2010). A number of theories 
have been put forward to explain the seasonality but the exact reasons are 
unclear (Eccles 2002; Lofgren et al. 2007; Lowen et al. 2007). 
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The influenza virus is primarily spread through dispersion of small-particle 
aerosols by the respiratory route (Torok et al. 2009) and it is traditionally 
thought to infect children more commonly than any other age group (Wilks et 
al. 2003). However, depending on the dominating strain of the circulating 
virus, each epidemic may affect a particular population more than the others 
and this has been documented for past epidemics in the UK (Fleming et al. 
2003; Fleming and Elliot 2008). 
 
For most encounters in primary care, a diagnosis of influenza is made solely 
based on clinical features that are suggestive of an infection (National Institute 
for Health and Care Excellence [NICE] 2009b). However, studies have found 
signs of common symptoms are not always an accurate indicator (Call et al. 
2005). Diagnostic assessment is often aided by knowledge about the presence 
of influenza in the community, as positivity rates confirmed by virological 
analysis during seasonal epidemics have been shown to be as high as 80% to 
90% (Boivin et al. 2000; Monto et al. 2000). Laboratory testing remains the 
only reliable method to confirm an influenza infection but it is not 
recommended as part of the routine management of seasonal influenza in the 
UK (NICE 2009b; Torok et al. 2009). 
 
In uncomplicated influenza, symptom onset is usually rapid. Systemic 
symptoms, such as feverishness, chilliness, headache, myalgia, malaise and/or 
anorexia, are prominent. They occur one to two days post-exposure and lasting 
typically up to three days. Systemic symptoms could be presented at the same 
time with, or followed by, respiratory symptoms. The latter include cough, 
pharyngeal pain, nasal obstruction and discharge, and occasionally ocular 
symptoms, such as tearing and/or burning. These localised symptoms could 
last for more than two weeks (Eccles 2005; Torok et al. 2009; Treanor 2010). 
 
The use of antiviral drugs in uncomplicated cases is not normally required for 
healthy individuals unless risk factor are present that could lead to 
complications (British National Formulary [BNF] 2013). The latest NICE 
guideline considers the following as high risk for developing complications 
from influenza: pregnancy, age over 65, chronic diseases (cardiac, pulmonary, 
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renal, hepatic or neurological), diabetes mellitus, immunosuppression and 
obesity (Health Protection Agency [HPA] 2012a). For the majority of patients, 
practising simple self-care measures such as ensuring an adequate fluid intake, 
bed rest and use of over-the-counter (OTC) medicines to relieve bothersome 
symptoms form the main management strategy (Blenkinsopp et al. 2009; NICE 
2009b; Robb and Berrington 2012). 
 
6.1.2 Common cold 
Sometimes mistaken to be the same as an influenza infection, the term 
'common cold' refers an array of symptoms that is the result of an upper 
respiratory tract infection (URTI) caused by a multitude of viruses other than 
influenza (Robb and Berrington 2012). The majority of URTIs is caused by the 
rhinovirus family but others such as coronavirus, parainfluenza virus and 
respiratory syncytial virus are also known to be causative agents (Treanor 
2009). Like influenza, common colds exhibit a seasonal pattern in the Northern 
Hemisphere, with higher incidence in the autumn through to winter and lower 
in the spring through to summer (Heikkinen and Järvinen 2003). It has been 
estimated that, on average, adults experience two to four episodes of colds per 
year and higher in children who experience six to eight episodes per year 
(Treanor 2009). 
 
The initial symptoms of a common cold include: sore throat, rhinorrhoea, nasal 
obstruction, sneezing and cough. Over the course of the infection a 
combination of sinusitis, hoarseness, headache, malaise, chilliness and/or 
feverishness with varying severity may also develop but occur less frequently 
(Heikkinen and Järvinen 2003; Treanor 2009, 2010; NICE 2011). The overlap 
in symptomatology of a common cold and a flu means it is difficult to 
determine the underlying causative agent based on symptoms alone. However, 
it has been suggested that if prominent macular pain or fever are present an 
influenza infection may be suspected (NICE 2011).  
 
The diagnosis of a common cold (or a ‘cold’) is primarily symptom-based and 
patients can often recognise symptoms easily themselves (Arruda et al. 1997); 
no clinical examination or investigation is normally required for routine patient 
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care (NICE 2011). Given the benign and self-limiting nature of a common 
cold, with most severe symptoms lasting up to seven days and minor symptoms 
such as cough lasting up to several weeks (Eccles 2005), no specific treatment 
is normally needed in healthy individuals. Self-care measures such as 
maintaining an adequate fluid intake, a nutritious diet and plenty of rest is 
advisable (NICE 2009b). In the UK, a wide range of medicines indicated for 
the relief colds and flu symptoms are available OTC without the need of a 
prescription. Whilst the use of many of these products are not recommended by 
NICE due to the lack of efficacy (NICE 2011), OTC cough, cold and flu 
medicines are nonetheless extremely popular among the UK population 
(Boardman et al. 2005; McIntyre et al. 2003; Proprietary Association of Great 
Britain [PAGB] 2005a, 2005b, 2011a; Wazaify et al. 2005). 
 
In the present study, ‘URTI’ is used to refer to infections that are caused by 
influenza as well as viruses that could rise to symptoms associated with a 
common cold. 
 
6.1.3 Surveillance of influenza 
Every year, influenza (Molinaria et al. 2007) and other viral respiratory tract 
infections (Fendrick et al. 2003) are associated with significant economical 
costs to the society and can place the National Health Service (NHS) under 
enormous pressure (Elliot et al. 2008; Fleming 2000, 2001; Meier et al. 2013; 
Pitman et al. 2007). The main reason for their substantial impact on healthcare 
demand is the ability to rapidly infect susceptible individuals and at times do so 
on a large scale causing epidemics or pandemics (Torok et al. 2009). 
Consequential to the high volume of people who might be affected and 
therefore requiring medical care, there has been an emphasis on surveillance of 
respiratory diseases in order to better manage healthcare resources, particularly 
during time of high healthcare demand (Davies and Finch 2003; Fleming 2001; 
Hanratty and Robinson 1999). 
 
Other reasons for monitoring, particularly for influenza, are to gather 
information on when the flu season has started, which are the dominant strains 
circulating in the community, and to contribute knowledge towards the 
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decision on vaccine composition for the following season. Furthermore, 
surveillance information produce up to date reports on trends and spread in 
influenza activity, burden of disease, uptake and effectiveness of clinical 
countermeasures, for health professionals and the public (HPA 2012b). The 
emergence of the novel A/H1N1 (2009) influenza virus in the summer of 2009, 
which lead to the declaration of the first pandemic for 40 years (World Health 
Organization 2009), highlighted the need to strengthen influenza surveillance 
to better support the above goals to effectively manage an unexpected 
influenza outbreak (HPA 2010c). 
 
In England and Wales, a variety of influenza surveillance systems are in place 
and they can be broadly divided into three categories as shown in Table 6.1. 
 
 
Table 6.1 Sources of influenza surveillance data for England and Wales 
 
Primary Care Surveillance 
General practitioners surgeries 
Telephone health helpline 
GP Out-of-Hour consultation 
Passive reporting of respiratory-related outbreaks 
Flusurvey 
Emergency department attendance (England only) 
Medical Officers of School Association (South 
England only) 
Community influenza telephone survey (England only) 
 
Microbiological Surveillance 
Virological Analysis 
Sentinel virological surveillance scheme 
Hospital Reports 
Data Mart (England only) 
 
Disease Severity and Mortality 
Hospitalization 
Mortality 
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Surveillance in primary care monitors unconfirmed cases of influenza in the 
general population and is based on data derived from clinical diagnosis by a 
doctor or from non-clinical surrogates that are known to resemble influenza 
activity (HPA 2013d; Public Health Wales [PHW] 2013a). The heterogeneity 
of the data ensures a good coverage of surveillance in the community. This 
potentially allows capturing of incidences in specific and vulnerable 
populations, such as school children, as well as individuals who may not be 
able or choose not to access healthcare services, such as users of telephone 
health helpline services. 
 
Microbiological surveillance entails the collection and analysis of patient 
samples obtained through various networks of general practitioners (GP) 
surgeries, hospitals or private microbiology laboratories across the UK (HPA 
2013d; PHW 2013a). Data collected via this route represents confirmed cases 
of true influenza infection, which enables the identification of circulating 
strains and provides statistics on positivity rates and guide the physician 
diagnosis of influenza. 
 
Lastly, disease severity associated with influenza is estimated based on 
morbidity and mortality statistics derived from hospital admission for 
respiratory complications, such as pneumonia (HPA 2011), and all-cause death 
registration (Donaldson et al. 2009; HPA 2012b). Details about each of the 
schemes are documented elsewhere (HPA 2010c, 2012b; Public Health 
England [PHE] 2012). 
 
6.1.4 Syndromic Surveillance 
Outside of the UK, particularly in the US, the use of syndromic surveillance 
systems is becoming increasingly common in supporting the detection and 
management of influenza and respiratory disease outbreaks (Buehler et al. 
2008; Paterson and Durrheim 2013). In comparison to traditional surveillance 
data described in the previous section, a syndromic surveillance system utilises 
novel, pre-diagnostic data that resembles the activity or onset of a particular 
disease, and adopts: 
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“an investigational approach where health department staff, assisted by 
automated data acquisition and generation of statistical signals, monitor 
disease indicators in real time or near real time to detect outbreaks of diseases 
earlier and more completely than might otherwise be possible with traditional 
public health methods” (Buehler et al. 2004). 
 
A variety of disease indicators have been used as data input for syndromic 
surveillance systems to monitor influenza. Some examples include: emergency 
department visits (Bourgeois et al. 2006; Elliot et al. 2012; Josseran 2006), 
outpatient clinic visits (Harcourt et al. 2012), school absenteeism (Kara et al. 
2011; van den Wijngaard et al. 2008), sales of prescription (Patwardhan and 
Bilkovski 2012; Sugawara et al. 2012) or OTC medicines (Anon. 2009e; Das et 
al. 2005; Hogan et al. 2003; Liu et al. 2013; Magruder 2003; Ohkusa et al. 
2005; Vaergu et al. 2006; Villamarín et al. 2013), telephone triage or calls to 
health helpline services (Cooper et al. 2007; Espino et al. 2003) and data 
derived from web searches (Johnson et al. 2004) and social media (Culotta 
2013). Many of these data sources have already demonstrated the potential to 
be a valuable tool for influenza surveillance (Buehler et al. 2008; Dailey et al. 
2007). 
 
Beside the ability to detect and track the spread of an influenza outbreak in a 
population (Smith et al. 2011; van den Wijngaard et al. 2011), several other 
advantages have been suggested to be associated with non-traditional 
compared to traditional influenza surveillance data. These include improved 
monitoring of disease burden (Liu et al. 2013), detecting a shift in antigenicity 
of influenza viruses (van den Wijngaard et al. 2011), providing an earlier 
warning for emerging influenza outbreaks (Dailey et al. 2007) and 
confirmation for the absence of unusual increase of disease cases (van den 
Wijngaard et al. 2011).  
 
In England, the provision of syndromic surveillance for influenza and 
respiratory diseases currently consists of the routine monitoring of URTI 
symptom calls to NHS Direct (NHSD), which is a telephone health helpline 
service accessible to the general public living in England (Cooper et al. 2007). 
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Data on the number of respiratory-related admissions to emergency 
departments (Elliot et al. 2012) and GP out-of-hours consultations for ILI have 
also been utilised for influenza surveillance (Harcourt et al. 2012). At the time 
of writing, in Wales, the only example of syndromic surveillance is the use of 
cold and flu telephone call data from NHS Direct Wales (NHSDW) to monitor 
the activity ILI in community (PHW 2010b). 
 
6.1.5 Over-The-Counter medicines sales data 
As mentioned earlier, a syndromic surveillance system can utilise a myriad of 
data that are indicative of disease activity in a population. Among the data that 
have been tested, a number of studies explored using the sales of OTC cough, 
cold and flu medicines for the syndromic surveillance of influenza (Das et al. 
2005; Hogan et al. 2003; Liu et al. 2013; Magruder 2003; Ohkusa et al. 2005; 
Villamarín et al. 2013). Some of these studies have been described in detail in 
Section 1.4.1. The rationale for using such sources is multifold and may apply 
to the UK population as described below. 
 
Firstly, the symptoms of cold and flu are common in the UK population 
(McAteer et al. 2011; PAGB 2009) and they are frequently managed using a 
range of cold and flu medicines available without a prescription (PAGB 
2005b). Secondly, the self-management of these cold and flu symptoms 
through the use OTC medicines often occurs prior to, or even instead of, 
seeking medical attention (Banks 2010; Willemsen and Harrington 2012). This, 
by implication, means sales of OTC cold and flu remedies could potentially be 
timelier in spotting an increase of influenza infection than healthcare service 
based surveillance. 
 
Thirdly, in many community pharmacies automatic recording of sales 
information is already being undertaken through computers at the point of sale. 
A detail electronic record, including information on the type of medicine and 
location of the pharmacy, potentially could be made instantly available for 
transmission and subsequent analysis. This provides the opportunity for rapid 
detection of unusual increase in sales and initiation of public health measures. 
 
 190 
Lastly, it has been suggested the cost of implementing a syndromic 
surveillance system using OTC medicines sales data would be lower than 
setting up a new, dedicated surveillance system (Wagner et al. 2003). This 
suggestion makes the assumption that the infrastructure and hardware required 
to enable data collection are already in place and maintained by the data 
suppliers. In addition, it assumes that the surveillance activity is embedded into 
the day-to-day operation of the data providers and imposes no additional 
burden. 
 
At the time of writing this thesis, no syndromic surveillance system yet exists 
in the UK that utilises medicines sales data for of influenza surveillance. This 
is despite pharmacy businesses, medicine manufacturers and pharmaceutical 
marketing firms have already been, for many years, collecting and utilising 
these sales information for internal monitoring and sales forecasting. 
Syndromic surveillance studies conducted in non-UK populations indicated 
that sales of OTC cough, cold and flu remedies possess the potentials for 
detecting and monitoring influenza epidemics (Section 1.4.1). Whether or not 
the same could be applied to the UK population is unknown and no such study 
has been undertaken. 
 
6.1.6 Aims and objectives 
The aim of the current study was to explore whether the readily available 
medicine wholesale data for the sales of OTC cough, cold and flu medicines 
would be of value to the monitoring of seasonal influenza in Wales. 
 
The specific objectives of the study were to: 
• identify the pattern of sales for the selected OTC cough, cold and flu 
remedies 
• determine the temporal relationship between sales of such medicines 
and influenza activity indicators 
• determine which of those medicines studied are most sensitive to the 
activity indicators of influenza in the Welsh population  
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6.2 Method 
 
6.2.1 Study design 
The current study utilised historical pharmacy wholesale data for the sales of 
selected OTC cough, cold and flu medicines and compared the levels of sales, 
retrospectively, with two influenza activity indicators routinely used in Wales. 
Details about each of the datasets are described in the next section. 
 
6.2.2 Medicines sales data 
Pharmacy wholesale (herein referred to as pharmacy or medicines sales data) 
were obtained from the Regional Sales Analysis (RSA) database which was 
maintained by IMS Health. This was the same pharmacy sales database as 
utilised in Chapter 2 (Section 2.2.2.2), Chapter 3 (Section 3.2.2.2) and Chapter 
4 (Section 4.2.2.2). Data obtained from the RSA database represented the 
purchase of medicines by pharmacies from wholesalers as a surrogate for 
pharmacy-to-patient sales which may occur at a later date. 
 
In the present study, medicines sales data were expressed as the total number 
of unit packs sold on a monthly basis from May 2003 to April 2009 across 
Wales. One unit sale described the sale of one item, regardless of the volume 
or quantity contained in a pack. 
 
The medicines included in the current analysis were any pharmacy (P) or 
General Sales List (GSL) medicine manually identified in the RSA database 
indicated for the relief of general cold and flu symptoms (e.g. all-in-one 
preparations), nasal congestion, sinusitis or coughs in adults. Products not 
available as oral dosage forms were excluded. In addition, generic products 
that were listed in the RSA database as a single-ingredient medicine, for 
example: paracetamol tablets/liquid, pseudoephedrine tablets/liquid or codeine 
phosphate linctus, were also excluded due to uncertainty as to whether they 
were sold OTC or used to dispense a prescription. Preparations that were 
considered suitable for the current study were grouped into three categories 
based on the classification used in the Chemist and Druggist: Guide to OTC 
Medicines and Diagnostic reference book (September 2008 issue). The three 
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categories were: (1) cold and flu, (2) cough and (3) sinusitis and nasal 
congestion medicines. Lists of all preparations in each of the category are 
shown in Appendix 18, Appendix 19 and Appendix 20, respectively. 
 
6.2.3 Disease activity indicators 
 
6.2.3.1 Influenza diagnostic data 
Seasonal influenza data were provided by the PHW Communicable Disease 
Surveillance Centre (CDSC); an epidemiological investigation arm of PHW. 
The CDSC serves several public health functions concerning mainly infections 
from detecting and investigating infectious disease outbreaks to their 
monitoring and dissemination of relevant information within Wales (PHW 
2011b). The influenza data were collected by a sentinel surveillance network 
that were comprised of 44 volunteer, GP practices across the whole of Wales, 
covering approximately 10% (355,000 patients) of the Welsh population (PHW 
2011b). This network of GP practices is the routine data provider for the 
monitoring seasonal influenza in Wales (PHW 2011b). The participating GP 
practices recorded anonymised basic patient information and the date of 
influenza diagnosis based on the clinical case definition of: URTI symptoms, 
fever, chills, myalgia and cough.  
 
Prior to 2010, influenza diagnostic data were manually recorded using 
notepads by the practitioner and reported to PHW using post, email or fax. This 
has subsequently been replaced by an automated system named ‘Audit+ Data 
Quality System’ which started operating in October 2010 (PHW 2011b). The 
new surveillance system include an improved coverage of 400 (80%) GP 
practices in Wales (Keramarou et al. 2011). The current study did not include 
data collected by the Audit+ Data Quality System as the new system was set up 
post the data collection period. 
 
In the current study, the numbers of clinically diagnosed cases of influenza for 
each of the seven age bands (0-4, 5-14, 15-24, 25-34, 35-44, 45-64, 65+ years 
old) were obtained for Wales in a weekly format for a six-year period between 
May 2003 and April 2009. The weekly data were aggregated into their 
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corresponding month. Diagnosis of influenza in children under 15 years old 
were excluded from the study to reflect the range of cough, cold and flu 
products included in the pharmacy sales data which were primarily indicated 
for adults. 
6.2.3.2 Telephone health data 
NHSDW is a confidential, nurse-led, telephone health helpline service that was 
set up in 2000 for Wales and is similar to NHSD operating in England (Hanlon 
et al. 2009). The NHSDW service, managed by Welsh Ambulance Service 
NHS Trust, operates 24 hours a day and seven days a week. The goal of the 
service is to provide an open-to-all gateway to reliable and timely health 
information and advice for everyone in Wales. In addition to handling calls 
made to NHSDW via a dedicated telephone number NHSDW also provides 
out-of-hour call handling and clinical telephone triage for GP out-of-hour, 
emergency dental and medical care services and ensures unscheduled care 
resources are allocated appropriately according to the urgency of the call 
(Colman 2009). Calls to NHSDW are charged at the same rate as any local 
landline number. 
 
When a call is made to NHSDW, a call handler will first take some basic 
personal details and determine the urgency of the call, for example, whether 
the call was for a request of health information or query regarding a medical 
condition. Depending on the nature of the call, it may then be transferred to a 
nurse, a health information advisor or a dental nurse advisor where the caller’s 
symptoms are assessed in more detail and the best course of action determined. 
 
The clinical assessment process is aided by Clinical Assessment System, a 
computer-based decision support software, whereby the nurse uses his or her 
own clinical judgement and chooses the most appropriate, symptom-based, 
clinical algorithms to respond to caller’s symptoms (Jones 2008). There are 
around 200 clinical algorithms and each consists of a series of questions 
relating to the symptoms described, which eventually leads to a recommended 
outcome (Cooper 2008). The outcome may result in the caller receiving 
information about how to care for themselves at home, details of a local 
pharmacy to attend, or if the problem is more serious, they might be advised to 
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see their GP or go to a hospital. If needed, NHSDW can also arrange an 
ambulance to be sent to the caller (Cooper and Chinemana 2004; Colman 
2009). 
 
In the current study, NHSDW call data for clinical algorithms for cold and flu 
symptoms and symptoms affecting the nose, sinuses and throat were obtained 
directly from Welsh Ambulance Service NHS Trust. The specific clinical 
algorithms included in the study were: (1) cold and flu, (2) nasal congestion, 
(3) stuffy nose, (4) coughs and (5) sore throat. Call data for children 15 years 
old and below were excluded from the NHSDW analysis. 
 
NHSDW call data were obtained for a three-year period from May 2006 to 
April 2009 (three years less data than both GP diagnostic data and OTC 
medicine sales data). The call data were provided in a daily format with the 
following details about each call: clinical algorithm used, caller’s home 
location in 22 Local Health Board (LHB) geography and date of the call. Daily 
call data were aggregated into their corresponding month and the total monthly 
calls made to NHSDW for Wales were calculated. In addition to the call data 
obtained for the five selected clinical algorithms, daily data for the total 
number of calls to NHSDW, irrespective of the clinical algorithm used, were 
also obtained. The call volume for each of the selected clinical algorithm was 
expressed as a percentage of total calls each month. 
 
6.2.4 Data processing 
Each of the three datasets was obtained from a different source and they had to 
be processed into appropriate format before statistical analysis could be 
undertaken. All processed and reorganised data were manually screened for 
errors before transferring to the statistical software  for analysis (PASW v18). 
 
Influenza diagnostic data were provided by PHW in a weekly format in 
Microsoft Excel spreadsheet. The corresponding monthly aggregates of 
numbers of influenza diagnoses were computed using Microsoft Excel 
spreadsheet. 
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NHSDW call data were provided in Microsoft Excel spreadsheet in a list 
format and the calls were arranged in chronological order based on the date and 
time of each call. Two new variables were created in Microsoft Excel 
spreadsheet that corresponded to the month and the year of the call using the 
built-in date and time functions before importing into PASW v18 for further 
analysis. 
 
Crosstabs function in PASW v18 was used to compute the count of the calls by 
clinical algorithm and LHB geography for each month of each year. The data 
were then exported into a Microsoft Excel spreadsheet and calls made in each 
of the 22 LHBs were combined to give the total number of calls for Wales. 
Finally, the volumes of cold and flu symptom calls as a percentage of total 
calls were calculated in Microsoft Excel spreadsheet. 
 
Pharmacy sales data were extracted from the IMS Health Dataview and 
exported into Microsoft Excel spreadsheet as described in Appendix 9. The 
packs of OTC preparations sold in each of the 22 LHBs were combined to give 
the total figures for Wales using Microsoft Excel.  
 
6.2.5 Analysis 
 
6.2.5.1 Descriptive analysis 
The times series for the sales of OTC (1) cold and flu, (2) cough and (3) nasal 
congestion and sinusitis medicines were each separately compared with the 
time series of (a) cold and flu symptom calls made to NHSDW and (b) 
numbers of influenza diagnosis and their patterns examined. 
 
In order to present the time series of medicines sales data, NHSDW call data 
and influenza diagnostic data on the same time series chart their data values 
needed to be standardised. The standardised time series was computed by 
converting each data point for the sales of medicines, number of symptomatic 
calls and influenza diagnosis to number of standard deviations away from their 
respective data mean. The data mean was the mean of all available data points 
for the respective time series.  
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The times series for the sales of OTC medicines were compared with GP 
diagnostic time series for the period May 2003 to April 2009; and with 
NHSDW call data for the period May 2006 to April 2009. 
6.2.5.2 Cross-correlation function 
Cross-correlation function is a common method used to help to understand the 
temporal relationship between one signal relative to another (Dailey et al. 
2007). It does so by calculating the correlation coefficient (r) between two time 
series, by moving one in time relative to the other, at different time latencies or 
time lag (t). This process identifies at what specific time latency the correlation 
between two time series would be at their maximum. This indicates the 
timeliness of one signal (e.g. sales of OTC medicines) in relation to another 
(e.g. cold and flu symptom calls or influenza diagnosis). In other words, if one 
time series demonstrated a significantly similar pattern to another time series 
but earlier, it may possess the capability for early detection. It has been 
suggested cross-correlation function is useful in the early phase of exploring 
the potential of a new disease surveillance data (Dailey et al. 2007; Edge et al. 
2006; Espino et al. 2003; Hogan et al. 2003; Johnson et al. 2004; Magruder 
2003). 
 
In the current study, cross-correlation function was used to determine the 
maximum correlation between two time series at time latencies between t=-3 
and t=3. A correlation of r=1 indicates the two time series are identical; r=0 
means they share no correlation; r=-1 suggests the two time series are identical 
but showing the opposite trend. In terms of timeliness, a maximum and 
statistically significant correlation observed at a positive time latency (e.g. t=1, 
2 or 3), this would suggest the medicine sales time series preceded the disease 
activity indicator time series and provided a timelier detection. Conversely, if it 
was observed at a negative time latency, this would suggest the medicines sales 
time series lagged behind the disease activity indicator time series and 
provided a delayed detection. If the maximum correlation is observed at a time 
latency of zero, this would suggest the medicines sales time series was no more 
or less timely than disease indicator time series.  
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An example of a cross-correlation chart is shown in Figure 6.1. A correlation 
exceeding the 95% confidence interval, as marked by the upper and lower 
confidence limits (two standard errors), was considered to be statistically 
significantly different from no correlation. In the example shown in Figure 6.1, 
upper and lower confidence limits mark the bounds of 95% confidence 
interval. The vertical bars indicate the maximum correlation of r=0.77 was 
observed at the time latency of 1 and exceeded the 95% upper confidence limit. 
These results suggest (a) there is a significant positive correlation between the 
two time series, and (b) this occurred when one time series preceded the other 
by one unit of time and therefore the former data source potentially possess an 
early detection capability for the latter. 
 
 
 
 
Figure 6.1 An example of a cross-correlation chart showing the correlations of two 
time series at a time latency between t=4 and t=-4. Upper and lower confidence 
limits mark the bounds of 95% confidence interval (± two standard errors) 
 
 
All data analysis and statistics were performed using PASW version 18 
(PASW Inc., Chicago, IL, USA).  
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6.3 Results 
 
6.3.1 Descriptive analysis 
 
6.3.1.1 Sales of Over-the-Counter medicines 
A total of 117 preparations (cold and flu medicines [n=88], cough medicines 
[n=9], nasal congestion or sinusitis [n=20]) were identified and extracted 
successfully from the RSA database. As shown in Figures 6.2, 6.3 and 6.4, 
respectively, a marked seasonal pattern was associated with the sales of each of 
the three categories of medicines. Each year, peak sales generally occurred 
between September and January, corresponding to the winter months, and the 
nadirs between May and August, corresponding to the summer months.  
 
 
 
 
Figure 6.2 Sales of selected over-the-counter cold and flu medicines and number of 
general practitioner diagnosed influenza for Wales presented as the number of 
standard deviations away their respective mean 
 
 
The increase in the sales of cold and flu medicines during the winter consisted 
of two distinctive peaks and could be characterised by the observation of one 
larger spike in October followed by a smaller spike in December (Figure 6.2). 
This pattern for the cold and flu category of medicines was observed every 
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winter during the study period with the exception of 2003/04 and 2006/07. 
During the former period, only one spike in sales was observed and in the latter 
the second smaller spike occurred in January instead of December. 
 
 
 
 
Figure 6.3 Sales of selected over-the-counter cough medicines and number of 
general practitioner diagnosed influenza for Wales presented as the number of 
standard deviations away their respective mean 
 
 
Similar to cold and flu medicines, cough medicines saw the highest levels of 
sales between October and December but this was only observed for four out 
of the six winters that were monitored (2003/04, 2004/05, 2007/08, 2008/09). 
In the two winters that did not match this trend (2005/06 and 2006/07), the 
observation of the second sales spike was in February instead of December 
(Figure 6.3). Unlike cold and flu medicines, not every winter season during the 
study period demonstrated a two-peak sales pattern during the winter, nor was 
it the case that a large spike was always followed by a smaller spike. For 
example, only one spike was observed in the winters of 2007/08. In the winters 
of 2004/04, 2005/06 and 2008/09, whilst two peaks were present the second 
spike was larger than the first. Nadirs for the sales of cough medicines 
generally occurred between May and September each year. 
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Sales patterns for the nasal congestion and sinusitis category of medicines were 
similar to the pattern of cold and flu medicines (Figure 6.4). Their peak sales 
occurred between September and January each year and this was also 
characterised by the presence of two peaks with one large spike observed in 
October followed by a smaller, second spike in December. The only exception 
to this pattern was in the winter of 2007/08, during which the October peak 
was absent but the December peak was observed. 
 
 
 
 
Figure 6.4 Sales of selected over-the-counter nasal congestion or sinusitis medicines 
and number of general practitioner diagnosed influenza for Wales presented as the 
number of standard deviations away their respective mean 
 
 
6.3.1.2 Influenza diagnosis 
The pattern of GP diagnosed influenza from May 2003 to April 2009 in 
relation to the sales of (1) cold and flu, (2) cough and (3) nasal congestion and 
sinusitis medicines are shown in Figure 6.2, Figure 6.3 and Figure 6.4, 
respectively. Over the six year study period, influenza diagnosis was the 
highest in either January or February for four out of six of the winters 
(2004/05, 2005/06, 2006/07, 2007/08). In two of the winters (2003/04 and 
2008/09), the highest level of influenza diagnosis was observed in December. 
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The timing of peak sales for each of the three categories of medicines and peak 
influenza diagnosis were compared. For cold and flu medicines the occurrence 
of highest point of sales all preceded peak influenza diagnosis by two to four 
months except for 2008/09. During the winter of 2008/09, the second sales 
spike was observed in December and this coincided with peak influenza 
diagnosis. 
 
Cough medicines saw the month of peak sales matched with peak influenza 
diagnosis for three out of the six winter seasons (2003/04, 2005/06, 2006/07). 
For two of the winter seasons the month of peak sales preceded peak influenza 
diagnosis by one month (2007/08, 2008/09). 
 
Nasal congestions and sinusitis medicines saw matching peak sales and peak 
influenza diagnosis for two of the winter seasons only (2003/04, 2008/09). In 
all other winters the month of peak sales preceded the month of peak influenza 
diagnosis by three to four months. 
 
6.3.1.3 Calls to NHS Direct Wales 
Cough symptom and cold and flu symptom calls to NHSDW both 
demonstrated a strong seasonal trend during the three years between 2006 and 
2009. The timing of peak call volume for cough symptoms and cold and flu 
symptoms calls was observed within the same month or within one month 
difference (Figure 6.5). 
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Figure 6.5 (1) Cough symptom and (2) cold and flu symptom calls as a percentage of 
total calls to NHS Direct Wales presented as the number of standard deviations away 
their respective mean 
 
 
In contrast, sore throat calls showed no marked seasonal trend or any 
discernible pattern over the study period. However, a distinctive peak in 
December could be identified each year (Figure 6.6). 
 
 
 
 
Figure 6.6 Sore throat symptom calls as a percentage of total calls to NHS Direct 
Wales presented as the number of standard deviations away their respective mean 
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Comparisons between the peak sales of medicines and calls to NHSDW 
revealed where there were two peaks in a winter season for the sale of 
medicine the timing of the first spike, in all cases, preceded the timing of peak 
calls to NHSDW by two to four month. By contrast, the timing of the second 
spike for the sales of medicine generally coincided with the timing of peak 
calls to NHSDW. These features were observed for (1) cold and flu, (2) cough, 
and (3) nasal congestion and sinusitis categories of medicines studied (Figure 
6.7, Figure 6.8, Figure 6.9, respectively). 
 
 
 
Figure 6.7: Sales of selected over-the-counter cold and flu medicines and calls 
made to NHS Direct Wales about cough or cold and flu symptoms presented as the 
number of standard deviations away from their respective mean 
 
 
The analysis of NHSDW call data revealed calls reporting (1) nasal congestion 
and (2) stuffy nose symptoms were both low. During the period of available 
call data from 2006 to 2009, the cumulative numbers of calls in each 12 month 
period for nasal congestion symptoms were 47, 52, 80, 63, respectively. Stuffy 
nose symptoms were 15, 16, 2, 4, 2, respectively. In the 12 months to April 
2009 calls reporting these two symptoms represented less than 0.05% of the 
total calls made to NHSDW. As a consequence of the low numbers these calls 
data were not analysed. The mean percentages of calls to NHSDW for (1) cold 
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and flu, (2) cough and (3) sore throat symptoms were 0.3%, 1% and 1.8%, 
respectively. 
 
 
 
Figure 6.8: Sales of selected over-the-counter cough medicines and calls made to 
NHS Direct Wales about cough or cold and flu symptoms presented as the number of 
standard deviations away from their respective mean 
 
 
 
 
Figure 6.9: Sales of selected over-the-counter nasal congestion or sinusitis 
medicines and calls made to NHS Direct Wales about cough or cold and flu symptoms 
presented as the number of standard deviations away from their respective mean 
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6.3.2 Cross-correlation analysis 
The results for the cross-correlation analysis are shown in Table 6.2. Out of the 
three categories of OTC medicines studied, cough medicines demonstrated a 
significant positive correlation with influenza diagnosis (r=0.61) and calls to 
NHSDW for cough (r=0.74), cold and flu (r=0.64) symptoms. The time latency 
in which these maximum correlations was observed were all t=1. This suggests 
sales of cough medicines provided a one month earlier signal for peak 
influenza activity than the disease activity indicators. A significant positive 
correlation (r=0.50) was also observed at a time latency of t=1 between the 
sales of cold and flu medicines and influenza diagnosis.  
 
A significant positive correlation was observed between sales of nasal 
congestion and sinusitis medicines and influenza diagnosis (r=0.37), cough 
symptom calls (r=0.63), cold and flu symptom calls (r=0.52). The time latency 
in which these maximum correlations occurred were all observed at a time 
latency of t=0. This suggests sales of nasal congestion and sinusitis medicines 
was no different in timeliness for signalling influenza compared to the disease 
activity indicators. The maximum correlation between the sales of cold and flu 
medicines and cough symptom and cold and flu symptom calls to NHSDW 
were both significantly positive (r=0.53 and r=0.60, respectively). The time 
latency in which they were observed was at t=0 and t=2, respectively.  
 
Contrary to the finding thus far, cross-correlation for the sales of the cold and 
flu, cough and nasal congestion or sinusitis medicines with sore throat 
symptom calls revealed a weak and significant negative correlation (r=−0.5, 
−0.39, −0.45) at a time latency of t=−3, t=−2, t=−2, respectively. The cross-
correlation chart for the sales of cough medicines and sore throat calls to 
NHSDW is shown in Figure 6.10 to illustrate the observation of a negative 
correlation and at a negative time latency. 
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Table 6.2 Results of the cross-correlation analysis for the sales of over-the-counter 
(OTC) medicines, number of influenza diagnosis (May 2003 to April 2009) and calls to 
NHS Direct Wales for cold and flu symptoms (May 2006 to April 2009). The time 
latency (t) in which the maximum correlation (r) occurred between medication sales 
and disease activity indicator is reported (r, t [95% CI]). A positive t value indicates 
that change in the sales medicines preceded (i.e. more timely than) those of the 
disease activity indicator or vice versa. If a t=0 then neither data source is timelier 
or later than the other 
 
  Cold and flu medicines  
Cough 
medicines  
Nasal congestion 
or sinusitis 
medicines  
 
        
Influenza 
diagnosis  
0.50, 1  
-0.24, 0.24)  
0.61, 1 
(-0.24, 0.24)  
0.37, 0 
(-0.24, 0.24)  
        
        
Cold and flu 
calls  
0.53, 0 
(-0.33, 0.33)  
0.64, 1 
(-0.34, 0.34)  
0.52, 0 
(-0.33, 0.33)  
        
Cough calls  0.60, 2 (-0.34, 0.34)  
0.74, 1 
(-0.34, 0.34)  
0.63, 0 
(-0.33, 0.33)  
        
Sore throat 
calls  
-0.50, -3 
(-0.35, 0.35)  
-0.39, -2 
(-0.34, 0.34)  
-0.45, -2 
(-0.34, 0.34)  
        
 
 
 
 
Figure 6.10 Cross-correlation chart for the sale of OTC cough medicines and calls to 
NHS Direct Wales for nasal congestion and sinusitis symptoms. Upper and lower 
confidence limits mark the bounds of 95% confidence interval 
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6.4 Discussion 
 
6.4.1 Main findings 
The results from the current study showed pharmacy wholesale data for (1) 
cold and flu, (2) cough and (3) nasal congestion or sinusitis categories of OTC 
medicines are well-correlated with clinically diagnosed influenza by GPs as 
well as with self-reported URTI symptoms to NHSDW, namely cough, cold 
and flu symptoms. These findings suggest (a) an increase in the sales of these 
products reflect the presence of some of the symptoms in the community and 
(b) a signal corresponding to seasonal influenza activity potentially exists in 
the pharmacy wholesales data. These observations are in agreement with the 
findings reported by others in non-UK populations (Das et al. 2005; Edge et al. 
2006; Espino et al. 2003; Hogan et al. 2003; Johnson et al. 2004; Liu et al. 
2013; Magruder 2003; Ohkusa et al. 2005; Pelat et al. 2010; Vergu et al. 2006) 
and lend support to further explore OTC medicines sales data as a potential 
source of surveillance information for seasonal influenza and upper respiratory 
diseases. An exception was the sales of OTC medicines and sore throat 
symptoms which revealed a significant negative correlation at negative time 
latency. The exact reason for this is unknown. 
 
Of all the medicines studied, the cough medicine category correlated with 
influenza diagnosis the strongest and therefore warrants attention for further 
investigation. This is possibly because cough symptoms have been found to be 
one of the most predictive signs in differentiating patients with a true influenza 
infection from those with an influenza-like illness (Monto et al. 2000; 
Woolpert et al. 2012). The clinical case definition used by GPs in making a 
clinical diagnosis of influenza also included cough as a criterion and may have 
contributed to the high correlation between the time series. In line with this 
finding, a study by Liu et al. (2013) conducted in the US also showed sales of 
cough medicines were, among others, the group of medicines most strongly 
associated with hospital volumes of patients with influenza-like illnesses.  
 
The variation observed in correlation between the different categories of 
medicines and respiratory disease indicators could be attributed to a number 
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factors. This may include the local availability of OTC products, usage pattern 
and accessibility to local healthcare services. Furthermore, depending on the 
dominating strain of influenza virus circulating at the time, symptoms 
experienced by the general population may differ between seasons. In addition, 
symptoms may also vary by age group, such as in the case of H1N1 influenza 
A virus as cough has been reported to be more prevalent in adults but not in 
children (Kuo et al. 2011). Consequently, cough may not always be a universal 
early symptom for influenza and the predictability of other therapeutic class of 
OTC medicines should be explored (e.g. sore throat medicines). 
 
A two-peak pattern was identified for the sales of OTC medicines between the 
month of September and January. This feature was particularly prominent, 
although not exclusively observed, for cold and flu medicines. In nearly all of 
the winter seasons monitored the first of the two spikes almost all appeared in 
October and was followed by a second spike at around January or February 
time. One possible explanation for this is that the early October peak 
represented community pharmacy making advance purchases of stock in 
anticipation for the upcoming winter season. By contrast, the onset of the 
second sales peak corresponded well with the onset of peak influenza activity 
in some of the winters during the study. This potentially suggests the second 
sales peaks were associated with actual disease incidents taking place in the 
community. The presence of these two different signals in the pharmacy sales 
data could have reduced the correlations between the sales of medicines and 
influenza activity indicators.  
 
The temporal relationship between sales of medicines and diseases activity 
indicators was examined using cross-correlation function. This was a simple 
procedure and utilised all of the data points in the statistical analysis. Cross-
correlation has been used by many studies, either alone or in combination with 
another signal detection method, for evaluating the potential of a new type of 
syndromic surveillance data (Das et al. 2005; Edge et al. 2006; Espino et al. 
2003; Hogan et al. 2003; Johnson et al. 2004; Kirian and Weintraub 2010; Liu 
et al. 2013; Magruder 2003; Pelat et al. 2010; Vergu et al. 2006). 
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The results from the cross-correlation analysis showed the medicines sales data 
appeared to have provided at least an equal or earlier indicator for influenza 
and URTI symptoms than the GP surveillance system and calls data collected 
by NHSDW. However, a difference in the early detection capability between 
the three categories of medicines was observed. For examples, sales of nasal 
congestion or sinusitis medicines provided no early signal for influenza 
diagnosis and URTI symptoms. In contrast, cough medicines consistently 
provided a one-month earlier signal for influenza diagnosis and URTI 
symptoms. Sales of cold and flu medicines provided between no early signal to 
two months earlier signal for influenza diagnosis and URTI symptoms. These 
variations were not unexpected as they probably reflected the different 
symptoms that are experienced at different stages of an infection (Eccles 2005; 
Heikkinen and Järvinen 2003) and has been reported by other also (Liu et al. 
2013). However, the buy-in nature of the wholesale data could have 
confounded these results (discussed in Section 6.4.3.1) and therefore they need 
to be interpreted with caution. 
 
A number of studies conducted outside the UK has demonstrated the early 
detection capability of medicine sales data for influenza and respiratory 
infections (Das et al. 2005; Hogan et al. 2003; Liu 2013; Magruder 2003; 
Vaergu et al. 2006). In these studies the earliness of detection has been 
reported to be ranged between 2 days and up to three weeks. Results from the 
present study indicate the current pharmacy sales data preceded GP diagnosed 
influenza and self-reported URTI symptoms by up to two month. This level of 
early detection outperformed that reported by any of the previous studies. This 
may have been associated with the buy-in nature of the current pharmacy sales 
data and should be interpreted with caution.  
 
6.4.2 Strengths of the study 
The current study utilised readily available surveillance data which have been 
collected via a consistent method over a seven-year period. The large amount 
of historical data was useful for identifying patterns and trends to allow 
comparison between the different winter seasons. 
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The collection of medicine sales data was facilitated by an existing and 
extensive network of community pharmacy in Wales. It was an inexpensive 
and convenient way of collating surveillance data compare to other kinds of 
influenza surveillance systems, such as the sentinel GP surveillance network. 
Since many community pharmacies, particularly large multiple chains, already 
operate and maintain electronic systems of their own for recording sales of 
medicines for commercial purposes, the technical effort and time required for 
obtaining such data was low. Although there were some limitations about the 
pharmacy sales data used (Section 6.4.3.1), they were considered suitable for 
generating preliminary results that may inform future research direction. 
 
Medicine sales data were compared with robust and routinely used datasets for 
the surveillance of seasonal influenza in Wales (PHW 2010b). Data from the 
two systems (NHSDW and GP sentinel network) are reliable and acted as a 
reference for disease activity in which new types of surveillance data could be 
evaluated against. Other surveillance data, such as results from microbiological 
surveillance, were also obtained from PHW at the time of the study but were 
not used due irregularity in patient sample submission between the months of 
perceived high and low risk of influenza infection by the GPs. Furthermore, no 
or low numbers of samples submitted during periods other than the winter 
months also prevented them from being useful for trend and pattern 
identification. 
 
The comparison between sales of cough medicines and cough symptom calls 
yielded a stronger correlation than with (1) sore throat and (2) cold and flu 
symptom calls. This was a positive outcome as it provided some reassurance 
that the pharmacy sales data was correlating with the symptom of which the 
product is primarily indicated. The moderately-positive correlations observed 
between the sales of medicines and what appeared to be an unrelated disease 
indicator, such as cough symptom calls and sales of nasal congestion or 
sinusitis medicines, may have been a reflection of onset of multiple symptoms 
during the course of a cold or a flu infection (Eccles 2005; Heikkinen and 
Järvinen 2003). 
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6.4.3 Study limitations 
This was the first study in Wales to examine the potential of pharmacy sales 
data as an alternative data source for the surveillance of seasonal influenza. A 
number of limitations have been identified and these are discussed in this 
section. 
 
6.4.3.1 Medicines sales data 
 
Range of products 
The OTC medicines included in the present study were limited to preparations 
that were ready available for extraction in the RSA database. Consequently, 
data for less than a complete coverage of products were obtained for each of 
the medicine categories. For example, the cough medicine category contained 
the least number of preparations and was made up of mostly generic products. 
In contrast, the cold and flu medicine and nasal congestion or sinusitis 
medicine category consisted predominantly proprietary products. Whether a 
different sales trend would have been observed between the proprietary and 
generic product for each category of medicines is unknown. Future studies 
should include a greater range of products for each of the medicine categories 
and test if doing so would improve the sensitivity of medicine sales data to 
influenza activity or vice versa. 
 
Grouping strategy 
Medicines were placed into separate categories based on their main indication 
using a reference book for OTC medicines (Chemist and Druggist: Guide to 
OTC Medicines and Diagnostic reference book, September 2008 issue). This 
method of grouping assumes there was a universal usage pattern for these 
products across all geographical regions and is associated with two potential 
issues in disease surveillance. Firstly, differences in customers’ perception of 
which product is most useful for a certain symptom can vary from population 
to population. Secondly, a grouping strategy based on clinical indication may 
not be the most effective way to discover medicinal products that are most 
sensitive to a particular disease. 
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To address these two issues, sophisticated statistical methods have been 
developed with the goal to identify medicinal products that are most sensitive 
to a disease in a population (Cami et al. 2009; Magruder 2004; Pelat et al. 
2010; Wallstrom and Hogan 2007). However, these techniques have mainly 
been applied in studies where sales data are available for a large number of 
medicines. The present study included a total of 117 products which was a 
small number of products compared to studies that have utilised these 
specialised clustering techniques (n=768 unique products [Wallstrom and 
Hogan 2007], n=384 therapeutic classes [Pelat et al. 2010]). Nonetheless, 
adopting a specialist clustering method may become increasingly important as 
more complete and larger database of OTC medicine sales data becomes 
available over time. 
 
Factors unrelated to disease activity 
Sales of OTC cold and flu medicines are often accompanied by promotions and 
advertising campaigns particularly during the winter seasons. These activities 
could be targeted at pharmacies to encourage stock purchase or at the general 
public to raise product awareness. An increase in awareness about a product 
could potentially give rise to an unexpected increase in sales that may be 
misinterpreted as the emergence of an influenza outbreak. This could result in 
public health resources being wasted on subsequent investigations. Several 
studies approached this problem by obtaining marketing information relevant 
to the products monitored and interpreted suspicious increases in sales in 
conjunction with these information (Das et al. 2005; Kirian and Weintraub 
2010; Liu 2013; Wagner et al. 2003; Welliver 1979). However, the current 
pharmacy sales data obtained from IMS Health was not accompanied by such 
data and thus the impact of promotion status on medication sales is not known. 
 
As mentioned before (Section 6.4.1), one problem associated medicines 
wholesales data was that it could be affected by advance purchases of cold and 
flu medicines before the arrival of winter season each year. This provides a 
possible explanation for the two-peak sales pattern observed during the winter 
period. The onset of the first of the two peaks (October and January/February, 
respectively) could not be explained by either an increase in influenza 
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diagnoses or URTI symptoms experienced in the community during the same 
time. Having recognised that the early peak in sales may not have been due to 
the onset of actual respiratory infections in the community, the study attempted 
to control for this by creating a time series model that would eliminate this 
signal. However, this endeavour was unsuccessful and was not explored 
further. 
 
As the study was unable to exclude the possibility that an increase in medicine 
sales may have been, in part, caused by the advance purchase of stock by 
pharmacies, the findings on medicines sales data as a potential early indicator 
for influenza and URTI symptoms need to be interpreted with caution. To 
overcome this challenge, actual pharmacy-to-patient sales data should be 
obtained instead of wholesale data.  
 
Data reporting interval 
The medicines sales data used in the current study were only available in a 
monthly format. Consequently, the earliness of medicines sales data in terms of 
identifying a change in influenza activity could only have been measured on a 
monthly scale. This reporting interval is substantially longer than weekly or 
daily sales data that have been used in other disease surveillance studies (Das 
et al. 2005; Edge et al. 2006; Kirian and Weintraub 2010). One drawback about 
the long data reporting interval is that an early detection of a disease signal by 
a few days could potentially be interpreted as having provided no early 
warning. Conversely, an early detection of a disease by a few weeks may be 
interpreted as having provided a one-month early warning. To overcome this, 
future studies should obtain daily or weekly sales data and verify the early 
detection ability of medicines sales data for influenza. 
 
6.4.3.2 Disease activity indicators 
 
Influenza diagnostic data 
Data for clinically diagnosed influenza cases were collected through a 
volunteer sample of 44 GP practices which formed the Wales Sentinel 
Surveillance Scheme (PHW 2011b). This group of GP practices has been 
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collecting data since 1985 with no change in case definition and covers 
approximately 10% of the entire Welsh population (PHW 2011b). Although a 
10% coverage of the population may appear low, an early review of the 
scheme indicated the proportions of patients in each age groups were 
comparable to the Welsh population (Palmer and Smith 1991). 
 
The provision of the original Wales Sentinel Surveillance Scheme was 
superseded by the new ‘Audit+ Data Quality System’ introduced in 2010. The 
new system consisted of an improved coverage of 80% of all GP practice in 
Wales (PHW 2010b). It is now, at the time of writing, the main source of 
influenza surveillance data for Wales. 
 
One of the changes introduced as part of the new system was the use of a Read 
Code based definition of influenza diagnosis instead of clinically diagnosed 
influenza based on symptoms (PHW 2010b). The Read code is a standardised 
coding system that classifies clinical terminologies used in the general medical 
practice, including codes for the diagnosis of a disease (Health and Social Care 
Information Centre 2013). Whether or not the new coding system would have 
an impact on influenza statistics and, by implication, influence the correlation 
between medication sales and influenza diagnosis observed in the current is not 
clear. A revalidation of the correlation between sales of the selected medicine 
and influenza diagnosis derived from Read codes may be necessary in the 
future once the Audit+ Data Quality System has accumulated sufficient data 
for historical comparison. 
 
NSH Direct Wales call data 
Unlike data for the sales of OTC medicines and clinically diagnosed influenza, 
which covered a total of six winter periods, NHSDW call data were only 
available for three winter periods. This was due to a system-wide change in 
how the NHSDW calls were recorded in 2006 and therefore data prior to 2006 
could not be used. A longer period of study would have increased the 
confidence in the results.  
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6.4.3.3 Statistical analysis 
Sales of selected OTC medicines were compared to influenza diagnosis and 
symptomatic calls to NHSDW by comparing the onset of their peak activity. 
As noted by Dailey et al. (2007), one weakness about the peak comparison 
method is that it only acknowledges data points that are of the highest value. 
Other features which might also be important about a peak, such as its size and 
width, are ignored. Whether or not these other features would provide 
additional information about an influenza epidemic was not explored in the 
present study. 
 
Cross-correlation measures the association between two variables and does not 
imply a cause-and-effect relationship between medication sales and either 
URTI or infections of influenza. It was possible that some of the correlations 
observed between medication sales and the influenza indicators were attributed 
to the seasonal feature that was associated with the data used in the present 
study. Removing these seasonal features from the data would increase the 
confidence in the relationship between medication sales and the indicators of 
influenza activity. Other potential confounders, such as the beginning of school 
term, weather pattern and public holidays, could also influence the correlation 
between the time series (Magruder 2003). Future studies could consider 
constructing mathematical models to account for these variables and verify the 
correlations observed between medication sales and influenza activity. Such 
could not be undertaken in the current study due to time and resource 
constraints. 
 
6.4.4 Implications of findings 
Within the UK, experience in using OTC medicines sales data for the 
monitoring of seasonal influenza at any regional level is lacking despite it has 
been an area of public health interest in England (HPA 2010a), Scotland 
(Public Health Institute of Scotland 2003) and Wales (Jones 2009). The 
absence of a UK based study in this regard has been described in Chapter 1. 
This situation in the UK is in stark contrast to the US, where sales of non-
prescription medicines have been found to be the third most frequently used 
information source for syndromic surveillance systems and their greatest 
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application has been for the monitoring of influenza (Buehler et al. 2008). The 
current study provided the first experience in using medicines sales data for the 
monitoring seasonal influenza in a UK population. 
 
Subject to the limitations described in Section 6.4.3, the pharmacy sales data 
utilised in the present study for OTC cough, cold and flu medicines appear to 
contain a signal that corresponds to the activity of influenza and level of 
associated respiratory symptoms in Wales. Given that many people may not be 
able or indeed choose not to seek medical attention for a simple cold or flu, the 
ability of OTC medicine sales data to describe disease prevalence in this 
population addresses a surveillance gap that could not be achieved by the 
current, healthcare service based surveillance systems. Questions as to how 
such surveillance information can be integrated into existing public health 
protocol, in terms of outbreak detection, investigation of alerts, response to 
threats, and day-to-day workflow of local public health agencies remain to be 
examined. 
 
A number of limitations has been identified for the medicines sales data 
currently available to PHW if they were to be utilised for influenza 
surveillance (Section 6.4.3.1). Among them the biggest challenge probably 
relates to the wholesale nature of the data. This ascertains the need to use 
medicine sales data that represent actual pharmacy and patient transactions for 
disease surveillance tasks. However, such data are not currently available to 
public health agencies in the UK and presents a major barrier for further 
research to be conducted in this field. As such, there may be a need to 
encourage collaboration between the public and the private sector to facilitate 
the sharing of these information for public health purposes. 
 
The publication of the draft professional standards for public health practice for 
pharmacy (Royal Pharmaceutical Society [RPS] 2013) stressed that 
pharmacists should contribute to public health protection by being involved in 
the reporting of seasonal and pandemic influenza. As demonstrated in the 
current study, making use of medicines sales information may be a way to 
realise this public health goal for pharmacy.  
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6.5 Summary 
Over the six-year study period, pharmacy wholesale data of OTC (1) cold and 
flu, (2) cough and (3) nasal congestion or sinusitis medicines demonstrated a 
significant positive correlation with GP diagnosis of influenza and cold and flu 
symptoms calls to NHSDW in Wales. In particular, cough medicines correlated 
with influenza indicators the highest and indicated the greatest potential for 
influenza surveillance. Although the sales of OTC cough, cold and flu 
medicines appeared to have provided up to two months advance warning for 
the onset of seasonal influenza, such could have been influenced by the 
wholesale nature of the pharmacy sales data used. Actual pharmacy-to-patient 
sales data should be obtained in future studies to verify the relationship 
between medication sales and influenza activity observed. 
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Chapter 7: 
 
General Discussion 
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General Discussion and Conclusion 
In 2013, the Royal Pharmaceutical Society (RPS) published its draft 
professional standards for public health practice for pharmacy (RPS 2013). In 
this document, a framework for the design, implementation, delivery and 
monitoring of public health services was proposed for pharmacy for the first 
time. The intention of the framework was to support pharmacists, the pharmacy 
team and commissioners in all pharmacy settings to develop new public health 
services and improve existing public health provisions. 
 
Among the nine core areas of public health practice recognised by the draft 
framework, the use of over-the-counter medicines (OTC) sales data for public 
health as demonstrated in this thesis was particularly relevant to three areas of 
public health practice. These are summarised in Table 7.1. 
 
The potential contribution of OTC medicines sales data to public health was 
investigated utilising two approaches. The first involved medicines that had 
undergone regulatory changes affecting their OTC availability and included (a) 
codeine and dihydrocodeine (DHC), (b) pseudoephedrine (PSE) and ephedrine 
and (c) ophthalmic chloramphenicol. OTC medicines sales data were used to 
investigate whether or not these changes had any impact on their supply either 
OTC or on prescription in Wales. The second approach explored whether or 
not OTC medicines sales data would be of any potential use for disease 
surveillance. This involved using sales data for OTC ophthalmic 
chloramphenicol to identify outbreaks of infective conjunctivitis and sales of 
OTC cough, cold and flu medicines to monitor seasonal influenza. 
 
The current chapter discusses the main findings for each of these studies, 
considers the possible implications on policy and summarises the study 
limitations. Finally, future work is proposed followed by the overall 
conclusions.
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Table 7.1 Draft professional standards for public health practice for pharmacy, their goals and possible contributions to each area by utilising over-the-
counter (OTC) medicines sales information from community pharmacy (Adapted from source: Royal Pharmaceutical Society [2013]) 
 
Professional standards Goal Possible uses of OTC medicines sales data 
   
Surveillance and 
assessment of the 
population health and 
wellbeing 
Collect data from a variety of sources to 
support better understanding of the health 
and wellbeing needs of a population or 
community 
• Understand local health needs 
• Identify population at risk of developing problems with 
OTC medicines (e.g. opioid containing analgesics) 
• Quantify effect of social deprivation on the health of 
population and self-care behavior 
      
Public health 
intelligence 
Information and analysis of the health and 
wellbeing needs of the population or 
community is used to inform development 
of pharmacy public health services 
• Evaluate effectiveness and outcomes of pharmacy 
interventions (e.g. impact of medicine reclassification or 
pack size restriction on sales of OTC medicines) 
• Identify potential links between consumption of OTC 
medicines and morbidity data (e.g. OTC sales of 
paracetamol and statistics on deliberate self-poisoning) 
      
Public health 
protection 
Protect health by supporting the prevention 
and transmission of infectious diseases, 
screening for risk factors and disease, 
ensuring prudent use of antibiotics to 
mitigate the risks of antimicrobial 
resistance, protecting against 
pharmaceutical hazards and supporting the 
pharmacy response to an emergency 
• Monitor supply of non-prescription antibiotics from 
pharmacies (e.g. ophthalmic chloramphenicol and 
azithromycin) 
• Contribute to the identification of emerging 
communicable disease epidemic or pandemic (e.g. 
elevated sales of OTC cough, cold and flu medicines and 
possible circulation of influenza) 
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7.1 Major findings 
 
7.1.1 Impact of restrictions on Over-the-Counter availability 
Due to concern over their potential of misuse and/or abuse (All-Party 
Parliamentary Drug Misuse Group [APPDMG] 2009; Medicines and 
Healthcare products Regulatory Agency [MHRA] 2005a), OTC sales of 
codeine and DHC containing analgesics became subject to various voluntary 
and legal restrictions between 2005 and 2009. To understand what the impact 
of these regulatory measures were on their supply in the primary care, 
medicines wholesale data for selected products were analysed. The results from 
Chapter 2 revealed there was a decline in sales of OTC codeine and DHC 
containing analgesics in Wales following the implementation of both voluntary 
and legal changes. Therefore, MHRA’s intention to minimise the risk of 
addiction by restricting OTC availability of these medicines appeared to have 
been achieved (MHRA 2005a, 2009a). However, how much of reduction in 
sales had prevented users from developing problems with codeine and DHC 
containing products is unclear and was not examined. This was not one of the 
objectives for the current study but may be included in future work. 
 
In Chapter 3, another example where sales of OTC medicines from pharmacy 
became subject to additional control involved oral and topical nasal 
decongestants containing PSE and ephedrine. In this particular case, legal 
changes regarding non-prescription supply were introduced because of their 
potential to be used as precursors in the illicit manufacture of the class A drug, 
methylamphetamine (MHRA 2007a). The actions taken by the MHRA 
included limiting the total weight of PSE and ephedrine that was allowed in an 
OTC pack and that could be sold to a customer in a single transaction (MHRA 
2009c). Using medicines wholesale data, the study investigated the impact of 
these measures on OTC supply and the results revealed the sales of selected 
PSE containing products had significantly reduced in Wales. This finding was 
consistent with the sales trends reported for the UK as a whole (MHRA 2012b) 
and suggests the legal measures for PSE and ephedrine containing products had 
the required, desirable impact on OTC supply in Wales. However, it should be 
noted that in this study OTC sales data for ephedrine containing nasal 
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decongestants were unavailable and the impact of the policy change on these 
products could not be determined.  
 
A potential concern about pack size restriction as a strategy to limit the 
availability of a medicine, or to deter deliberate misuse and/or abuse, was how 
easy individuals could bypass the regulatory effort, for example by making 
more frequent purchases of smaller packets. Such a change in consumer 
behaviour subsequent following a reduction in product pack size has been 
previously observed with paracetamol (Hawton et al. 2001). However, analyses 
of the medicines wholesale data revealed there was a simultaneous reduction in 
both the number of packs and total quantity of tablets/capsules sold in Chapter 
2 (Figure 2.2). Similarly in Chapter 3, reduction in the number of packs and 
weight of active ingredient sold was observed (Figure 3.1). These observations 
suggest, overall, that consumers probably have not engaged in the practice of 
purchasing more packs. 
 
Finally, another potential concern over restricting the OTC availability of a 
medicine is whether or not this encouraged individuals to obtain the same drug 
from their GP on prescription (Maguire 2010). This possibility was explored in 
both Chapter 2 and Chapter 3 by analysing GP prescribing data for Wales. The 
results from Chapter 2 indicate there was no significant increase in prescription 
supply of DHC following the pack size restriction; whilst prescription supply 
of codeine containing preparations increased year-on-year but followed the 
same trend as seen before the pack size restriction was introduced. In Chapter 
3, there was no significant increase in the prescribing of either PSE or any 
other nasal decongestant on GP prescriptions. These findings provide 
reassurance that increased restriction on the OTC sale of these medicines did 
not result in an increase in patients seeking prescriptions for the same drug 
from their GPs. 
 
7.1.2 Impact of increase Over-the-Counter availability 
When a medicine is switched from POM to P status, its availability and 
accessibility to the general public is increased. For ophthalmic 
chloramphenicol, it had been reported that OTC supply in Wales increased in 
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the first three years following reclassification to a P medicine in 2005 (Walker 
and Hinchliffe 2009). The study in Chapter 4 monitored the supply of OTC 
ophthalmic chloramphenicol beyond the first three years and examined the 
long term impact following reclassification. Furthermore, additional medicines 
sales data were obtained for the present analysis from a multiple pharmacy 
company (Company A) in Wales for which OTC data was not available. 
 
The results suggest that following the initial three-year growth, sales of OTC 
ophthalmic chloramphenicol declined and stabilised for the first time in 
2008/2009. In the present study access was granted to previously unavailable 
sales data. It was not surprising, therefore, to find the total quantities of OTC 
ophthalmic chloramphenicol sold in Wales was more than previously 
calculated (Walker and Hinchliffe 2010). Despite the increase in use of OTC 
ophthalmic chloramphenicol, supply on prescription remained unaffected five 
years on. As a consequence there was no reduction in NHS drug spending 
and/or the burden on GPs in managing these patients. The exact reason why 
despite the additional quantity of ophthalmic chloramphenicol supplied OTC 
there was no impact on its prescription supply could not be determined from 
the present study and warrants further research. 
 
When the temporal relationship between OTC sales of ophthalmic 
chloramphenicol and items dispensed on prescription was explored, it was 
found that there was a significant and positive correlation between the two 
variables. This may, in part, suggest that community pharmacists and GP 
prescribers were responding to similar presenting symptoms. However, 
whether or not prescribing and/or OTC sales of ophthalmic chloramphenicol 
were appropriate remains unknown. It has been reported that primary care 
practitioners commonly misdiagnose and mismanage infective conjunctivitis 
(Statham et al. 2008). In light of the high volume of ophthalmic 
chloramphenicol sold OTC, the question as to whether those supplied by 
pharmacists represent clinically appropriate decisions is an important question 
that needs to be answered. This was not explored in the present study but could 
be studied further. 
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7.1.3 Identification of local infective conjunctivitis outbreak 
The study presented in Chapter 6 utilised sales data for OTC ophthalmic 
chloramphenicol to explore its sensitivity to identify known outbreaks of 
infective conjunctivitis in the local community. 
 
Two separate outbreaks of infective conjunctivitis in South Wales were studied 
(Section 5.1.4). Sales of OTC ophthalmic chloramphenicol during one of the 
outbreaks (Pontypool) were found to be significantly higher than in 
corresponding non-outbreak period in one of two preceding years. Although 
the increase in sales of OTC ophthalmic chloramphenicol coincided with the 
period of the known outbreak, the number of additional packs sold was small 
(11 packs) and increase was not consistently higher than the supply during 
corresponding non-outbreak periods. As a consequence, how robust this would 
be to detect further outbreaks is unclear.  
 
The low volume of OTC ophthalmic chloramphenicol sold in this particular 
study was, in part, due to the low coverage of medicines sales data in the study 
areas. The study could not exclude the possibility that sales of OTC ophthalmic 
chloramphenicol might have increased in pharmacies outside the area of those 
monitored. Investigating an outbreak in a larger area and involving more 
pharmacies may have improved the sensitivity to detect an outbreak. 
 
Public Health Wales (PHW) currently possesses medicines wholesale data for 
OTC ophthalmic chloramphenicol, which includes data from pharmacies other 
than those owned by Company A. However, these data are not available down 
to individual pharmacy level and could not be analysed on a weekly basis. As 
such, unless these shortcomings can be resolved the value of OTC medicines 
sales data for local outbreak detection may be limited. 
 
7.1.4 Influenza monitoring 
In Chapter 5, the potential of medicines wholesale data to detect outbreaks of 
seasonal influenza and upper respiratory tract infections (URTI) was explored. 
This was undertaken by examining the temporal relationship between the sales 
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of selected OTC medicines and indicators of community-level influenza and 
upper respiratory tract infection (URTI) symptoms. 
 
Over the six-year study period, wholesale data for selected preparations to treat 
(a) cough, (b) cold and flu and (c) nasal congestion medicines all demonstrated 
seasonal, year-on-year patterns. During the winter months each year 
(November to January), sales of all three categories of medicines could be 
characterised by a two-peak model. The first of the two peaks persistently 
occurred 2 to 4 months before the peak influenza diagnosis reported by GPs 
and peak calls to NHS Direct Wales (NHSDW) for URTI symptoms. On the 
other hand, the occurrence of the second sales peak was found to match with 
the month of peak influenza diagnosis and calls about URTI symptoms. The 
temporal mismatch between the first sales spike and peak influenza/URTI 
activity suggests there were other unknown factors influencing the sales of the 
selected medicines. Their exact nature could not be determined and require 
further investigation. 
 
Results from cross-correlation analysis revealed the supply of (a) cough, (b) 
cold and flu and (c) nasal congestion medicines all demonstrated a significant 
and positive correlation with cases of GP diagnosed influenza and symptomatic 
calls to NHSDW at various time latencies. This suggests two possible 
properties about the medicines wholesale data in terms of disease surveillance. 
First, changes in the sales of the selected medicines are sensitive to changes in 
the activity of influenza and related symptoms in the community. Second, the 
different time latencies for which maximum correlation was observed suggest 
the three categories of medicines vary in their early detection capability. 
 
Of the three categories of medicines studied, cough medicines sales 
demonstrated the highest correlation with each of the disease indicators. In 
addition, they consistently provided up to one month early warning to changes 
in influenza activity. Therefore, cough medicines as a group could be studied 
further for their application in disease surveillance. A longer study period and 
wider range of cough products could provide more confidence for the 
relationship observed between medicine sales and influenza activity. 
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The association between sales of OTC medicine and respiratory diseases found 
in the current study are consistent with that reported in the US population (Das 
et al. 2005; Liu et al. 2013; Magruder et al. 2004). However, the medicines 
wholesale data currently available to PHW is has a number of disadvantages 
and its usefulness for influenza surveillance may be limited (Section 6.4.3.1). 
Most notable of its drawback is that the buy-in nature of the data makes it 
vulnerable to factors unrelated to actual diseases activity in the community. 
This highlights the requirement for actual pharmacy-to-patient sales data if 
surveillance of communicable diseases, based on OTC medicines sales data, is 
to be an area of development for community pharmacy in the future (Jones 
2009). 
 
7.2 Implication of research findings 
 
7.2.1 Widened availability of ophthalmic chloramphenicol 
Removing the prescription barrier of a medicine through reclassification 
improves patient access to treatment and presents opportunities for self-care. 
This was exemplified with the reclassification of ophthalmic chloramphenicol 
as discussed in Chapter 4. 
 
The availability of OTC ophthalmic chloramphenicol prompted self-
management of infective conjunctivitis in individuals who previously may 
have left it untreated. This outcome could be considered a success from a 
reclassification perspective. Supplies of ophthalmic chloramphenicol on 
prescription, on the other hand, remained unaffected five years on. It would 
appear that people who previously visited their GP for an eye infection 
continued to do so even though ophthalmic chloramphenicol could be obtained 
without a prescription. In this regard, the reclassification policy may be 
considered to have been less successful as it failed to shift the burden of 
managing infective conjunctivitis from GP surgeries to community pharmacies 
or deliver any cost saving to the NHS. 
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For the policy makers, there may be a need to further promote patients to 
engage in self-care such as through events like the ‘Self-Care Week’ campaign 
(Welsh Government 2012a). Raising the awareness about specific conditions 
where effective treatment can be purchased from a pharmacy may help to focus 
public awareness. Making patients aware of the importance of choosing the 
right kind of service proportional to the seriousness of a health problem may 
also help to address this issue. The ‘Choose Well’ health campaign in Wales 
would be an example of such an endeavour (Anon. 2011). 
 
Though the study was not designed to investigate the abolition of the NHS 
prescription charge in Wales in 2007 this may have prevented patients from 
practicing self-care. This was demonstrated by the year-on-year reduction in 
prescription supply of ophthalmic chloramphenicol up to 2007, followed by a 
sudden increase in prescribing when the prescription charge was removed 
(Table 4.11). This observation is in agreement with the findings reported by 
Grove et al. (2010) as participants in a before-and-after survey study showed 
there was a reduction in the purchase of non-prescription medicines and 
increase in prescription medicine utilisation after the abolition of the 
prescription charge in Wales. 
 
The cost associated with purchase of OTC medicines may be a barrier to self-
care and is well documented (Hanna and Hughes 2010; Paudyal et al. 2012c; 
Weidmann et al. 2011). This may have been one of the reasons why some 
individuals continued to obtain ophthalmic chloramphenicol on prescription. 
The to be established Common Ailments Service (CAS) in Wales (Welsh 
Government 2012b) may help lessen the burden of minor ailments on GPs, 
whereby eligible patients will be provided with free treatment for minor 
conditions under the NHS from community pharmacies. At the time of writing, 
ophthalmic chloramphenicol is considered to be one of the medicines that will 
be supplied under CAS (All Wales Medicines Strategy Group [AWMSG] 
2013). Whether this approach will encourage patients to visit a community 
pharmacy instead of their GP remains to be studied.  
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7.2.2 Inappropriate use of Over-the-Counter medicines 
Issues surrounding the misuse and abuse of OTC medicines, particularly 
addiction to analgesics that contain codeine and DHC, have attracted attention 
in recent years from healthcare professionals (Mackridge et al. 2013; Royal 
College of General Practitioners 2013), public health agencies (Reed et al. 
2011; Public Health England [PHE] 2013b) and the medicine regulator 
(MHRA 2011b) in the UK. The need for more detailed information on the 
individuals who are affected, the type of medicines being misused/abused to 
guide the development and delivery of treatment services has been recognised 
(National Treatment Agency for Substance Misuse [NTA] 2011; Reed et al. 
2011; PHE 2013; Welsh Government 2013a). It is an area of active research 
(Cooper 2013a, 2013b, 2013c). 
 
As illustrated in Chapter 2 and Chapter 3, information generated from the sales 
of OTC medicines can provide trend data and quantify the volume of OTC 
medicines supplied. They may serve to be the first signs to indicate the scale of 
the problem associated with the inappropriate use of OTC medicines. The 
flexibility to analyse medicine sales data at a local level means identification of 
areas with higher than normal volume of sales is possible. This enables the 
population more at risk of developing problems to be spotted. 
 
Using medicine sales data has lead to the identification of one particular Local 
Health Board (LHB) that showed unusually high volume of sales and 
prescription for non-soluble codeine (Section 2.3.3). This information may 
help to guide public health interventions, such as a review of local medicine 
sales or prescribing protocol. This was an example that shows how OTC 
medicine sales data could support the harm reduction objectives outlined in 
Welsh Government’s national substance misuse strategy (Welsh Government 
2013b). Objectives could include greater attention on the inappropriate use of 
OTC medicines and improving the monitoring of usage. 
 
Findings presented in Chapter 2 demonstrated there has been a decline in the 
sales of OTC codeine and DHC containing products following the change in 
legislation regarding their supply. On-going monitoring of the supply situation 
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is essential to evaluate whether this has been sustained. Interpretation of 
medicines sales data should be supplemented by primary care prescribing data 
to determine if there was a switch from OTC purchases to obtain supplies from 
GPs. This does not appear to have been the case in Wales but could have 
changed given the study only examined data up to 12 months after the legal 
changes were introduced. 
 
It has been reported that the regulatory changes for OTC codeine and DHC 
containing analgesics were ineffective in stopping supplies for non-medical 
purposes (Cooper 2013c). Methods adopted by users to circumvent detection 
included making purchases from more than one pharmacy and rehearsing 
answers to questions from staff (Cooper 2011, 2013c; Nielsen et al. 2012). 
Therefore, despite the fact that there has been a decline in the sales of OTC 
codeine and DHC containing products, it would appear the indicators relied 
upon by pharmacy staff to identify improper OTC requests may be unreliable 
(Cooper 2013b). More effective strategies to detect inappropriate OTC requests 
for codeine and DHC may be necessary. To this end, a pharmacist training 
package has recently been developed by the Centre for Pharmacy Postgraduate 
Education (CPPE) on the subject of addiction to OTC medicines (CPPE 2013). 
The learning programme considers what can be done to recognise the key risk 
factors, patient identifiers and triggers that may prevent OTC medicines from 
being misused. However, this training material is not currently available to 
pharmacists in Wales. 
 
7.2.3 Self-selection of Pharmacy medicines 
In 2012, the General Pharmaceutical Council (GPhC) launched a public 
consultation on the draft standards for registered pharmacies (GPhC 2012). 
Among the items that were raised include the proposal to allow pharmacy 
owners to selectively display P medicines for self-selection by customers. It 
has been argued that the move would allow a wider access to medicines and 
benefits the patient (Connelly 2012). However, many pharmacists and 
pharmacy professional bodies have opposed the decision on the grounds of 
patient safety (Anon. 2012d, 2013a; Sukkar 2013). Concerns over the lack of 
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monitoring for the sales of selected high risk OTC medicines, such as nasal 
decongestants, have been raised (Anon. 2012e).  
 
At the time of writing this thesis, details as to how self-selection of P 
medicines will be implemented in practice have not been finalised. However, 
should it become a reality it could impact on how P medicines are consumed 
(Pharmacists’ Defence Association 2013). It is not improbable that once a P 
medicine becomes more patient-accessible through self-selection, an increase 
in its non-prescription supply may ensue (Sukkar 2013). This holds two 
potential implications for OTC medicines sales data and these are discussed 
below. 
 
First, the impact of the self-selection arrangement on the purchase of medicines 
with high misuse and/or abuse potential would be of interest to the medicine 
regulator (Sukkar 2013). OTC medicines sales data could serve as a tool to 
monitor non-prescription supply and used to support policy decisions regarding 
OTC availability. Secondly, OTC medicines sales data could facilitate robust 
pharmacoepidemiological studies (Bond and Hannaford 2003). Such studies 
could also be useful to identify unusual trends with adverse drug events in the 
community related to the use of OTC medicines. By way of an example, the 
MHRA has recently issued a new warning over the use OTC diclofenac in 
patients with cardiovascular disease (MHRA 2013c). Reverting its legal status 
from P to POM is currently being considered (Anon. 2013b). In this example, 
OTC medicine sales data could be used to help quantify and interpret the trends 
of related adverse events in the community and provide evidence to inform the 
reclassification decision. 
 
Given the limited OTC medicines sales data that is currently available to 
government agencies, there may be a need to strengthen collection to support 
the self-selection initiative in the interest of patient safety. The GPhC could 
consider making the collection and sharing of sales data for self-selectable 
products a requirement for pharmacy businesses. This may have the added 
benefit of encouraging pharmacy owners to adopt a more responsible approach 
towards implementing self-selection of P medicines.   
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7.2.4 Antibiotic stewardship 
The increased supply of ophthalmic chloramphenicol in primary care continues 
to cause concern eight years on (Price 2013). To date, no study has yet been 
carried out to investigate the clinical appropriateness of each supply. 
Therefore, how much of the supply reported in this study represents 
inappropriate sales remains unanswered. Even if bacterial conjunctivitis could 
be diagnosed accurately, the high level of ophthalmic chloramphenicol use 
could increase bacterial resistance (Price 2013). 
 
Pharmacy staff need to demonstrate they are aware of the latest recommended 
treatment for acute infective conjunctivitis by promoting the practice of 
‘delayed’ or ‘no antibiotic’ use. To this end, it is likely that sales data for OTC 
ophthalmic chloramphenicol will continue to be monitored. The applications to 
reclassify trimethoprim and nitrofurantoin to P status were both withdrawn in 
2010 over concerns of antibiotic resistance (Anon. 2010b). These unsuccessful 
reclassifications should serve as a reminder for the pharmacy profession to act 
cautiously and responsibly when faced with requests for OTC ophthalmic 
chloramphenicol. 
 
The launch of OTC ophthalmic chloramphenicol in 2005 was supported by a 
range of training and educational materials for pharmacists and medicine 
counter assistants (MCAs) (Anon. 2005; Elton 2005; Royal Pharmaceutical 
Society [RPSGB] 2005). Many of these resources were provided by medicine 
manufacturers as it is a common requirement for the application of a POM-to-P 
switch (MHRA 2012a). Understandably, much of the training effort focused on 
the initial phase of the product launch when the training needs of pharmacy 
staff were at their highest. However, in contrast, there is a much weaker 
emphasis on on-going training to keep up with the latest evidence. For 
ophthalmic chloramphenicol, the updated advice for their OTC supply were 
communicated in a single practice document produced by the Royal 
Pharmaceutical Society (RPS) in 2011 (RPS 2011c). Access to this document, 
however, was limited only to registered members of the pharmacy professional 
body. Whether this single document was sufficient to drive compliance among 
pharmacy staff to minimise antibiotic use remains to be studied. Further 
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collection of medicine sales data is recommended to monitor if the supply 
situation has changed. 
 
One factor that may have contributed to the marked increase in use of 
ophthalmic chloramphenicol could have been patients’ perception about 
infective conjunctivitis as a disease. A number of studies have examined this 
and found many patients believed an antibiotic is required to clear the infection 
(Everitt et al. 2003). As a consequence, a better awareness about the self-
limiting nature of infective conjunctivitis may help reduce the use of 
ophthalmic chloramphenicol. Whilst a number of public health campaigns 
already exist to raise the awareness about the ineffectiveness of antibiotics in 
certain conditions, the target population has primarily been GP attendees 
suffering from colds or flu (RPS 2012; PHW 2013b). There may be a need for 
future campaigns to include information customised for pharmacy users, 
including information on infective conjunctivitis. The recent national public 
health campaign in Wales that focused on eye care was an opportunity where 
non-medicinal management of infective conjunctivitis could have been 
promoted (Community Pharmacy Wales [CPW] 2013; PHW 2013c) 
 
In summary, the results from the current study support the recommendation 
that further reclassifications of antibiotics to OTC status should not be allowed 
(Anekwe 2010, Dryden et al. 2009). The risks of increased bacterial resistance, 
lack of comprehensive post-marketing surveillance data and mechanism to 
support long term training needs are some of the obstacles faced by the 
pharmacy profession.  
 
7.2.5 Wales Common Ailments Service 
In March 2012, the Welsh Government announced its plan to establish the 
CAS that will be delivered by all NHS contracted community pharmacies in 
Wales (CPW 2012a, Welsh Government 2012b). At the time of writing thesis, 
some of the conditions planned to be treated under the scheme include 
indigestion, scabies, sore throats, bacterial conjunctivitis, athlete’s foot, thrush, 
head lice, diarrhoea, verrucas and threadworms (AWMSG 2013). As the 
service will be provided free of charge for eligible NHS patients, it is hoped 
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that individuals who previously chose to visit a GP for a free prescription 
would instead visit a pharmacy. As for individuals who already self-manage 
minor conditions by purchasing OTC medicines, it is anticipated they will 
continue to do so without the help from the NHS (Welsh Government 2013c). 
 
The results from Chapter 4 indicate a large proportion of the Welsh population 
chose to manage infective conjunctivitis by purchasing OTC ophthalmic 
chloramphenicol. For some individuals, it was probably because the benefits of 
being able to purchase the treatment when and where desire outweighed the 
inconvenience associated with visiting a GP. Whether they will be just as 
motivated to continue to do so after CAS becomes available is unclear. It has 
been suggested the CAS initiative will encourage patients to over rely on the 
NHS for even minor conditions (Bro Taf Local Medical Committee 2013). 
Consequently, it would be pertinent that sales data for OTC ophthalmic 
chloramphenicol are monitored further to ensure CAS is not used as a means 
by which patients can shift drug acquisition costs on to the NHS. Likewise, 
sales data for other therapeutic classes of medicine that are to be supplied 
under CAS should also be monitored to allow the evaluation of the service on 
self-care behaviour. 
 
The to-be-implemented CAS is envisaged to be supported by a centrally stored, 
electronic database that is accessible by every NHS contracted community 
pharmacy in Wales (Welsh Government 2013c). Under the proposed plan, 
users of CAS will have to be to registered with a pharmacy with basic personal 
information such as name, age, gender and address. Details about the product, 
quantity and date will also be recorded for each supply (Welsh Government 
2013c). In comparison to the pharmacy sales data utilised in the current study, 
the availability of detailed patient record will be associated with several 
advantages. For example, local communities where health improvements are 
needed the most could be identified. Patient profiles could be generated to 
identify vulnerable patient groups. An interconnected and up-to-date patient 
record could allow pharmacists to identify individuals suffering from more 
frequent episodes of illness and initiate appropriate referral. These are some 
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unintended but possible uses of the data that are not available with the existing 
pharmacy wholesale data. 
 
7.2.6 Disease surveillance 
The capacity of the community pharmacy profession in rising up to the 
challenge of a major influenza outbreak has been demonstrated during the 
H1N1 (2009) influenza pandemic. In England, for example, community 
pharmacies played a key role in distributing health information to the public 
and supplied antivirals through pharmacy collection points during the 
pandemic (Richards 2009). In Wales, community pharmacists disseminated 
self-care and vaccination advice to the public (PHW 2009a, 2009b) and 
supported the care of vulnerable patient groups (Anon. 2009f). During seasonal 
influenza epidemics, community pharmacy has been the first port of call for the 
general public to seek advice and obtain OTC medicines for cold and flu 
symptoms. Recently, for the first time, community pharmacy in Wales were 
involved in the flu vaccination programme under NHS for the 2012/2013 
winter season (CPW 2012b; Welsh Government 2012c). This was an 
encouraging development for community pharmacies in Wales and shows they 
are beginning to be recognised as a potential partner in the delivery of health 
protection strategy for seasonal influenza (UK Influenza Pandemic 
Preparedness Team 2011). 
 
The first experience of using medicines sales data for disease surveillance in 
Wales was presented in Chapter 5 and 6. The two studies demonstrated how 
medicines sales data could contribute to "new investigative techniques and 
non-traditional source of data to produce public health intelligence" as 
identified in the public health strategy for Wales (Welsh Government 2009a). 
Recently published public health surveillance strategy in England has also 
highlighted the need to utilise novel sources of information and analytical 
approaches to support health protection and emergency preparedness 
(Department of Health [DH] Public Health England Transition Team 2012). 
The community pharmacy profession should capitalise on these opportunities 
for a greater involvement in public health and infectious disease prevention. 
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Offers to collaborate with the public sector would not only support these public 
health endeavours but could also raise the profile of community pharmacy. 
 
Progress in understanding the use OTC medicines sales data for diseases 
surveillance is hampered by a number of barriers. Firstly, actual sales data as 
opposed to wholesale data, is required if timely detection of a disease outbreak 
is to be achieved. However, sales data are difficult to obtain due to the 
concerns of individual companies’ over confidentiality and security. The 
research opportunity is therefore limited. Secondly, there is a need for regular 
and on-going supply of sales data to establish a baseline level of sales. This 
means the additional work involved may be unattractive to pharmacy owners. 
Thirdly, nearly 40% of all community pharmacies in Wales are independent 
pharmacies (Welsh Government 2012d) and they may not have a monitoring 
system in place that records the sales of OTC medicines. Lastly, the required 
IT infrastructure to facilitate downloading and sharing of medicine sales data 
and surveillance information between the data providers and public health 
agencies is at present lacking in Wales.  
 
A variety of strategies could be considered to overcome the barriers outlined 
above. These may include public health agencies forming an agreement with 
private companies on issues surrounding data confidentiality and how data may 
be used for research and public health purposes. Furthermore, sales figures 
could be anonymised. To encourage as many pharmacies to participate as 
possible, experience from the US suggest personal invitations written by 
respected government or public health officials was key to promote private 
sector participation (Wagner et al. 2003). Offering a financial reward for the 
work involved may also encourage collaboration. To maximise sales data 
coverage, partnerships with large pharmacy multiples could be given priority in 
exchange for better data coverage earlier on. The need for a better data linkage 
between community pharmacy and other healthcare services has recently been 
recognised in Wales (National Assembly for Wales Health and Social Care 
Committee 2012). The establishment of CAS in Wales, underpinned by an 
improved IT infrastructure, offers potential opportunity where information 
sharing functionality could be included in the system design.  
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In summary, the utilisation of OTC medicines sales data for disease 
surveillance is an area of potential public health development in both England 
and Wales. It is in the best of interest of the community pharmacy profession to 
seize the opportunity to ensure progress continues on this issue.  
 
7.3 Limitations 
It was intended that, where possible, the studies reported in the thesis would 
use available data sources. This would ensure the findings were relevant to the 
work of PHW who facilitated the supply of medicines sales data from IMS 
Health and Company A (Section 4.2.2.3). The studies presented in this thesis 
have investigated (a) the impact of increased medicine regulation and 
reclassification on the supply of selected medicines, and (b) the relationship 
between medicines sales data and known disease outbreaks. All were of an 
ecological nature and involved retrospective data analysis. In the following 
section general limitations associated with the methods and data used are 
discussed. 
 
7.3.1 Internet pharmacy 
The pharmacy sales data utilised in the current study represent sales of OTC 
medicines from traditional high street pharmacies. Whilst the majority of the 
medicines studied were P medicines and could only be obtained from a 
pharmacy, it should be noted they could also be obtained through other routes. 
One notable channel of supply is through internet pharmacies for which sales 
data were unavailable. The difficulty in regulating medicines supply by internet 
pharmacies has been acknowledged by medicine regulators (MHRA 2012c). 
Inappropriate sales of OTC medicines by some internet pharmacies have been 
reported (Cooper 2011, 2013c). It was possible the extent of impact of the 
regulatory changes studied in Chapters 2 and 3 were different for the internet 
pharmacy sector. Therefore, the interpretations of the findings presented in 
those chapters should be limited to the context of traditional high street 
pharmacy.  
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7.3.2 Generic and proprietary medicines 
In Chapters 2, 3 and 4, the majority of the OTC medicines studied were 
proprietary products. The reasons for excluding generic medicines from the 
analysis have been described (Section 2.4.2.3, Section 3.4.1.3 and Section 
4.4.2.7) and related to ease of identification of the relevant data. As a 
consequence, the impact of medicine reclassification and pack size restrictions 
on the sales of generic or non-brand medicines were unknown. One solution to 
this is to acquire actual pharmacy-to-patient sales data directly from 
pharmacies for generic or non-brand medicines sold OTC. 
 
7.3.3 Attitude, views and experience of healthcare professionals 
To further understand the impact of the quantitative results presented in this 
thesis it is important the attitude, views and experience of healthcare 
professionals and patients in Wales are obtained. For instance, how were 
pharmacists and MCAs managing inappropriate requests of OTC medicines 
following the pack size restriction? Who were conducting sales of OTC 
ophthalmic chloramphenicol in a pharmacy and what was their level of 
awareness of antibiotic resistance? What were patients’ views on the increasing 
restriction to their access of certain non-prescription medicines? These are 
important questions but were not explored due to time and resource constraints. 
 
7.3.4 Settings of a disease outbreak 
Outbreaks of infectious diseases are naturally occurring and unpredictable. 
Therefore, given the time frame for which medicine sales data were available, 
only a small number of outbreak incidents could be investigated. Moreover, the 
kind of disease outbreak that could have been studied was limited by the OTC 
medicine sales data available. For example, pharmacy wholesale data for anti-
diarrhoeal medications was initially obtained from IMS Health to investigate 
outbreaks of diarrhoea. However, the sales data available consisted of mainly 
generic products and these were not a reliable indicator of OTC sales. Other 
difficulties encountered during the study relating to medicines sales data and 
disease surveillance are described below. 
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In May 2011, a viral conjunctivitis outbreak involving at least 51 individuals 
was reported in Rhondda Cynon Taf, Wales (PHW 2011c). As this outbreak 
had affected more people than either of the conjunctivitis outbreaks described 
in Chapter 5, it was of particular interest to study. However, there were two 
issues about the medicines sales data which prevented this from being used. 
Firstly, wholesales data obtained for the time around the outbreak were only 
available in Local Health Board (LHB) geography. This was too large to 
identify a local outbreak. Secondly, pharmacy retail data obtained from 
Company A (Section 5.2.2) was limited to 2008 − 2010 and therefore did not 
include the period of the large outbreak. These issues highlight the difficulties 
in studying local disease outbreaks that occur infrequently, particularly when 
OTC medicines sales data are not routinely collected over time. 
 
The H1N1 influenza (2009) pandemic that affected Wales in the summer of 
2009 was also considered for study using the sale of OTC cough, cold and flu 
medicines from IMS Health. However, this was not undertaken as a 
preliminary analysis showed that the sales of these medicines during the year 
of the outbreak were not different to that observed during non-outbreak years 
(Du et al. 2010). This lack of change in sales may be the result of two 
confounding factors. The first was that, at the time, public health agencies and 
healthcare professionals actively encouraged individuals experiencing 
symptoms not to attend a pharmacy (PHW 2009a). Secondly, the general 
public were advised to manage their symptoms using non-medicinal measures 
or take single ingredient paracetamol or ibuprofen to reduce their fever (PHW 
2009c). The absence of another major influenza outbreak in the UK during the 
period of the study meant it was not possible to test if medicine sales data was 
sensitive to an unexpected influenza outbreak. This example highlights the 
difficulty in having a suitable outbreak setting in which the disease surveillance 
capability of medicines sale data can be studied. 
 
7.4 Future work 
There are a number of areas where further research would help to better 
understand the findings of the current study. This could be supported by on-
going collection of OTC medicine sales data through existing public health 
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arrangements in Wales. Collaboration between public health agencies and 
retail pharmacy businesses for new data provisions need to be explored to 
improve on the quality of medicine sales data currently available. Furthermore, 
implementation of new pharmacy services and improvements to the IT 
infrastructure in community pharmacies creates opportunities for 
pharmaceutical data to be utilised for public health research. Suggestions for 
further study include:  
 
• Extend the duration of study to examine the long term impact of 
regulatory changes and updated professional guidance on the supply of 
selected medicines 
• Obtain actual medicine sales data to quantify the OTC supply of own-
brand and generic medicines and examine the impact of regulatory 
changes on the generic medicine market  
• Undertake a qualitative study to determine the factors that contribute to 
the changes in sale of OTC medicines 
• Undertake a qualitative study to identify the determinants for the supply 
of OTC medicines, particularly those associated with misuse and/or 
abuse potential, to identify relevant training needs and the development 
of educational materials 
• Investigate the factors driving the high level of prescribing and OTC 
sale of codeine containing analgesics in Blaenau Gwent Local Health 
Board 
• Obtain pharmacy sales data that is of better data coverage, in daily or 
weekly format and available by postcode to explore its sensitivity and 
ability to detect local disease outbreaks 
• Obtain pharmacy sales data in a daily or weekly format to verify the 
correlation observed between sales of OTC cough, cold and flu 
medicines and indicators for influenza 
• Extend the therapeutic class of medicines and explore whether the OTC 
sales data would be of value for the monitoring of other kinds of 
infectious diseases in the community 
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7.5 Conclusion 
An aspect of pharmacy practice that has considerable public health potential 
but has not been fully exploited in the UK is the knowledge and data 
community pharmacy have about the supply of OTC medicines. The present 
study utilised OTC medicine sales data and explored its contribution to public 
heath. 
 
The study investigated the impact of regulatory changes on the OTC supply of 
two therapeutic classes of potentially misused and/or abused medicines in 
Wales. The findings revealed these regulatory measures reduced the OTC 
supply of these medicines from community pharmacies. This provided 
reassurance to policy makers that the actions taken had the intended impact in 
practice and demonstrated the role of medicine sales data in policy evaluation. 
Whether the supply situations could change after an extended period of time is 
unknown and should be monitored further. 
 
The impact of the reclassification of ophthalmic chloramphenicol was explored 
using OTC medicine sales data. The results showed that OTC supply has 
grown substantially and contributed to an overall increase in primary care use 
in Wales. This was despite a growing body of evidence that advised against its 
routine use in infective conjunctivitis and warnings about the risks of bacterial 
resistance. There may be a need for further training of pharmacy staff and 
patient education to promote the latest treatment recommendations for infective 
conjunctivitis. 
 
OTC medicine sales data were utilised for infective conjunctivitis outbreak 
detection. In addition, the potential for monitoring seasonal influenza was also 
explored. The findings suggest the value of medicines wholesale data for 
diseases surveillance is limited in its current form. The ideal dataset should 
cover all pharmacies in the study area, available on a daily or weekly basis and 
at a geographical level that corresponds to the size of the disease outbreak. 
Such data is currently not available to public health agencies in Wales and 
serves to highlight the challenge if OTC medicine sales data are to be utilised 
for disease surveillance purposes. 
 241 
In summary, it is recommended that government and public health agencies 
continue to strengthen the collection of OTC medicines sales data by 
collaborating with retail pharmacy businesses, and make use of this 
information to support the delivery of wider public health goals in Wales. 
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Appendix 1 
Local Health Boards (LHBs) in Wales and their respective population size 
 
Prior to 
October 2009 
After 
October 2009 
Population 
(Thousands) 
Bridgend 
Abertawe Bro Morgannwg 
133.9 
Neath Port Talbot 137.6 
Swansea 230.1 
Blaenau Gwent 
Aneurin Bevan 
68.8 
Caerphilly 172.4 
Monmouthshire 87.8 
Newport 139.7 
Torfaen 90.6 
Anglesey 
Betsi Cadwaladr 
68.8 
Conwy 111.4 
Denbighshire 96.7 
Flintshire 149.7 
Gwynedd 118.6 
Wrexham 132.7 
Cardiff 
Cardiff and Vale 
330.5 
Vale of Glamorgan 124.1 
Merthyr Tydfil 
Cwm Taf 
55.6 
Rhondda Cynon Taff 234.4 
Carmarthenshire 
Hywel Dda 
180.7 
Ceredigion 76.8 
Pembrokeshire 117.6 
Powys Powys 131.7 
Total 2990.2 
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Appendix 2 
Geographical representation of the Local Health Boards (LHBs) in Wales 
before (the 22 LHBs are indicated in words) and after the NHS Wales 
reorganisation in October 2009 (the seven new LHBs are color coded and 
indicated by letters A=Betsi Cadwaladr, B=Hywel Dda, C=Powys, 
D=Abertawe Bro Morgannwg, E=Cwm Taf, F=Cardiff and Vale, G=Aneurin 
Bevan) 
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Appendix 3 
Deprivation indicators that are utilised to determine scores for each the 
deprivation component in Welsh Index of Multiple Deprivation 2008 (Welsh 
Government 2008) 
 
Income 
• Adult and children in income support households 
• Adult and children in pension credit households 
• Adult and children in income-based jobseekers allowance households 
• Adult and children in tax credit (child tax credit and working tax credit) 
households below a low income threshold 
• National Asylum Support Service supported asylum seekers in Wales in 
receipt of subsistence only and accommodation support 
Employment 
• Claimants of unemployment-related benefits 
• Claimants of incapacity benefit / severe disablement allowance 
• Participants on new deal for young people and intensity activity period 
(for new deal 25+) not included in unemployment-related benefits 
count 
• Participants on new deal for lone parents 
Health 
• Limiting long-term illness 
• Standardised all-cause death rate 
• Standardised cancer incidence rate 
• Singleton low birth weights 
Education, skills and training 
• Key Stage 2, average point scores 
• Key Stage 3, average point scores 
• Key Stage 4, average point scores 
• Primary School all absence rate 
• Secondary school all absence rate 
• Proportion of people not entering Higher Education aged 18-19 
• Proportion of adults aged 25 – 59 / 64 with no qualifications 
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Appendix 4 
List of codeine containing preparations extracted from the NHS prescription 
database for Wales 
 
Effervescent powders  Non-effervescent tablets 
Co-codamol 30mg/500mg  Co-codamol 10/500 
Co-codamol 60mg/1g  Co-codamol 12.8mg/500mg 
Kapake Insts 30mg/500mg  Co-codamol 15mg/500mg 
Kapake Insts 60mg/1g  Co-codamol 30mg/500mg 
  Co-codamol 8mg/500mg 
Effervescent tablets  Co-Codaprin 8mg/400mg 
Aspirin/codeine 500/8mg  Codafen Continus  
Co-codamol 30mg/500mg  Codagesic 8mg/500mg 
Co-codamol 8mg/500mg  Codanin 10mg/500mg 
Co-Codaprin 8mg/400mg  Codeine Phos 15mg 
Kapake 30mg/500mg  Codeine Phos 30mg 
Medocodene 30mg/500mg  Codeine Phos 60mg 
Solpadeine Plus  Codipar 15mg/500mg 
Solpadol 30mg/500mg  Cuprofen Plus  
Tylex 30mg/500mg  Ibuprofen/codeine Phos 200mg/12.5mg 
Ultramol  Kapake 30mg/500mg 
  Migraleve Complete  
Non-effervescent capsules  Migraleve Pink  
Boots Migraine Relief 8/500  Migraleve Yellow  
Co-codamol 30/500  Nurofen Plus  
Co-codamol 8/500  Painex  
Feminax Period Pain 8mg/500mg  Panadol Ultra 12.8mg/500mg 
Kapake 30mg/500mg  Panerel Pain Relief 8.1mg/450mg 
Medocodene 30mg/500mg  Parake  
Paracodol 8mg/500mg  Propain  
Solpadeine Plus   Propain Plus  
Solpadol 30mg/500mg  Solpadeine Max 12.8mg/500mg 
Tylex 30mg/500mg  Solpadeine Mig Ibuprofen/codeine  
Zapain 30mg/500mg  Solpadeine Plus  
  Solpadol 30mg/500mg 
  Solpaflex 
  Tylex 30mg/500mg 
  Zapain 30mg/500mg 
  Ibuprofen/codeine Phos 200mg/12.8mg 
Phos = Phosphate  
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Appendix 5 
List of dihydrocodeine containing preparations extracted from the NHS 
prescription database for Wales 
 
Effervescent tablets  Non-effervescent tablets 
Paracetamol/Dihydrocodeine 
500mg/7.46mg  Co-dydramol 10mg/500mg 
Paramol 500mg/7.46mg  Codydragesic 10mg/500mg 
Remedeine Forte  DF 118 Forte 40mg 
Remedeine  DF 118 30mg 
  DHC continus 120mg 
  DHC continus 60mg 
  DHC continus 90mg 
  Dihydragesic 30mg 
  Dihydrocodeine Tart 30mg 
  Dihydrocodeine Tart 40mg 
  Dihydrocodeine Tart 60mg M/R 
  Dihydrocodeine Tart 90mg M/R 
  Galake 10mg/500mg 
  Paracetamol/dihydrocodeine  500mg/7.46mg 
  Remedeine Forte 
  Remedeine  
M/R = Modified Release 
Tart = Tartrate 
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Appendix 6 
List of over-the-counter codeine containing analgesics and their respective 
pack sizes (number of tablets/capsules) extracted from the Regional Sales 
Analysis database for Wales 
 
Effervescent tablets  Non-Effervescent tablets (continued) 
Paracodol 8/500 (12)  Migraleve Pink (12) 
Paracodol 8/500 (24)  Migraleve Pink (24) 
Paracodol 8/500 (32)  Migraleve Pink PI (24) 
Solpadeine Max 500/12.8 (16)  Migraleve, Yellow (12) 
Solpadeine Max 500/12.8 (32)  Migraleve, Yellow (24) 
Solpadeine Plus 500/8/30 (12)  Nurofen Plus (12) 
Solpadeine Plus 500/8/30 (16)  Nurofen Plus (16) 
Solpadeine Plus 500/8/30 (24)  Nurofen Plus (24) 
Solpadeine Plus 500/8/30 (32)  Nurofen Plus (32) 
Solpadeine Plus 500/8/30 (60)  Painex (32) 
Ultramol (12)  Panadol Ultra (20) 
Ultramol (24)  Propain (16) 
Ultramol (32)  Propain (32) 
Ultramol (60)  Propain Plus (16) 
  Propain Plus (32) 
Non-Effervescent capsules  Solpadeine Max 500/12.8 (20) 
Paracodol  8/500 (10)  Solpadeine Max 500/12.8 (30) 
Paracodol  8/500 (20)  Solpadeine Plus 500/8/30 (12) 
Paracodol  8/500 (32)  Solpadeine Plus 500/8/30 (16) 
Phensic Dual Action (24)  Solpadeine Plus 500/8/30 (24) 
Solpadeine Plus 500/8/30 (12)  Solpadeine Plus 500/8/30 (32) 
Solpadeine Plus 500/8/30 (16)  Solpaflex (12) 
Solpadeine Plus 500/8/30 (24)  Solpaflex (24) 
Solpadeine Plus 500/8/30 (32)  Syndol Easy Swallow (10) 
Ultramol (24)  Syndol Easy Swallow (20) 
  Syndol Easy Swallow (30) 
Non-Effervescent tablets  Syndol (20) 
Cuprofen Plus (12)  Ultramol (32) 
Cuprofen Plus (24)  Veganin (10) 
Feminax (20)  Veganin (30) 
Migraleve Complete (12)   
   
PI = Parallel Import  
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Appendix 7 
List of over-the-counter dihydrocodeine containing analgesics and their 
respective pack size (number of tablets/capsules) extracted from the Regional 
Sales Analysis database for Wales 
 
Soluble  Non-soluble 
Paramol (12)  Paramol (12) 
Paramol (24)  Paramol (24) 
  Paramol (32) 
  Paramol Swallow (12) 
  Paramol Swallow (24) 
  Paramol Swallow (32) 
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Appendix 8 
The extraction and transfer of NHS prescription data from CASPA.net into a 
Microsoft Excel spreadsheet 
 
 
Step 1 Select (1) the desired time period 
 
Step 2 (2) Select ‘Entity Selection’ and then select (3) the desired Local Health 
Boards 
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Step 3 Select (4) the ‘BNF selection’ tab and then select (5) the drug of interest 
 
 
Step 4 Select (6) the ‘League Table’ button to generate a league table. After 
the league table has appeared select (7) the ‘Trend Graph’ button and a trend 
graph will appear 
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Step 5 Choose the desired output measure by selecting (8) ‘Measure’. Choose 
the desired data interval (monthly or quarterly) by selecting (9) ‘Period’. Lastly, 
export the data by clicking on (10) the Microsoft Excel button 
 
 
Step 6 Prescription data will appear in Excel spreadsheet 
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Appendix 9 
The extraction and transfer of pharmacy wholesale data from the Regional 
Sales Analysis database into a Microsoft Excel spreadsheet 
 
 
Step 1 Select (1) the ‘Data Icons’ button to bring up (2) the data element panel 
 
 
Step 2 Drag (3) the ‘Time Period’ and ‘Variable’ and (4) ‘PCO ULT-DS’ and 
‘PRD PCK’ data elements box from the data element panel into pre-defined 
areas (as indicated by the arrows) 
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Step 3 Click on (5) ‘Time Period’ data element box and then select (6) the 
desired time period. Then (7) transfer them across to the empty column. Press 
OK. 
 
 
Step 4 Click on (8) ‘PCO UTL-DS’ data element box and then select (9) the 
desired Local Health Boards. Then (10) transfer them across to the empty 
column. Press OK. 
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Step 5 Click on (11) ‘PRD PCK’ data element box and then select (12) the 
desired medicinal product. Then (13) transfer them across to the empty column. 
Press OK. 
 
 
Step 6 Click on (14) ‘Fetch’ button will create a result worksheet containing 
the data 
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Step 7 Result worksheet appear automatically. If not, click on (15) the 
‘Worksheet’ tab. Select (16) all of the rows containing the data and press 
[Control + C] to copy data 
 
 
Step 8 Paste (Control + v) the copied data into Excel spreadsheet 
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Appendix 10 
List of pseudoephedrine (PSE), phenylephrine (PE), ephedrine and inhalation 
based nasal decongestants prescribed and dispensed on NHS prescription that 
were extracted from the NHS Wales prescription database 
 
PE Tablets or Capsules  PSE Tablets or Capsules (cont) 
Galpharm Max Strength 
Decongestant  Sudafed 12 Hour Relief 120mg M/R 
Non-Drowsy Sudafed 
Congestion Relief   Sudafed Plus 
PE Hcl 12mg  Sudafed-Sa 120mg 
Boots Decongestant 12mg  Haymine 
   
PSE Tablets or Capsules  PSE Liquids 
Contac Non-Drowsy Dual 
Relief  
Meltus Decongestant Oral Solution 
30mg/5ml Sugar Free 
Ibuprofen/PSE Hcl 
200mg/30mg  
Actifed Multi Action Syrup 
30mg/1.25mg 
Nurofen Cold & Flu  Galpseud Plus Linctus Sugar Free 
Paracetamol/PSE Hcl 
500mg/30mg  Galpseud Linctus 30mg/5ml Sugar Free 
Sinutab Non-Drowsy  Galsud Linctus 30mg/5ml Sugar Free 
Ibuprofen/PE Hcl 300mg/45mg  Linctus Galpseud Plus Sugar Free 
Actifed Multi Action  PSE Hcl Elixir 30mg/5ml 
Boots Decongestant  PSE Hcl Linctus 30mg/5ml Sugar Free 
Galpseud 60mg  PSE HCl Liquid Spec 30mg/5ml 
Galsud 60mg  Sudafed Plus Syrup 
Non-Drowsy Sudafed 
Congestion  Sudafed Elixir 30mg/5ml 
Otrivine Mu-Cron 500mg/60mg   
Paracetamol/PSE Hcl 
500mg/60mg  Ephedrine Tablets 
PSE Hcl 60mg  Haymine 
Sudafed 60mg   
Contac Non-Drowsy 120mg  Inhalation Therapy 
Sudafed Plus  Olbas For Child Oil 
PSE Hcl 120mg M/R  Benz Co Tincture 
  Benz Tincture BPC 
  Menthol & Eucalyptus Inhalator BP 1980 
  Menthol & Eucalyptus Ointment 
  Karvol Decongestant Inhalation Capsules 
  Karvol Family Decongestant Inhalation 
Hcl = Hydrochloride 
M/R = Modified Release  
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Appendix 11 
List of topical nasal decongestants containing ephedrine, ipratropium, sodium 
chloride, phenylephrine or xylometazoline prescribed and dispensed on NHS 
prescription that were extracted from the NHS Wales prescription database 
 
Topical Ephedrine  Topical Sodium Chloride (continued) 
Nasal Drops 0.25%  Nebulizer Solution 7% 10ml Ampules 
Nasal Drops 0.5% BP  Nebulizer Solution 7% 5ml Ampules 
Nasal Drops 1% BP  Nebulizer Solution 7% 
Ephedrine in Normal Saline Nasal 
Drops 0.25%  Nebulizer Solution 3% 
Ephedrine in Normal Saline Nasal 
Drops 0.5%  Nebulizer Solution 5% 10ml Vl 
Ephedrine In Normal Saline Nasal 
Drops 1%  Nebulizer Solution 7% 4ml Vl 
Nasal Drops 0.1%  Nebulizer Solution 3% 10ml Unit Dose 
Nasal Drops 2%  Saline Steri-Neb Solution 0.9%/2.5ml Unit Dose 
Nasal Spray 2%  Nucare Sigma Normal Saline Nasal Drops 0.9% 
  Salex Saline Nasal Spray 0.72% 30ml 
Topical Ipratropium  Select Pharma Normal Saline Nasal Drops 0.9% 
Aqueous Nasal Spray 21mcg  Saline Steripoule Inhalation Solution 0.9% 20ml Unit Dose 
Rinatec Nasal Spray 20mcg  Saline Steripoule Inhalation Solution 0.9% 2.5ml Unit Dose 
Rinatec Aqueous Nasal Spray 21mcg  Tubilux Nasal Drops 0.9% 
   
Topical Sodium Chloride  Topical Phenylephrine 
Nasal Drops 0.5%, 0.9%, 5%  Nasal Drops 0.5% 
Solution 0.9% 2.5ml Unit Dose  Fenox Nasal Drops 0.5% 
Nasal Mist 0.9%   
Nasal Solution 0.9%  Topical Xylometazoline 
Nebulizer Solution 7% 10ml Pre-filled   Nasal Drops Pediatric 0.05% 
Nebulizer Solution 10% 10ml Vl  Nasal Spray 0.1% 10ml, 15ml 
Nebulizer Solution 5% 20ml Vl  Otrivine Nasal Pump Spray 0.1% 10ml 
Nebulizer Solution 4.5% 10ml Vl  Otrivine Pediatric Nasal Solution 0.05% 
Nasal Douche Powder  Otrivine Nasal Solution 0.1% 
Sterile Respiratory Solution 3%, 7%  Otrivine Menthol Nasal Spray 0.1% 10ml 
Respiratory Solution 0.9% 20ml Unit 
Dose  Otrivine Sinusitis Spray 0.1% 10ml 
Inhalation Solution 7% 5ml Unit Dose  Otrivine Adult Metered Nasal Pump Spray 0.1% 10ml 
Inhalation Solution 3%  Otradrops Nasal Drops Pediatric 0.05% 
Nasal Douche 0.9%  Otradrops Nasal Drops Adult 0.1% 
Inhalation Solution 1.8%, 7%  Otraspray Nasal Pump spray 0.1% 10ml 
Inhalation Solution 0.9% 20ml Unit 
Dose  Tixycolds Cold & Allergy Nasal Drops 0.05% 
Nebulizer Solution 7% 5ml Vl  Sudafed Non-Drowsy Decongest Nasal Spray 0.1% 15ml 
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Appendix 12 
List of over-the-counter pseudoephedrine (PSE) containing products extracted 
from the Regional Sales Analysis database for Wales 
 
PSE containing preparations 
(pack size in tablets/capsules/mls) 
Benadryl Plus Capsules (12) 
Benadryl Plus Capsules (24) 
Benylin 4 Flu Liquid (200ml) 
Benylin 4 Flu Tablets (24) 
Benylin Day & Night Tablets (16) 
Benylin Day & Night Tablets (20) 
Day And Night Nurse Capsules (24) 
Day Nurse Capsules (20) 
Day Nurse Liquid (160ml) 
Day Nurse Liquid (240ml) 
Lemsip Caps Sinus 12hr (8) 
Lemsip Max Flu Strength Sachet (10) 
Lemsip Max Power Capsules (10) 
Lemsip Max Sinus Cold & Flu 12 Hour Relief Capsules (8) 
Mucron Tablets (12) 
Nurofen Cold & Flu Tablets (12) 
Nurofen Cold & Flu Tablets (24) 
Nurofen Cold & Flu Tablets (36) 
Sinutab Tablets (15) 
Sinutab Tablets (30) 
Sinutab Tablets Non-Drowsy (15) 
Sinutab Tablets Non-Drowsy (30) 
Sudafed Dual Relief Max Tablets Non-Drowsy (12) 
Sudafed Dual Relief Max Tablets Non-Drowsy (24) 
Vicks Medinite Liquid (180ml) 
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Appendix 13 
List of over-the-counter phenylephrine containing products extracted from the 
Regional Sales Analysis database for Wales  
 
Phenylephrine containing preparations 
(pack size in tablets/capsules/sachets/mls) 
Anadin Cold Control Capsules (16) 
Anadin Cold Control Sachets (5) 
Beechams All In 1 Liquid (160ml) 
Beechams All In 1 Liquid (240ml) 
Beechams All In 1 Liquid Pocket Pack (2) 
Beechams All In 1 Liquid Pocket Pack (6) 
Beechams All In 1 Hot Lemon Sachet (10) 
Beechams All In 1 Tablets (16) 
Beechams All In 1 Tablets (8) 
Beechams All In 1 Tablets Non-Drowsy (24) 
Beechams All In 1 Ultra Capsules (16) 
Beechams Decongestant Plus Capsules (16) 
Beechams Flu Plus Berry Fruit Sachet (5) 
Beechams Flu Plus Caplets (16) 
Beechams Flu Plus Caplets (24) 
Beechams Flu Plus Caplets (8) 
Beechams Flu Plus Hot Berry Fruit Stick (10) 
Beechams Flu Plus Hot Berry Fruit Stick (5) 
Beechams Flu Plus Hot Berry Fruit Sachet (10)  
Beechams Flu Plus Hot Lemon Sachet (10) 
Beechams Flu Plus Hot Lemon Sachet (5) 
Beechams Flu Plus Hot Lemon Stick (10) 
Beechams Flu Plus Hot Lemon Stick (5) 
Benylin Day & Night Cold & Flu Capsules (16) 
Galpharm Flu Relief Decongestant Capsules (16) 
Galpharm Flu Relief Flu Strength Liquid (160ml) 
Galpharm Flu Relief Hot Lemon Sachet (10) 
Lemsip Blackcurrant Sachet (10) 
Lemsip Blackcurrant Sachet (5) 
Lemsip Breathe Easy Sachet (10) 
Lemsip Breathe Easy Sachet (5) 
Lemsip Max All Night Cold & Flu Tablets (16) 
Lemsip Max All in 1 Easy Breath Sachets (10) 
Lemsip Max All in 1 Capsules (16) 
Lemsip Max All in 1 Lemon Sachet (16) 
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Appendix 13 (continued) 
List of over-the-counter phenylephrine containing products extracted from the 
Regional Sales Analysis database for Wales 
 
Phenylephrine containing preparations 
(pack size in tablets/capsules/sachets) 
Lemsip Max All In One Sachets (10)  
Lemsip Max All In One Sachets (5) 
Lemsip Max All In One Winter Berry & Orange Sachet (10) 
Lemsip Max All In One (10) 
Lemsip Max All In One (160ml) 
Lemsip Max All In One (5) 
Lemsip Max Breath Easy Sachet (10) 
Lemsip Max Capsules (16) 
Lemsip Max Capsules (8) 
Lemsip Max Capsules Daytime (16) 
Lemsip Max Cold & Flu Capsules (16) 
Lemsip Max Day & Night Cold & Flu Capsules (16) 
Lemsip Max Day & Night Capsules (16) 
Lemsip Max Day & Night Capsules (8) 
Lemsip Max Direct Blackcurrant Sachet (10)  
Lemsip Max Direct Lemon Sachet (10)  
Lemsip Max Sachet Blackcurrant (10) 
Lemsip Max Sachet Blackcurrant (5) 
Lemsip Max Lemon Sachets (10) 
Lemsip Max Lemon Sachets (5) 
Lemsip Max Sinus Max Strength Capsules (16) 
Lemsip Max Sinus Sachet (10) 
Lemsip Max Swallow Lemon Tablets (12) 
Lemsip Original Lemon (10) 
Lemsip Original Lemon (5) 
Sudafed Dual Relief Non-Drowsy Capsules (16) 
Sudafed Dual Relief Non-Drowsy Capsules (32) 
Uniflu Gregovite C Tablets (12) 
Uniflu Gregovite C Tablets (24) 
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Appendix 14 
List of ophthalmic chloramphenicol preparations extracted from the NHS 
prescription database for Wales 
 
Eye Drops Eye Ointment 
Chloramphenicol 0.5% Chloramphenicol 0.5% 
Chloramphenicol 1% Chloramphenicol 1% 
Chloramphenicol 0.5% Ud Chloromycetin 1% 
Chloramphenicol/Polyalc 0.5% Optrex Infected Eyes 1% 
Chloromycetin Redidrops 0.5% Brochlor 1% 
Minims Chloramphenicol 0.5% Ud p/f* Golden Eye Antibiotic 1% 
Sno Phenicol 0.5%  
Optrex Infected Eyes 0.5%  
Brochlor 0.5%  
Golden Eye Antibiotic 0.5%  
Ud = Unit dose, p/f = preservative free, Polyalc = Polyalcohol 
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Appendix 15 
A list of proprietary ophthalmic chloramphenicol preparations sold in the UK, 
together with their respective retail price, pack size and availability 
 
Eye drops 0.5% (10ml) Retail price (£) UK availability 
Brochlor 4.85 October 2006 
Galpharm Vision 
Chloramphenicol 4.38 October 2005 
Golden Eye Antibiotic 5.10 June 2007 
I-Care Chloramphenicol 
Antibiotic 4.48 N/A 
Numark Chloramphenicol 
Antibiotic 4.05 September 2005 
Optrex Infected Eyes 5.18 June 2005 
Tubilux 4.34 September 2006 
   
Eye Ointments 1% w/w (4g)   
Brochlor 5.06 July 2007 
Galpharm Vision Antibiotic 4.96 July 2007 
Golden Eye Antibiotic 5.50 March 2008 
I-Care Chloramphenicol 
Antibiotic 4.69 N/A 
Optrex Infected Eyes 5.72 July 2007 
 
N/A: Information unavailable 
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Appendix 16 
List of ophthalmic chloramphenicol preparations for which pharmacy 
wholesale data were extracted from the Regional Sales Analysis database for 
Wales 
 
Eye Drops (10ml) Eye Ointments (4g) 
Brochlor 0.5% Brochlor 1% 
Golden Eye Antibiotic 
0.5% 
Golden Eye Antibiotic 
1% 
Galpharm Vision 
Antibiotic 0.5% 
Galpharm Vision 
Antibiotic 1% 
Optrex Infected Eyes 0.5% Optrex Infected Eyes 1% 
Tubilux Infected Eyes 
0.5%  
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Appendix 17 
List of ophthalmic chloramphenicol preparations for which pharmacy retail 
data were obtained from Company A 
 
Eye Drops (10ml) Eye Ointment (4g) 
Own-brand Antibiotic 0.5% Golden Eye Antibiotic 1% 
Golden Eye Antibiotic 0.5% Optrex Infected Eyes 1% 
Optrex Infected Eyes 0.5%  
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Appendix 18 
List of over-the-counter oral cold and flu medicines and their respective pack 
sizes extracted from the Regional Sales Analysis database which were 
monitored between May 2003 and April 2009 
 
Liquid Preparations Product pack size(s) 
Beechams All In 1  160, 240ml 
Beechams All In 1 Pocket Pack 2, 6 sachets 
Benylin 4 Flu 200ml 
Cold Relief Cold Flu 160, 200ml 
Day Nurse 240ml 
Galpharm Flu Relief Flu Strength 160ml 
Lemsip Max All In One 160ml 
Night Nurse 160ml 
Vicks Medinite 180ml 
  
Soluble Preparations  
Beechams All In 1 Hot Lemon 10 sachets 
Beechams Flu Plus Berry Fruit 5, 10 sachets 
Beechams Flu Plus Hot Berry Fruit 5, 10 sticks 
Beechams Flu Plus Hot Lemon 5, 10 sachets 
Beechams Flu Plus Hot Lemon 5, 10 sticks 
Cold Relief All In 1 Powder 10 sachets 
Cold Relief Hot Blackcurrant 5 sachets 
Cold Relief Hot Lemon 5, 10 sachets 
Cold Relief Maximum Flu Strength 10 sachets 
Cold Relief Powder  8, 10 sachets 
Galpharm Flu Relief Hot Lemon  10 sachets 
Lemsip Blackcurrant  5, 10 sachets 
Lemsip Breathe Easy  5, 10 sachets 
Lemsip Max All In 1 Breath Easy  10 sachets 
Lemsip Max All In 1 Lemon  16 sachets 
Lemsip Max All In 1  5, 10 sachets 
Lemsip Max All In 1 Winter Berry & Orange  10 sachets 
Lemsip Max Easy Breath  10 sachets 
Lemsip Max Direct Blackcurrant  10 sachets 
Lemsip Max Direct Lemon  10 sachets 
Lemsip Max Flu Strength  10 sachets 
Lemsip Max Blackcurrant  5, 10 sachets 
Lemsip Max Lemon  5, 10 sachets 
Lemsip Original Lemon  5, 10 sachets 
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Appendix 18 (continued) 
List of over-the-counter cold and flu medicines and their respective pack sizes 
extracted from the Regional Sales Analysis database which were monitored 
between May 2003 and April 2009 
 
Solid Preparations Product pack size(s) 
Beechams All In 1  8, 16 tablets 
Beechams All In 1 Non-Drowsy  24 tablets 
Beechams All In 1 Ultra  16 capsules 
Beechams Flu Plus  8, 16, 24 caplets 
Benylin 4 Flu  24 tablets 
Benylin Day &Night Cold & Flu  16 capsules 
Benylin Day &Night  16, 20 tablets 
Cold Relief All In 1  16 tablets 
Cold Relief  16, 24, 32 capsules 
Cold Relief Max Strength  16 capsules 
Cold Relief Inhalant  10 capsules 
Cold Relief 12, 16 tablets 
Day And Night Nurse  24 capsules 
Day Nurse  20 capsules 
Galpharm Flu Relief Decongestant  16 capsules 
Lemsip Max All Night Cold & Flu  16 tablets 
Lemsip Max All In One  16 capsules 
Lemsip Max All In One  5, 10 tablets 
Lemsip Max  8, 16 capsules 
Lemsip Max Daytime  16 capsules 
Lemsip Max Cold & Flu  16 capsules 
Lemsip Max Day & Night Cold & Flu  24 capsules 
Lemsip Max Day & Night  8, 16 capsules 
Lemsip Max Lemon  6 tablets 
Lemsip Max Power  10 capsules 
Lemsip Max Swallow / Dispersible Lemon  12 tablets 
Night Nurse  10 capsules 
Nurofen Cold & Flu  12, 24, 36 tablets 
 
  
 309 
Appendix 19 
List of over-the-counter cough medicines and their respective pack sizes 
extracted from the Regional Sales Analysis database which were monitored 
between May 2003 and April 2009 
 
Cough preparations Product pack size(s) 
Cough Cold Unbranded Adult Chesty 
Non-Drowsy  200ml 
Cough Cold Unbranded Chesty Adult  200ml 
Cough Cold Unbranded Chesty Cough  150, 200ml 
Cough Cold Unbranded Expectorant Adult 
+ Decongestant  100, 150ml 
Cough Cold Unbranded Adult Linctus  200ml 
Lemsip Chesty Cough  100ml 
Lemsip Dry Cough  100ml 
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Appendix 20 
List of over-the-counter nasal congestion or sinusitis medicines and their 
respective pack sizes extracted from the Regional Sales Analysis database 
which were monitored between May 2003 and April 2009 
 
Nasal Congestion or Sinusitis preparations Product pack size(s) 
Beechams Decongstant Plus  16 capsules 
Cold Relief Decongestant Non-Drowsy  16 capsules 
Cold Relief Decongestant  12 capsules 
Cold Relief Decongestant  12, 24 tablets 
Lemsip Sinus 12hr Relief  8 capsules 
Lemsip Max Sinus Max Strength  16 capsules 
Lemsip Max Sinus  10 sachets 
Lemsip Max Sinus Cold & Flu 12h  8 capsules 
Lemsip Non-Drowsy Decongestants  10 sachets 
Sinutab  15, 30 tablets 
Sudafed Congestion Non-Drowsy  12, 16 tablets 
Sudafed Dual Relief Non-Drowsy  16, 32 capsules 
Sudafed Dual Relief Max Non-Drowsy  12, 24 tablets 
 
